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Abstract 
The global increase in the prevelance and abuse of new psychoactive 
substances (NPS) has required the development of new analytical methods for 
rapid, selective and inexpensive protocols for both their separation and detection. 
Electrochemical sensing of these compounds has been demonstrated to be an 
effective method for their in-field detection, either in their pure form or the presence 
of common adulterants. The electrochemical technique can differentiate between 
structurally-related phenethylamines (for example (±)-paramethoxyamphetamine 
and (±)-3,4-methylene dioxymethamphetamine, however it is limited in its ability to 
distinguish between structurally-related cathinone-derivatives, for example (±)-4-
mephedrone and (±)-4-methyl-N-ethycathinone. 
 
The HPLC-AD protocol obtained a cost-effective, reproducible, and reliable 
sensor platform for detection of the target analytes by simultaneous HPLC-UV and 
amperometric detection protocol. Additionally, the simultaneous HPLC-UV and 
amperometric detection protocol detailed herein shows a marked improvement in 
selectively discriminating between structurally related compounds. 
 
This thesis demonstrates, for the first time, the combination of HPLC-UV with 
amperometric detection (HPLC-AD) for the detection and quantitative analysis of 
new psychoactive substances using a commercially available impinging jet (LC-FC-
A system) or using a custom-made iCell channel flow-cell system (LC-FC-B), both 
incorporating embedded graphite screen-printed macroelectrodes. The method 
demonstrates the application of a cost-effective, reproducible, and reliable sensor 
platform for the simultaneous HPLC-UV and amperometric detection of target 
analytes. 
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Although the amperometric detection (HPLC-AD) system that has been 
developed is not as sensitive as standard HPLC-UV detection,both LC-FC-A and 
LC-FC-B show a good agreement between the quantitative electroanalytical data. 
Therefore, they are suitable for the detection and quantification of new psychoactive 
substances, either in their pure form or within complex mixtures.  
 
Additionally, the simultaneous HPLC-AD protocol shows a marked 
improvement and advantage over previously reported electroanalytical 
methods.The electroanalytical methods were either unable to selectively 
differentiate between structurally related synthetic cathinones (e.g. (±)-mephedrone 
and (±)-4-MEC (Smith et al., 2014a), or utilised harmful and restrictive materials in 
their design by adding the illegal compounds in combination with the legal 
compounds. 
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1 Chapter 1: Introduction and literature review 
 
1.1 New psychoactive substances. 
New psychoactive substances (NPS) are defined by the Advisory Council on 
the Misuse of Drugs (ACMD) as: “Psychoactive drugs which are not prohibited by 
the United Nations Single Convention on Narcotic Drugs or by the Misuse of Drugs 
Act (1971), and which people in the UK are seeking for intoxicant use‟ (ACMD, 
2011). 
 
The designer drugs, legal highs, herbal highs and bath salts in the market have 
been termed ‘new psychoactive substances’ (NPS) (Addiction, 2012; Wilkins, 2014), 
and this preferred term was adopted by the European Community in 2005 (King and 
Kicman, 2011; Council Decision, 2005; EMCDDA, 2007)King and Kicman, 2011). 
The new psychoactive substances (designer or synthetic drugs) include legal highs 
and club drugs (Dunne et al., 2015); the term  ‘designer drugs’ was created in 1984 
and in recent times these have been described informally as ‘legal highs’ (King and 
Kicman, 2011). Designer drugs are  defined as ‘analogues, or chemical cousins, of 
controlled substances that are designed to produce effects similar to the controlled 
substances they mimic’ (King and Kicman, 2011). These substances have the 
pharmacological effect to cause euphoria, central nervous system stimulation, 
and/or hallucination (Dunne et al., 2015). These effects are based on the chemical 
formula of opioids, mescaline, and cannabis, and they are synthesised in the 
laboratory under lax conditions for no defined medical purposes.  
 
NPSs are potentially dangerous for the user due to the variation in the 
composition from batch to batch. Furthermore, laboratories are continually changing 
the chemical structure of the substances to avoid legislative control; therefore, the 
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user often does not know exactly what they are taking. These substances are 
produced by altering the molecular structure of controlled psychoactive drugs. The 
term ‘designer drugs’ includes all substances which are used recreationally and not 
controlled by the Misuse of Drugs Act (1971) (UK-Governement, 1971) , and not 
licensed for legal use and not regulated under the Medicines Act (1986) (Dunne et 
al., 2015). 
 
NPSfall outside legislative controls and include a diverse range of chemical 
classes including (but not limited to): synthetic cathinones, phenethylamines, 
piperazines, aminoindanes and synthetic cannabinoids, their chemistry or process 
of synthesis have been slightly modified to produce effects similar to known illicit 
substances (UNODC, 2013). These substances are not entirelynew phenomena  
and many were synthesized and patented in the early 1970s or even earlier, but 
only recently they have been controlled under the Psychoactive Substances Act 
(PSA) 2016 (UK-Government, 2016).The descriptor ’legal high‘ is a media-coined 
term which is considered by many professionals to be misleading as it can lead to 
the misconception that these substances which, though legal to possess prior to the 
PSA 2016, were indeed safe to use – which has been shown in some cases not to 
be true (UK-Governement, 1971). 
 
Some NPSs have been identified as having some negative side effects on 
health, but, because they are relatively new materials, there is very little research 
undertaken on the short and long-term health risks of prolonged use (Addiction, 
2012). Many of these substances are created by subtly changing the chemical 
structure of the parent psychotropic substance (for example a cathinone or 
amphetamine) that is already controlled, to produce a similar pharmacological 
response (i.e. CNS stimulatory effect) but which fall outside the definitions of the 
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controlling legislation. The most well-known example of a synthetic cathinone is (±)-
mephedrone hydrochloride (±)-mephedrone (Zuba, 2012) (Section 1.5.2). Herbal 
dietary supplements, herbal highs, and party pills, which contain products from 
natural sources, are also considered NPSs in many regions. Pre 2016 these 
products could be legally possessed and purchased online or through high street 
retail stores known as ’head shops’.  According to a UK-based internet market 
survey at the time, their low cost, ease of supply and the relatively high quality of 
the active ingredients made these products extremely attractive to recreational drug 
users (Arunotayanun and Gibbons, 2012; Gibbons and Zloh, 2010). 
 
1.2 Emergence/prevalence of NPS 
In recent years, the world has seen the emergence of new drugs (NPS) that 
have similar effects to drugs that are internationally controlled. These drugs are 
represented worldwide as an underestimated health risk (Zanda and Fattore, 2017; 
Dargan and Wood, 2013). NPS are a global issue and the widespread trade of such 
substances is drawing international concern.  
 
The brand names of NPSs are used to describe them such as Benzo Fury, NRG-
1 and NRG-2. These names do not always pertain to what is the actual psychoactive 
substance present, for example,(±)-mephedrone was sold as naphyrone (or NRG-1) in 
the UK after it was banned (Brandt et al., 2010). In addition, another study reported 70 
% of NRG-1 and NRG-2 analysed were found to be a mixture of substituted cathinones 
(Smith et al., 2015). The typical marketing for NPSs is as ‘not for human consumption’ 
or labelled as plant food or bath salts in order to bypass legislative controls pre-PSA 
2016 (Johnson et al., 2013; Smith et al., 2015). The identification of NPSs are a novel 
investigation field (Smith et al., 2015). The customers purchasing such products have 
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no assurance that these products contain what they are advertised as containing (Smith 
et al., 2015). 
 
1.3 Prevalence of NPSs 
In 2009, the abuse of NPSs had been reported to have increased and has 
continued to be an ever-growing market (EMCDDA, 2013), emerging at an 
extraordinary rate of online vendors in the UK reflected in the online marketplace 
increasing by more than 300% between 2010 and 2011 (EMCDDA, 2011; Smith et al., 
2015).  NPSs notification increased between  2012-2015 as shown in figure 1.1. and 
were reported for the first time to the EU early warning system (EWS) run by the 
European Monitoring Center for Drugs and Drug Addiction EMCDDA (EMCDDA, 2015). 
 
In addition, sixty-six NPSs were notified during for the first time in 2016 in 
Europe. Recently, the total number of NPSs monitored by the EMCDDA increased 
to more than 620, more than twice the total number of substances currently 
controlled under the United Nations drug conventions  (Figure 1.1) (EMCDDA, 
2016). 
 
Figure 1.1 Number of new psychoactive substances formally notified for the first time in Europe 
(dots) and the total number of new psychoactive substances monitored by the EMCDDA, 2005–16 
(bars) (reproduced with permission from reference (EMCDDA, 2016). 
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The two most significant categories of new psychoactive substances identified 
by the EMCDDA through the EU Early Warning System in 2016 were the synthetic 
cathinones (14) and synthetic cannabinoids (11).  Moreover, nine opioids, six 
phenethylamines, six arylcyclohexylamines, six benzodiazepines, three 
arylalkylamines, one piperidine/pyrrolidine and ten other substances that do not 
conform to any of the previous groups were identified for the first time (Figure 1.2) 
(EMCDDA, 2016).  
 
 
 
Figure 1.2 Number and categories of new psychoactive substances formally notified for the first time 
in Europe, 2005–16 (reproduced with permission from reference (EMCDDA, 2016)). 
 
The internet is the main method of supply of such drugs in the UK. Synthetic 
cathinones, piperazines and synthetic cannabinoids are being used as substances 
of abuse. The most popular abused recreational drugs such as ‘ecstasy’, 
amphetamine, cocaine, and LSD are taken to make the user awake, energetic, feel 
euphoric and feel intoxicated. Some of these substances can cause relaxation and 
create a sense of wellbeing (empathogens), and some stimulants lead to euphoria. 
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However, these compounds were banned in the UK under the revision of Misuse of 
Drugs Act (1971) (UK-Governement, 1971). 
 
1.4 Misuse of Drugs Act (1971) 
The United Kingdom has legalisation  to control the drugs of abuse and this 
was called the Misuse of Drugs Act (1971) (UK-Governement, 1971). (UK-
Government, 2016; Reuter and Pardo, 2017). In 1971, the United Kingdom 
government established the Misuse of Drugs Act for the control of substances, 
which were believed to pose a significant risk to society and the individual. This 
legislation was in alignment with the United Kingdom’s obligations under the United 
Nation’s Conventions on Narcotic Drugs (1961) (UNODC, 1961; UNODC, 2013) and 
Psychotropic Substances (1971) (UK-Governement, 1971; UNODC, 2013) and 
supported the development of the 1988 international agreement to limit the illicit 
traffic in narcotic drugs and psychotropic substances (Neue, 1997). 
 
The Misuse of Drugs Act (1971) refers to what cannot be done with a controlled 
substance and the level of control relates to a drugs potential for harm. Drug 
addiction is a state of physical or psychological dependence on a drug (Dragan, 
2003). All substances, which are capable of producing a psychoactive effect in a 
person who consumes it, and which are not controlled under the Misuse of Drugs 
Act (1971)(UK-Governement, 1971), are controlled under the Psychoactive 
Substances Act 2016  
 
The UK Government has had to evolve drug control legislation to allow the 
regulation of NPS. In 2014, the UK government convened an NPS expert panel 
looking for a range of approaches and as a result, on the 26th May 2016, the 
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Psychoactive Substances Act (2016) came into force in the UK (UK-Government, 
2016).  
 
Under the Misuse of Drugs Act (1971), it is an offence to produce, possess or 
possess with intent to supply a controlled drug (Phillips et al., 1997). The Misuse of 
Drugs Act (1971) divided drugs into three different classes: Class A, B, and C. Class 
A, considered most dangerous substances, while class C substances are 
considered the least dangerous (Table 1.1) (Gibbons and Zloh, 2010; Brandt et al., 
2010; UK-Governement, 1971). 
Table 1.1 Drug Class specifications within the Misuse of Drugs Act (1971) (HomeOffice, 2009) 
Class Class A Class B Class C 
Example of 
drugs 
- ’ecstasy’ 
- LSD 
- heroin 
- cocaine 
- crack 
- magic mushrooms 
- amphetamines (if 
prepared for injection) 
- amphetamines 
- cannabis 
- methylphenidate (Ritalin) 
- Pholcodine. 
- synthetic cathinones 
- synthetic cannabinoids 
- tranquilisers 
- some painkillers 
- gamma 
hydroxybutyrate 
(GHB) 
- ketamine 
Possession Up to seven years in prison 
or an unlimited fine or both. 
Up to five years in prison or 
an unlimited fine or both 
Up to two years in 
prison or an unlimited 
fine or both. 
Supplying Up to life in prison or an 
unlimited fine or both. 
Up to 14 years in prison or 
an unlimited fine or both 
Up to 14 years in 
prison or an unlimited 
fine or both. 
 
Additionally, there are regulations (Misuse of Drugs Regulations (2001)) (UK-
Governement, 2001) which are concerned with the supply, import, and export of the 
controlled drugs. Misuse of Drugs Regulations (2001) essentially states what can 
be done with a controlled substance and has five schedules for controlled drugs, 
which are based on their medical use. Substances in the first schedule, such as (±)-
mephedrone, are considered to have no medical use, with the following schedules 
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relating to materials which have a therapeutic use but remain controlled due to their 
risk of abuse (Neue, 2010). The schedules, as specified by the Misuse of Drugs 
Regulations (2001)(UK-Governement, 2001), are as follows: 
Schedule 1 Controlled Drugs: It includes the most stringently controlled 
drugs. These drugs are not permitted for medical use and can be supplied, 
possessed or administered only by a person authorised by a licence issued by the 
Home Office. The licences are approved for research or particular purposes. 
Schedule 1 Controlled Drugs are subject to the Misuse of Drugs (Safe Custody) 
Regulations (1973) to safe custody requirements. Drugs in Schedule 1 must be 
stored in a locked cabinet or approved safe, which can be opened only by the person 
in lawful possession of the controlled drugs, or a person authorised by 
him/her.These drugs are not allowed to be prescribed by doctors or dispensed by 
pharmacists; this is the closest that British law comes to total prohibition.Examples 
of drugs listed in Schedule 1 include cannabis and cannabis resin, ectasy (MDMA) 
and lysergide (LSD). 
 
Schedule 2 Controlled Drugs: Schedule 2 controlled drugs include heroin, 
cocaine, morphine, pethidine, quinalbarbitone, and amphetamine. It is illegal to 
possess drugs in Schedule 2 without a prescription or other authority. For 
production, import, export or supply substances in this Schedule require a Home 
Office licence.  
 
Schedule 3 Controlled Drugs: Schedule 3 drugs include the majority of 
barbiturates (excluding quinalbarbitone), temazepam and buprenorphine. Itis not 
legal to possess drugs in Schedule 3 without a prescription or other authority. A 
Home Office licence is required to export, or import and authority is needed for 
production, possession, and supply. Certain Schedule 3 controlled 
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drugs,e.g.temazepamare are also subject under the Misuse of Drugs (Safe 
Custody) Regulations (1973) (UK-Governement, 1973). 
Schedule 4 Controlled Drugs: This Schedule is currently split into two parts, 
Part 1 and Part 2. Part 1 contains mainly the benzodiazapines, e.g. diazepam, 
lorazepam, nitrazepam, and oxazepam. Schedule 4 controlled drugs are subject to 
minimal control, but they need a prescription or other authority to legally possess 
them, so long as it is in the form of a medicinal product. The licences are not needed 
to import or export Schedule 4 controlled drugs. 
 
Part 2 contains mainly drugs such as anabolic steroids, e.g.nandralone, 
stanozolol and testosterone, but also contains specific growth hormones and 
clenbuterol. All the substances listed in Part 2 are substances, which may be 
(mis)used by athletes and/or bodybuilders. 
 
Schedule 5 Controlled Drugs:  The drugs in Schedule 5 are considered to 
pose minimal risk of abuse. These non-injectable, low-dose preparations are not 
necessary to have a prescription for because they can be purchased over the 
counter at a pharmacy but, once obtained, it is illegal  to supply them to another 
person. Many of these preparations include well-known cough mixtures and 
painkillers. However, some Schedule 5 controlled drugs are prepared from drugs 
that appear in Schedule 2 and therefore make misuse a risk. The safe custody and 
register requirements do not apply to these types of drugs (UK-Governement, 2001). 
 
In 2001, the UK parliament passed an amendment to the Misuse of Drugs Act 
(1971).  The amendments were slight changes to the wording within the original 
legislation (for example: removal of the definition “medicinal product”).  The most 
significant amendment was to allow a nurse independent prescriber and/or a 
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pharmacist independent prescriber to prescribe, possess, supply, offer to supply, 
administer and give directions for the administration of any controlled drug specified 
in Schedules 2 to 5 of the 2001 Regulations. The amendments also allow a nurse 
independent prescriber and a pharmacist independent prescriber to supply certain 
articles for administering or preparing controlled drugs.   
The Psychoactive Substances Act (2016) (UK-Government, 2016) became 
law on 26th of May 2016.  The Act made it an offence to produce, supply or offer 
psychoactive substances with the exeption of caffeine, nicotine, alcohol and 
medicinal products as defined by the Human Medicines Regulations (2012) (UK-
Governement, 2012). It is important to note that the PSA 2016 does not replace the 
Misuse of Drug Act (1971) and substances controlled under the early legislation 
remain unchanged (Reuter and Pardo, 2017; UK-Government, 2016). 
 
In general, the Psychoactive Substances Act (2016) defines many offences 
such as possession, importation, supply, production, penalties (Table 1.2), powers to 
stop and search; whereas the police will have powers for that and also for premises 
and prohibition notices (UK-Government, 2016; Reuter and Pardo, 2017). 
 
Table 1.2 Penalties under the legalisation.gov.uk 2016 (Reuter and Pardo, 2017; UK-Government, 
2016) 
Offence Summary (Magistrates 
Court) 
Indictment (Crown Court) 
Possession  Not an offence  Not an Offence 
Possession in a custodial institution  Up to 12 months and/or a fine Up to 2 years and/or a fine  
Possession with intent to supply  Up to 12 months and/or a fine Up to 7 years and/or a fine  
Supply/offer to supply etc.  Up to 12 months and/or a fine Up to 7 years and/or a fine  
Production  Up to 12 months and/or a fine Up to 7 years and/or a fine  
Importation/exportation  Up to 12 months and/or a fine Up to 7 years and/or a fine  
Failure to comply with a  
Prohibition or Premises notice  
Up to 12 months and/or a fine Up to 2 years and/or a fine  
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1.5 Classification of controlled and new/novel psychoactive substances 
Controlled substances are classified based on their psychotropic effects as 
stimulants, empathogens/entactogens (such as (±)-MDMA, ’ecstasy‘), 
hallucinogens or classified depending on their chemical family as phenethylamines, 
amphetamines, cathinones, piperazines, pipradrol/piperidines, aminoindanes, 
benzofurans, and tryptamines (Hill and Thomas, 2011; Liechti, 2015). In addition, 
controlled substances are also classified by the United Nations Office on Drugs and 
Crime (UNODC) and the EMCDDA to the following sub-categories: 
phenethylamines (Hanson et al., 2015), synthetic cathinones (Valente et al., 2014), 
ketamine (Wolff and Winstock, 2006), synthetic cannabinoids (Shevyrin et al., 
2016), piperazines (Castaneto et al., 2015), plant-based substances (Kalix, 1996): 
Khat, Kratom, Salvia divinorum and miscellaneous examples (which fall outside the 
classes listed above): aminoindanes, phencyclidine, tryptamines (Smith et al., 
2015). 
 
This section provides an overview of the most common/prevalent substances 
of abuse, relevant to this study. The group of substances collectively referred to as 
NPSs include a wide range of primarily synthetic compounds that fit into pre-existing 
categories of existing drugs. They include phenethylamines: ((±)-
methamphetamine, (±)-Paramethoxyamphetamine ((±)-PMA), and (±)-3,4-
Methylenedioxymethamphetamine ((±)-MDMA), synthetic cathinone, and its 
derivatives ((±)-mephedrone, (±)-4-Methyl-N-ethylcathinone (±)-4-MEC, and (±)-
mexedrone) and dissociative anaesthetic substances (methoxyephenidine 
regioisomers and fluoroephenidine regioisomers). 
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1.5.1 Phenethylamine (amphetamine, methamphetamine and MDMA) 
Phenethylamine molecules (Figure 1.3a) are the backbone of many stimulant 
NPS (Whelpton, 2007; Liechti, 2015; Dargan and Wood, 2013; Freeman and Alder, 
2002). The amphetamines (Figure 1.3b) are formed by inserting an alpha methyl 
group into phenethylamine that protects against metabolism by monoamine oxidase 
(MAO). The higher CNS activity of methamphetamine (Figure 1.3c) is produced from 
the methylation of the terminal amine of amphetamine, which increases the duration 
of sympathomimetic activity and protects against metabolism by MAO(Whelpton, 
2007; Liechti, 2015; Dargan and Wood, 2013; Freeman and Alder, 2002; Shulgin, 
1978). 
 
 
Figure 1.3 Structures of representative new/novel psychoactive Substances (stimulants and 
empathogens). Chemically, the substances shown include phenethylamine: (a), amphetamine (b), 
(±)-methamphetamine, (c), (±)-MDMA (d), and (±)-PMA (e). 
 
Amphetamine and methamphetamine have been used clinically as classic 
psychostimulants recreationally and by the military services since the 1930s 
(Whelpton, 2007; Liechti, 2015). The term ‘designer amphetamine’ is used to 
describe the synthetic chemical substances that are derived from amphetamine or 
methamphetamine such as (±)-MDMA (Figure 1.3d) and (±)-PMA (Figure 1.3e)).  
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1.5.1.1 (±)-3,4-Methylenedioxymethylamphetamine ((±)-MDMA) 
 One of the most important of the amphetamine-derivatives is (±)-MDMA; 
Figure 1.3d), which is not a novel psychoactive substance as it has been used for 
decades. (±)-MDMA, commonly known as ’ecstasy’, is one of the most popular 
addictive synthetic drugs (synthetic amphetamine). (±)-MDMA was first synthesised 
by the German pharmaceutical company Merck in 1912 as part of a new pathway 
for a potential appetite suppressants, and over the next seventy years, a number of 
researchers explored its psychedelic properties of (±)-MDMA with little success 
(Isabel Colado et al., 2007).  
 
During the 1970s, (±)-MDMA surfaced on the recreational drugs market. Its 
widespread abuse and potential long-term health effects led many countries to 
prohibit its possession, supply and manufacture. In the 1980s, (±)-MDMA entered 
the lists of internationally controlled substances (Muller and Windberg, 2005). 
Currently, in the UK, (±)-MDMA (or ’ecstasy’) is controlled as a Class A, Schedule 1 
substance due to its illicit use as a recreational drug and its implication in some 
highly publicised fatalities (Soar et al., 2001; Liechti and Vollenweider, 2001; 
Verschraagen et al., 2007; White et al., 2014; Cumba et al., 2016).  
 
 (±)-MDMA is usually found in tablet form (containing 60–70 mg (±)-MDMA) 
with each batch being stamped with a particular motif, e.g. a Mitsubishi™ logo, 
smiley faces, or letters. However, it has also been seized as a high purity (circa. 95 
– 98%) crystalline powder sold in wraps. Since the global prohibition of (±)-MDMA. 
and its precursors (e.g. 3,4-methylenedioxyphenyl-2-propanone, piperonal, safrole 
and isosafrole), a wide range of structurally-related phenethylamines have 
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appeared on the recreational drugs market, including the designer drug, (±)-PMA 
(Cumba et al., 2016). 
 
Currently, (±)-MDMA is predominantly a ‘club drug’ and is commonly used 
recreationally within many “night time economies”. In addition, (±)-MDMA is one of 
the recreational drugs widely used, and many of new psychoactive substances were 
synthesised and designed to mimic effects of (±)-MDMA and added in ‘ecstasy’ pills 
instead of the (±)-MDMA. (±)-MDMA used to enhance sociability and produces 
feelings of empathy or ‘being touched’ because it has the prototypical empathogen 
or entactogen activity (Morgan et al., 2013). In some studies, (±)-MDMA is used to 
increase emotional empathy, extroversion, trust, and sociality relatively (Hysek et 
al., 2014). 
 
The term ‘ecstasy’ is commonly used to refer to (±)-MDMA, but a number of 
different amphetamine derivatives, and other drugs may be present in ‘ecstasy 
tablets’. The majority of ‘ecstasy’ product contains another related chemical such as 
3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxyethamphetamine 
(MDEA), (±)-PMA and methamphetamine, amphetamine, or sometimes another 
type of drug like ketamine, ephedrine and over-the-counter painkiller (Cole et al., 
2002; Soares et al., 2004).   
 
1.5.1.2 (±)-Paramethoxyamphetamine [(±)-PMA] 
(±)-PMA is one of the monomethoxy derivatives of amphetamine [para-(4)-
phenyl-substituted (serotonergic) amphetamines] (Figure 1.3e) (Dargan and Wood, 
2013). (±)-PMA is typically sold as ‘ecstasy’ although; its substitution for (±)-MDMA 
is unwanted because (±)-PMA is associated with higher morbidity and mortality 
particularly attributable to hyperthermia (Paton et al., 1975; Martin, 2001; Lurie et 
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al., 2012). In addition, this para-substituted amphetaminehad hyperthermic 
properties which are stronger than those of (±)-MDMA (Daws et al., 2000) and 
associated with serotonergic and adrenergic receptor activation (Carmo et al., 
2003). Therefore, hyperthermic complications are of particular concern when the 
amphetamines or new psychoactive substances with a comparable 
pharmacological profile are used (Simmler et al., 2014).  
 
In addition, (±)-PMA is structurally related to phenethylamine and acts on the 
CNS producing mood enhancement, heightened sexual arousal and energy by 
increasing the release of intra-synaptic serotonin and inhibiting its reuptake resulting 
in hyperthermia (i.e. serotonin syndrome). Animal models suggest that (±)-PMA is 
more toxic than (±)-MDMA (Paton et al., 1975; Martin, 2001; Caldicott et al., 2003). 
 
1.5.1.3 Pharmacological activity of synthetic amphetamine and its derivatives 
All of the novel psychoactive drugs have the same psychostimulants of 
cocaine, amphetamine and (±)-MDMA, although with differences in their 
psychological effects. The prototypical psychostimulant of amphetamine produces 
agitation, insomnia, and loss of appetite, and produces amphetamine psychosis that 
is characterised by paranoia, hallucinations and delusions at high doses. (±)-MDMA 
and ‘ecstasy’ have both properties of a psychostimulant effect leading to euphoria 
and an intense love of self and others. It is described as an ‘empathogen’ (Iversen, 
2008; Iversen et al., 2014). There is the difficulty of a clear distinction between 
‘empathogen’ and ‘psychostimulants’. The amphetamines, (±)-MDMA and (±)-PMA 
designer drugs’ act by increasing extracellular levels of the monoamines dopamine 
(DA), serotonin (5-HT) and noradrenaline (norepinephrine) (NE) (Iversen et al., 
2014). Many new/novel psychoactive substances have interacted with 
neurotransmitter transporters.  
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Amphetamine and its derivatives including methamphetamine and (±)-MDMA 
decrease the dopamine (DAT), serotonin (SERT) and noradrenaline 
(norepinephrine; NET) transporters and release these monoamines through their 
respective transporter. Methamphetamine predominantly increases dopamine and 
noradrenaline, but (±)-MDMA mostly increases serotonin, noradrenaline, and 
oxytocin (Hysek et al., 2014; Hysek et al., 2012; Liechti, 2015). (±)-MDMA has the 
entactogenic effects dependent on its serotonergic effects (Liechti, 2015). 
 
Consequently, all substances releasing serotonin, similar to (±)-MDMA, can be 
expected to produce (±)-MDMA -like entactogenic effects. (±)-MDMA and these 
substances are also associated with serotonergic toxicity including serotonin 
syndrome, hyponatremia, hyperthermia, and seizures (Liechti et al., 2005; Simmler 
et al., 2011; Liechti, 2015). In contrast, methamphetamine, is a psychostimulants 
andmostly enhances dopaminergic neurotransmission (Simmler et al., 2013a; 
Simmler et al., 2013b). 
 
1.5.2 Synthetic cathinones 
Synthetic cathinone’s are a subgroup of NPS  structurally derived from 
cathinone (Figure 4.1 a).Cathinone is the principal active ingredient in the Khat plant 
(Catha Edulis)(Kalix and Braenden, 1985). In addition, cathinone and its derivatives 
are structurally related to the phenethylamine family such as amphetamine (Figure 
4.1b). Most people who use Khat mainly within the East African and Arabic 
peninsula, chew the fresh leaves to ingest the principal natural ingredient, 
cathinone, to produce a psychostimulatory effect. The natural monoamine alkaloids, 
cathinone, and norephedrine are present within the fresh leaves (Kalix, 1981; Litman 
et al., 1986; Al-Motarreb et al., 2002).  
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Figure 1.4The relationship between the cathinone (a) and amphetamine (b). 
 
 
In the early 1980s, Khat use was prominent in some countries and can be 
considered the forerunner of the ‘designer drugs’ phenomenon, which developed in 
the 1990s. The seriousness of the use of this plant recreationally led the World 
Health Organization (WHO) to classify Khat as a drug of abuse with the ability to 
produce mild-to-moderate psychological dependence (Neville, 1995). Since the late 
1990s, with the increase in restrictions on the supply and production of recreational 
amphetamines and designer drugs, such as (±)-MDMA, clandestine drug 
manufacturers began seeking ‘legal alternatives to fill the void on the club market. 
Although the initial motivation was probably to drive the development of novel 
psychoactive agents and sidestep drug laws, it did not take long for a broad range 
of products enter the recreational drug market (Neville, 1995).   
 
The popularity of these drugs has grown. One of the most prominent classes 
are the synthetic cathinone’s, leading to sensationalised media attention. In addition 
to the wide availability of these products through the internet, synthetic cathinone’s 
have been marketed under some different guises including legal highs, bath salts or 
plant food and are usually labelled as ‘not for human consumption’ to circumvent 
drug legislation. Since the early 2000s, these recreational drugs have appeared on 
the European market with unregulated ring-substituted cathinone derivatives, such 
as (±)-mephedrone ( Figure 1.5a) (Santali et al., 2011), (±)-4-MEC; Figure 1.5b) (Gil 
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et al., 2013; Santali et al., 2011) , (±)-flephedrone ((±)-4-FMC; Figure 1.5c) (Prosser 
and Nelson, 2012) and (±)-mexedrone (Figure 1.5d) (Gillman, 2005). International 
legislation regarding synthetic cathinone derivatives are now in place, for example, 
cathinone’s are illegal in the UK, Germany, and many others countries (Fass et al., 
2012; Morris, 2010).  
 
The EMCDDA) Early Warning System (EWS) has reported the seventy-four 
new synthetic cathinones between 2005 and 2014, with 30 synthetic cathinones 
detected in 2014 alone. The development of methods for their detection and 
quantification is timely and urgently required. 
 
This project focuses on three synthetic cathinones, which are (±)-mephedron, 
(±)-4-MEC, and (±)-mexedrone and the application of new analytical methods for 
their detection and quantification. 
 
 
Figure 1.5The chemical structure of cathinone (a), (±)-mephedrone (b), (±)-4-MEC (c), and 
mexedrone (d). 
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1.5.2.1 (±)-Mephedrone [(±)-4-MMC] 
The most infamous synthetic cathinone, which has appeared since 2000, is 
(±)-mephedrone which was first reported in 1929 and was little more than a chemical 
footnote before its rediscovery, by recreational users, in the mid-2000s. (±)-
mephedrone is a substituted methcathinone, with a degree of divergence from the 
parent molecule that has been found in NPS products such as Benzo Fury, Afghan 
incense, NRG-1 and NRG-2 (Smith et al., 2015). 
 
 Subsequent media reports about incidents of fatalities through the alleged use 
of this material across many countries led to the UK, Germany, Sweden, Ireland, 
Denmark and Norway, Israel and United States to legislate and control this 
substance (McElrath and O'Neill, 2011; Kelly, 2011). In the UK, an online survey of 
1006 secondary school, college, and university students in February 2010, indicated 
that 20.3% had tried (±)-mephedrone at least once (Dargan et al., 2010). In the US, 
it has enjoyed similar growth in popularity. In 2009, no calls reporting bath salt 
overdoses were received by the poison control centres, but about 303 calls were 
fielded in 2010, and in 2011 there were about 5625 calls received (Winstock et al., 
2010).  
 
1.5.2.2  (±)-4-Methylethcathinone [(±)-4-MEC] 
(±)-4-MEC [(±)-4-methyl-N-ethylcathinone] is derived from cathinone. Its 
effects are very similar to (±)-mephedrone, but it is apparently not as euphoric, has 
a shorter duration and is less potent than (±)-mephedrone (Brandt et al., 2010). In 
2010, (±)-4-MEC was available for sale over the internet as ‘NRG-2’ (Brandt et al., 
2010; Gil et al., 2013), but now all cathinone derivatives are banned. 
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 (±)-4-MEC appeared  as an alternative product following the ban on (±)-
mephedrone in June 2010 (Gil et al., 2013). It was detected in powder form in both 
Hungary and the United Kingdom (Jankovics et al., 2011; Gil et al., 2013). In 2011, 
the Institute of Forensic Research (IFR, Poland) reported that (±)-4-MEC was the 
most prevalent substitute of (±)-mephedrone in Poland (Gil et al., 2013). (±)-4-MEC 
has often been described as a ‘legal replacement for (±)-mephedrone’, ‘mephedrone 
– new formula’ or ‘modified mephedrone’ – suggesting similar psychoactive action. 
The UK introduced a broad ban through an amendment of the MDA 1971 on all 
substituted cathinones, including (±)-4-MEC in April 2010 (Ayres and Bond, 2012).  
 
People are aware that the these substanceslabelled with ‘not for human use’,  
are ‘legal highs’ and sold not only as a sole compound but also as mixtures with 
other psychoactive substances, especially substituted cathinones such as  3',4'-
methylenedioxy-α-pyrrolidinobutyrophenone (MDPBP) and 3,4-methylenedioxy-
pyrovalerone (MDPV), and rarely with 4'-methyl-α-pyrrolidinopropiophenone 
(MPPP), pentylone, benzedrone, and other substances. There is little available 
information on the effects of (±)-4-MEC, but it appears to be less potent than most 
other cathinones. The effects of (±)-4-MEC include excitation, gentle euphoria, 
mood elevation, relaxation, feeling of bliss, empathy, increased tactile and musical 
appreciation (Gil et al., 2013).  
 
1.5.2.3 (±)-Mexedrone  
(±)-Mexedrone [3-methoxy-2-(methylamino)-1-(4-methylphenyl) propane-1-
one.hydrochloride], is a (±)-mephedrone derivative created by adding an alpha-
methoxy to the (±)-mephedrone structure. The effect of (±)-mexedrone is to inhibit 
the re-uptake of serotonin and dopamine, depending on the dose, and it has an 
21 
 
affinity for serotonin and dopamine membrane transporters and receptors (5-HT2 
and DA2 receptors), producing similar sympathomimetic effects to amphetamines 
(Gillman, 2005). To date ,mexedrone use has rarely been analytically confirmed 
(Gillman, 2005). However, mexedrone has a weak releasing activity at the serotonin 
transporter (SERT) and is a weak non-selective uptake blocker at the dopamine 
transporter (DAT) and norepinephrine transporter (NET). 
 
1.5.2.4 Pharmacological activity of synthetic cathinone derivatives 
Pharmacologically, cathinone is classed as stimulant. However, it is significantly 
less potent than amphetamine, despite having structural similarities to the 
phenethylamine family i.e. cathinone (Figure 1.4a) contains a β-keto group adjacent 
to the aromatic ring of amphetamine (Figure 1.4b) (Al-Motarreb et al., 2002; Kalix, 
1996). The presence of the β-keto group in the cathinone derivatives increases the 
polarity of the synthetic cathinones and results in a decrease in their ability to cross 
the blood-brain barrier (BBB). Therefore, their psychostimulatory (CNS stimulant 
and sympathomimetic) effects have been shown to be markedly lower than their 
closest relatives, the amphetamines (Schifano et al., 2011; Valente et al., 2014; 
Kalix, 1992; Kalix, 1983; Kalix and Braenden, 1985). 
 
The presence of the α-methyl group in the phenylethylamine side chain 
prevents the metabolism and inactivation of cathinones through monoamine 
oxidase (MAO), and they have been shown to inhibit this enzyme (Siegel and 
Agranoff, 1999). Furthermore, cathinones strongly inhibit MAO to a greater extent 
than amphetamine (Nencini et al., 1984) and have been shown to be more selective 
toward the isoenzyme MAO-B (Osorio-Olivares et al., 2004; Simmler, 2018). 
Cathinones are more lipophilic than their corresponding metabolites and are 
believed to be able to penetrate the CNS more effectively (Kalix, 1991). However, 
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with the lack of in vivo studies, many of the conclusions drawn are anecdotal and 
resort to comparisons with illicit drugs with similar subjective effects and chemical 
structures (i.e. cocaine, amphetamines, and (±)-MDMA) (Carvalho et al., 2012). In 
the central nervous system, it is believed that the main effects of cathinone are  to 
increase the release of the dopamine, noradrenaline, and serotonin (Kalix and 
Braenden, 1985; Gibbons and Zloh, 2010) in a similar way that amphetamine, 
methamphetamine and (±)-MDMA exert their CNS activities (McElrath and O'Neill, 
2011; Carhart-Harris et al., 2011; Hadlock et al., 2011). 
 
If a synthetic cathinone is taken orally, for example (±)-mephedrone, the effects 
will appear within 15–45 minutes; but if administered intranasal, the effects start 
within a few minutes, producing a maximum effect within half an hour and will last 
between two and three hours. Other reported effects include euphoria, increased 
sexual stimulation, sociability and re-dosing (Brunt et al., 2011). In same survey 
(February 2010), 947 of (±)-mephedrone users who reported that they had 
previously used cocaine; 20.4% said the effects of (±)-mephedrone, were as 
rewarding as cocaine with 54.6% reporting that (±)-mephedrone effects were 
significantly better (Winstock et al., 2011). 
 
In 2011, the US National Poison Information Service summarised this 
evidence and concluded that, (±)-mephedrone and its derivatives may have 
significant effects on:  
(i) The cardiovascular system (e.g. palpitations, tachycardia, arrhythmias, 
hypertension, and hot flushes). 
(ii) The central nervous system (e.g. headaches, light-headedness, dizziness, 
tremors, convulsions, loss of concentration, and memory loss). 
(iii) The gastrointestinal system (e.g. abdominal pain, nausea and vomiting). 
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(iv) The respiratory system (e.g. chest pain and respiratory difficulties).  
Nasal insufflation of (±)-mephedrone has been reported to be associated with 
significant nasal irritation and pain, which has led to some users switching to the 
oral use of (±)-mephedrone. The long-term effects of (±)-mephedrone are currently 
unknown (EMCDDA, 2010). 
 
1.5.3 Dissociative anaesthetics (regioisomers of methoxyephenidine and 
fluoroephenidine) 
In 2008, ephenidine appeared on the NPS scene together with 
isopropylphenidine (NPDPA) (another leftamine derivative) as reported by the 
German police (Beharry and Gibbons, 2016). In some countries, ephenidine is 
illegal as a structural isomer of the banned opioid drug lefetamine (Wink et al., 2014; 
Wink et al., 2015).  
 
Phencyclidine (PCP) and ketamine were developed as potential general 
anaesthetics (Greifenstein et al., 1958; Kang et al., 2017). Both were globally 
abused for their dissociative effects (Kang et al., 2017). The misuse of  PCP has 
reduced in Europe because of severe and long lasting psychotomimetic effects, 
including lethality (Moeller et al., 2008). Interestingly, 1,2-diarylethylamines, e.g. 
ephenidine (Kang et al., 2017), diphenidine and 2-methoxydiphenidine are the most 
common structures, like phencyclidine (Morris and Wallach, 2014). 
 
In 2013, the UK controlled all arylcyclohexylamines under the MDA (1971) in 
an attempt to decrease the spread of novel PCP and ketamine derivatives (NPS 
class).The dissociative diarylethylamines (Table 1.3a) are not new compounds, 
being orginally synthesised as far back as 1924.They have appeared on the NPS 
market as crystal or powder ephenidine (Beharry and Gibbons, 2016). 
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In addition, ephenidine (Table 1.3b) is a diarylethylamine and synthesised 
recently to become popular with recreational users for its dissociative hallucinogenic 
effect (Kang et al., 2017). Recent studies show that the new psychoactive 
substance, ephenidine, is a selective NMDA receptor antagonist with a voltage-
dependent profile similar to phencyclidine (PCP) and ketamine. Such properties 
help explain the dissociative, cognitive and hallucinogenic effects in man (Kang et 
al., 2017). Ephenidine [N-ethyl-1, 2-diphenyl ethylamine; NEDPA; EPE] is 
dissociative anaesthetic which ellicits activity by antagonizing (inhibiting) N-methyl-
D-aspartate (NMDA) receptors. It has been used as an anaesthetic drug for animals 
and humans, therefore, ephenidine’s action is referred to as ‘dissociative 
anaesthesia’ and used as a recreational drug (Morris and Wallach, 2014). 
 
Table 1.3 shows the chemical structure of the ephenidine derivatives 
methoxyephenidine and fluoroephenidine and their regioisomers, (2-
methoxyephenidine (Table 1.3c), 3-methoxyephenidine (Table 1.3d), 4-
methoxyephenidine (Table 1.3e), 2-fluoroephenidine (Table 1.3f), 3-
fluoroephenidine (Table 1.3g), and 4-fluoroephenidine (Table 1.3h). 
 
There is littile information reported in the literature about the derivatives of 
ephenidine and  their regioisomers, however, the pharmacological effect of 
ephenidine and ephenidine derivatives and its regioisomers are likely to be similar 
as they have the same backbone of chemical structure (Table 1.3). 
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Table 1.3 Chemical structure of ephenidine, lefetamine, 2-MEP, 3-MEP and 4-MEP,   2-FEP, 3-
FEP and 4-FEP. 
 
Compound R1 R2 R3 R4 R5 
Lefetamine  CH3 CH3 H H H 
Ephenidine  H CH2CH3 H H H 
2-MEP  H CH2CH3 O-CH3 H H 
3-MEP  H CH2CH3 H O-CH3 H 
4-MEP  H CH2CH3 H H O-CH3 
2-FEP  H CH2CH3 F H H 
3-FEP  H CH2CH3 H F H 
4-FEP H CH2CH3 H H F 
 
1.5.3.1 Pharmacological effect of ephenidine (synthetic diarylethylamine) 
and its derivatives 
Dissociative anaesthetic substances including ketamine, PCP, and 
dextromethorphan produce feelings of detachment and induce a state of 
anaesthesia by antagonising ionotropic N-methyl-D-aspartate receptors (NMDAR) 
in the central nervous system (Morris and Wallach, 2014). One of the most recent 
classes of NMDAR antagonists to emerge on the NPS market are the 
diarylethylamines, e.g. diphenidine (Wallach et al., 2015), and 2-methoxphenidine 
(McLaughlin et al., 2016).  
 
The pharmacological effect of ephenidine (and its derivatives) and its neural 
actions were investigated by assessing its effect on central nervous system receptor 
in targeted electrophysiological studies(Kang et al., 2017). The ephenidines also 
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showed modest activity at dopamine and noradrenaline transporters and at sigma 
1 and sigma two binding sites (Kang et al., 2017). 
 
Ephenidine has mild psychedelic effects, inducing fear (Beharry and Gibbons, 
2016). Recently, ephenidine became available and anecdotally appears popular 
with dissociative users (e.g. an alternative to ketamine). In the previous study 
comparison of ephenidine and ketamine showed that ephenidine is a relatively 
selective, voltage-dependent NMDA antagonist,explaining the psychotomimetic 
effects of ephenidine and predicts the side-effects including memory impairment 
(Kang et al., 2017).  
 
1.6 Analytical techniques for the detection of NPS 
There is an increasing interest in the study and development of rapid, selective, 
and sensitive methods for the identification and quantification of phenethylamines, 
synthetic cathinones, dissociative anaesthetic substances and their derivatives in 
seized samples and biological fluids. Numerous studies have demonstrated the 
analysis of NPS drugs and described the significant improvements in analytical 
methods for analysis of the drugs in biological specimens (Table 1.4). 
 
In the literature, there are currently no validated methods reported for each of 
the (±)-Mexedrone or for the regioisomers of methoxyephenidine or 
fluoroephenidine. McLaughlin et al. reported the GC-MS and HPLC-MS separation 
for (±)-Mexedrone but without validation information The regioisomers of 
methoxyephenidine and fluoroephenidine have not been not reported in the 
literature because they are new substances (McLaughlin et al., 2017). 
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The separation, identification and quantification of NPSs in biological samples 
have been described using, for example, high performance liquid chromatography 
(HPLC) (Butler and Guilbault, 2004; Kumihashi et al., 2007) or gas chromatography 
(GC) (Dams et al., 2003), capillary electrophoresis (Nieddu et al., 2007) and 
electrochemistry techniques (Smith et al., 2014b; Cumba et al., 2016; Michel et al., 
1993) and other analytical techniques. The chromatography technique is the most 
commonly used methodology for the separation of NPS and the recreational drug 
(±)-MDMA) (Butler and Guilbault, 2004; Kumihashi et al., 2007; Garrido et al., 2010). 
Liquid chromatography with UV spectrometry (Soares et al., 2004; Khreit et al., 
2012), diode array detector (DAD) (de Figueiredo et al., 2010),  mass spectrometry 
(Lee, 2013; Saito et al., 2011; Arora et al., 2016; Xiang et al., 2015; Brandt et al., 
2010; Jankovics et al., 2011) and gas chromatography (Saito et al., 2011; Arora et 
al., 2016) with mass spectrometry have been widely used. 
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Table 1.4 Analytical methods currently reported in the literature for the detection of New Psychoactive Substances and recreational drugs. 
Analyte Analytical method Matrix Analytical, linear range Limit of detection References 
MDMA HPLC-UV urine 4.2-150.0 µg mL-1 84.0 µg mL-1 (Soares et al., 2004) 
MDMA HPLC-DAD Potassium phosphate buffer: acetonitrile (90:10 
v/v) pH = 3.2±0.02 
1.4-111.0 µg mL-1 1.0 µgmL-1 (Muller and Windberg, 2005) 
PMA HPLC-DAD Potassium phosphate buffer: acetonitrile (90:10 
v/v) pH = 3.2±0.02 
N/A N/A (Muller and Windberg, 2005) 
PMA Capillary electrophoresis with 
diode array 
Plasma 
Urine 
50.0-5000.0 ng mL-1 20.92 ng mL-1 
24.26 ng mL-1 
(Nieddu et al., 2007) 
MDMA HPLC-DAD Methanol: water (90:10 v/v) 5.0-100.0 ppm 2.94 ppm (de Figueiredo et al., 2010) 
MDMA fluorescence 
HPLC-chemiluminescence 
Plasma 
Hair root 
Hair shaft 
0.01-1.0 ng mL-1 
0.10-10.0 ng mL-1 
0.10-10.0 ng mL-1 
3.0 ng mL-1 
17.0 ng mL-1 
14.0 ng mL-1 
(Wada et al., 2012) 
MDMA Square wave voltammetry Supporting electrolytes  
Human serum 
8.0-45.0 µM 
12.0-45.0 µM 
1.2 µM 
2.4 µM 
(Garrido et al., 2010) 
MDMA Cyclic voltammetry – dip coating/ 
spin coating 
KCl (0.1 mol L-1) 4.2-48.0 µmol L-1 3.5/2.7 µmol L-1 (Tadini et al., 2014) 
MDMA 
PMA 
MDMA/PMA 
Electrochemical analysis (cyclic 
voltammetry-dip coating/spin 
coating)  
Potassium phosphate buffer and KCl (0.1 mol L-
1): acetonitrile) (90:10 v/v) pH = 3.2±0.02 
0.50-4.98 µg mL-1 
0.50-4.98 µg mL-1 
2.0-19.60 µg mL-1 
0.04 µg mL-1 
0.03 µg mL-1 
0.25 µg mL-1/ 0.14 
µg mL-1 
(Cumba et al., 2016) 
MDMA 
PMA 
MDMA/PMA 
HPLC-UV Potassium phosphate buffer acetonitrile (90:10 
v/v) pH = 3.2±0.02 
0.50-4.98 µg mL-1 
0.50-4.98 µg mL-1 
 
0.04 µg mL-1 
0.08 µg mL-1 
 
(Cumba et al., 2016) 
MA HPLC-FL Plasma 
Hair  
1.49-746 ng mL-1 
0.149-149.2 ng mL-1 
0.87 ng mL-1 
0.12 ng mL-1 
(Nakashima et al., 2003) 
4-MEC 
 
LC–MS/MS Acetonitrile: Water: formic acid (50:50:1%)  2.0 ng mL−1 (Jankovics et al., 2011) 
4-MMC HPLC-UV Methanol:10 mM ammonium formate (40:60 v/v) 
pH = 3.5±0.02 
0.5-10.0 µg mL-1 0.09 µg mL-1 (Santali et al., 2011) 
4-MMC 
4-MEC 
HPLC-UV Methanol:10 mM ammonium formate (46:54 v/v) 
pH = 3.5 
0.5-10.0 µg mL-1 0.03 µg mL-1 
0.03 µg mL-1 
(Khreit et al., 2012) 
4-MMC 
4-MEC 
Electrochemistry  
(electrochemical oxidation) 
Phosphate buffer solution (pH = 2) 16–350 mg mL-1 39.8 µg mL-1 
84.2 mg mL-1 
(Smith et al., 2014a) 
4-MEC HPLC-DAD Acetonitrile: water (containing 100 mL 85% 
orthophosphoric acid per 1 L) 
200-400 ng mL-1 0.5 % (Gil et al., 2013) 
4-MEC LC-MS/MS Blood 
Urine 
10-1000 ng mL-1 0.96 ng mL-1 
0.68 ng mL-1 
(Gil et al., 2013) 
4-MEC LC-MS/MS Hair 1-1000 pg mg-1 0.5 pg mg-1 (Alvarez et al., 2017) 
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1.6.1 The principle of chromatography 
In pharmaceutical analysis, chromatography is the most frequently analytical 
technique. For example, liquid chromatography with UV spectroscopy (LC-UV) has 
gained more and more popularity for drug analysis because it is generally faster, 
easy to use and has good sensitivity and specificity (Soares et al., 2004; Khreit et 
al., 2012) compared to other analytical techniques. 
 
The fundamental purpose of chromatography is to separate compounds in 
complex mixtures of individual components using a variety of interactions on the 
surface of an adsorbent. The process of separation depends on the mobile phase, 
which can be a liquid, or a gas phase and a stationary phase which can be solid or 
liquid. Furthermore, affinity is a measure of the strength of the interaction between 
the stationary phase and the components in the dissolved mobile phase. The 
stronger the interaction, the higher the affinity of the analyte to the stationary phase 
and the longer the retention time (Kazakevich and Lobrutto, 2007) . 
 
1.6.1.1 High performance liquid chromatography 
High performance liquid chromatography is the most valuable tool used for 
quality control in the pharmaceutical industry. HPLC-UV is a technique to separate 
mixtures of substances into their components based on their molecular structure 
and molecular composition (Kazakevich and Lobrutto, 2007). This involves a 
stationary phase (a solid) and a mobile phase (a liquid). The mobile phase flows 
through the stationary phase and carries the components of the mixture with it. 
Sample components that display stronger interactions with the stationary phase will 
move more slowly through the column than components with weaker interactions. 
This difference in rates causes the separation of the various components. The 
sample is introduced into the mobile phase flow through an injector. HPLC columns 
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contain the stationary phase. The different types of stationary phase include C18 
(octadecylsilyl) which is the most widely used (c. 90% of chromatographic 
applications) (Figure 1.6). In this study, reverse phase HPLC was used, in which the 
stationary phase is nonpolar (hydrophobic) in nature, while the mobile phase is a 
polar liquid, such as mixtures of water and methanol or acetonitrile. It works on the 
principle of hydrophobic interactions, hence the more nonpolar the analyte is, the 
longer it will be retained on the column and the longer it will take to elute. 
 
 
 
Figure 1.6 High Performance Liquid Chromatography diagram 
 
Muller and Windberg described the HPLC method for the quantitation of the 
(±)-MDMA in the presence other (±)-MDMA derivatives and adulterants 
(amphetamine, ephedrine, metamphetamine, phentermine, MDE, PMA, 
paramethoxymetamphetamine (PMMA) and caffeine).  In most cases the MDMA 
derivatives (or caffeine) were fully resolved from (±)-MDMA, however, samples 
containing PMMA were unable to be discriminated using the method and required 
secondary confirmation using GC-MS. (±)-MDMA linearity and accuracy were 
confirmed, and the precision was acceptable for routine testing of bulk samples 
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(Muller and Windberg, 2005). Cumba et al. used HPLC-UV for the detection and 
quantification of (±)-MDMA in the presence of (±)-PMA and reported the 
development and validation of the analytical method (Cumba et al., 2016).  
 
In addition, Santali et al. reported for the first time the fully validated 
chromatographic methods for the detection and quantitative analysis of (±)-
mephedrone in its pure form, and the presence of a number of common adulterants 
used in illicit drug manufacture (Santali et al., 2011). In 2012, Khreit et al. presented 
full synthetic and chemical characterisation data for the two (±)-mephedrone 
derivatives (±)-4-MEC and 4′-methyl-N-benzylcathinone (4-MBC) which have been 
identified in purchased NRG-2 samples. Khreit et al. described for the first time the 
fully validated chromatographic methods for the detection and quantitative analysis 
of (±)-mephedrone derivatives in their pure form, and the presence of adulterants 
used in illicit drug manufacture (Khreit et al., 2012). McLaughlin et al. reported the 
analysis of (±)-Mexedrone using HPLC-MS but did not present the limit of detection 
and limit of quantification (McLaughlin et al., 2017). However, in the literature there 
are no reported analytical methods for analysis of the regioisomers of 
methoxyephenidine and regioisomers of fluoroephenidine. 
 
Principally, the detection by UV-visible and fluorescence spectroscopy and 
mass spectrometry have been utilised with liquid chromatography (Honeychurch, 
2016). The UV-visible and fluorescence spectrometry methods are based on the 
absorbance of light. Liquid chromatography combined with mass spectrometry is 
widely used in industry and forensic analysis. LC-MS is extremely selective and 
sensitive and can be successfully used for a wide range of analytes (Honeychurch, 
2016). However, it is relatively expensive and suffers from issues with selectivity 
resulting from ‘isobaric’ interferences and unpredictable ion yield attenuations from 
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‘ion suppression effects’ (Seger, 2012). Nevertheless, these issues can be 
overcome by using deuterated internal standards, however, these can be 
expensive.  
 
1.6.2 Electrochemistry 
Electrochemical techniques are powerful analytical techniques that have high 
sensitivity, accuracy, precision and relatively inexpensive instrumentation. These 
techniques are more regularly used in the pharmaceutical industry for drug analysis 
in their dosage forms and forensic science for the analysis of biological samples 
(Farghaly et al., 2014). The concept of most electroanalytical techniques is based 
on continuously changing the applied potentials on the electrode-solution interface 
and the resulting measured current (Uslu and Ozkan, 2011; Farghaly et al., 2014). 
Most of the chemical compounds have electrochemical activity (Farghaly et al., 
2014). Voltammetry is based on the relation between the potential, current and time. 
This relationship could be explained when the applied potential (E) serves as a 
driving force for the reaction (reduction or oxidation reactions) on the working 
electrode and records the resulting current (i) flowing through the electrochemical 
cell over a period (t) (Farghaly et al., 2014). Cyclic voltammetry and amperometry 
are electroanalytical techniques that are widely used for the analysis of NPSs and 
other pharmaceutical compounds (Smith et al., 2014b; Zuway et al., 2015; Waddell 
et al., 2017). 
 
Cyclic voltammetry (CV) is widely used for the study of reduction-oxidation 
reactions, and a rapid voltage scan technique with reversed direction of voltage 
scan. While the potential is applied to the working electrode in both forward and 
reversed directions, the resulting current is recorded (Farghaly et al., 2014). Cyclic 
voltammetry has previously been used for the analysis of NPSs. Smith et al. used 
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CV for the analysis of the cathinone derivatives such as (±)-mephedrone and (±)-4-
MEC) but could not discriminate between them (Figure 1.7A) (Smith et al., 2014a). 
Also, Cumba et al. used CV for the differentiation of MDMA and PMA in mixtures 
(Figure 1.7B) (Cumba et al., 2016).  
 
 
Figure 1.7The cyclic voltammetry for cathinone derivatives (A) (Smith et al., 2014a) and cyclic 
voltammetry to differentiate between MDMA and PMA (B) (Cumba et al., 2016). 
 
 
Amperometry is used by applying a constant potential to the working 
electrode and measuring the current as a function of time. In addition, the 
amperometric measurement depends on recording the current flow in the flow cell 
at a single applied potential (Stradiotto et al., 2003). Recently, several types of 
disposable electrochemical sensors have been developed. Screen-printed 
electrodes (SPEs) have offered high-volume production of extremely inexpensive, 
and yet highly reproducible and reliable single-use sensors (Ochiai et al., 2017). 
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Graphite screen-printed electrodes have received significant consideration in recent 
years due to their simplicity, efficiency, speed, cost-effectiveness and disposability 
(Cumba et al., 2015). They offer a reproducible and reliable sensor platform for 
amperometric detection for target analytes (Zuway et al., 2015).  
 
The detection of illegal drugs at low concentrations can be carried out using 
voltammetry techniques. These techniques can be quite selective, quantitative and 
low-costand have been used in the determination of cocaine (Ribeiro et al., 2016; 
de Oliveira et al., 2013), as well as (±)-MDMA; ‘ecstasy’ (Balbino et al., 2016; Tadini 
et al., 2014; Cumba et al., 2016; Garrido et al., 2010). 
 
A comparison between the detection limits reported for HPLC-MS, HPLC-ED, 
and HPLC-UV for several drugs of abuse are shows in Error! Reference source 
not found.. For a number of compounds, detection limits of the HPLC-ED technique 
are better; however, as a general approach LC-MS is a better technique across the 
range of analytes investigated. Liquid chromatography combined with UV detection 
(LC-UV) is simple, reliable and can be gained using various wavelength by using 
diode array detection (DAD) where spectra can be obtained for each eluting peak. 
LC-ED offers, in some cases, better detection limits and is considerably less 
expensive than LC-MS (Honeychurch, 2016). However, the limitation of HPLC-ED 
is its being affected by fouling of the electrodes leading to loss of sensitivity. In 
addition, the presence of oxygen in the mobile phase can be an issue, but this can 
be overcome by degassing. 
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Table 1.5 Comparisons between LC-ED, LC-MS, and LC-UV for analysis of abused drugs. 
Analyte 
LC-ED 
µg mL-
1 
Ref. 
LC-MS 
µg mL-1 
Ref. 
LC-UV 
µg mL-
1 
Ref. 
THC 0.5 
(Nakahara et al., 
1989) 
1.0 
(Hudson et 
al., 2013) 
0.746 
(de 
MenezesA 
et al., 2012) 
Methadone 9×10-4 
(Somaini et al., 
2011) 
1×10-4 
(Liu et al., 
2015) 
/ / 
Morphine 5×10-4 
(Masui et al., 
1968) 
5×10-4 
(Liu et al., 
2015) 
0.01 
(Masui et 
al., 1968) 
Codeine 0.024 
(Huettl et al., 
1999) 
1×10-3 
(Liu et al., 
2015) 
6×10-3 
(He et al., 
1998) 
Amphetamine <0.05 
(Santagati et al., 
2002) 
25×10-5 
(Liu et al., 
2015) 
0.1 
(Moeller et 
al., 1998) 
Rohypnol 0.02 
(Honeychurch 
and Hart, 2008) 
2×10-4 
(Bogusz, 
2000) 
0.03 
(Borges et 
al., 2009) 
Nitrozepam 0.1 
(Honeychurch et 
al., 2006) 
125×10-
5 
(Glover and 
Allen, 2010) 
/ / 
 
This technique has been used for analysis a wide range of abused substances, 
including cannabinoids, ethanol, opiates, morphine, and benzodiazepines. The 
target analytes are separated chromatographically depending on their interactions 
with the stationary phase (column) and mobile phase. Different electrochemical 
detector systems have been utilised; including conductivity, potentiometric, 
amperometry and coulometry (Honeychurch, 2016). One of the most common 
electrochemical detection modes employed is amperometry which is based on the 
analyte being oxidised or reduced at the electrode interface (Honeychurch, 2016). 
The current formed from the redox reaction is linearly related to the concentration 
of the analytes and can therefore be used for the quantification of the analytes. In 
amperometric detection, the analytes flow over the surface of the working electrode 
(Honeychurch, 2016).  
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1.6.3 Application of high performance liquid chromatography-
electrochemical detection (HPLC-D) 
 
 
Table 1.6 details published studies where the use of HPLC-AD was reported. 
Nakahara et al. used HPLC-ED for the highly sensitive and simultaneous 
determination of free cannabinoids and cannabinoid acids without derivatisation in 
marijuana cigarettes and in tar and ash obtained by using an automatic smoking 
machine (Nakahara and Sekine, 1985). The linear range was 5 to 500 
ng/injection for all cannabinoids and the LOD of this method was 0.5-0.9 
ng/injection for free cannabinoids and 1.2-2.5 ng/injection for cannabinoid acids 
(Nakahara and Sekine, 1985).  
 
Nyoni et al. described a method for determining small quantities of Δ9-THC 
in rat brain tissue using a high performance liquid chromatography-electrochemical 
detector (HPLC-ED) (Nyoni et al., 1996). The solvent employed was methanol-
hexane-ethyl acetate, followed by HPLC-ED using a linear range up to 10 µg mL-1 
and the LOD was 1.5 ng mL-1 (Nyoni et al., 1996). 
 
In addition, Bourquin and Brenneisen utilised the reverse phase in HPLC-ED 
for analysis of urine to determine the metabolite of THC, 11-nor-Δ9-
tetrahydrocannabinol-9-carboxylic acid (II) (THC–COOH) (Bourquin and 
Brenneisen, 1987; ElSohly et al., 1983). Further investigations using HPLC-ED for 
the simultaneous determination of the pure synthetic form of THC which has been 
developed as the drug dronabinol by Kokubun et al. (Kokubun et al., 2014).  
Kokubun et al. developed a HPLC-amperometric method to investigate the 
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pharmacokinetics of dronabinol in cancer patients and its quantitation in blood 
(Kokubun et al., 2014). The calibration curve was linear in the range of 10-00 ng mL-
1,and the lower limit of quantification was 0.5 ng mL-1 (Kokubun et al., 2014).  
 
Sawyer et al. developed an HPLC-ED method for the analysis of morphine, 
heroin, and hydromorphone in post-mortem tissues. Whole blood, urine, or vitreous 
humours were assayed without pre-treatment. The LODs for extracted samples 
were reported to be 0.5 ng mL-1, 3.1 ng mL-1 and 12.5 ng mL-1 for morphine, 
hydromorphone and heroin respectively (Sawyer et al., 1988). 
 
The use of HPLC-ED was recommended for the determination of morphine in 
biological fluids for its high sensitivity (Tagliaro et al., 1989).   Xu et al. developed 
HPLC and amperometric determination of morphine in rat brain microdialysates. 
The amperometric detection of morphine was performed by using potential of +0.60 
V (vs Ag/AgCl),and a linear response for morphine was reported over the range 1.0 
× 10−6 - 5.0 × 10−4 M with a detection limit of 5.0 × 10−7 M (Xu et al., 2002) . 
Moreover, the determination of morphine using liquid chromatography with 
amperometric determination at a glassy carbon electrode was investigated by 
Jordan and Hart (Jordan and Hart, 1991).  They reported that the LOD for the 
morphine was 1.24 x 10-13 M over the linear range 1.2 x 10-12- 4.0 x 10-10 M of 
morphine injected (Jordan and Hart, 1991). The high-performance liquid 
chromatography with dual-electrode electrochemical detection has been 
successfully used in the redox mode to determine the benzodiazepine tranquilizer, 
Nitrazepam, in serum (Honeychurch et al., 2006). A large number of psychoactive 
compounds required a technique that was capable of separating, identifying and 
quantifying such compounds in complex samples. Min et al. reported a liquid 
chromatographic multichannel electrochemical detection (MECD) method for the 
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determination of 31 different tryptamines, phenethylamines and piperazines. These 
compounds were separated by using reverse phase HPLC (Min et al., 2010).  
 
Table 1.6 Analytical methods in the literature using high performance liquid chromatography-
electrochemical detection 
Analytes 
Technique 
HPLC-AD 
Referen
ce 
Electrod
e 
Matrix Linear range 
Limit of 
detection 
Ref. 
THC-COOH 
Amperomet
ric mode; 
+1.2 V 
Ag/AgCl Urine 25-300 ng mL-1 5 ng mL-1 
(ElSohly et 
al., 1983) 
∆ 9 -
Tetrahydrocannab
inol levels 
Amperomet
ric mode; 
+1.2 V 
Ag/AgCl 
Brain 
tissue 
Up to 10 
µg/mL 
1.5 ng on 
column 
(Nyoni et 
al., 1996) 
Cannabinoid 
contents 
Amperomet
ric mode; 
+1.2 V 
Ag/AgCl 
In 
marijua
na 
cigarett
es and 
tar and 
ash 
5-500 
ng/injection 
0.5 to 0.9 
ng/injection for 
free 
cannabinoids 
and 1.2 to 2.5 
ng/injection for 
cannabinoid 
acids 
(Nakahara 
and Sekine, 
1985) 
THC levels in 
patients given the 
drug dronabinol 
Amperomet
ric mode; 
+0.40 V 
Ag/AgCl Blood 10–100 ng/mL 0.5 ng/mL 
(Kokubun 
et al., 2014) 
Morphine 
Amperomet
ric mode; 
+0.60 V. 
Ag/AgCl 
Rat 
brain 
dialysat
es 
1.0 × 10−6-5.0 
× 10−4 M 
5.0 × 10−7 M 
(Xu et al., 
2002) 
Morphine 
Amperomet
ric mode; 
+0.45 V 
Ag/AgCl Serum 
1.2 × 10−12 - 4 
× 10−10 M 
1.24 × 10−13 M 
(Jordan 
and Hart, 
1991) 
Heroin, morphine 
and 
hydromorphone 
Amperomet
ric mode; 
+0.5 V 
Ag/AgCl 
Post-
mortem 
sample 
of whole 
blood, 
urine, or 
vitreous 
humour 
10 to 500 
ng/mL 
(morphine), 62 
to 1000 ng/mL 
(hydromorpho
ne), and 250 to 
2000 ng/mL 
(heroin) 
0.5 ng/mL 
(morphine), 
3.1 ng/mL 
(hydromorpho
ne), and 12.5 
ng/ mL 
(heroin) 
(Sawyer et 
al., 1988) 
Rohypnol 
(flunitrazepam) 
Dual 
amperomet
ric 
reductive-
reductive 
mode; 
electrode 1; 
−2.4 V and 
electrode 2; 
−0.2 V 
Stainless 
steel 
(generat
or cell); 
Ag/AgCl 
(detector 
cell) 
Bovine 
and 
human 
serum 
0.5–100 
mg/mL 
20 ng/mL 
(Honeychur
ch et al., 
2006) 
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1.7 Study aims and objectives 
The principle of basic analytical testing in a forensic science laboratory begins with 
receiving the drug sample(s) and then recording the physical description, evidential 
information (e.g. evidence bag number).  This allows the forensic scientist to fully 
document the sample and ensure tracability through the analytical processes. The 
bulk sample may be qualitatively tested to ascertain the type of substance present 
(i.e presumptive tests and/or instrumental analysis).  In some cases the substance 
may require quantitative analysis to determine the amount of the principle 
component  (or adulterants) which are present or trace analysis which may 
determine impurities and provide information on routes of manufacture (Cole, 2003).  
It the case of bulk samples, where potentially the ability to discriminate between 
either new substances or potentially regioisomers of a substance of concern, the 
need for robust and novel methods (though these may be extensions or new 
applications of existing technologies) are of interest to refine the capabilities within 
laboratory environments. The overall aim of this study is to develop novel 
applications of high performance liquid chromatography with amperometric 
detection (HPLC-AD) to the detection, analysis and quantification of controlled 
materials (for example: MDMA and mephedrone) and NPS (for example, 
regiosmeric methoxephedinines and fluoroephenidines) both in their pure form and 
in the presence of their derivatives or the common adulterants. The specific 
objectives are as follows:  
 
1. To design, develop and validate (using ICH guidelines) a HPLC-AD 
protocol for detection and quantification of the controlled substance (±)-MDMA 
in the presence of two other illicit amphetamines: MA and (±)-PMA.  The 
technique/protocol will be tested on seized samples (e.g. MDMA tablets) to 
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demonstrate its potential for forensic application towards rapid separation and 
detection of the principle components. 
 
2. To develop, optimise and validate (using ICH guidelines) a suitable 
method to discriminate between controlled N-alkylcathinones such as (±)-
mephedrone and (±)-4-MEC, which cannot be discriminated using other 
electrochemical analytical techniques (Smith et al., 2014a). The 
technique/protocol will be tested on seized bulk forensic samples of NRG-2, 
for the detection and quantification of the active components and levels of 
adulterants, and to demonstrate its potential application to the rapid forensic 
detection of these materials. 
3. Carry out full physical and chemical characterisation, using NMR, IR, UV and 
GC-MS analysis, of the synthetic cathinone-derivative, mexedrone.  Develop, 
optimise and validate (using ICH guidelines) an HPLC-AD protocol for the 
analysis of mexedrone (both in its pure form and in bulk forensic samples). 
 
4. Extend this HPLC-AD methodology to study the separation, detection and 
quantification of regioisomeric new psychoactive substances – namely 
methoxyephenidines and fluoroephenidines, which have recently emerged 
on the recreational market. The optimised method will be ICH validated and 
then tested against seized samples, obtained from law enforcement 
agencies, to determine its forensic application to the discrimination of 
regioisomeric substances. 
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2 Chapter 2: Materials and methods 
 
2.1 Chemicals 
All chemicals used in this project were of analytical grade, obtained from 
commercial sources (Sigma-Aldrich, Gillingham, UK and Alfa-Aesar Limited, 
Heysham, UK) and used without any further purification. Acetonitrile, methanol 
(HPLC grade) supplied by Fisher Scientific International Company (Loughborough, 
UK). All solutions were prepared with deionised water with resistivity not less than 
18.2 Ω cm, and vigorously degassed with nitrogen gas to remove all oxygen before 
the analysis. (±)-MDMA.HCl and (±)-MA.HCl were obtained, under Home Office 
licence, from Sigma-Aldrich (Gillingham, UK) and used without further purification. 
(±)-PMA.HCl was prepared in-house as described by Cumba et al. in previous work 
(Cumba et al., 2016). (±)-mexedrone.HCl was obtained from BRC Fine Chemicals 
(London UK), recrystallised from acetone and structurally characterised by NMR, 
IR, UV and GC-MS before use. (±)-mephedrone.HCl and (±)-4-MEC.HCl were 
synthesised, from the prerequisite α-bromopropiophenones, in-house under Home 
Office licence, using adaptations of the published methods (Santali et al., 2011; 
Khreit et al., 2012). Table 2.1 shows the street samples utilised in this study were 
obtained in accordance with Home Office licence requirements. 
 
All samples were provided by authorised/licenced personnel in accordance 
with the legislation and under the approved Memorandum of Understanding 
operating between MANchester DRug Analysis & Knowledge Exchange 
(MANDRAKE) and Greater Manchester Police.  All materials were stored, 
transferred, used and destroyed in compliance with the UK Misuse of Drugs Act 
(1971) and the UK Misuse of Drugs Regulations (2001). 
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Table 2.1. The sources of the street samples utilised in this study. 
Street sample Purported contents Source 
MDMA-1 MDMA CAHID, University of Dundee 
MDMA-2 MDMA CAHID, University of Dundee 
MDMA-3 MDMA. CAHID, University of Dundee 
MDMA-4 MDMA CAHID, University of Dundee 
MDMA-5 MDMA CAHID, University of Dundee 
NRG-2-A 4-MEC EuChemicals (www.euchemicals.com) 
NRG-2-B 4-MMC EuChemicals (www.euchemicals.com) 
NRG-2-C 4-MEC EuChemicals (www.euchemicals.com) 
NRG-2-D 4-MMC EuChemicals (www.euchemicals.com) 
NRG-2-E 4-MEC EuChemicals (www.euchemicals.com) 
MEX-1 Mexedrone Research Chemicals (www.rcnetchemicals.com) 
MEX-2 Mexedrone Research Chemicals UK (www.rcuk.co.uk) 
MEX-3 Mexedrone Research Chemicals (www.rcnetchemicals.com) 
MEX-4 Mexedrone Buckled.eu (www.buckled.eu) 
MEP-1 2-MEP Greater Manchester Police (GMP) 
MEP-2 2-MEP Greater Manchester Police (GMP) 
FEP-1 2-FEP Greater Manchester Police (GMP) 
FEP-2 2-FEP Greater Manchester Police (GMP) 
FEP-3 2-FEP Greater Manchester Police (GMP) 
 
2.1.1 Synthesis of (±)-methoxyephenidine regioisomers 
Synthesis of (±)-2-methoxyephenidine,HCl [(±)-2-MEP], (±)-3-
methoxyephenidine.HCl [(±)-3-MEP] and (±)-4-methoxyephenidine.HCl [(±)-4-MEP] 
was performed by Mr Matthew Hulme (unpublished work) using an adaptation of the 
published method for substituted diphenidine derivatives (Le Gall et al., 2009). The 
target compounds were fully characterised using NMR, IR, GC-MS and elemental 
analysis and confirmed to have a >99.5% purity. The analytes were used without 
further purification. 
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2.1.2 Synthesis of (±)-fluoroephenidine regioisomers 
Synthesis of the (±)-2-fluoroephenidine.HCl [(±)-2-FEP], (±)-3-
fluoroephenidine.HCl [(±)-3-FEP] and (±)-4-fluoroephenidine.HCl [(±)-4-FEP] was 
performed by Mr Matthew Hulme (unpublished work) using an adaptation of the 
published method for substituted diphenidine derivatives (Le Gall et al., 2009). The 
target compounds were fully characterised using NMR, IR, GC-MS and elemental 
analysis and confirmed to be of >99.5% purity. The analytes were used without 
further purification. 
 
2.2 Instrumental details 
2.2.1 High performance liquid chromatography (HPLC) 
High performance liquid chromatography (HPLC) was performed with an 
integrated Agilent HP Series 1100 Liquid Chromatograph (Agilent Technologies, 
Wokingham, UK) fitted with an in-line degasser (G1322A, Serial # JP73017007), 
pump (G1310A, Serial # DE80301064), 100-place autosampler (G1313A, Serial # 
DE54901543), column compartment (G1318A, Serial # DE91610205), and UV 
absorbance detector (G1314A, Serial # JP73705698). Data collection and analysis 
were carried out using ChemStation for LC (Ver. 10.02) software (Agilent 
Technologies, Wokingham, UK). Columns were used with different stationary 
phases provided by HiChrom Limited (Reading, UK) as shown in Table 2.2. 
 
Table 2.2 HPLC columns utilised in this project 
Column 
 
Stationary 
Phase 
Length 
[cm] 
Internal diameter 
[mm] 
Particle 
size [µm] 
Pore size 
[Å] 
HPLC mode 
A ACE-3-C18 15 4.6 3 150 Reverse Phase 
B ACE-5-C18AR 15 4.6 5 150 Reverse Phase 
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2.2.2 Electrochemistry flow cells used in liquid chromatography-
amperometric detection (HPLC-AD) 
One of the flow cells used in this study were obtained from Metrohm UK, 
Runcorn, UK (impinging jet flow cell; product code: DRP-FLWCL-TEF-71306; 3.3 × 
6.0 × 3.3 cm, flow chamber volume = 8 μL; denoted as LC-FC-A, Figure 2.1a and 
Figure 2.1b). The second flow cell was obtained from the University of Leeds, UK 
(iCell channel flow cell; 4.5 × 4.5 × 4.0 cm, flow-chamber volume = 120 μL; denoted 
as LC-FC-B, Figure 2.1c and 2.1d). The iCell (LC-FC-B) was fabricated as 
previously reported (Pike et al., 2012). 
 
Figure 2.1(a) Impinging jet flow cell (LC-FC-A; closed). (b) The impinging jet flow cell (LC-FC-A; 
open). (c) iCell channel flow cell (LC-FC-B; closed).(d) iCell channel flow cell (LC-FC-B; open). 
 
The HPLC-UV was connected, in series with the flow-cell (LC-FC-A or LC-FC-
B). The flow cells housed the Graphite Screen-printed electrode (GSPE) Error! 
Reference source not found. ) to give the HPLC-AD protocol. To distinguish the 
HPLC-AD system employing either of the  flow-cells, the two systems were denoted 
LC-FC-A and LC-FC-B respectively. Data analysis (HPLC-UV) was carried out using 
Chemstation for LC (Ver. 10.02) software (Agilent Technologies, Wokingham, UK) 
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and amperometric measurements were performed using a Palmsens (Palm 
Instruments BV, The Netherlands) potentiostat/galvanostat and controlled by 
PSTrace (Ver. 4.4-4.8) (Zuway et al., 2015). 
 
2.2.3 Screen-printing electrodes 
GSPEs with a working electrode (3 mm diameter) were fabricated in-house 
with appropriate stencil designs using a DEK 248 screen-printing machine (DEK, 
Weymouth, UK) (Smith et al., 2014b). To produce the screen-printed sensors, a 
carbon-graphite ink formulation (Gwent Electronic Materials Ltd, UK; Product Code: 
C2000802P2) was screen-printed onto a polyester (Autostat, 250 µm thickness) 
flexible film (denoted throughout as standard screen-printed electrodes). This layer 
was cured in a fan oven (60 oC/30 min) and an Ag/AgCl reference electrode 
incorporated by screen-printing Ag/AgCl paste (Gwent Electronic Materials Ltd, UK; 
Product Code: C2040308D2) onto the polyester substrate. Finally, a dielectric paste 
(Gwent Electronic Materials Ltd, UK; Product Code: D2070423D5) was then printed 
onto the polyester substrate to cover the connections. After curing (60 oC/30 min) 
the screen-printed electrodes were ready to be used. Note that Dr Christopher W. 
Foster performed the GSPEs fabrication (Zuway et al., 2015; Blanco et al., 2016), 
and a new GSPE utilised for each experiment performed, including during the ‘street 
sample’ analysis study. 
 
2.2.4 HPLC-AD protocol 
There is a demand for analytical techniques capable of determining the  drugs 
and their metabolites in different sample mixtures (Honeychurch, 2016). 
 
HPLC combined with electrochemical detection has been shown to be highly 
sensitive and specific as well as it’s a more economical option than the HPLC-UV 
technique (Honeychurch, 2016). This technique has been used for the analysis of a 
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wide range of abused substances, The target analytes are separated 
chromatographically depending then the separated compounds pass with the 
mobile phase into the UV detector, then the electrochemical detector (Figure 2.2).  
Different electrochemical detector systems have been utilised, including 
amperometry (Honeychurch, 2016). One of the most common electrochemical 
detection modes employed is amperometry which is based on the analyte being 
oxidised or reduced at the electrode interface (Honeychurch, 2016). The current 
formed from the redox reaction is linearly related to the concentration of the analyte 
and can therefore be used for the quantification of the analytes. In amperometric 
detection, the analytes flow over the surface of the working electrode (Honeychurch, 
2016).  
 
 
 
 
 
 
Figure 2.2 Flow diagram of the High performance liquid chromatography-UV-amperometric 
detection (HPLC-AD) systems (LC-FC-A and LC-FC-B). 
 
2.3 Preparation of buffer solutions: 
2.3.1 Preparation of aqueous-50 mM potassium dihydrogen phosphate 
(K2H2PO4)-100 mM potassium chloride buffer (pH 3.2). 
Potassium dihydrogen phosphate (6.8 g) and potassium chloride (7.46 g; 
supporting electrolyte) were weighed accurately, transferred into a 1 L clear glass 
volumetric flask, and dissolved indeionised water (800 mL). The pH of the solution 
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was adjusted by dropwise phosphoric acid to pH 3.2, then the solution was made 
up to volume (1L) using ultra-pure deionised water. 
 
2.3.2 Preparation of aqueous 10 mM ammonium acetate-100 mM potassium 
chloride buffer (pH 4.3) 
Ammonium acetate (0.77 g), and potassium chloride (7.46 g; supporting 
electrolyte) were weighed accurately, transferred into a 1 L clear glass volumetric 
flask and dissolved indeionised water (800 mL). The pH of the solution was adjusted 
by dropwise addition of glacial acetic acid to pH 4.3. The solution was made up to 
volume (1L) using ultra-pure deionised water. 
 
2.3.3 Preparation of aqueous 10 mM ammonium formate-100 mM potassium 
chloride buffer (pH 3.5) 
Ammonium formate (0.63 g) and potassium chloride (7.46 g; supporting 
electrolyte) were weighed accurately, transferred into a 1 L clear glass volumetric 
flask, and dissolved indeionised water (800 mL). The pH of the solution was 
adjusted by dropwise addition of formic acid (98–100%) to pH 3.5. The solution was 
made up to volume (1L) using ultra-pure deionised water. 
2.3.4 Preparation of aqueous 20 mM ammonium acetate-100 mM potassium 
chloride buffer (pH 7) 
Ammonium acetate (1.54 g) and potassium chloride (7.46 g; supporting 
electrolyte) were weighed accurately, transferred into a 1 L clear glass volumetric 
flask and dissolved in deionised water (800 mL). The pH of the solution was adjusted 
by dropwise addition of glacial acetic acid to pH 7. The solution was made up to 
volume (1L) using ultra-pure deionised water. 
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2.4 Preparation of mobile phases 
The mobile phases were prepared by mixing amounts of the buffer solution 
with an organic solution in the appropriate proportions as mentioned in Table 2.3. 
The mobile phase was vacuum-filtered by using a 0.45 mm pore filter paper and 
degassed by ultrasonication for 10 mins and the residue of oxygen removed by 
flashing nitrogen gas through the mobile phase. 
 
Table 2.3. Mobile phases used in this study. 
Mobile phase Composition 
1 10:90 % v/v acetonitrile: buffer solution pH = 3.2, Section 2.3.1 
2 30:70 % v/v methanol: buffer solution pH = 4.3, Section 2.3.2 
3 38:62 % v/v methanol: buffer solution pH = 3.5, Section 2.3.3 
4 18:82 % v/v acetonitrile: buffer solution pH = 7, Section 2.3.4 
5 25:75 % v/v acetonitrile: buffer solution pH = 7, Section 2.3.5 
 
2.5 Determination the void time (t0) of HPLC 
Uracil (10 mg) was weighed accurately and transferred into a 100 mL clear 
glass volumetric flask, dissolved in the mobile phase (50 mL). The solution was 
made up to 100 mL with mobile phase to give a solution containing uracil at 100 µg 
mL-1 then the resultant solution was diluted to obtain 10 µg mL-1. The void time was 
determined from duplicate injections of this solution and the retention time of uracil 
(un-retained component) eluting from the column.
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2.6 Detection and quantification of (±)-MDMA in the presence of (±)-MA and 
(±)-PMA by using high performance liquid chromatography-amperometric 
detection 
 
2.6.1 Preparation of standard solutions fordetermination of λmax of the UV 
detector 
(±)-MDMA (1 mg) was weighed accurately and transferred into a 10 mL clear 
glass volumetric flask, dissolved and made up to the mark with mobile phase: Mobile 
Phase 1 (Table 2.3). The resultant solution (100 µg mL-1) was used in the 
determination of the wavelength of maximum absorbance. Solutions of (±)-PMA 
(100 µg mL-1) and (±)-MA (100 µg mL-1) were prepared in an analogous manner. 
 
2.6.2 Sample preparation for HPLC method development 
(±)-MDMA (1.0 mg) was weighed accurately and transferred into a 10.0 mL 
clear volumetric glass flask, dissolved in mobile phase 1 (Table 2.3) (5.0 mL). The 
resultant solution was made up to the mark with mobile phase 1 to give a solution 
of (±)-MDMA (100.0 µg mL-1). This solution was further diluted with mobile phase 1 
to a standard solution containing (±)-MDMA (10.0 μg mL−1). In addition, (±)-MA (1.0 
mg), (±)-PMA (1.0 mg) and a solution containing [(±)-MDMA (1.0 mg), (±)-MA (1.0 
mg) and (±)-PMA (1.0 mg)] were prepared in the same manner. Three replicate 
injections were performed for each of the individual analytes using LC-FC-A and 
LC-FC-B systems. 
 
2.6.3 Optimisation of potential for amperometric detection (AD) 
The resultant mixture solution of (±)-MDMA, (±)-MA and (±)-PMA (100.0 μg 
mL−1 for each component) was prepared as in Section 2.6.1. The solution was 
injected, in triplicate, into both LC-FC-A and LC-FC-B systems and the 
amperometric response (peak current, μA) was measured for each analyte, as a 
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function of anodic potential (E V−1) between the range +1.1 to +1.8 E V−1. The data 
was analysed by using PSTrace version 4.6.  
 
2.6.4 Optimisation of linear velocity for amperometric detection (AD) 
A solution of (±)-MDMA, (±)-MA and (±)-PMA (100.0 μg mL−1 for each 
component) was prepared as in Section 2.6.1. The solution was injected ten times 
in both LC-FC-A and LC-FC-B systems and the amperometric response (peak 
current, μA) was measured for each analyte, as a function of flow rate between the 
range 0.9 to 1.2 mL min−1. The data was analysed under the same conditions using 
PSTrace version 4.6.  
 
2.6.5 Optimisation of HPLC-AD amperometric response under varying pH 
Different pH mobile phases were prepared by adjusting Mobile Phase 1 (Table 
2.3) by dropwise addition of phosphoric acid to obtain the desired pH in the modified 
mobile phases (Table 2.4). 
 
Table 2.4 Different pH of Mobile Phase 1 
Mobile phase 1 pH 
Mobile phase 1A 7.2 
Mobile phase 1B 5.2 
Mobile phase 1 3.2 
 
(±)-MDMA (1.0 mg), (±)-MA (1.0 mg) and (±)-PMA (1.0 mg) were weighed 
accurately and transferred into a 10.0 mL clear glass volumetric flask,  and dissolved 
in the appropriate mobile phase (Table 2.4) (5 mL). The resultant solution was made 
up to 10.0 mL to give a solution containing 100.0 µg mL-1 of each analyte. The 
resultant solution of (±)-MDMA, (±)-MA and (±)-PMA (100.0 μg mL−1) was injected 
(ten replicates) using both LC-FC-A and LC-FC-B systems. The amperometric 
response (peak current, µA), was measured by using a different range of pH (3.2-
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7.2), and the data analysed under the same conditions by using PSTrace version 
4.6. In addition, the HPLC-UV data was analysed by using Chem-Station for LC 
(Ver. 10.02) software.  
 
2.6.6 Calibration standards (pure substances): 
A solution of (±)-MDMA, (±)-MA and (±)-PMA (100.0 μg mL−1) was prepared in 
Section 2.6.1, and diluted with mobile phase 1 (Table 2.3) to give calibration 
standards containing 100.0 µg mL-1, 80.0 µg mL-1, 60.0 µg mL-1, 40.0 µg mL-1, 20.0 
µg mL-1 and 10.0 µg mL-1 of (±)-MDMA, (±)-MA and (±)-PMA (containing 5.0 µg mL-
1 of uracil). Six replicate injections of each calibration standard were performed by 
using both systems LC-FC-A and LC-FC-B. The column A (Table 2.2) was used as 
stationary phase. The column was fitted with C18 and maintained at an isothermal 
temperature of 22⁰C with an Agilent HP series 1100 column oven with a 
programmable controller. The detection wavelength was 210 nm; flow rate was 1.2 
mL min-1 and the injection volume 10.0 µL. 
 
2.6.7 Specificity standards 
Sucrose (5.0 mg), mannitol (5.0 mg) and lactose (5.0 mg) were weighed 
accurately into separate 10.0 mL clear glass volumetric flasks, then dissolved with 
mobile phase 1 (Table 2.3) (5.0 mL). The resultant solution was made up to volume 
with mobile phase 1 to give solutions containing the components at 500.0 μg mL−1 
of each analyte. 
2.6.8 Accuracy of the study 
5.0 mg (±)-MA, (±)-PMA and (±)-MDMA were weighed accurately into a 10 mL 
clear volumetric glass flask and diluted to volume with mobile phase 1 (Table 2.3)to 
give a solution containing 500.0 µg mL-1 (±)-MA, (±)-PMA and (±)-MDMA. This 
solution was then further diluted with mobile phase 1 to give solutions containing 
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60.0 µg mL-1, 80.0 µg mL-1 and 100.0 µg mL-1 of (±)-MA, (±)-PMA and (±)-MDMA. 
Three replicate injections of each solution were performed. 
 
2.6.9 Street samples 
Five samples of (±)-MDMA were obtained from CAHID (University of Dundee, 
Dundee, UK) and were arbitrarily labelled as MDMA-1, MDMA-2, MDMA-3, MDMA-
4 and MDMA-5 (Table 2.1). Each sample (8.0 mg) was weighed in duplicate and 
transferred into a 100 mL clear glass volumetric flask, then dissolved with mobile 
phase 1 (Table 2.3) (5 mL).  The resultant solution was made up to volume to give 
a solution of 80.0 µg mL-1which was then injected in triplicate. 
 
2.7 Detection and quantification of (±)-mephedrone; (±)-4-MEC and caffeine 
using high performance liquid chromatography-amperometric detection 
 
2.7.1 Preparation of solutions to determination λmax of the UV detector: 
(±)-mephedrone (1 mg)was weighed accurately and transferred into a 10 mL 
clear glass volumetric flask, dissolved and made up to the mark with mobile phase 
2 (Table 2.3). The resultant solution of (±)-mephedrone (100 µg mL-1) was used to 
determine the wavelength of maximum absorbance. The solutions of (±)-4-MEC 
(100 µg mL-1) and caffeine (100 µg mL-1) were prepared in an analogous manner. 
 
2.7.2 Sample preparation for HPLC method development 
(±)-mephedrone (5.0 mg) was weighed accurately and transferred into a 10.0 
mL clear glass volumetric flask, then dissolved with mobile pase 2 (Table 2.3) (5 
mL). The resultant solution was made up to the mark with the mobile phase 2 to 
give a solution containing 500.0 µg mL-1 of (±)-mephedrone. This solution was 
further diluted with mobile phase 2 to a standard solution containing 50.0 µg mL-
1(±)-mephedrone. In addition, (±)-4-MEC (5.0 mg), caffeine (5.0 mg) and a solution 
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containing [(±)-mephedrone (5.0 mg), (±)-4-MEC (5.0 mg) and caffeine (5.0 mg)] 
were prepared by using the same above procedure. Three replicate injections were 
performed for all analytes by using LC-FC-A and LC-FC-B.  
 
2.7.3 Optimisation of potential for amperometric detection (AD) 
A mixture of (±)-4-MMC, (±)-4-MEC and caffeine (500.0 μg mL−1), as prepared 
in Section 2.7.2, was diluted with mobile phase 2 to give a standard solution 
containing 100 μg mL−1. Three replicate injections of 100 μg mL−1 of the resultant 
mixture solution [(±)-mephedrone, (±)-4-MEC and caffeine] were injected using both 
LC-FC-A and LC-FC-B systems, and the amperometric responses (peak current, 
μA) were measured for each analyte as a function of anodic potential (E V−1) over 
the range +1.1 to +1.4 E V−1. The data was analysed by using PSTrace version 4.4.  
 
2.7.4 Optimisation of linear velocity for amperometric detection (AD) 
A solution of (±)-mephedrone, (±)-4-MEC and caffeine (500.0 μg mL−1) was 
prepared in Section2.7.2. This solution was then further diluted with mobile phase 2 
(Table 2.3) to a standard solution containing 150 μg mL−1 of mixture solution [(±)-
mephedrone, (±)-4-MEC and caffeine]. Ten replicate injections were performed 
(using both LC-FC-A and LC-FC-B systems) and the amperometric responses (peak 
current, μA) were measured for each analyte as a function of flow rate between the 
range 0.8 to 1.0 mL min−1. The data was analysed under the same conditions using 
PSTrace version 4.4. The optimisation of linear velocity for amperometric detection, 
for LC-FC-B, was carried out in an analogous manner. 
 
2.7.5 Optimisation of HPLC-AD amperometric response under varying pH 
Mobile phase 2 at three different pH was prepared by dropwise addition of 
glacial acetic acid to obtained three mobile phases. 
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Table 2.5 Different pH of mobile phase 2 
Mobile phase 2 pH 
Mobile phase 2A 7.3 
Mobile phase 2B 5.3 
Mobile phase 2 4.3 
 
(±)-mephedrone (1.0 mg), (±)-4-MEC (1.0 mg) and caffeine (1.0 mg) were 
weighed accurately and transferred into a 10.0 mL clear glass volumetric flask, then 
dissolved with different pHs of  mobile phase 2 (Table 2.5). The resultant solution 
was made up to 10.0 mL to give a solution containing 100.0 µg mL-1 of each analyte. 
The resultant mixture solution was injected as ten replicates using the LC-FC-A. The 
amperometric response (peak current, µA), was measured as a function of pH over 
the different range of pH (4.3-7.3), and the data analysed under the same conditions 
by using PSTrace version 4.4. In addition, the HPLC-UV data was analysed by using 
ChemStation for LC (Ver. 10.02) software. The optimisation of pH for amperometric 
detection for LC-FC-B, was carried out in an analogous manner. 
 
2.7.6 Calibration standards (pure substances): 
The resultant mixture solution (500.0 μg mL−1) of (±)-mephedrone, (±)-4-MEC 
and caffeine was prepared as in Section 2.7.2. The resultant solutions were further 
diluted with mobile phase 2 (Table 2.3) to give calibration standards containing 
500.0 µg mL-1, 400.0 µg mL-1, 300.0 µg mL-1, 200.0 µg mL-1, 100.0 µg mL-1 and 50.0 
µg mL-1 of (±)-mephedrone, (±)-4-MEC and caffeine  (containing 5.0 µg mL-1 of 
uracil). Six replicate injections of each calibration standard were performed. Column 
A (Table 2.2) was used as the stationary phase. The column was fitted with a guard 
cartridge and maintained at an isothermal temperature of 22⁰C with an Agilent HP 
series 1100 column oven with a programmable controller. The detection wavelength 
was 264 nm; flow rate was either 0.8 mL min-1 (using LC-FC-A) or 1.0 mL min-1 
(using LC-FC-B) with an injection volume of 10.0 µL. 
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2.7.7 Specificity standards 
Sucrose (5.0 mg), mannitol (5.0 mg) and lactose (5.0 mg) were weighed 
accurately into separate 10.0 mL clear glass volumetric flasks, dissolved with mobile 
phase 2 (Table 2.3) (5 mL) and sonicated using an ultrasonic bath to completely 
dissolve them. The resultant solution was made up to volume with mobile phase 2 
to give solutions containing 500.0 μg mL−1 of each analyte. 
 
2.7.8 Accuracy of the study 
5.0 mg (±)-mephedrone and (±)-4-MEC were weighed accurately into a 10 mL 
clear glass volumetric flask and diluted to volume with mobile phase 2 (Table 2.3) 
to give a solution containing 500.0 µg mL-1 (±)-mephedrone and (±)-4-MEC. This 
solution was then further diluted with mobile phase 2 to give solutions containing 
240.0 µg mL-1, 300.0 µg mL-1 and 360.0 µg mL-1 of (±)-mephedrone and (±)-4-MEC 
Three replicate injections of each solution were performed.   
 
2.7.9 Street samples 
Five street samples of NRG-2 were obtained from web vendors in January 
2013 as off-white crystalline powders in sealable bags. These samples were 
arbitrarily labelled NRG-2-A, NRG-2-B, NRG-2-C, NRG-2-D and NRG-2-E (Table 
2.1).  5.0 mg of each substance was weighed (in triplicate) accurately into a 10.0 
mL clear glass volumetric flask, dissolved with mobile phase 2 (Table 2.3) (5.0 mL) 
and the solution sonicated  using an ultrasonic bath for 10 mins to completely 
dissolve them. The resultant solution was made up to volume with mobile phase 2 
to give a 500.0 µgmL-1 solution.. Each sample was injected in duplicate. 
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2.8 Detection and quantification of (±)-mexedrone and (±)-mephedrone  
2.8.1 Characterisation 
Melting points were determined using a Stuart melting point apparatus SMP10 
(Stuart, Bibby Sterlin Ltd, UK). Thin-Layer Chromatography (TLC) was carried out 
on aluminium-backed SiO2 plates (Merck, Darmstadt, Germany) and spots 
visualised using ultra-violet light (254 nm). Infrared spectra were obtained in the 
range of 4000–400 cm-1 using a ThermoScientific Nicolet FTIR Smart ITR 
instrument (ThermoScientific, Rochester, USA). 1H and 13C NMR spectra were 
recorded on a JEOL ECS-400 (400 MHz) instrument (JEOL, Tokyo, Japan). 
Ultraviolet spectra were obtained using a Cary 100 Bio UV-visible 
spectrophotometer (Agilent Technologies, Wokingham, UK). 
 
2.8.1.1 Gas chromatography–mass spectrometry (GC–MS) 
Santali et al. reported a gas chromatography-mass spectrometry method for 
the analysis of mephedrone (Santali et al., 2011). GC–MS analysis was performed 
using an Agilent HP 5890 Series II GC and a HP 5972 mass selective detector 
(MSD) (Agilent Technologies, Wokingham, UK). The mass spectrometer was 
operated in the electron ionisation mode at 70 eV. Using a capillary column (HP5 
MS, 30 m × 0.25 mm i.d., 0.25 µm) with helium as the carrier gas at a constant flow 
rate of 1.2 mL min-1, separation was achieved. The temperature programme of the 
oven started at 50 ºC for 1 minute. It was increased to 220 ºC at a rate of 30 ºC min-
1 and held for 7 minutes then increased by 30 ºC min-1 to 320 ºC and held for 2 mins. 
Solutions of 1 mg mL-1 (±)-mexedrone and (±)-mephedrone were prepared in 
methanol (including 1 mg mL-1 of eicosane as internal standard). A 1 µL aliquot of 
each solution was injected in the split (100:1) mode with a purge time of 1 minute. 
The injector and the GC interface temperatures were kept constant at 280 ºC.  The 
MS source and quadrupole temperature were set at 230 ºC and 150 ºC, 
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respectively. The full scan mode (40-550 amu) was utilised for the mass spectra and 
the chromatographic separation was monitored in SIM mode. Overall, run time was 
16 minutes and mass detected temperature at 300 ⁰C. 
 
2.8.2 Preparation of solution to determine λmax: 
(±)-Mexedrone (1.0 mg) was weighed accurately and transferred into a 10 mL 
clean glass volumetric flask, dissolved and made up to the mark with mobile phase 
3 (Table 2.3). The solution of (±)-Mexedrone (100.0 µg mL-1) was diluted to obtained 
a solution containing 9.1µg mL-1.This solution was used to determine the 
wavelength of maximum absorbance. The same procedure was used to prepare a 
solution of (±)-mephedrone with a concentration of 9.1 µg mL-1. 
 
2.8.3 Sample preparation for HPLC method development: 
(±)-Mexedrone (1.0 mg) was weighed accurately and transferred into a 10.0 
mL clean glass volumetric flask, and dissolved with mobile phase 3 (Table 2.3) (5 
mL). The resultant solution was made up to the mark with the mobile phase 3 to 
give solution containing 100.0 µg mL-1 of (±)-mexedrone. This solution was further 
diluted with mobile phase 3 to make a standard solution containing at 10.0 µg mL-1. 
In addition, (±)-mephedrone (1.0 mg) and a solution containing [(±)-Mexedrone (1.0 
mg) and (±)-mephedrone (1.0 mg)] were prepared by the same procedure. Three 
replicate injections were performed by using LC-FC-A. 
 
2.8.4 Optimisation of potential for amperometric detection (AD) 
A solution (100.0 µg mL-1) of (±)-Mexedrone and (±)-mephedrone mixture was 
prepared as described in Section 2.8.3. This solution was injected three times using 
LC-FC-A. The amperometric response (peak current, μA), for the analyte, was 
measured as a function of anodic potential (E V−1) over the range +1.1 to +1.4 E 
V−1. The data were analysed under the same conditions using PSTrace version 4.4.  
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2.8.5 Optimisation of linear velocity for amperometric detection (AD) 
A solution (100.0 µg mL-1) of (±)-Mexedrone and (±)-mephedrone mixture was 
prepared as described in Section 2.8.3 and injected ten times using LC-FC-A.  The 
amperometric response (peak current, μA), for each analyte, was measured as a 
function of flow rate over the range 0.8 to 1.2 mL min−1. The data were analysed 
under the same conditions using PSTrace version 4.4.  
 
2.8.6 Optimisation of HPLC-AD amperometric response under varying pH 
Different pH mobile phases 3 were prepared by adjusting mobile phase 3 
(Table 2.3) by dropwise addition of formic acid to obtain the desired pH in the 
modified mobile phases 3 – 3B (Table 2.6).  
 
Table 2.6 Different pH of Mobile Phase 3 
Mobile phase 3 pH 
Mobile phase 3A 7.5 
Mobile phase 3B 5.5 
Mobile phase 3  3.5 
 
(±)-Mexedrone (1.0 mg) and (±)-mephedrone (1.0 mg) were weighed 
accurately and transferred into 10.0 mL clear glass volumetric flask, dissolved with 
different pHs of mobile phase 3 (Table 2.3) (5.0 mL). The resultant solutions were 
made up to 10.0 mL to give a solution containing 100.0 µg mL-1 of each analyte. The 
resultant mixture solution (100.0 µg mL-1) of (±)-Mexedrone and (±)-mephedrone 
mixture was injected ten times by using LC-FC-A. The amperometric response 
(peak current, µA), was measured as a function of pH over the range of pH 3.5-7.5, 
and the data analysed under the same conditions by using PSTrace version 4.4. In 
addition, the HPLC-UV data were analysed by using ChemStation for LC (Ver. 
10.02) software. 
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2.8.7 Calibration standards (pure substances): 
A solution (100.0 µg mL-1) of (±)-Mexedrone and (±)-mephedrone mixture was 
prepared as described in Section 2.8.3. This solution was further diluted with mobile 
phase 3 (Table 2.3) to give calibration standards containing 500.0 µg mL-1, 400.0 
µg mL-1, 300.0 µg mL-1, 200.0 µg mL-1 and 100.0 µg mL-1 (±)-Mexedrone and (±)-
mephedrone (containing 5.0 µg mL-1 of uracil). Six replicate injections of each 
calibration standard were performed by using LC-FC-A. Column A (Table 2.2) was 
used as the stationary phase. The column was maintained at an isothermal 
temperature of 22⁰C with an Agilent HP series 1100 column oven with a 
programmable controller. The detection wavelength was 264 nm; flow rate was 0.8 
mL min-1 with an injection volume of 10 µL. 
 
2.8.8 Specificity standards of HPLC-UV 
Sucrose (5.0 mg), mannitol (5.0 mg) and lactose (5.0 mg) were weighed 
accurately into separate 10.0 mL clear glass volumetric flasks, and dissolved with 
mobile phase 3 (Table 2.3) (5 mL). The resultant solutions were  made up to volume 
with mobile phase 3 to give solutions containing the components at 500.0 μg mL−1 
of each analyte. 
 
2.8.9 Selectivity study of HPLC-UV 
10.0 mg of each component (paracetamol, caffeine, (±)-mexedrone and (±)-
mephedrone) was weighed accurately into a 100 mL clear glass volumetric flask 
and diluted to volume with mobile phase 3 to give a solution containing each 
component at 10.0 µg mL-1 (containing 5 µg mL-1of uracil as internal standard). 
Three replicate injections of the solution were performed. 
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2.8.10 Accuracy study 
5.0 mg (±)-Mexedrone and (±)-mephedrone were weighed accurately into a 10 
mL clear glass volumetric flask and diluted to volume with mobile phase 3 (Table 
2.3) to give a solution containing 500.0 µg mL-1 (±)-Mexedrone and (±)-mephedrone. 
This solution was then further diluted with mobile phase 3 to give solutions 
containing 240.0 µg mL-1, 300.0 µg mL-1 and 360.0 µg mL-1 (±)-Mexedrone and (±)-
mephedrone. Three replicate injections of each solution were performed. 
 
2.8.11 Street samples 
Four street samples of (±)-Mexedrone were obtained from internet vendors 
(MEX-1, MEX-2 and MEX-3 obtained from Research Chemicals, and MEX-4 
obtained from Buckled.eu as explained in table 1 Section 2.1).  3.0 mg of each (±)-
Mexedrone street sample was weighed (in duplicate) accurately into a 10.0 mL clear 
glass volumetric flask and diluted to volume with mobile phase 3 (Table 2.3)  to give 
solutions containing the samples at 300 µg mL-1. The solutions were injected in 
triplicate for each sample. 
 
2.9 Detection and quantification of (±)-2-MEP, (±)-3-MEP and (±)-4-MEP. 
 
2.9.1 Preparation of solutions to determine  λmax 
(±)-2-MEP (1 mg) was weighed accurately and transferred into a 10 mL clear 
glass volumetric flask, dissolved and made up to the mark with mobile phase 4 
(Table 2.3). The resultant solution of (±)-2-MEP (100 µg mL-1) was used in 
determination of the wavelength of maximum absorbance. The solutions of (±)-3-
MEP (100 µg mL-1) and (±)-4-MEP (100 µg mL-1) were prepared in an analogous 
manner. 
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2.9.2 Sample preparation for HPLC method development 
(±)-2-MEP (3.0 mg) was weighed accurately and transferred into a 10.0 mL 
clear glass volumetric flask, dissolved with mobile phase 4 (Table 2.3) (5 mL). The 
resultant solution made up to the volume with the mobile phase 4 (Table 2.3) to give 
a solution containing 300.0 µg mL-1 of (±)-2-MEP. This solution was further diluted 
with mobile phase 4 (Table 2.3) to a standard solution containing at 20 µg mL-1. In 
addition, (±)-3-MEP (3.0 mg), (±)-4-MEP (3.0 mg) and a solution containing [(±)-2-
MEP (3.0 mg), (±)-3-MEP (3.0 mg) and (±)-4-MEP (3.0 mg)] were prepared using 
the same procedure. Three replicate injections were performed by using LC-FC-A. 
 
2.9.3 Optimisation of potential for amperometric detection (AD) 
A solution (100.0 µg mL-1) of (±)-2-MEP, (±)-3-MEP and (±)-4-MEP mixture 
was prepared as described in Section 2.9.1 and injected three times by using LC-
FC-A and the amperometric response (peak current, μA), for each analyte, was 
measured as a function of anodic potential (E V−1) over the range +1.0 to +1.4 E 
V−1. The data were analysed under the same conditions using PSTrace version 4.6. 
 
2.9.4 Optimisation of linear velocity for amperometric detection (AD) 
A solution (300.0 µg mL-1) of (±)-2-MEP, (±)-3-MEP and (±)-4-MEP mixture 
was prepared as described in Section 2.9.2 and injected ten times by using LC-FC-
A and the amperometric response (peak current, μA), for all analytes, was measured 
as a function of flow rate over the range 1, 1.5 and 2 mL min−1. The data were 
analysed under the same conditions using PSTrace version 4.6.  
 
2.9.5 Optimisation of HPLC-AD amperometric response under varying pH 
Three mobile phases with different pH were prepared by dropwise glacial 
acetic acid to produced mobile phases 4 -4B (Table 2.7). 
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Table 2.7 Different pH of mobile phase 4 
Mobile phase 4 pH 
Mobile phase 4 7 
Mobile phase 4A 5 
Mobile phase 4B 3 
 
(±)-2-MEP (3.0 mg), (±)-3-MEP (3.0 mg) and (±)-4-MEP (3.0 mg) were 
weighed accurately and transferred into 10.0 mL clear glass volumetric flasks,  then 
dissolved  in mobile phase 4 of different pHs (Table 8) (5 mL). The resultant 
solutions were made up to 10.0 mL to give a solution containing 300.0 µg mL-1 of 
each analyte. The resultant mixture solution was injected three times by using LC-
FC-A and the amperometric response (peak current, µA), was measured as a 
function of pH over the range of pH (3-7). The data were analysed under the same 
conditions by using PSTrace version 4.6. In addition, the HPLC-UV data was 
analysed by using Chem-Station for LC (Ver. 10.02) software. 
 
2.9.6 Calibration standards (pure substances): 
 (±)-2-MEP (50.0 mg), (±)-3-MEP (50.0 mg) and (±)-4-MEP (50.0 mg) were 
weighed accurately and transferred into a 100.0 mL clear glass volumetric flask, and 
dissolved with mobile phase 4 (Table 2.3) (5 mL). The resultant solution was made 
up to the volume with mobile phase 4 to give a solution containing the components 
at 500 µg mL−1. This solution was further diluted with mobile phase 4 to give 
calibration standards containing 500 μg mL−1, 400 μg mL−1, 300 μg mL−1, 200 μg 
mL−1 and 100 μg mL−1 of each analyte. Six replicate injections of each calibration 
standard were performed by using LC-FC-A. Column B (Table 2.2) was maintained 
at an isothermal temperature of 50⁰C with an Agilent HP series 1100 column oven 
with a programmable controller.  The detection wavelength was 279 nm; flow rate 
was 2 mL min-1 with an injection volume of 10 µL. 
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2.9.7 Specificity standards 
Sucrose (5.0 mg), mannitol (5.0 mg) and lactose (5.0 mg) were weighed 
accurately into separate 10.0 mL clear glass volumetric flasks, and dissolved with 
mobile phase 4 (Table 2.3) (5 mL). The resultant solutions were made up to volume 
with mobile phase 4 to give solutions containing the components at 500.0 μg mL−1 
for each analyte. 
 
2.9.8 Accuracy of the study 
5.0 mg (±)-4-MEP, (±)-2-MEP and (±)-3-MEP  were weighed accurately into a 
10 mL clear glass volumetric flask and diluted to volume with mobile phase 4 (Table 
2.3) to give a solution containing 500.0 µg mL-1 of (±)-4-MEP, (±)-2-MEP and (±)-3-
MEP. This solution was then further diluted with mobile phase 4 to give solutions 
containing 240.0 µg mL-1, 300.0 µg mL-1 and 360.0 µg mL-1 (±)-4-MEP, (±)-2-MEP 
and (±)-3-MEP. Three replicate injections of each solution were performed. 
 
2.9.9 Street samples: 
Two street samples of (±)-MEP were obtained from Greater Manchester Police 
(GMP) and arbitrarily labelled as MEP-1 and MEP-2 (Table 2.1). 5.0 mg of each 
street sample of (±)-MEP were twice weighed accurately and labelled as (MEP-1-A, 
MEP-1-B, MEP-2-A and MEP-2-B) into a 100.0 mL clear glass volumetric flask, and 
dissolved with mobile phase 4 (Table 2.3) (50 mL). The resultant solution made up 
to volume with Mobile Phase 4 (Table 2.3) to obtain a solution with 50 µg mL-1 and 
each sample was injected in triplicate. 
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2.10 Detection and quantification of (±)-2-FEP, (±)-3-FEP and (±)-4-FEP. 
 
2.10.1 Preparation of solutions to determine λmax 
(±)-2-FEP (1 mg) was weighed accurately and transferred into a 10 ml clear 
glass volumetric flask, dissolved and made up to the mark with mobile phase 5 
(Table 2.3). The resultant solution (±)-2-FEP (100 µg mL-1) was used in 
determination of the wavelength of maximum absorbance. The solutions of (±)-3-
FEP (100 µg mL-1) and(±)-4-FEP (100 µg mL-1) were prepared in an analogous 
manner. 
 
2.10.2 Sample preparation for HPLC method development: 
(±)-FEP (5.0 mg) was weighed accurately and transferred into a 10.0 mL clear 
glass volumetric flask, and dissolved with mobile phase 5 (Table 2.3) (5 mL). The 
resultant solution made up to the mark with the mobile phase 5 to give a solution 
containing 500.0 µg mL-1. This solution was further diluted with mobile phase 5 to a 
standard solution containing 50.0 µg mL-1 of (±)-2- FEP. In addition, (±)-3-FEP (5.0 
mg), (±)-4-FEP (5.0 mg) and a solution containing [(±)-2-FEP (5.0 mg), (±)-3-FEP 
(5.0 mg) and (±)-4-FEP (5.0 mg)] were prepared by using the same procedure. 
Three replicate injections were performed by using LC-FC-A. 
 
2.10.3 Optimisation of potential for amperometric detection (AD) 
The resultant solution mixture (500.0 µg mL-1) of (±)-2-FEP, (±)-3-FEP and (±)-
4-FEP was prepared as in Section 2.10.1. This solution was further diluted to obtain 
a solution mixture of (300.0 µg mL-1) of each analyte. By using LC-FC-A, three 
replicate injections were performed and the response (peak current, μA), for each 
analyte, was measured as a function of anodic potential (E V−1) over the range +1.0 
to +1.4 E V−1. The data were analysed under the same conditions using PSTrace 
version 4.8. 
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2.10.4 Optimisation of linear velocity for amperometric detection (AD) 
The resultant solution mixture (500.0 µg mL-1) of (±)-2-FEP, (±)-3-FEP and (±)-
4-FEP was prepared as in Section 2.10.1. This solution was further diluted to obtain 
a solution mixture (300.0 µg mL-1) of each analyte. Ten replicate injections were 
made by using LC-FC-A. The amperometric response (peak current, μA), for all 
analytes, was measured as a function of flow rate over the range 1, 1.5 and 2 mL 
min−1. The data were analysed under the same conditions using PSTrace version 
4.8. 
2.10.5 Optimisation of HPLC-AD amperometric response under varying pH 
Mobile phase 5 at different pH was prepared by dropwise addition of glacial 
acetic acid to obtain three mobile phases with different pH (mobile phase 5-5B; table 
9). 
Table 2.8 Different pH of mobile phase 5 
Mobile phase 5 pH 
Mobile phase 5 7 
Mobile phase 5A 5 
Mobile phase 5B 3 
 
(±)-2-FEP (1.0 mg), (±)-3-FEP (1.0 mg ) and (±)-4-FEP (1.0 mg) were weighed 
accurately and transferred into a 10.0 mL clear glass volumetric flask,  then 
dissolved with different pHs of mobile phase 5 (Table 2.3) (5 mL). The resultant 
solutions were made up to 10.0 mL to give a solution containing 100.0 µg mL-1 of 
each analyte. Ten replicate injections were performed by using the LC-FC-A. The 
amperometric response (peak current, µA), was measured as a function of pH over 
the range of pH 3-7, and the data analysed under the same conditions by using 
PSTrace version 4.8. In addition, the HPLC-UV data were analysed by using Chem-
Station for LC (Ver. 10.02) software. 
 
66 
2.10.6 Calibration standards (pure substances): 
The resultant solution mixture (500.0 µg mL-1), of (±)-2-FEP, (±)-3-FEP and 
(±)-4-FEP was prepared as in Section 2.10.1.This solution was then further diluted 
with mobile phase 5 (Table 2.3) to give calibration standards containing 500 μg 
mL−1, 400 μg mL−1, 300 μg mL−1, 200 μg mL−1 and 100 μg mL−1 of each analyte. Six 
replicate injections of each calibration standard were performed by using LC-FC-A. 
Column B (Table 2.2) was fitted with a guard cartridge and maintained at an 
isothermal temperature of 50⁰C with an Agilent HP series 1100 column oven with a 
programmable controller. The detection wavelength was 270 nm; flow rate was 1.5 
mL min-1 with an injection volume of 10.0 µL. 
 
2.10.7 Specificity standards 
Sucrose (5.0 mg), mannitol (5.0 mg) and lactose (5.0 mg) were weighed 
accurately into separate 10.0 mL clear glass volumetric flasks, then dissolved with 
mobile phase 5 (Table 2.3) (5 mL) and sonicated using an ultrasonic bath to 
completely dissolve them. The resultant solutions were made up to volume with 
mobile phase 5 to give solutions containing the components at 500.0 μg mL−1for 
each analyte. 
 
2.10.8 Accuracy of the study 
5.0 mg (±)-4-FEP, (±)-2-FEP and (±)-3-FEP were weighed accurately into a 10 
mL clear glass volumetric flask and diluted to volume with mobile phase 5 (Table 
2.3) to give a solution containing 500.0 µg mL-1 (±)-4-FEP, (±)-2-FEP and (±)-3-FEP. 
This solution was then further diluted with mobile phase 5 to give solutions 
containing 240.0 µg mL-1, 300.0 µg mL-1 and 360.0 µg mL-1 of (±)-4-MEP, (±)-2-MEP 
and (±)-3-MEP. Three replicate injections of each solution were performed. 
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2.10.9 Street samples 
Two samples of fluoroephenidine obtained from Greater Manchester Police 
were arbitrarily labelled as FEP-1 and FEP-2. 5.0 mg of each street sample were 
weighed (in duplicate) into 100.0 mL clear glass volumetric flasks then diluted to 
volume with mobile phase 5 to obtain a solution of 50.0 µg mL-1. Each sample was 
injected in triplicate. 
 
2.11 HPLC-UV validation 
HPLC-UV method was validated in accordance with the ICH guidelines(ICH, 
1996; Marchand et al., 2005)( by using the following parameters: linearity, precision, 
specificity, limit of detection (LOD), limit of quantification (LOQ) and system 
suitability [resolution (Rs), column efficiency (N), peak asymmetry (As)]. Six 
replicate injections of the calibration standard solutions were performed to obtain 
the data of the system suitability, linearity, precision, specificity, %RSD, LOD and 
LOQ for the HPLC-UV method validation. The LOD and LOQ were calculated based 
on the standard deviation of the response and the slope. 
 
2.12 Amperometric detection validation: 
The validation of Amperometric detection (AD) method was performed 
according to the ICH guidelines(ICH, 1996; Marchand et al., 2005)by using the 
following parameters: linearity, precision, limit of detection (LOD) and limit of 
quantification (LOQ). Six replicate injections of the calibration standard solutions 
were performed to obtain the linearity, precision, LOD and LOQ and the data were 
analysed. The LOD and LOQ were calculated based on the standard deviation of 
the response and the slope. The RSD% was calculated for each 6 replicate 
injections of the samples. 
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3 Chapter 3: Detection and quantification of (±)-MDMA in the presence of 
(±)-MA and (±)-PMA by using high-performance liquid chromatography-
amperometric detection (HPLC-AD) 
 
3.1 Introduction 
The detection of controlled drugs and substances of concern that may be 
present in the recreationally (ab)used drugs is becoming increasingly essential. (±)-
PMA); (Table 3.1a) has attracted considerable media and scientific attention due to 
its being linked to fatalities internationally, and is often found either in isolation or in                                                                                                                                                                                                                                                                                                                                                                                                                                                           
combination with (±)-MDMA (Table 3.1b) in recreational drug products sold under 
the alias ‘ecstasy’. Both (±)-MDMA and (±)-MA (Table 3.1c)] are increasingly 
popular drugs amongst recreational users (Clemens et al., 2007).The (±)-MA has a 
similar structure to (±)-MDMA and sometimes (±)-MA is sold as, or with, (±)-MDMA 
in combination. (±)-MDMA and (±)-MA in combination are potentially more 
dangerous than using each drug in isolation, as suggested by recent research, 
because they may produce greater adverse neurochemical and behavioural effects 
(Clemens et al., 2007). This is of some concern given recent evidence that party 
drug users may frequently be exposed to this combination of drugs (Clemens et al., 
2007). 
Table 3.1 Chemical structures of methamphetamine, PMA, and MDMA 
 
 Name Acronym R1 R2 R3 
a) Para-methoxyamphetamine (±)-PMA H CH3 4-methoxy 
b) 3,4-Methylenedioxymethamphetamine (±)-MDMA CH3 CH3 3,4-methylendioxy 
c) Methamphetamine MA CH3 CH3 H 
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The chromatographic analysis of (±)-MDMA is routinely performed in forensic 
laboratories around the world but not fully validated (Natalia Biziak de Figueiredo1 
and Oliveira1*, 2010; Cumba et al., 2016). The detection of MDMA in biological 
specimens has been obtained using high performance liquid chromatography 
(HPLC) with electrochemical (Michel et al., 1993; Zhao et al., 2001), UV (Soares et 
al., 2004), or diode array detection (DAD) (Helmlin et al., 1996; de Figueiredo et al., 
2010), or with fluorescence detection (da Costa and Chasin, 2004). 
 
In previous work, Cumba et al. reported a HPLC separation methodology for 
(±)-MDMA and (±)-PMA. The limit of detection and quantification for (±)-MDMA were 
0.04 µg mL-1 and 0.12 µg mL-1 respectively and for (±)-PMA were 0.08 and 0.26 µg 
mL-1 (Cumba et al., 2016). In the literature, various analytical methods have been 
used in the detection of (±)-MA (±)-PMA and (±)-MDMA (Gura et al., 2009; Pichini 
et al., 2003; Riezzo et al., 2010; Chèze et al.; Martin, 2001; Garrido et al., 2010; 
Moreno et al., 2012; Nieddu et al., 2007; Tadini et al., 2014; Kato et al., 2008; Wada 
et al., 2012; Clemens et al., 2007). Table 3.2 summarises the different protocols. 
The utilisation of electrochemical detection (ED) alongside HPLC has been used for 
a range of applications such as toxicology, therapeutic drug monitoring, drug 
metabolism, and pharmacokinetics (Zuway et al., 2015; Kusu, 2015; R. J. 
Flanagan). 
 
Electrochemical detection using screen-printed graphite electrodes (SPEs) 
has been studied as a potential analytical technique for simultaneous quantification 
of (±)-MDMA and (±)-PMA. These SPEs allow for disposable electrochemical 
devices, potentially providing a simple, cost-effective point-of-care analytical 
screening tool (Zuway et al., 2015; Kusu, 2015; R. J. Flanagan). 
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The electroanalytical technique was used in the previous study by Cumba et 
al. for the detection of (±)-MDMA and (±)-PMA (in their pure form), and gave a 
detection limit of 0.04 mL and 0.08 µg mL-1 respectively. In addition, the 
differentiation between (±)-MDMA and (±)-PMA utilising cyclic voltammetry has also 
been reported, where two oxidation peaks were observed at +0.92 V (vs Ag/AgCl) 
and +1.20 V (vs Ag/AgCl) with limits of detection determined to be 0.25 µg mL-1 and 
0.14 µg mL-1 (Cumba et al., 2016).  
 
This chapter investigates a new methodological approach for the qualitative and 
quantitative analysis of the psychoactive substances (±)-MDMA, and (±)-MA present 
in NPSs such as (±)-PMA, using a combination of high performance liquid 
chromatography with amperometric detection (HPLC-AD). In addition, the difference 
between commercially available flow cells with an impinging jet flow cell (LC-FC-A) 
and an iCell channel flow-cell (LC-FC-B) (D. J. Pike) with both incorporating 
embedded graphitic screen-printed macroelectrodes (GSPE), is presented. GSPEs 
offer a cost-effective, reproducible and reliable sensor platform for the amperometric 
detection (AD) of the target analytes and the validation of the technique. Validation 
has been carried out using the recommended ICH guidelines for analytical 
confirmation and the most characteristic analytical performances were used ; such 
as the stability of the solution, and the selectivity, recovery, accuracy, precision, 
linearity, limits of detection, and limits of quantification were  investigated (ICH, 
1996; ICH, 2017). 
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Table 3.2 Analytical methods in the literature used to detect (±)-Paramethoxyamphetamine hydrochloride ((±)-PMA),(±)-3,4-methylenedioxymethamphetamine hydrochloride 
((±)-MDMA). 
Analyte Analytical method Matrix Analytical linear range Limit of detection References 
PMA GC equipped with a 
nitrogen phosphorus 
Peripheral and heart blood 0.125 mg L-1 to 1.0 mg L-1 N/A (Martin, 2001) 
MDMA Square wave voltammetry Supporting electrolytes, 
human serum 
8 - 45 µM 
12 - 45 µM 
1.2 µmol L-1 - 2.4 µmol L-1 (Garrido et al., 
2010) 
PMA Capillary electrophoresis 
with diode array 
Plasma 
Urine 
50 - 5000 ng mL-1 20.92 ng mL-1 
24.26 ng mL-1 
(Nieddu et al., 
2007) 
MDMA 
MDMA 
 
MDMA 
Turn-on fluorogenic probe 
Thin layer chromatography/ 
fluorescence 
HPLC-chemiluminescence 
Water 
Urine 
 
Plasma 
Hair root 
Hair shaft 
N/A - not disclosed 
N/A - not disclosed 
 
0.01 - 1.0 ng mL-1 
0.10 - 10 ng mL-1 
0.10 - 10 ng mL-1 
0.13 µM 
50 ng mL-1 
 
3 ng mL-1 
17 ng mL-1 
14 ng mL-1 
(Moreno et al., 
2012) 
(Kato et al., 
2008) 
 
(Wada et al., 
2012) 
MDMA Cyclic voltammetry – dip 
coating/ spin coating 
KCl (0.1 mol L-1) 4.2 - 48 µmol L-1 3.5/2.7 µmol L-1 (Tadini et al., 
2014) 
MDMA 
PMA 
MDMA/PMA 
Deferential plus 
voltammetry 
Mobile phase 0.50 - 4.98 µg mL-1 
0.50 - 4.98 µg mL-1 
2.00 – 19.6 µg mL-1 (for both) 
0.04 µg mL-1 
0.03 µg mL-1 
0.25 µg mL-1/ 0.14 µg mL-1 
(Cumba et al., 
2016) 
MDMA 
PMA 
HPLC-UV Mobile phase 1.25-40 µg mL-1 0.08 µg mL-1 
0.04 µg mL-1 
(Cumba et al., 
2016) 
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3.2 Ultraviolet-visible spectroscopy (UV) Determination of λmax 
The UV/vis spectrophotometer was used to determine the wavelength of 
maximum absorbance for (±)-MA, (±)-MDMA and (±)-PMA. The strongest 
absorption for all was obtained at λmax = 210 nm, and provided the highest 
absorbance reading for (±)-MA (A = 0.4794, 1.0×10-3 g 100mL-1), (±)-MDMA (A = 
0.671, 1.0×10-3 g 100mL-1) and (±)-PMA (A = 0.4661, 1.0×10-3 g 100mL-1),in 
agreement with the results of (Muller and Windberg, 2005). 
 
3.3 HPLC Method Development 
Other researchers have reported utilising HPLC and LC-MS techniques to 
determine (±)-MDMA and (±)-PMA separately in the toxicological screening of the 
target analytes (Muller and Windberg, 2005; Stoll et al., 2006). The HPLC method 
was developed by employing a modified isocratic elution protocol (Section 2.6), to 
ensure both optimal detection of the analytes and a rapid analysis time. The aim 
was to develop a HPLC-UV method which could resolve and detect (±)-MDMA, (±)-
PMA and (±)-MA with good resolution and a short overall run time. The method was 
adapted from the HPLC-UV method of Cumba et al.(Cumba et al., 2016), which was 
itself adapted from the method reported by (Muller and Windberg, 2005). They used 
a Chromspher B column as the stationary phase (C18, 100 x 3 mm; particle size: 5 
µm) with a mobile phase consisting of 0.05M phosphate buffer (pH 3.2): acetonitrile 
(90:10, % v/v). 
 
 In the current study, column A (Table 2.2) was used, with a 3 µm particle size 
to decrease the eddy diffusion and mass transfer effects, and to improve both the 
efficiency of the column and the resolution of (±)-MDMA, (±)-PMA and (±)-MA. 
Decreasing the particle size from 5 µm to 3 µm is known to limit the effect of flow 
rate on peak efficiency. In this case, reducing the particle size increased the surface 
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area of the column and improved mass transfer, thereby reducing the effect of band-
broadening. Moreover, the smaller particle sizes yielded better overall efficiencies, 
or less peak dispersion, across a much wider range of proper flow rates. The mobile 
phase of Muller’s et al. method was modified by adding KCl as electrolyte support 
to improve the electrochemical conductivity of the mobile phase. In addition, the flow 
rate of the mobile phase in this study was increased to 1.2 mL min-1 to decrease 
longitudinal diffusion according to the Van Deemter equation and to improve the 
resolution between the peaks of analytes. The final modification was a decrease in 
the injection volume to 10 μL from 20 μL to decrease peak width and improve the 
resolution between peaks (Ren et al., 2013). The temperaturewas decreased from 
30⁰C to the ambient temperature (22⁰C). 
 
Using this new method, (±)-MA, (±)-PMA and (±)-MDMA were eluted at 10.56 
(10.84), 11.36 (11.68) and 12.09 (12.40) mins respectively by using HPLC-UV 
detection in LC-FC-A (or LC-FC-B) systems. The resolution for all analytes in both 
systems was in the range 2.13-2.36 (Figure 3.1).  
 
 
Figure 3.1 Chromatogram of a solution containing (±)-MA, (±)-PMA and (±)-MDMA obtained on a 
HPLC-UV system (UV detection) using an ACE 3 C18 column (150 mm × 4.6 mm i.d. particle size: 3 
μm); flow-rate: 1.2 mL min−1; mobile phase 1; detector wavelength (UV): 210 nm. 
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Both amperometric detectors used in this study were either of impinging jet flow cell 
(LC-FC-A) (Gunasingham et al., 1984; Gunasingham, 1984) or iCell channel flow 
cell (LC-FC-B) design (Pike et al., 2012). These flow cells accommodated graphite 
screen-printed electrodes without any further modification. The HPLC-AD system 
required the amperometric detector to be connected behind the UV detector, via 
PTFE tubing (230 × 1.6 mm, i.d. 0.3 mm, internal volume: 16.25 μL). This 
configuration reduced the system back pressure and thereby prevented leakages 
from the flow-cells. To distinguish the HPLC-AD system employing the impinging jet 
(LC-FC-A) from the iCell channel (LC-FC-B) flow-cells, the two systems were 
denoted LC-FC-A and LC-FC-B respectively. 
 
3.4 Amperometric detection method development 
Optimisation of the anodic potential, linear velocity and pH were performed to 
achieve the optimal current response and determine the optimal conditions for the 
maximum electrochemical response before applying this method to the purchased 
street samples. 
 
3.4.1 Optimisation of the potential of amperometric detection: 
The anodic potentia lwas determined using the peak maxima for a solution of 
(±)-MA, (±)-PMA and (±)-MDMA (all 80 μg mL−1) in mobile phase 1 (Table 2.3), in 
using optimised instrumental configuration. The optimal instrumental conditions 
were used for optimisation of the potential according to the best conditions obtained 
in the method development in Section 3.3 (temperature = 22 ⁰C, flow rate = 1.2 mL 
min-1 and pH = 3.2). The potential required to obtain the optimal response for the 
mixture was determined for both LC-FC-A and LC-FC-B systems, by measuring the 
amperometric response (peak current, μA) as a function of the anodic potential (E 
V−1), using the range +1.1 to +1.6 E V−1. 
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Table 3.3. The anodic potential (80 µg mL-1) of (±)-MA, (±)-PMA and (±)-MDMA over the range + 1.1 
to + 1.6 V-1 using mobile phase 1, column: an ACE 3 C18 column (150 mm × 4.6 mm i.d., particle 
size: 3 μm); at temperature = 22 ⁰C, flow rate = 1.2 mL min-1 and pH = 3.2  using HPLC-AD detection 
in LC-FC-A and LC-FC-B systems. 
Flow rate Linear velocity = 1.2 mL min-1 
System LC-FC-A LC-FC-B 
Detection Peak Current (µA) Peak Current (µA) 
Potential (V) MA PMA MDMA MA PMA MDMA 
1.1 n.d. n.d. 0.755 n.d. n.d. 0.286 
1.2 n.d. 0.299 1.874 n.d. 0.103 0.338 
1.3 n.d. 0.310 1.252 n.d. 0.113 0.369 
1.4 n.d. 0.800 1.037 n.d. 0.299 0.367 
1.5 n.d. 0.887 0.954 n.d. 0.197 0.218 
1.6 n.d. 0.677 0.807 n.d. 0.189 0.163 
Key: n.d. = not detected 
 
Table 3.3 shows no response for (±)-MA, however, there was a high 
response for both (±)-PMA and (±)-MDMA (0.800 µA and 1.037 µA respectively) at 
1.4 E V−1 and pH = 3.2 using LC-FC-A system. In addition, using the LC-FC-B 
system also gave no response for (±)-MA, but (±)-PMA and (±)-MDMA produced a 
good response (0.299 V and 0.367 V respectively) at 1.4 E V−1 and pH = 3.2. The 
anodic peaks observed for (±)-PMA and (±)-MDMA were produced due to the 
oxidation of the aromatic nucleus of the molecules leading to the formation of a 
radical cation at low pH (pH = 3.2 ), but the anodic peak of (±)-MA cannot be 
observed at pH < 9 (Garrido et al., 2010; Masui et al., 1968; Adenier et al., 2004; 
Gulaboski et al., 2007; Švorc et al., 2014). 
 
Garrido et al. described the electrochemical oxidation mechanism of 
amphetamine-like drugs and this mechanism matched and explained the reasons  
why (±)-MDMA and (±)-PMA oxidised and produced an anodic peak at pH = 3.2 but 
no response was observed for (±)-MA at the same pH (Garrido et al., 2010). 
Methamphetamine has just one functional group (a secondary amine group) and the 
anodic peak was not observed because the secondary amine is present only in the 
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aliphatic part of (±)-MA. This is the most likely electro-oxidisable group (Garrido et 
al., 2010). The oxidation of the secondary amine group of (±)-MA occurs more 
readily in alkaline solution, and that was in agreement with the pKa = 9.5 of the 
amino group in (±)-MA (Logan, 2002; Švorc et al., 2014). Garrido et al. reported that 
at pH 2, (±)-MDMA produced an anodic peak corresponding to an oxidation on the 
aromatic nucleus of the (±)-MDMA molecules leading to the formation of a radical 
cation (Figure 3.2a). At pH 4, another anodic peak corresponding to the oxidation of 
a species formed by dimerisation of the initial radical cation was observed (Figure 
3.2b). Above pH 9, there is another anodic peak due to the oxidation of the 
secondary amine (Figure 3.2c) and this behaviour has been previously observed 
within the voltametric profile of (±)-MA (Garrido et al., 2010). 
 
 
Figure 3.2 Mechanism for the electrochemical oxidation of (±)-MDMA (Garrido et al., 2010) 
 
 
(±)-MDMA and (±)-PMA are electroactive drugs due to the oxidation of the 
primary and secondary amino groups and oxidation of the aromatic nucleus (Garrido 
et al., 2010; Milhazes et al., 2007; Adenier et al., 2004; Švorc et al., 2014). The 
oxidation of aliphatic amines in aqueous solution is believed to follow the 
mechanism shown in Figure 3.3 through the abstraction of an electron from the lone-
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pair of electrons on the nitrogen atom. In the case of (±)-PMA and (±)-MDMA, the 
oxidative process occurs more readily under acidic conditions (pH <5) (Garrido et 
al., 2010; Masui et al., 1968) (Figure 3.3). 
 
 
Figure 3.3 Electrochemical oxidation of aliphatic amines, E is the electrode surface (Adenier et al., 
2004). 
 
3.4.2 Optimisation of the linear velocity of amperometric detection 
The flow rate used in Section 3.3 and Section 3.4.1 was 1.2 mL min-1 because 
this flow rate produced the optimal response in both sections. However, in this part, 
due to the variation of the internal chamber volumes of the flow cells (LC-FC-A = 8 
μL vs LC-FC-B = 120 μL), the solution of the mixture (100 µg mL-1; prepared in 
section 2.6.2) was injected (n = 10) over the range of flow rates 0.9-1.2 mL min-1. 
The amperometric response was measured to determine the optimal linear velocity 
required for each system. Table 3.4 shows no response for (±)-MA (the reason is as 
explained in Section 3.3), but a good response for both (±)-PMA and (±)-MDMA 
(0.800 µA and 1.037 µA respectively) at a flow rate of 1.2 mL min-1, 1.4 E V−1 and 
pH = 3.2 using the LC-FC-A system. In addition, using the LC-FC-B system gave no 
response for (±)-MA, but with both (±)-PMA and (±)-MDMA, produced a good 
response (0.299 V and 0.367 V respectively) at a flow rate of 1.2 mL min-1, 1.4 E 
V−1. In fact, no response was observed at a flow rate less than 1 mL min-1 or more 
than 1.2 mL min-1.
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Table 3.4 The linear velocity for (100 µg mL-1) of (±)-MA, (±)-PMA and (±)-MDMA over the range 0.9 
to 1.2 mL min-1 using mobile phase 1, column: an ACE 3 C18 column (150 mm × 4.6 mm i.d., particle 
size: 3 μm); at temperature = 22 ⁰C and pH = 3.2 by using HPLC-AD detection in LC-FC-A and LC-
FC-B systems. 
Potential 1.4 V-1 
System LC-FC-A LC-FC-B 
Detection Peak Current (µA) Peak Current (µA) 
Linear Velocity  
(mL min-1) 
MA PMA MDMA MA PMA MDMA 
1.0 n.d. 0.555 0.786 n.d. 0.223 0.257 
1.2 n.d. 0.800 1.037 n.d. 0.299 0.367 
Key: n.d. = not detected 
 
3.4.3 Optimisation of pH of HPLC-UV and amperometric detection: 
Different pH (3.2– 7.2) were used to find the best pH to obtain the highest 
response for the analytes. However, the best response for HPLC-UV and HPLC-AD 
systems were at pH = 3.2. When the pH was increased, the detection response 
decreased.At pH 9, the drugs are in their free-base form with the ionisation in basic 
solution, , and will be precipitated from the solution. 
 
At pH extremes (2 or 8), the silica support of the HPLC columns begins to 
degrade via dissolution, reducing the performance of the column. The maximum 
amperometric response using the LC-FC-A system was 0.80 μA for (±)-PMA and 
1.03 μA for (±)-MDMA) observed at +1.4 E V−1 and a flow rate of 1.2 mL min-1 pH = 
3.2. As before, there was no response with (±)-MA. For the LC-FC-B system, the 
best amperometric responses were 0.30 μA for (±)-PMA and 0.37 μA for (±)-MDMA) 
observed at +1.4 EV−1, flow rate of 1.2 mL min-1 and pH = 3.2. Also, there was no 
response with the (±)-MA. In addition, the HPLC-UV detection in both systems was 
affected when the pH changed from 3.2 with a loss of resolution. 
 
Following the optimisation of amperometric detection (Sections 3.4.1, 3.4.2, 
and 3.4.3) in LC-FC-A and LC-FC-B systems, the analytes were eluted at 11.38 and 
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12.11 minutes for (±)-PMA and (±)-MDMA respectively in LC-FC-A system. In LC-
FC-B system, the elution was at 11.70 for (±)-PMA and 11.42 for (±)-MDMA. In 
addition, there was no peak current observed for (±)-MA in both systems (Figure 3.4 
and Figure 3.5). 
 
 
Figure 3.4 Amperogram of a solution containing (±)-MA, (±)-PMA (a) and (±)-MDMA (b) obtained on 
the LC-FC-A system (amperometric detection) using an ACE 3 C18 column (150 mm × 4.6 mm i.d., 
particle size: 3 μm); flow-rate: 1.2 mL min−1; mobile phase 1. 
 
Figure 3.5 Amperogram of a solution containing (±)-MA, (±)-PMA (a) and (±)-MDMA (b) obtained on 
the LC-FC-B system (amperometric detection) using an ACE 3 C18 column (150 mm × 4.6 mm i.d., 
particle size: 3 μm); flow-rate: 1.2 mL min−1; mobile phase 1. 
 
3.5 HPLC-AD method validation 
Method validation was performed by evaluating system suitability, selectivity 
and specificity, resolution, linearity, LOD, LOQ, robustness, inter- and intra-day 
(a) 
(a) 
(b) 
(b) 
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precision, and accuracy parameters in accordance with the ICH guideline (ICH, 
1996). Using simultaneous UV and amperometric detection to separate and detect 
a standard mixture of (±)-MA, (±)-PMA and (±)-MDMA, the HPLC-UV (UV detection) 
system and the two HPLC-AD systems (amperometric detection) (LC-FC-A and LC-
FC-B), required validation prior to deploying them in the analysis of the purchased 
street samples. The optimal conditions were used in this study are shown in Table 
3.5. The HPLC-UV and HPLC-AD systems used in this study were validated using 
standard mixtures containing (±)-MA, (±)-PMA and (±)-MDMA over a 10–100.0 μg 
mL−1 range. 
 
Table 3.5 Summary of the optimal conditions utilised for method validation in the analysis (±)-MA, 
(±)-PMA and (±)-MDMA by using LC-FC-A and LC-FC-B systems. 
Optimised chromatographic conditions 
Column 
Column A (Section 2.2.1; ACE 3 C18 column (150 
mm × 4.6 mm i.d. particle size: 3 μm)) 
Flow rate 1.2 mL min-1 
Solvent Mobile phase 1(Table 2.3) 
Column temperature (⁰C) 22 
Wavelength (nm) 210  
Injection volume (µL) 10  
Run time (mins) 15  
Optimised amperometric detection parameters 
Potential (V) +1.4  
Equilibration time (s) 10  
Data interval (s) 0.05  
Current range (mA) 1×10-6 – 1  
Total run time (s) 5000  
 
Table 3.6 summarises the validation data for the quantification of (±)-MA, (±)-
PMA and (±)-MDMA obtained by HPLC-UV (UV detection) in both LC-FC-A and LC-
FC-B systems and using a column A (Section 2.2.1), mobile phase 2 (Table 2.3) 
and detector wavelength (UV): 210 nm.  
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Table 3.6 Summary of HPLC-UV  validation data for the quantification of (±)-MA, (±)-PMA and (±)-
MDMA obtained on HPLC-UV with the LC-FC-A (impinging jet flow cell) or LC-FC-B (iCell flow cell) 
systems, using column (A) (Table 2.2); mobile phase 1(Section2.4); UV wavelength: 210 nm. 
System (Detection) LC-FC-A (HPLC-UV) 
Analyte MA PMA MDMA 
tR(min) 10.56a 11.36a 12.09a 
RRTc 1.14 1.06 1 
Capacity factor (k’) 9.56 10.36 11.09 
N (plates)d 20860.5 (139070) 21077 (140513) 20780 (138533) 
H (m) 7.19×10-06 7.1210-06 7.22×10-06 
Resolution (Rs) - 2.36 2.13 
Asymmetry factors 0.81 0.83 0.83 
LODc (µg mL-1)e 0.35 0.33 0.54 
LOQd (µg mL-1)f 1.05 0.99 1.62 
Co-efficient of regression 
(r2) 
0.999g 0.999h 0.999i 
10 µg mL-1 0.71 0.95 0.44 
20 µg mL-1 0.17 0.38 0.31 
40 µg mL-1 0.26 0.42 0.16 
60 µg mL-1 0.10 0.27 0.10 
80 µg mL-1 0.06 0.13 0.05 
100 µg mL-1 0.16 0.20 0.08 
aMeasured from the retention time of uracil (10 μg mL−1) eluting from the column (t0 = 
1.3).bMeasured from the retention time of uracil (10 μg mL−1) eluting from the column (t0 = 1.45) c 
Relative retention time (concerning MDMA). d N is plates per m. eLimit of Detection. fLimit of 
Quantification. gy = 18.436x - 1.782. hy = 14.133x - 1.7333. iy = 14.233x - 1.6383. 
 
Table 3.7 shows a summary of the validation data for the quantification of (±)-
MA, (±)-PMA and (±)-MDMA obtained on either flow cell LC-FC-A (impinging jet flow 
cell; amperometric detection) or LC-FC-B (iCell channel flow cell; amperometric 
detection) systems using a column A (Section 2.2.1), mobile phase 2 (Table 2.3). 
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Table 3.7 Summary of HPLC-AD) validation data for quantification of (±)-MA, (±)-PMA and (±)-MDMA 
obtained on either the LC-FC-A (impinging jet flow cell) or LC-FC-B (iCell flow cell) systems using 
column (A) Table 2.2; mobile phase 2. 
System 
(Detection) 
LC-FC-A (AD) LC-FC-B (AD) 
Analyte MA PMA MDMA MA PMA MDMA 
tR(min) n.d. 11.37b 12.10b n.d. 11.69a 12.41a 
RRTc n.d. 1.06 1.00 n.d. 1.06 1.00 
LODd (µg mL-1) n.d. 5.86 4.68 n.d. 6.12 4.64 
LOQe (µg mL-1) n.d. 17.60 14.19 n.d. 18.56 14.07 
Co-efficient of 
regression (r2) 
n.d. 0.975h 0.984i n.d. 0.969f 0.982g 
Precision (%RSD) (n=6) 
10 µg /mL n.d. 0.99 0.51 n.d. 0.88 0.81 
20µg /mL n.d. 0.62 0.25 n.d. 0.50 0.81 
40µg mL-1 n.d. 0.70 0.11 n.d. 0.65 0.47 
60µg mL-1 n.d. 0.58 0.12 n.d. 0.73 0.43 
80µg mL-1 n.d. 0.60 0.11 n.d. 0.94 0.54 
100 µg mL-1 n.d. 0.39 0.08 n.d. 0.45 0.41 
aMeasured from the retention time of uracil (10 μg mL−1) eluting from the column (t0 = 1.3). 
bMeasured from the retention time of uracil (10 μg mL−1) eluting from the column (t0 = 1.45). 
cRelative retention time (with respect to MDMA). d Limit of Detection Limit of Quantification, fy = 
0.0022x + 0.0814. gy = 0.0029x + 0.0733. hy = 0.0104x - 0.0699.  iy = 0.0154x - 0.0991. Note: n.d. 
= not detected. 
 
3.5.1 System suitability test 
These tests were used for both systems (LC-FC-A and LC-FC-B) to confirm 
that the resolution and reproducibility of the chromatographic system were suitable 
and that the entire chromatographic system was effective, not only before use, but 
also during the time of analysis. System suitability was established by using UV 
detection data (resolution, number of plates and peak asymmetry factor obtained 
from HPLC-UV software) (ICH, 1996). 
 
The number of theoretical plates (N) explained the sharpness of the peaks and 
efficiency of the column. The number of theoretical plates of all analytes in HPLC-
UV for both LC-FC-A and LC-FC-B systems were >20,000). The greater the number 
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of theoretical plates, the greater the efficiency of the column. For (±)-MA, the number 
of theoretical plates was determined (Equation 3.1) to be about  20860.5 and, in 
addition, the parameter was calculated for the other two analytes: N = 21077 for (±)-
PMA and N = 20780 for (±)-MDMA respectively using both the LC-FC-A and LC-
FC-B systems (Table 3.6).Moreover, the similarity in the number of theoretical plates 
in both systems (LC-FC-A and LC-FC-B) confirmed that both systems were stable 
and had the same performance and effectiveness of the columns. 
 
𝑵 = 𝟓. 𝟓𝟒 (
𝒕𝑹
𝑾𝟎.𝟓
)2  
Equation 3.1Number of Plates 
Where: N = number of theoretical plates 
tR = retention time of peak of interest 
W0.5 = width at half the peak height 
 
Capacity factor (K) indicated how long each compound was retained by 
stationary phase in the column and was calculated as follows: 
𝑲 = 𝒕𝑹 − 𝒕𝟎/𝒕𝟎   
Equation 3.2Capacity factor (K) 
Where:  t0= unrestrained peak retention time 
              tR =retention time of peak of interest 
 
The capacity factor(s) were calculated to be found in both LC-FC-A and LC-
FC-B systems as 9.56 for (±)-MA, 10.36 for (±)-PMA and 11.09 (±)-for MDMA (Table 
3.6).  
 
Asymmetry factor (As) 
It’s characterised the peak shape of the chromatogram and any deviation of 
the peak shape makes difficulty to acquisition of information from the 
chromatographic signal, such as the retention time, the peak area, the peak 
overlapping, etc.(Pápai and Pap, 2002).   
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If asymmetric factor> 1, there is peak tailing. In this study, the asymmetric factor for 
all analytes using both LC-FC-A and LC-FC-B (UV detection data) systems were 
found within the limit < 1 (Table 3.6). 
 
3.5.2 Resolution (Rs) 
The resolution is defined in a chromatographic separation as a quantitative 
measure of how well two elution peaks are differentiated from each other (Equation 
3.3). It is expressed as the difference of the distance between the twopeak in 
retention times (tR2 – tR1), divided by the combined widths (w1 and w2) of the two 
closely eluting peaks (ICH, 1996). 
𝑹𝑺 = (𝒕𝑹𝟐 − 𝒕𝑹𝟏)/𝟐(𝑾𝟏 − 𝑾𝟐)  
Equation 3.3 Resolution (Rs) 
Where: tR2= retention time of second peak  
tR1= retention time of first peak  
W1 = width of first peak  
W2 = width of second peak  
 
Table 3.6 shows (±)-MA was eluted in both LC-FC-A and LC-FC-B systems at 
10.56 min, (±)-PMA eluted at 11.36 min with a high resolution of 2.36 and (±)-MDMA 
eluted at 12.09 min with a high resolution of 2.13. Therefore, the values of 2.36 and 
2.13 obtained in this present study suggest that the HPLC-UV system was able to 
sufficiently separate target compounds during the analysis. 
 
3.5.3 Selectivity (separation) factor (α) and specificity: 
Selectivity is the most important parameter used in analytical method 
validation. It is the ability to separate the target analyte from interference present in 
the sample to provide accurate analyte measurements. Commonly, the term 
‘selectivity’ refers to the ability of the method to produce responses for a number of 
analytes in a complex matrix and its ability to discriminate between them (Vessman, 
1996). The selectivity factor is usually measured as a ratio of the retention factors 
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(capacity factor, k) of the two peaks in Equation 3.4 and can be visualised as the 
distances between the two peaks. 
𝜶 =  𝑲𝟐/𝑲𝟏  = (𝒕𝟐 − 𝒕𝟎)/(𝒕𝟏 −  𝒕𝟎)  
Equation 3.4 Selectivity (separation) factor (α) 
Where: K2= capacity factor of second peak  
K1= capacity factor of first peak  
t2 = retention time of first peak 
t1 = retention time of second peak 
t0 = unrestrained peak retention time 
 
Selectivity, therefore, is greatest priority in analytical method developments 
(Aboul-Enein, 2000). By using UV detection in HPLC analysis, the term of selectivity 
is very common since it can detect many components present in a sample. The 
selectivity should be tested against all components present in the sample matrix and 
these components or interferences have to be separated with acceptable resolution 
(Rs >1.5) (Maldener, 1989). 
 
The selectivity, tested by using both LC-FC-A and LC-FC-B systems, showed 
that (±)-MA eluted at 10.56 mins and (±)-PMA at 11.36 mins with a resolution (Rs) 
of 2.36 and (±)-MDMA eluted at 12.09 mins, Rs = 2.13. That means this method has 
good selectivity to separate (±)-MDMA from the other analytes (Figure 3.1). In 
addition, the specificity of this method was expressed by using the solutions of the 
UV-inactive analytes sucrose, mannitol, and lactose (which are commonly used as 
diluents, prepared in Section 2.6.7). These were shown not to interfere with the three 
target analytes – thereby confirming the specificity of the proposed method. 
 
3.5.4 Linearity 
Linearity is used to assess the ability (within a given range) of obtaining a 
directly proportional relationship between an analyte response and its 
concentration. Linearity was evaluated across a range of concentrations by visual 
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inspection of the plot of signals as a function of analyte concentration or using the 
correlation coefficient, r (usually represented as R2). Moreover, the statistical 
calculation was performed to provide the degree of linearity (ICH, 1996). The 
standards used were 10-100 µg mL-1 injected as six replicates using the optimised 
chromatographic condition at 210 nm using an ACE 3 C18 column (150 mm × 4.6 
mm i.d., particle size: 3 μm). The calibration was constructed (Figure 3.6a) and a 
good linear response was obtained for HPLC-UV detection in LC-FC-A and LC-FC-
B systems. For (±)-MA, R2 = 0.999 with precision (%RSD = 0.06–0.71%; n = 6); for 
(±)-PMA, R2 = 0.999 with precision (%RSD = 0.13–0.95%; n = 6) and for (±)-MDMA, 
R2 = 0.999 with precision (%RSD = 0.05–0.44%; n = 6). That explained the excellent 
linearity for the HPLC-UV system (Appendix Table 9.1, Table 9.2, and Table 9.3). 
 
The corresponding liquid chromatography-amperometric detection system, 
[LC-FC-A], employing the commercially available, impinging jet, flow cell (LC-FC-
A), was validated using standard mixtures containing 10-100 μg mL−1 of (±)-MA, (±)-
PMA and (±)-MDMA. However, there was not an electrochemical response to (±)-
MA Figure 3.6c. The good linear response of HPLC-AD (amperometric detection) in 
LC-FC-A system for (±)-PMA, R2 = 0.975 with precision (%RSD = 0.39–0.99%; n = 
6), and for (±)-MDMA, R2 = 0.984 with precision (%RSD = 0.08–0.51%; n = 6) 
(Appendix Table 9.4 and Table 9.5). 
 
The liquid chromatography-amperometric detection system [LC-FC-B], 
employing the iCell channel flow cell (LC-FC-B), was validated (in terms of UV-
detection) using standard mixtures containing the strongly UV-absorbing 
components (±)-MA, (±)-PMA and (±)-MDMA over a 10–100 μg mL−1 range. There 
was no electrochemical response observed for (±)-MA (Figure 3.6d) as explained in 
Section 3.4.1. The good linear response of amperometric detection in the LC-FC-B 
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system for (±)-PMA, R2 = 0.969 with precision (%RSD = 0.50 – 0.94%; n = 6) and 
for (±)-MDMA, R2 = 0.982 with precision (%RSD = 0.41 – 0.81%; n = 6) (Appendix: 
Table 9.6). In comparing the linearity of three systems (HPLC-UV, LC-FC-A and LC-
FC-B), it was observed that the linearity of HPLC-UV is the best, and then the 
linearity of LC-FC-A and the last one is the linearity of LC-FC-B. Therefore, the 
HPLC-UV system still the best analytical technique with high sensitivity for the 
analysis of (±)-MA, (±)-PMA and (±)-MDMA. 
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Figure 3.6 The linearity of (±)-MA (circles), (±)-PMA (squares) and (±)-MDMA (triangles) by using a) HPLC-UV of LC-FC-A and LC-FC-B systems. b) HPLC-
AD detection of LC-FC-A system. c) HPLC-AD detection of LC-FC-B system. 
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3.5.5 Limit of detection (LOD) 
The detection limit was calculated to determine the lowest analyte 
concentration which can be detected, and not necessarily to quantitate it. There are 
several methods to determine the LOD (ICH, 1996), and in this study, the LOD was 
determined based on the standard deviation of the response and the slope of the 
calibration curve expressed as:  
 
𝑳𝑶𝑫 = 𝟑. 𝟑(𝑺𝑫)/𝑺 
Equation 3.5 Limit of detection 
Where: S = the slope of the calibration curve (estimated from the calibration curve of the analyte)  
SD = the standard deviation of the response (determined based on calibration curve, 
the standard deviation of y-intercepts of regression lines used as the standard deviation 
(Shabir, 2003). 
 
The limits of detection of (±)-MA, (±)-PMA and (±)-MDMA obtained using 
HPLC-UV detection of LC-FC-A and LC-FC-B systems (using the standard deviation 
of the response and the slope of the calibration graph) were found to be 0.35, 0.33 
and 0.54 µg mL-1 respectively (the validation parameters, for the HPLC-UV system, 
are summarised in Table 3.6). In a previous study, the LOD reported by Cumba et 
al. (Cumba et al., 2016) for (±)-MDMA and (±)-PMA  was lower than the LOD 
reported in this study, 0.04 μg mL−1 and 0.08 μg mL−1 respectively. This variation is 
because in this study the linear range used was 10-100 μg mL−1, which is higher 
than the linear range of by Cumba et al. (1.25-40 μg mL−1) in their previous study. 
 
In the corresponding amperometric detection; the limits of detection using 
HPLC-AD detection of LC-FC-A system for (±)-PMA and (±)-MDMA were 
determined (using the standard deviation of the response and the slope of the 
calibration graph) as being 5.86 μg mL−1 and 4.45 μg mL−1 respectively. The LODs 
using HPLC-AD in LC-FC-B system for (±)-PMA and (±)-MDMA were 6.12 μg mL−1 
and 4.64 μg mL−1 respectively. In addition, the LODs using HPLC-AD detection of 
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LC-FC-B system for PMA and (±)-MDMA were 6.12 μg mL−1 and 4.64 μg 
mL−1respectively. The validation parameters, for the LC-FC-A system, are 
summarised in Table 3.7. 
 
The LODs for amperometric detection in both LC-FC-A and LC-FC-B 
systems were higher than the limit of detection of HPLC-UV detection techniques 
due to used high analytical linear range (high concentration). The LODs in this study 
by using amperometric detection are higher than the LODs were described by 
Cumba et al. using cyclic volumetric detection (0.04 µg mL-1 of (±)-MDMA and 0.03 
µg mL-1 of (±)-PMA). This variation is because in this study a dynamic system 
through the flow cell was used instead of the static system used by Cumba et al. 
Therefore, the time of the analytes on the surface of the electrode was not long for 
oxidation. 
 
3.5.6 Limit of quantification 
The limit of quantification was performed to determine the lowest 
concentration of the analytes in the sample with acceptable precision and accuracy 
under the stated operating conditions of the method. The LOQ was determined 
based on the standard deviation of the response and the slope expressed as: 
𝑳𝑶𝑸 = 𝟏𝟎(𝑺𝑫 𝑺⁄ ) 
Equation 3.6 Limit of quantification 
Where S = the slope of the calibration curve (estimated from the calibration curve of the 
analyte)  
SD = the standard deviation of the response ( estimated based on calibration curve, the 
standard deviation of y-intercepts of regression lines used as the standard deviation 
(Shabir, 2003).  
 
The calculation of LOQs for (±)-MA, (±)-PMA and (±)-MDMA using HPLC-UV 
detection (LC-FC-A and LC-FC-B systems) was determined by the standard 
deviation of the response and the slope to be 1.05, 0.99 and 1.62 μg mL−1 
respectively as summarised in Table 3.6. The LOQs of Cumba’s et al. study were 
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0.26 and 0.12 μg mL−1 for (±)-PMA and (±)-MDMA respectively. These LOQs were 
lower than the LOQs in this study because Cumba et al. used a lower linear range 
concentration (1.25-40 μg mL−1).  
 
The limit of quantification using HPLC-AD detection of LC-FC-A system was 
calculated to be 17.60 μg mL−1 for (±)-PMA and 14.19 μg mL−1 for (±)-MDMA (Table 
3.7). The limits of quantification by using HPLC-AD detection of LC-FC-B for (±)-
PMA and (±)-MDMA were 18.56 μg mL−1 and 14.07 μg mL−1 respectively (Table 
3.7). In comparing the LOQs of this study with that obtained by Cumba et al. (0.04 
μg mL−1 and 0.03 μg mL−1 of (±)-PMA and (±)-MDMA respectively (pure sample), or 
0.25 μg mL−1 and 0.14 μg mL−1 of (±)-PMA and (±)-MDMA as mixture), in this study, 
the LOQs were higher due to this study using a linear range concentration of 10-
100 μg mL−1 in the LOD, (Section 3.7.6).  
 
3.5.7 Robustness 
ICH defined the robustness as a measure of the capacity of the analytical procedure 
to remain unaffected by small variations in method parameters, and it indicates the 
reliability during normal usage. One of the robustness evaluations is the system 
suitability test (resolution test etc.) to ensure the validity of the HPLC method. The 
HPLC experimental variations include: 1) the effect of a minor change in 
temperature; 2) the effect of minor variations in the composition of the mobile phase; 
3) chromatographic column variation; 4) the effect of minor changes in flow rate; 5) 
the effect of minor changes in pH of the mobile phase (USE, 2005; Kumar et al., 
2010; Bhoomaiah, 2012; Kumar et al., 2012; Baldania et al., 2008; Kaur et al., 2010; 
Sreedevi et al., 2013; Dhakane and Ubale, 2012; PYLA et al.; Sandhya et al., 2013). 
 
In this study, the effect of temperature variation and change of composition 
ratio of the mobile phase were analysed to ensure that the HPLC-UV method was 
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unaffected by these changes. Solutions of (±)-MA, (±)-PMA and(±)-MDMA (all at 60 
µg mL-1) using six injections at different temperatures (20⁰C, 22⁰C, and 24⁰C) were 
tested  on the HPLC-UV equipment for both LC-FC-A and LC-FC-B systems (the 
optimal conditions are highlighted and represented for comparison in Tables 3.8 and 
3.9). The tables present the effect of small changes of temperature by measuring 
the relative retention time (RRT) of (±)-MA, (±)-PMA and (±)-MDMA. There was no 
change with the different temperatures that were used. That means this method has 
good robustness. At the same time, in comparing the relative retention time data in 
Table 3.8 (the optimal conditions are highlighted and presented for comparison for 
both systems LC-FC-A and LC-FC-B),no change was found in the RRT with minor 
modifications of temperature although both systems had the same method 
conditions. These results produced confirmation that this method has excellent 
robustness. 
 
Mixture solutions of (±)-MA, (±)-PMA and (±)-MDMA (all at 60 µg mL-1) were 
prepared with different proportions of acetonitrile: 10mM phosphate buffer – 100mM 
potassium chloride (pH 3.2) in mobile phase 1. The proportions were 11: 89 v/v, 
10:90 v/v and 9:91v/v and six injections were made for each mixture solution. Table 
3.9 shows the effect of a minor change in the composition ratio of mobile phase on 
the HPLC-UV analysis method by measuring relative retention time of (±)-MA, (±)-
PMA and (±)-MDMA. The data in Table 3.9 (the optimal conditions are highlighted 
and represented for comparison) confirm the method was unaffected by changing 
the composition ratio of the mobile phase. Moreover, in comparing the results of 
systems LC-FC-A and LC-FC-B, there were similar RRTs, confirming that this 
method has good robustness.
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Table 3.8 Relative retention time (RRT) data of (±)-MA, (±)-PMA and (±)-MDMA using HPLC-UV 
detection in LC-FC-A and LC-FC-B systems with different temperatures used in the analysis. 
Concentration 
 (µg mL-1) 
RRT (20 °C) RRT (22 °C) RRT (24 °C) 
MA PMA MDMA MA PMA MDMA MA PMA MDMA 
60 1.141 1.062 1.000 1.146 1.063 1.000 1.148 1.063 1.000 
60 1.141 1.062 1.000 1.146 1.063 1.000 1.148 1.063 1.000 
60 1.149 1.062 1.000 1.148 1.063 1.000 1.151 1.063 1.000 
60 1.150 1.062 1.000 1.142 1.062 1.000 1.143 1.063 1.000 
60 1.148 1.063 1.000 1.145 1.062 1.000 1.147 1.063 1.000 
60 1.147 1.063 1.000 1.141 1.062 1.000 1.149 1.063 1.000 
Average 1.146 1.062 1.000 1.145 1.062 1.000 1.148 1.063 1.000 
RSD% 0.330 0.044 0.000 0.220 0.040 0.000 0.229 0.021 0.000 
 
 
Table 3.9 Relative retention time (RRT) of (±)-MA, (±)-PMA and (±)-MDMA using HPLC-UV detection 
in LC-FC-A and LC-FC-B systems with minor changes in the composition ratio of the mobile phase. 
Concentration 
µg mL-1 
RRT 
(12: 88% v/v) 
acetonitrile: buffer solution 
pH = 3.2, 
Section 2.4 
(10:90% v/v) 
 acetonitrile: buffer solution 
 pH = 3.2,  
Section 2.4 
(8:92% v/v) 
acetonitrile: buffer solution 
 pH = 3.2,  
Section 2.4 
MA PMA MDMA MA PMA MDMA MA PMA MDMA 
60 1.132 1.064 1.000 1.139 1.065 1.000 1.132 1.061 1.000 
60 1.133 1.065 1.000 1.139 1.065 1.000 1.134 1.065 1.000 
60 1.132 1.064 1.000 1.138 1.065 1.000 1.134 1.065 1.000 
60 1.132 1.064 1.000 1.138 1.065 1.000 1.133 1.065 1.000 
60 1.132 1.064 1.000 1.138 1.065 1.000 1.133 1.065 1.000 
60 1.131 1.064 1.000 1.137 1.065 1.000 1.133 1.065 1.000 
Average 1.132 1.064 1.000 1.138 1.065 1.000 1.133 1.064 1.000 
RSD% 0.039 0.023 0.000 0.047 0.024 0.000 0.073 0.172 0.000 
 
3.5.8 Inter-and intra-day precision 
The precision of the analytical procedure was measured over a short interval 
of time (repeatability) (ICH, 1996; Kumar et al., 2010; Bhoomaiah, 2012; Kumar et 
al., 2012; Baldania et al., 2008; Kaur et al., 2010).Twelve replicate injections of a 
mixed solution of (±)-MA, (±)-PMA and(±)-MDMA (all at 60 µg mL-1; section 2.6.2) 
were made on the same day (6 in the morning and 6 in the afternoon).The same 
procedure was repeated with six injections on the following day. However, the 
results’ precision showed little change between the HPLC-UV detection and 
amperometric detection in both systems LC-FC-A and LC-FC-B, and t the HPLC-
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UV detection in both systems had an excellent precision for the three compounds  
as shown by the RSD% of less than 1% (Table 3.10). In terms of amperometric 
detection, both systems (LC-FC-A and LC-FC-B) did not detect (±)-MA, as explained 
in Section 3.4.1, but achieved good precision for both (±)-PMA and (±)-MDMA.  
 
Table 3.10 The relative standard deviation (RSD %) of inter- and intra-day peak current values for 
(±)-MA, (±)-PMA and (±)-MDMA using HPLC-UV and HPLC-AD detection in both systems (LC-FC-
A and LC-FC-B). 
RSD % 
n =12 detection 
HPLC-UV 
peak area (mAU) 
HPLC-AD 
(LC-FC-A) 
peak current (µA) 
HPLC-AD 
(LC-FC-B) 
peak current (µA) 
Inter-day 
precision 
MA 0.099 n.d. n.d. 
PMA 0.199 0.933 0.943 
MDMA 0.115 0.128 0.412 
intra-day 
precision 
MA 0.069 n.d. n.d. 
PMA 0.223 0.740 0.943 
MDMA 0.161 0.664 0.412 
Key: (n.d.) = not detected. 
 
Table 3.10 shows the RSD% values were calculated from raw data (Appendix: 
Table 9.7) of the peak area of HPLC-UV detection (RSD% = 0.069 – 0.223 for LC-
FC-A and LC-FC-B) or peak current of amperometric detection (RSD% = 0.128 – 
0.933 for LC-FC-A and 0.412 - 0.943 for LC-FC-B) were less than 1%. The value of 
the RSD% is suggested to be ≤ 1% as an appropriate precision criterion for repetitive 
injections to assess the precision of the instrument in analytical method validation 
(Green, 1996). These results illustrate the ability of this method and the efficiency 
of these systems to be applied to routine analysis. 
 
3.5.9 Accuracy  
The accuracy test was performed to determine the closeness of agreement 
between the experimental values to an actual value, which is acceptable, either as 
a true conventional value or an accepted reference value (ICH, 1996; Kumar et al., 
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2010; Bhoomaiah, 2012; Kumar et al., 2012; Baldania et al., 2008; Kaur et al., 2010). 
Accuracy studies were performed at the 75, 100 and 125 % level of target 
concentration. Recovery data were obtained from triplicate samples at each level of 
label claim. Percentage recovery for (±)-MDMA and (±)-PMA were calculated for 
each sample and demonstrated an excellent accuracy range of 98.2% - 101.9% by 
using HPLC-UV and HPLC-AD in both system LC-FC-A and LC-FC-B. However, 
the percentage recovery for (±)-MA was between 99.5% - 101.1% using HPLC-UV 
but no peak was observed using HPLC-AD in either flow cells LC-FC-A or LC-FC-B 
(Table 3.11). 
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Table 3.11 Accuracy data expressed as the percentage recovery of a mixture of (±)-MA, (±)-PMA and (±)-MDMA by using HPLC-UV and HPLC-AD in both systems (LC-FC-
A and LC-FC-B). 
Detection HPLC-UV 
HPLC-AD 
(LC-FC-A) 
HPLC-AD 
(LC-FC-B) 
Compound 
Concentration (µg 
mL-1) 
Theoretical 
recovery 
(µg mL-1) 
Actual 
recovery 
(µg mL-1) 
%Recovery 
(n=3) 
Actual 
recovery (µg 
mL-1) 
%Recovery 
(n=3) 
Actual 
recovery 
(µg mL-1) 
%Recovery 
(n=3) 
MA 
60 (75%) 
60.6 61.29 101.1 (±0.22) n.d. n.d. n.d. n.d. 
PMA 60.6 61.21 101.0 (±0.35) 60.5 99.8 (±0.52) 61.36 101.2 (±0.90) 
MDMA 60.6 61.43 101.3 (±0.03) 63.76 105.2 (±0.11) 61.62 101.6 (±0.56) 
MA 
80 (100%) 
80.8 81.39 100.7 (±0.06) n.d. n.d. n.d. n.d. 
PMA 80.8 81.35 100.6 (±0.10) 81.04 100.2 (±1.94) 82.39 101.9 (±0.32) 
MDMA 80.8 81.65 101.1 (±0.03) 81.87 101.3 (±0.11) 82.3 101.8 (±0.40) 
MA 
100 (125%) 
101.0 100.75 99.7 (±0.14) n.d. n.d. n.d. n.d. 
PMA 101.0 101.04 100.0 (±0.20) 99.24 98.2 (±0.44) 101.08 100.0 (±0.88) 
MDMA 101.0 100.58 99.5 (±0.02) 101.1 100.0 (±0.08) 101.97 100.9 (±0.59) 
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3.6 Application of methodology in a forensic drug analysis context 
The viability of the proposed electroanalytical oxidation approach for detecting 
MA, PMA and MDMA in street samples was tested on five MDMA street samples 
that were obtained from the University of Dundee and who had previously analysed 
these samples and determined that these samples contained MDMA. These 
samples were arbitrarily labelled as MDMA-1, MDMA-2, MDMA-3, MDMA-4, and 
MDMA-5.  
 
The street samples were analysed (in triplicate) using the validated HPLC-AD 
protocol, using both flow cells (LC-FC-A and LC-FC-B), at a concentration of 80 μg 
mL−1[section 2.6.9]. The results of HPLC-UV in both systems, were similar and the 
five street samples contained MDMA (Table 3.12) the qualitative and quantitative 
results, obtained from the amperometric detector (HPLC-AD) in both systems also 
confirmed the constitution of the five street samples a containing MDMA (Table 
3.12). The variation in the results was due to the adsorption of the analytes onto the 
electrode surface of the GSPE. However, as the iCell channel flow cell (LC-FC-B) 
had a larger chamber volume that had an effect on reducing mass transfer/ diffusion 
to the electrode surface, due to sample dispersion which may also have been a 
factor in reducing the sensitivity of the GSPE sensor platform (Zuway et al., 2015). 
The above results indicate that the HPLC-AD (amperometric detection) system has 
lower sensitivity than simple HPLC-UV (UV detection). In this work, the proposed 
HPLC-AD protocol can be considered suitable for the detection and quantification 
of the MDMA either in its pure formor as a mixed product. In addition, MA and PMA 
were studied with MDMA in this chapter but not detected in all street samples. That 
means all the street samples of MDMA were pure. 
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Table 3.12 Direct comparison between quantitative data obtained by HPLC-UV and amperometric detection (AD), using the LC-FC-A (impinging jet flow cell), or LC-FC-B 
(iCell channel flow cell) systems, for the analysis of the street samples. 
Detection HPLC-UV (%w/w) (n=3) 
HPLC-AD (LC-FC-A) 
 (%w/w) (n=3) 
HPLC-AD (LC-FC-B) 
 (%w/w) (n=3) 
Sample MA PMA MDMA MA PMA MDMA MA PMA MDMA 
MDMA-1 n.d. n.d. 35.89 (±0.27) n.d. n.d. 32.29 (±2.70) n.d. n.d. 36.2 (±2.66) 
MDMA-2 n.d. n.d. 14.94 (±2.89) n.d. n.d. 16.71 (±2.95) n.d. n.d. 16.62 (±1.78) 
MDMA-3 n.d. n.d. 15.69 (±0.49) n.d. n.d. 16.51 (±1.64) n.d. n.d. 16.40 (±1.76) 
MDMA-4 n.d. n.d. 28.49 (±1.31) n.d. n.d. 24.77 (±2.34) n.d. n.d. 25.84 (±1.59) 
MDMA-5 n.d. n.d. 22.14 (±0.66) n.d. n.d. 19.64 (±2.20) n.d. n.d. 21.62 (±2.54) 
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3.7 Conclusions 
For the first time, the qualitative and quantitative analysis of (±)-MDMA using 
a combination of HPLC with amperometric detection has been reported using two 
types of flow cell, either an impinging jet flow cell (LC-FC-A) or iCell channel flow 
(LC-FC-B) cell, incorporating disposable, embedded graphite, screen-printed 
macroelectrodes (GSPE).  
 
The limit of detection and limit of quantification for both flow cell were similar. 
Both flow cells have higher detection limits than standard HPLC-UV detection, 
nevertheless, both flow cells showed good agreement between the quantitative 
electroanalytical data, thereby making them suitable for the detection and 
quantification of MDMA, either in its pure form or within a mixed product. However, 
this protocol can be used to detect and quantify MDMA and PMA using both UV-
detection and amperometric detection in LC-FC-A and LC-FC-B systems, but still 
has some limitations. The limitations of this protocol are such that it can be used just 
for electroactive analytes and analytes that can become oxidised over the pH range 
2-8 t to be suitable with the HPLC system (column).  
 
In addition, HPLC-AD cannot be used for oxidizing the analytes at potentials 
higher than those allowed by the potential window of electrodes (e.g. compounds 
containing primary amines such as amphetamine and methamphetamine (Pecková, 
2011). The composition of the mobile phase must be compatible with the material 
of the detection cells housing GSPEs (Pecková, 2011). Despite these limitations to 
using the high performance liquid chromatography–amperometric detection 
protocol, it was used in chapter 4 for the detection and quantification of NSPs which 
are the synthetic cathinones, (±)-mephedrone and (±)-4-MEC, in presence the 
common adulterant, caffeine. 
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4 Chapter 4: Detection and quantification of (±)-mephedrone (±)-4-MEC and 
common adulterants by using High Performance Liquid Chromatography-
Amperometric Detection 
 
 
4.1 Introduction: 
The increase in the abuse and production of cathinone-derived of NPS led to 
the requirement for rapid, selective and sensitive methods for their qualitative and 
quantitative analysis. The electrochemical detection for cathinone derivatives has 
been demonstrated to be an effective method either in their pure form or in mixtures 
with adulterants (Smith et al., 2014a; Smith et al., 2014b). However, the reported 
electrochemical techniques are limited in their ability to distinguish between 
structurally similar cathinone derivatives (for example: (±)-mephedrone and (±)-4-
MEC (Table 4.1) when they are both present in a mixture. 
 
The analytical method developed in chapter 3 was succesfulin detecting and 
quantifying (±)-MDMA in its pure form or in the presence (±)-PMA. The aim of this 
chapter was to demonstrate the combination of high performance liquid 
chromatography HPLC and amperometric detection (AD) for the qualitative and 
quantitative analysis of (±)-4-mephedrone and (±)-4-MEC using either a 
commercially available impinging jet (LC-FC-A) or custom-made iCell channel (LC-
FC-B) flow-cell system incorporating embedded graphite screen-printed 
macroelectrodes (GSPEs).  
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Table 4.1The chemical structures of (±)-mephedrone and (±)-4-MEC 
 
Compound R1 
(±)-Mephedrone CH3 
(±)-4-MEC CH2CH3 
 
Table 4.2 summarises various analytical methods reported in the literature that 
have been used for the detection of (±)-mephedrone and (±)-4-MEC. The results of 
different protocols that have been used include the results of this study for 
comparison. 
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Table 4.2 Analytical methods in the literature that have been used to detect (±)-mephedrone and (±)-4-MEC 
Analyte Analytical method Matrix Analytical linear range Limit of detection References 
(±)-Mephedrone.HCl LC-MS/MS Plasma 78–10,000 ng mL-1 39 ng mL-1 (Maskell et al., 2011) 
(±)-4-MEC.HBr LC-MS/MS Blood, urine 10–1,000 ng mL-1 
0.96 ng mL-1 (blood), 
0.68 ng mL-1 (urine) 
(Gil et al., 2013) 
(±)-Mephedrone.HCl LC-MS/MS Blood 1–100 ng mL-1 0.08 ng mL-1 (Adamowicz et al., 2013) 
(±)-Mephedrone.HCl LC-MS/MS Blood, urine 20–2,000 ng mL-1 
1 ng mL-1(blood), 
2 ng mL-1 (urine) 
(Cosbey et al., 2013) 
(±)-Mephedrone.HCl HPLC-UV Mobile phase 0.5 -25 µg mL-1 0.1 µg mL-1 (Santali et al., 2011) 
(±)-Mephedrone.HCl 
HPLC-UV Mobile phase 0.5-10 µg mL-1 
0.03 µg mL-1 
(Khreit et al., 2012) 
(±)-4-MEC.HBr 0.03 µg mL-1 
(±)-Mephedrone.HCl 
Electrochemistry (electrochemical 
reduction) 
Mobile phase 2.7×10-4– 1.8 µg mL-1 2.2 × 10-4 µg mL-1 (V. Krishnaiah) 
(±)-Mephedrone.HCl Electrochemistry (electrochemical 
reduction) 
Mobile phase 0.00–200.00 μg mL–1 
11.80 μg mL–1 
(Smith et al., 2014b) 
(±)-4-MEC.HBr 11.60 μg mL–1 
(±)-Mephedrone.HCl Electrochemistry (electrochemical 
oxidation) 
Mobile phase 16–350 μg mL–1 
39.8 μg mL–1 
(Smith et al., 2014a) 
(±)-4-MEC.HBr 84.2 μg mL–1 
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4.2 Ultraviolet-visible spectroscopy (UV) determination of λmax 
The UV/vis spectrophotometer was used to determine the wavelength producing the highest absorption for (±)-mephedrone and (±)-4-
MEC. The wavelength (λmax = 264 nm) showing the most intense absorption was recorded and provided the highest absorbance reading for (±)-
mephedrone (A = 0.895, c = 9.1x10-4 g/100 mL) and (±)-4-MEC (A = 0.382, c = 9.1x10-4 g/100 mL). This wavelength matched data reported by 
Santali et al. for (±)-mephedrone obtained in deionised water (λmax = 263.5 nm, A = 0.651, c = 9.1×10−4 g/100 mL) or 0.1 M aqueous hydrochloric 
acid (λmax = 263.5 nm, A = 0.662, c = 9.1×10−4 g/100 mL) (Santali et al., 2011). 
 
4.3 HPLC Method Development:  
The application of HPLC-UV and LC-MS techniques for the analysis of NRG-2 products has been reported by Khreit et al.  using an ACE 
3 C18 column (150 mm x 4.6 mm i.d., particle size: 3 µm) and a mobile phase consisting of methanol: 10 mM ammonium formate (46:54 % v/v) 
(Khreit et al., 2012). The validated HPLC-UV method (which can detect (±)-mephedrone hydrochloride, (±)-4-MEC and (±)-caffeine at levels of 
0.02 μg mL−1), was further developed and reported by Smith et al. to analysis the analytes in the presence of other synthetic cathinones and 
benzocaine based on new intelligence received from law enforcement agencies (Smith et al., 2014a). 
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A gradient elution program was employed to ensure a rapid analysis time with the optimal detection of the analytes. Gradient elution can 
change the performance of electrochemical detectors, due to changes in the composition of the electrolyte/eluent employed (Gunasingham et 
al., 1984).  
The original isocratic method was reported by Khreit et al. and adapted to screen the mixture of (±)-caffeine, (±)-mephedrone and (±)-4-
MEC in this study, by using HPLC-UV and amperometric detection simultaneously and employing mobile phase 2 (Table 2.3). The percentage 
of organic modifier in mobile phase 2 was a reduced (30% v/v methanol) and mixed with 10 mM ammonium acetate buffer containing a suitable 
electrolyte (100 mM KCl, as electrolyte support). The pH of the eluent was adjusted to (4.3) both to ensure the cathinones ((±)-mephedrone: pKa 
= 8.69 (Santali et al., 2011); (±)-4-MEC: pKa = 8.88 (Khreit et al., 2012)) were fully ionised and, as the electrochemical responses of (±)-
mephedrone and (±)-4-MEC have been shown to be sensitive to pH, to optimise their detection amperometrically (Smith et al., 2013; Smith et 
al., 2014a). 
 
The same amperometric detectors used in the previous study (chapter 3 section 3.3) were used in this study. Based on the previous 
reported and validated HPLC-UV methods, (Santali et al., 2011; Smith et al., 2014b; Khreit et al., 2012) employed in the separation of (±)-
caffeine, (±)-mephedrone and (±)-4-MEC (Santali et al., 2011; Khreit et al., 2012; Smith et al., 2014), an ACE 3 C18 column (150 mm x 4.6 mm 
i.d. particle size: 3 µm) was selected. The extra-column volumes associated with the system (e.g. connective tubing and /or flow cell internal 
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volumes) were reduced to minimise the contribution from the LC-FC-A and LC-FC-B parameters respectively - thereby optimising the efficiency 
of a chromatographic resolution between components within a mixture and ensuring the accuracy of their quantification. 
 
Following the incorporation of the above modifications, (±)-caffeine, (±)-mephedrone and (±)-4-MEC were eluted at 5.5, 9.4 and 11.7 mins 
respectively as detected using HPLC-UV detection with the LC-FC-A, and eluted at 4.3, 7.5 and 9.3 mins respectively by using HPLC-UV 
detection in the LC-FC-B system. The resolutions for all analytes in both system was> 2 (Figure 4.1 a & c). 
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Figure 4.1 Representative chromatogram and amperogram of a solution containing (±)-caffeine, (±)-4-mephedrone and (±)-4-MEC with mobile phase 2 obtained using: (a) 
HPLC-UV (UV detection) in LC-FC-A system with flow rate: 0.8 mL min-1. (b) HPLC-AD (amperometric detection) in the LC-FC-A system (c) HPLC-UV (UV detection) in the 
LC-FC-B system with flow rate: 1 mL min-1. (d) HPLC-AD (amperometric detection) in the LC-FC-B system. The t0 (for both systems) was determined from the retention time 
of a solution of uracil (10 µg mL-1). The peak (S) is a system peak associated with the sample injection. 
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4.4 Amperometric detection method development: 
4.4.1 Optimisation of potential of amperometric detection: 
The anodic over-potential for (±)-caffeine, (±)-mephedrone and (±)-4-MEC (100 μg mL−1, Section 2.7.3) in the mobile phase 2 (Table 2.3) 
was determined using the peak maxima. In conjunction with the optimised instrumental configuration, the potentials required to achieve the 
optimal detector response for (±)-caffeine, (±)-mephedrone and (±)-4-MEC, were determined for both LC-FC-A and LC-FC-B, by measuring the 
amperometric response (peak current, μA) as a function of the anodic potential (E V−1), over the range +1.1 to +1.5 E V−1. The maximum 
responses were observed by using HPLC-AD in the LC-FC-A system, for caffeine (1.36 μA, n = 3), (±)-mephedrone. (0.25 μA, n = 3) and (±)-4-
MEC (0.17 μA, n = 3) at +1.4 E V−1 and this potential, which was also shown to be optimal, was used herein for the detection of the target 
analytes. 
 
In terms of the LC-FC-B system,Table 4.3 shows the anodic potential (E V-1) by using HPLC-AD. The maximum peak response was 
observed for (±)-caffeine (0.596 µA ,n = 3), (±)-mephedrone (0.124 µA , n = 3) and (±)-4-MEC (0.07 µA ,n = 3) at +1.4 E V-1 and this potential 
was used as the best potential for the detection of the target analytes . 
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Table 4.3 Representation of the anodic potential (100 µg mL-1) of (±)-caffeine, (±)-mephedrone and (±)-4-MEC over the range + 1 to + 1.5 v-1 using mobile phase 2, column 
: an ACE 3 C18 column (150 mm × 4.6 mm i.d., particle size: 3 μm); at temperature = 22 ⁰C, flow rate = 0.8 mL min-1 and pH = 4.3 using HPLC-AD detection in LC-FC-A and 
LC-FC-B systems. 
System LC-FC-A LC-FC-B 
Flow rate 0.8 mL min-1 1 mL min-1 
Detection Peak Current (µA) Peak Current (µA) 
Potential (V) Caffeine mephedrone 4-MEC Caffeine mephedrone 4-MEC 
1.2 0.041 0.059 0.038 0.38 0.041 0.039 
1.3 0.259 0.167 0.110 0.4 0.059 0.047 
1.4 1.36 0.25 0.17 0.596 0.124 0.07 
 
4.4.2 Optimisation of linear velocity of amperometric detection:  
The variation in the volume of the internal chamber of both flow cells (LC-FC-A = 8 µL vs. LC-FC-B = 120 µL) a solution of (±)-mephedrone 
(150 µg mL-1, Section 2.7.4) was injected ten times at different flow rates (over the range 0.8 – 1 mL min-1) and the amperometric response 
measured to determine the optimal linear velocity required for a maximum amperometric response. The system employing the impinging jet flow 
cell (LC-FC-A, internal chamber volume = 8 µL) gave the highest response, 1.58, 0.47 and 0.39 µA for caffeine, (±)-mephedrone and (±)-4-MEC, 
respectively, at a flow rate of 0.8 mL min-1. Increasing the flow rate gave a decreased response with an increase in backpressure, due to the 
nature of the impinging jet design. The corresponding system employing the iCell channel flow cell (LC-FC-B, internal chamber volume = 120 
µL) gave, under similar conditions, the highest response, 0.596, 0.124 and 0.07 µA for caffeine, (±)-mephedrone and (±)-4-MEC, respectively at 
flow rate of 1.0 mL min-1.  
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4.4.3 Optimisation of pH for HPLC-UV and amperometric detection  
The pH of the eluent was adjusted to 4.3 to ensure that the analytes were fully ionised. The electrochemical responses of (±)-mephedrone 
and (±)-4-MEC have been previously been shown to be sensitive to pH, to optimise their detection amperometrically (Smith et al., 2013; Smith 
et al., 2014a). 
 
By the optimisation of the amperometric detection (section 4.4.1, 4.4.2, and 4.4.3) in LC-FC-A and LC-FC-B systems, the analytes were 
eluted at 5.52, 9.42 and 11.72 minutes for caffeine, (±)-mephedrone and (±)-4-MEC respectively in LC-FC-A system. In HPLC-FC-B system, the 
elution was at 4.32 for caffeine, 7.52 for (±)-mephedrone and 9.32 for (±)-4-MEC. (Table 4.1b & d). 
 
4.5 HPLC-AD method validation: 
The separation and detection of a standard mixture (500 µg mL−1) of (±)-caffeine, (±)-mephedrone and (±)-4-MEC had been demonstrated 
using simultaneous UV and amperometric detection. Both HPLC-AD systems (LC-FC-A and LC-FC-B) required validation before deploying them 
in the analysis of the purchased NRG-2 (street sample) products. The liquid chromatography-amperometric detection system (LC-FC-A), 
employing the commercially available, impinging jet flow cell (LC-FC-A), was validated (in terms of UV-detection) using standard mixtures 
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containing strongly UV-absorbing components, (±)-caffeine, (±)-mephedrone and (±)-4-MEC, over a 50 – 500.0 μg mL−1 range. Table 4.4 
summarises the optimal conditions used in this study.  
 
Table 4.4 Summary  of the optimal conditions utilised for method validation of the analysis of (±)-caffeine, (±)-mephedrone and (±)-4-MEC using LC-FC-A and LC-FC-B 
systems. 
Optimised chromatographic conditions 
Column Column A (Section 2.2.1; ACE 3 C18 column (150 mm × 4.6 mm i.d., particle size: 3 μm) 
Flow rate 
0.8 mL min-1 for LC-FC-A system 
1 mL min-1 for LC-FC-B system 
Solvent Mobile phase: mobile phase 2 C (Table 2.3) 
Column temperature (⁰C) 22 
Wavelength (nm) 264 
Injection volume (µL) 10  
Run time (mins) 15  
pH 4.3 
Optimised amperometric detection parameters 
Potential (V) +1.4  
Equilibration time (s) 10  
Data interval (s) 0.05  
Current range (mA) 1× 10-6 – 1  
Total run time (s) 5000  
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The validation data for the quantification of (±)-caffeine, (±)-mephedrone and (±)-4-MEC are summarised in Table 4.5. These data were 
obtained by HPLC-UV (UV detection) in both LC-FC-A and LC-FC-B systems and using a column A (Section 2.2.1),  mobile phase 2 C,(Table 
2.3); detector wavelength (UV): 264 nm. 
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Table 4.6 Table 4.6 summarises the data of amperometric detection for (±)-caffeine, (±)-mephedrone and (±)-4-MEC by using either the LC-
FC-A (impinging jet flow cell) or LC-FC-B (iCell flow cell) systems using column A (Section 2.2.1); mobile phase 2. 
 
4.5.1 System suitability test 
System performance was verified to ensure confidence in the analytical method and the results obtained. Table 4.5 shows the retention 
time, capacity factor, theoretical plates, resolution and asymmetric factor. These parameters are very important to confirm that the analytical 
equipment and method are suitable for their intended use. The high resolution >2 in both systems. In addition, the theoretical plates were > 
2000 and the asymmetric factor <1 for all analytes in both systems, which explained that both systems were stable, and they had similar 
efficiencies with good separation. The developed method, for both systems LC-FC-A or LC-FC-B, showed that all of the standard system 
suitability parameters were within acceptable limits according to ICH guidelines(ICH, 1996). The HPLC validation parameters, for both systems 
in Table 4.5 and Table
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Table 4.6were obtained from the calibration standard analysis with their 
respective correlation coefficients, slopes, and intercepts resulting from linear 
regression analysis. 
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Table 4.5 Summary of HPLC-UV (UV detection) validation data for the quantification of caffeine, (±)-mephedrone and (±)-4-MEC obtained on either the LC-FC-A (impinging 
jet flow cell) or LC-FC-B (iCell flow cell) systems, using column (A) (Table 2.2 mobile phase 2A (Section 2.4); UV wavelength: 264 nm. 
System HPLC-UV with LC-FC-A HPLC-UV with LC-FC-B 
Flow rate  
(mL min-1) 
0.8 mL min-1 (t0 = 2.01 min) 1 mL min-1 (t0 = 1.57 min) 
Analyte Caffeine mephedrone 4-MEC Caffeine mephedrone 4-MEC 
Rta (min) 5.5 9.4 11.7 4.3 7.5 9.3 
RRtb 0.56 1 1.24 0.57 1 1.24 
RRFc 0.8 1 1.1 0.8 1 1.1 
Capacity Factor (k’) 1.7 3.7 4.8 1.7 3.7 4.9 
N (plates) 
10,700 
(71,300)d 
13,000 
(86,700)d 
13,500 
(90,000)d 
10,200 
(68,000)d 
12,800 
(85,300)d 
13,000 
(86,700)d 
H (m) 1.40 x 10-5 1.15 x 10-5 1.11 x 10-5 1.47 x 10-5 1.17 x 10-5 1.15 x 10-5 
Resolution (Rs) - 14.3 5.9 - 14.2 5.98 
Asymmetry Factor(As) 0.59 0.54 0.53 0.64 0.58 0.56 
LODe(µg mL-1) 2.03 2.50 2.99 1.79 1.95 2.41 
LOQf(µg mL-1) 6.14 7.58 9.05 5.43 5.90 7.29 
Co-efficient of Regression 0.999g 0.999h 0.999i 0.999j 0.999k 0.999l 
Precision (%RSD, n = 6) 
50 µg mL-1 0.06 0.06 0.05 0.03 0.06 0.03 
100 µg mL-1 0.02 0.01 0.03 0.02 0.01 0.04 
200 µg mL-1 0.04 0.02 0.03 0.03 0.03 0.03 
300 µg mL-1 0.03 0.01 0.03 0.02 0.01 0.01 
400 µg mL-1 0.06 0.05 0.05 0.01 0.02 0.06 
500 µg mL-1 0.02 0.04 0.04 0.02 0.16 0.16 
Key: (a) Measured from the retention time of uracil (10 µg mL-1) eluting from the column. (b) Relative retention time (with respect to (±)-mephedrone). (c) Relative 
response factor (with respect to (±)-mephedrone). (d) N expressed in plates per m. (e) Limit of Detection. (f) Limit of Quantification. (g) y = 28.005x + 17.842. (h) y = 
42.457x – 59.662. (i) y = 40.176x – 72.103. (j) y = 22.325x + 31.399. (k); y = 33.8x – 16.925. (l) y = 32.083x – 34.811. 
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Table 4.6 Summary of HPLC-AD (amperometric detection) validation data for quantification of caffeine, (±)-mephedrone and (±)-4-MEC obtained on either the LC-FC-A 
(impinging jet flow cell) or LC-FC-B (iCell flow cell) systems. Using column A (Table 2.2; mobile phase 2. 
System HPLC-FC-A HPLC-FC-B 
Analyte Caffeine mephedrone  4-MEC  Caffeine mephedrone  4-MEC  
Rta (min) 5.52 9.42 11.72 4.32  7.52 9.32 
RRTb (min) 0.59 1 1.24 0.57 1 1.24 
LODc (µg mL-1) 12.23 14.66 9.35 23.38 57.92 26.91 
LOQd (µg mL-1) 37.06 44.42 28.33 70.86 175.51 81.54 
Co-efficient of regression 0.995d 0.993e 0.997f 0.992g 0.953h 0.990i 
Precision (%RSD, n = 6) 
50 µg mL-1 0.58 0.55 0.74 n.d. n.d. n.d. 
100 µg mL-1 0.32 0.87 0.81 n.d. n.d. n.d. 
200 µg mL-1 0.53 0.91 1.00 0.07 0.19 0.74 
300 µg mL-1 0.53 0.81 0.80 0.32 0.45 0.68 
400 µg mL-1 0.71 0.91 1.00 0.15 0.55 0.45 
500 µg mL-1 0.57 0.87 0.48 0.10 0.87 0.38 
Key: n.d. = not determined. (a) Measured from the retention time of uracil (10 µg mL-1) eluting from the column. (b) Relative retention time (with respect to 4-mephedrone). 
(c) Limit of Detection. (d) Limit of Quantification. (e) y = 0.0105x + 0.2039. (f) y = 0.0025x – 0.0211. (g) y = 0.0011x + 0.0082. (h) y = 0.0013x + 0.0563. (i) y = 0.0003x 
+ 0.0053. (j) y = 0.00009x + 0.026. 
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4.5.2 Resolution (Rs) 
Both systems (LC-FC-A and LC-FC-B) provided excellent analyte peak 
resolution (Rs = >2) for the UV detection data. The resolution for all analytes was 
obtained by injecting 500 µg mL-1 (prepared in Section 2.7.6; n = 6) and found the 
resolution of (±)-mephedrone was 14.3 and (±)-4-MEC was 5.9 by using the LC-FC-
A system. In terms of LC-FC-B system, the resolution of (±)-mephedrone was 14.2 
and (±)-4-MEC was 5.98. 
 
4.5.3 Selectivity factor (α) 
Using the optimised parameters (Table 4.4) a mixture of 500 µg mL-1 of (±)-
caffeine, (±)-mephedrone and (±)-4-MEC (prepared in Section 2.7.6) was rapidly 
separated on both systems. The three analytes eluted at different retention times 
using LC-FC-A system (Table 4.5), and LC-FC-B system (Table 4.5), exhibiting a 
baseline resolution Rs > 2 and a slight peak fronting (asymmetry factor, As ~ 0.53 – 
0.64) in each case. 
 
The amperometric response corresponding to these solutions showed a slight 
delay of 1.22 (LC-FC-A, flow-rate = 0.8 mL min-1) and 0.98 sec (LC-FC-B, flow-rate 
= 1 mL min-1) respectively, due to variation in flow rates and connecting PTFE tubing 
(230 x 1.6 mm, i.d. 0.3 mm, internal volume: 16.25 µL) between the HPLC-UV and 
amperometric detectors.  
 
There was no interference of the three target analytes with solution of the UV-
inactive analytes sucrose, mannitol and lactose (which are commonly used as 
diluents) - thereby confirming the specificity of the proposed method. 
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4.5.4 Linearity 
The liquid chromatography-amperometric detection system  employing the 
commercially available, impinging jet, flow cell (LC-FC-A), was validated (in terms 
of UV-detection) using standard mixtures containing strongly UV-absorbing 
components (±)-caffeine, (±)-mephedrone and (±)-4-MEC over a 50 – 500.0 μg 
mL−1 range (prepared in Section 2.7.6). All three analytes demonstrated a linear 
response (R2 = 0.999) (Figure 4.2a) with excellent repeatability (RSD = 0.01 – 
0.06%; n = 6) for (±)-caffeine, (±)-mephedrone and (±)-4-MEC (Appendix:  
 
Table 9.8, Table 9.9 and Table 9.10). 
 
In terms of amperometric detection (LC-FC-A), this was carried out using 
calibration standards 50.0 – 500.0 μg mL−1 (prepared in Section 2.7.6) employed in 
the UV-detection validation study. The data show that the three analytes (±)-
caffeine, (±)-mephedrone and (±)-4-MEC gave a linear response (R2 = 0.99) (Figure 
4.2b), with good repeatability (RSD = 0.32 – 1.00%; n = 6) (Appendix: Table 9.11, 
Table 9.12 and Table 9.13). 
 
The corresponding liquid chromatography-amperometric detection system 
employing the iCell channel flow cell (LC-FC-B) was also validated in terms of UV-
detection, after increasing the flow rate to 1 mL min−1 to ensure a satisfactory elution 
time of the three target analytes. As the HPLC-UV detection system was identical 
to that employed with the impinging jet flow cell (LC-FC-A), the repeatability, 
specificity and linear response showed no significant differences over the 50.0–
500.0 μg mL−1 range (prepared in Section 2.7.6) to the system employing the 
impinging jet flow cell (LC-FC-A). The UV detection in the LC-FC-B system obtained 
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excellent linearity for all analytes, in which R2 = 0.999 (Figure 4.2c), with good 
repeatability (RSD = 0.01 – 0.16%; n = 6) for (±)-caffeine,(±)-mephedrone and (±)-
4-MEC (Appendix: Table 9.14, Table 9.15 and Table 9.16).  
 
Interestingly, in terms of the amperometric detection, the modified system 
incorporating the iCell channel flow cell (LC-FC-B) demonstrated linearity 0.95-0.99 
with good repeatability (RSD = 0.07 – 0.87%; n = 6) for the three analytes (Appendix: 
Table 9.17, Table 9.18 and Table 9.19), However, the linear response was 
significantly reduced (R2 = 0.95 – 0.99) (Figure 4.2d) over the 200.0 – 500.0 μg mL−1 
range (Section 2.7.6). 
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Figure 4.2 The linearity of (±)-caffeine (triangles), (±)-mephedrone (squares) and (±)-4-MEC (circles) by using a) HPLC-UV in the LC-FC-A system. b) HPLC-UV detection 
in the LC-FC-B system. c) HPLC-AD detection in the LC-FC-A system. d) HPLC-AD detection in the LC-FC-B system.
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4.5.5 Limits of detection (LOD)  
The limits of detection for the LC-FC-A system for (±)-caffeine, (±)-
mephedrone and (±)-4-MEC (using the standard deviation of the response and the 
slope of the calibration graph; (Section 2.7.6)) were determined to be 2.03, 2.5 and 
2.99 µg mL-1 respectively, by using HPLC-UV (UV detection)(Table 4.5). In 
amperometric detection by using impinging jet flow-cell [LC-FC-A],  LODs of (±)-
caffeine, (±)-mephedrone and (±)-4-MEC were 12.23, 14.66 and 9.35 µg mL-1 
respectively (Table 4.6), though these are approximately 5× higher than UV-
detection, they  agree with the previously reported levels of 11.6 µg mL-1 for (±)-
mephedrone,and 11.8 μg mL−1 for (±)-4-MEC) reported by Smith et al. (Smith et al., 
2014b). 
 
In the LC-FC-B system using HPLC-UV (UV detection), the LODs were were 
1.79, 1.95 and 2.41 µgmL-1 for (±)-caffeine, (±)-mephedrone and (±)-4-MEC 
respectively (Table 4.5). The LODs for these components by amperometric 
detection using the iCell channel flow cell were confirmed as being 23.38, 57.92 and 
26.91 μg mL−1 for (±)-caffeine, (±)-mephedrone and (±)-4-MEC respectively (Table 
4.6), These values are significantly higher than those obtained for the impinging jet 
flow-cell (LC-FC-A). It is  suggested that in the case of the iCell channel flow cell, 
the larger chamber volume (120 μL), increased sample dispersion, diluting the 
analytes, and thereby reducing the sensitivity of the GSPE sensor platform via mass 
transfer/diffusion to the electrode surface (Guidelli, 1971b; Guidelli, 1971a; Oldham, 
1973). Therefore, by using LC-FC-B the concentration range was 200-500 µgmL-1 
unlike the LC-FC-A range that was 50-500 µgmL-1. 
 
The LODs calculated using amperometric detection in both systems (LC-FC-
A and LC-FC-B) were higher than the limits of detection for UV detection. In addition, 
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the LODs calculated using amperometric detection (HPLC-AD) were higher than the 
LODs obtained using UV detection (HPLC-UV) and HPLC-MS/MS. This was 
because in HPLC-AD, a high range of analyte concentrations were needed in this 
study. 
 
4.5.6 Limits of quantification (LOQ)  
The LOQs of (±)-caffeine, (±)-mephedrone and (±)-4-MEC by using UV 
detection of the LC-FC-A system were determined using the standard deviation of 
the response and the slope of the calibration graph (Section 2.7.6) to be 6.14 μg 
mL−1for (±)-caffeine, 7.58 μg mL−1 for (±)-mephedrone and 9.05 μg mL−1 for (±)-4-
MEC. The LOQ was approximately 50× less sensitive in these terms than with the 
previously reported HPLC methods employing UV detection,(Santali et al., 2011; 
Khreit et al., 2012; Smith et al., 2014a; Smith et al., 2014b). At concentrations lower 
than 50 μg mL−1, the ability to detect and accurately quantify the analytes using 
amperometry was shown not to be viable. In terms of amperometric detection by 
using LC-FC-A, the limits of quantification were determined from the standard 
deviation of the response and the slope of the calibration graph (Section 2.7.6), to 
be 37.06 for (±)-caffeine, 44.42 for (±)-mephedrone and 28.33 μg mL−1 for (±)-4-
MEC. The validation parameters for the LC-FC-A system are summarised in Table 
4.5 and Table 4.6. 
 
The LOQ of (±)-caffeine, (±)-mephedrone and (±)-4-MEC using UV detection 
of the LC-FC-B system were found to be 5.43 for (±)-caffeine, 5.90 for (±)-
mephedrone and 7.29 μg mL−1for (±)-4-MEC. These results were lower than those 
obtained for UV detection using LC-FC-A. The LOQ of amperometric detection using 
the LC-FC-B system were found to be 70.86 for (±)-caffeine, 175.5 for (±)-
mephedrone and 81.54 μg mL−1 for (±)-4-MEC. In comparing, the LOQ of both 
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systems LC-FC-A and LC-FC-B, the LC-FC-A had a higher sensitivity than the LC-
FC-B system (as explained in the LOD Section 4.5.5). The detection validation 
parameters, for the LC-FC-B system, are summarised in Table 4.5 and Table 4.6. 
 
4.5.7 Robustness 
This test described the ability to reproduce the HPLC-AD method under 
different circumstances and in different laboratories without the occurrence of 
unexpected differences in the obtained results, The assays for the robustness 
evaluation of the analytical method were carried out simultaneously in both systems. 
 
 
Minor changes in temperature were used as one of the parameters to ensure 
the reliability of the robustness test  using LC-FC-A and LC-FC-B systems for the 
analysis of (±)-caffeine, (±)-mephedrone and (±)-4-MEC. The robustness of this 
method was obtained by injecting 400 µg mL-1 of analytes ((±)-caffeine, (±)-
mephedrone and (±)-4-MEC, Section 2.7.6). The relative standard deviation (RSD 
%) of the relative retention time for all runs at different temperatures (20 ⁰C, 22 ⁰C 
and 24 ⁰C) was found to be less than  1  using LC-FC-A system (Table 4.7; the 
optimal conditions are highlighted for comparison). By using the LC-FC-B system, 
the RSD% were less than one (Table 4.9; the optimal conditions are highlighted for 
comparison). Therefore, this method is robust and indicated the methods’ reliability 
during normal usage. 
 
The second parameter of the robustness test was a change in the ratio of the 
organic composition of the mobile phase: mobile phase 2 (Table 2.3) by using 
different ratios (28:72, 30:70 and 32:68 % v/v of methanol: buffer solution A, Section 
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2.3.1). The RSDs% of relative retention time for all analytes were less than 1 as 
demonstrated in Table 4.8 and Table 4.10 (the optimal conditions are highlighted 
for comparison). This showed that this method is suitable to use in routine analysis 
under any minor change in ratio of mobile phase 2 composition. 
Table 4.7 The effect of minor changes of temperature on relative retention time (RRT) of (±)-caffeine, 
(±)-mephedrone and (±)-4-MEC using HPLC-UV detection in LC-FC-A systems (highlighted area is 
the standardised condition of this method). 
Concentration 
(µg mL-1) 
RRT 
(20 °C) (22 °C) (24 °C) 
Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC 
400 0.589 1.000 1.216 0.571 1.000 1.226 0.569 1.000 1.227 
400 0.590 1.000 1.217 0.571 1.000 1.227 0.570 1.000 1.228 
400 0.590 1.000 1.216 0.571 1.000 1.226 0.570 1.000 1.227 
400 0.590 1.000 1.216 0.571 1.000 1.226 0.570 1.000 1.227 
400 0.590 1.000 1.217 0.571 1.000 1.227 0.570 1.000 1.227 
400 0.591 1.000 1.216 0.572 1.000 1.226 0.570 1.000 1.227 
Average 0.590 1.000 1.216 0.571 1.000 1.226 0.570 1.000 1.227 
RSD% 0.591 0.692 0.746 0.611 0.692 0.740 0.612 0.692 0.739 
 
Table 4.8 The effect of minor changes of organic composition of mobile phase 3 on Relative 
Retention Time (RRT)of (±)-caffeine, (±)-mephedrone and (±)-4-MEC using HPLC-UV detection in 
LC-FC-A systems (highlighted area is standardised condition of this method). 
Concentration 
(µg mL-1) 
RRT 
 (28:72% v/v) 
methanol: buffer solution 
pH = 4.3 ±,  
Section 2.4 
 (28:72% v/v) 
methanol: buffer solution 
pH = 4.3, 
 Section 2.4 
 (28:72% v/v) 
methanol: buffer solution 
pH = 4.3,  
Section 2.4 
Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC 
400 0.577 1.000 1.252 0.571 1.000 1.226 0.569 1.000 1.227 
400 0.577 1.000 1.253 0.571 1.000 1.227 0.570 1.000 1.228 
400 0.578 1.000 1.253 0.571 1.000 1.226 0.570 1.000 1.227 
400 0.578 1.000 1.253 0.571 1.000 1.226 0.570 1.000 1.227 
400 0.578 1.000 1.253 0.571 1.000 1.227 0.570 1.000 1.227 
400 0.578 1.000 1.253 0.572 1.000 1.226 0.570 1.000 1.227 
Average 0.578 1.000 1.253 0.571 1.000 1.226 0.570 1.000 1.227 
RSD% 0.604 0.692 0.724 0.611 0.692 0.740 0.612 0.692 0.739 
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Table 4.9 The effect of minor changes of temperature on relative retention time (RRT) of (±)-caffeine, 
(±)-mephedrone and (±)-4-MEC using HPLC-UV detection in LC-FC-B systems (highlighted area is 
standardised condition of this method). 
Concentration 
(µg mL-1) 
RRT 
(20 °C) (22 °C) (24 °C) 
Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC 
400 0.563 1.000 1.230 0.570 1.000 1.226 0.572 1.000 1.226 
400 0.564 1.000 1.231 0.571 1.000 1.227 0.573 1.000 1.226 
400 0.564 1.000 1.230 0.571 1.000 1.226 0.573 1.000 1.225 
400 0.564 1.000 1.230 0.571 1.000 1.226 0.573 1.000 1.225 
400 0.564 1.000 1.230 0.571 1.000 1.227 0.573 1.000 1.226 
400 0.565 1.000 1.230 0.572 1.000 1.226 0.573 1.000 1.225 
Average 0.564 1.000 1.230 0.571 1.000 1.226 0.573 1.000 1.226 
RSD% 0.103 0.000 0.024 0.099 0.000 0.024 0.099 0.000 0.024 
 
Table 4.10 The effect of minor changes in organic composition of mobile phase 3 on Relative 
Retention Time (RRT) of (±)-caffeine, (±)-mephedrone and (±)-4-MEC using HPLC-UV detection in 
LC-FC-B systems (highlighted area is standardised condition of this method). 
Concentration 
(µg mL-1) 
  
RRT 
 (28:72% v/v) 
methanol: buffer solution 
pH = 4.3 ,  
Section 2.4 
 (30:70% v/v) 
methanol: buffer solution 
pH = 4.3, 
 Section 2.4 
 (32:68% v/v) 
methanol: buffer solution 
pH = 4.3,  
Section 2.4 
Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC 
400 0.567 1.000 1.228 0.570 1.000 1.226 0.574 1.000 1.224 
400 0.568 1.000 1.228 0.571 1.000 1.227 0.575 1.000 1.225 
400 0.569 1.000 1.228 0.571 1.000 1.226 0.576 1.000 1.224 
400 0.569 1.000 1.228 0.571 1.000 1.226 0.575 1.000 1.224 
400 0.569 1.000 1.228 0.571 1.000 1.227 0.576 1.000 1.224 
400 0.569 1.000 1.227 0.572 1.000 1.226 0.576 1.000 1.224 
Average 0.568 1.000 1.228 0.571 1.000 1.226 0.575 1.000 1.224 
RSD% 0.101 0.000 0.024 0.099 0.000 0.024 0.097 0.000 0.024 
 
4.5.8 Inter-and intra-day precision 
Intra- and inter-day precision was determined by the evaluation of (±)-caffeine, 
(±)-mephedrone and (±)-4-MEC using UV and amperometric detection in LC-FC-A 
and LC-FC-B systems. This test was applied to ensure that this method could be 
used in routine analysis. Table 4.11 shows the relative standard deviation using the 
LC-FC-A system for three analytes that were obtained from  12 replicate injections 
of a mixture solution of 400 µg mL-1 of (±)-caffeine, (±)-mephedrone and (±)-4-MEC 
(Section 2.7.6) in the same day (6 in the morning and 6 in the afternoon) or on 
different days. The RSD% of the three analytes of inter- and intra-day precision 
ranged from 0.012 to 0.0947% and precision ranged from 0.544 to 0.967 %. Both 
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RSD% were < 1, confirming that this method is precise. The value of RSD% was 
calculated by the supplementary data in Appendix Table 9.20 where the  RSD% of 
all analytes were found to be < 1%. This is an appropriate precision criterion for 
repetitive injections to assess the precision of an instrument in analytical method 
validation (Green, 1996). 
 
Table 4.11 Relative standard deviations (RSD %) of inter- and intra-day precision for 400 µg mL-1 
(±)-Caffeine, (±)-4-mephedrone and (±)-4-MEC using HPLC-UV and HPLC-AD in the LC-FC-A 
system. 
Number of 
injections 
=12 
System RSD % of LC-FC-A RSD % of LC-FC-B 
Detection 
HPLC-UV 
peak area, 
(mAU) 
HPLC-AD 
peak current, 
(µA) 
HPLC-UV 
peak area, 
(mAU) 
HPLC-AD 
peak 
current, 
(µA) 
Inter-day 
precision 
Caffeine 0.249 0.656 0.55 0.95 
Mephedrone 0.047 0.860 0.35 0.72 
4-MEC 0.053 0.829 0.35 0.97 
Intra-day 
precision 
Caffeine 0.012 0.544 0.87 0.91 
Mephedrone 0.814 0.830 0.68 0.59 
4-MEC 0.947 0.967 0.67 0.86 
 
In terms of the LC-FC-B system, the intra-day and inter-day tests were applied 
to confirm the suitability of this method to use in routine analysis. Inter- and intra-
day test swere carried out using the same analytes that were used by the LC-FC-A 
system with the same procedure. In the inter- and intra-day variation studies, 
RSDs%, were calculated and ranged from 0.35 to 0.87% using HPLC-UV and 
ranged from 0.59 to 0.95% using HPLC-AD (Table 4.11). RSDs for both inter- and 
Intra-day studies of the LC-FC-B system were less than 1, therefore this method 
was found to be precise. These results illustrate the ability of this method and the 
efficiency of these systems to be applied to routine analysis. The values of RSDs% 
were calculated by the supplementary data in Appendix Table 9.21 and were found 
to be< 1% for all the analytes. This is  an appropriate precision criterion for repetitive 
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injections to assess the precision of an instrument in analytical method validation 
(Green, 1996). 
 
4.5.9 Accuracy test 
This test was used to determine the closeness of agreement of experimental 
data to actual data. The accuracy studies were carried out at three levels of standard 
concentrations prepared as 80, 100, and 120% of (±)-caffeine, (±)-mephedrone and 
(±)-4-MEC (section 2.7.8). The prepared solutions were injected three times and 
detected using UV and amperometric detection in the LC-FC-A and LC-FC-B 
systems. The percentage recovery was calculated and presented in Table 4.12. This 
showed excellent recovery within the range of 100 ±2%, which in the LC-FC-A 
system were in the range 98.8 – 101% with RSD% ±0.01 – 0.53 by UV detection, 
and 99-100.6% with RSD% ±0.45 – 0.14 using amperometric detection. In terms of 
using the LC-FC-B system, the percentages of recovery were over the range 98.8 
– 101% with RSDs% of ±0.01 – 0.56 by UV detection and 99.8 – 100.9% with 
RSDs% of ±0.07 – 0.8. In both systems, the percentage recovery indicated that both 
protocols were accurate and precise. 
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Table 4.12 Accuracy data expressed as the percentage recovery of the mixture of (±)-caffeine, (±)-4-mephedrone and (±)-4-MEC using HPLC-UV and HPLC-AD detection 
in LC-FC-A and LC-FC-B systems. 
System LC-FC-A LC-FC-B 
Detection HPLC-UV HPLC-AD HPLC-UV HPLC-AD 
Analyte 
Concentration 
(µg mL-1) 
Theoretical 
recovery (µg 
mL-1) 
Actual 
recovery 
(µg mL-1) 
%Recovery 
(n=3) 
Actual 
recovery 
(µg mL-1) 
%Recovery 
(n=3) 
Actual 
recovery 
(µg mL-1) 
%Recovery 
(n=3) 
Actual 
recovery 
(µg mL-1) 
%Recovery 
(n=3) 
Caffeine 
240 (80%) 
241.0 236.5 98.0 (±0.015) 240.9 99.9 (±0.54) 243.8 101 (±0.01) 239.5 99.8 (±0.07) 
4-MMC 241.0 239.5 99.37 (±0.04) 241.0 100.0 (±0.89) 245.1 101 (±0.04) 241.0 100.6 (±0.14) 
4-MEC 241.0 237.9 98.7 (±0.037) 242.0 100.5 (±0.98) 247.9 101 (±0.02) 240.9 99.9 (±0.45) 
Caffeine 
300 (100%) 
301.0 297.0 98.6 (±0.01) 302.0 100.4 (±0.54) 298.4 99 (±0.0.04) 298.3 99.5 (±0.36) 
4-MMC 301.0 293.3 98.7 (±0.011) 299.7 99.5 (±0.73) 299.6 99.5 (±0.02) 301.0 100.9 (±0.53) 
4-MEC 301.0 293.4 100.0 (±0.017) 301.5 100.1 (±0.34) 303.0 100.7 (±0.15) 301.5 99.9 (±0.80) 
Caffeine 
360 (120%) 
361.5 357.3 98.8 (±0.22) 358.6 99.21 (±0.73) 357.0 98.8 (±0.56) 359.4 99.8 (±0.16) 
4-MMC 361.5 360.9 101 (±0.33) 359.5 99.47 (±0.92) 358.0 99 (±0.34) 360.6 100.3 (±0.32) 
4-MEC 361.5 356.8 98.8 (±0.53) 358.0 99.0 (±0.39) 362.0 100 (±0.34) 361.0 100.1 (±0.73) 
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4.6 Application of the technique to forensic drug analysis 
The five NRG-2 samples (Table 2.1) obtained from the internet vendors 
EuChemicals (www.euchemicals.com) (January 2013) were all purported to be > 99 
% pure and to contain 1 g of NRG-2. The samples were homogenised and arbitrarily 
labelled NRG-2-A, NRG-2-B, NRG-2-C, NRG-2-D and NRG-2-E. Preliminary LC-
MS analysis indicated that all five samples contained synthetic cathinones (Table 
4.13).  
 
Table 4.13 Direct comparison of LC-MSa and HPLC-UV data (obtained using either LC-FC-A 
(impinging jet flow cell) or LC-FC-B (iCell channel flow cell) systems) of purchased NRG-2 samples 
Street 
sample 
LC-MS(a) 
(n = 3) 
HPLC-UV in LC-FC-A  
(n = 3) 
HPLC-UV in LC-FC-B  
(n = 3) 
NRG-2-A tR = 5.34 min [m/z = 
192.2 [M+H]+, 4-MEC] 
tR = 11.7 min [24.03% w/w 
±0.03, 4-MEC.] 
tR = 9.3 min [24.01% 
w/w ±0.05, 4-MEC.] 
NRG-2-B tR = 4.48 min m/z = 
178.1 [M+H]+, 4-MMC] 
tR = 9.4 min [49.24% w/w 
±0.03,4-MMC] 
tR = 7.5 min [48.18% 
w/w ±0.02, 4-MMC] 
NRG-2-C tR = 2.57 min [major, 
m/z = 195.1 [M+H]+, 
caffeine; 5.34 min 
[minor, m/z = 192.2 
[M+H]+, 4-MEC] 
tR = 5.5 min [major, 
76.19% w/w ±0.22, 
caffeine; 11.7 min [minor, 
23.58% w/w ±0.49, 4-
MEC] 
tR = 4.3 min [major, 
74.83% w/w ±0.16, 
caffeine; 9.3 min 
[minor, 25.81% w/w 
±0.23, 4-MEC] 
NRG-2-D tR = 2.57 min [major, 
m/z = 195.1 [M+H]+, 
caffeine; 4.48 min 
[minor, m/z = 178.1 
[M+H]+, 4-MMC] 
tR = 5.5 min [major, 
83.04% w/w ±0.03, 
caffeine; 9.4 min [minor, 
15.64% w/w ±0.45, 4-
MMC] 
tR = 4.3 min [major, 
82.93% w/w ±0.35, 
caffeine; 7.5 min 
[minor, 16.58% w/w 
±1.13, 4-MMC] 
NRG-2-E tR = 2.57 min [m/z = 
195.1 [M+H]+, caffeine; 
4.48 min [m/z = 178.1 
[M+H]+, 4-MMC]; 5.34 
min [m/z = 192.2 
[M+H]+, 4-MEC] 
tR = 5.5 min [36.55% w/w 
±0.08, caffeine; 9.4 min 
[15.64% w/w ±0.46, 4-
MMC]; 11.7 min [24.03% 
w/w ±0.03, 4-MEC] 
tR = 4.3 min [34.09% 
w/w ±0.77, caffeine; 
7.5 min [16.71% w/w 
±0.05, 4-MMC]; 9.3 
min [25.84% w/w 
±0.01, 4-MEC] 
Key: (a) results of sample analysed using the method reported by Khreit et al.(Khreit et al., 
2012) 
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The synthetic cathinones [mephedrone or 4-MEC] were either pure (Khreit et 
al., 2012)[NRG-2-A contained  4-MEC and NRG-2-B contained mephedrone] or 
adulterated with significant quantities of caffeine (Smith et al., 2014b). [NRG-2-C 
contained caffeine and 4-MEC, and NRG-2-D caffeine and mephedrone] or 
combined together with caffeine (NRG-2-E caffeine, mephedrone and 4-MEC) 
(Table 2.1). With substantial evidence supporting an electroanalytical oxidation 
approach for detecting various substituted cathinones in street samples, the viability 
of the proposed protocol was tested. The NRG-2 samples were reanalysed (in 
triplicate) using the validated HPLC-AD method at a concentration of 500 μg mL−1.  
 
The HPLC-UV results (Table 4.14) were obtained using the commercial flow-
cell (LC-FC-A). That confirmed two of the samples contained only synthetic 
cathinones [NRG-2-A: 24.03 ±0.03% w/w 4-MEC and NRG-2-B: 49.24 ±0.03% w/w 
mephedrone]. Two of the samples contained caffeine predominantly (80% w/w) in 
combination with mephedrone or 4-MEC [NRG-2-C: 76.19 ±0.22% w/w caffeine, 
23.58 ±0.49% w/w 4-MEC and NRG-2-D: 83.04 ±0.03% w/w caffeine, 15.64 ±0.45% 
w/w mephedrone]. One sample contained a complex mixture of the three analytes 
[NRG-2-E: 36.55 ±0.08% w/w caffeine, 15.64 ±0.46% w/w mephedrone, 24.03 
±0.03% w/w 4-MEC]. 
 
These observations are in agreement with the information reported by Khreit 
et al., Brandt et al. and Smith et al., who noted that many second-generation “legal 
high” products contained increased levels of commonly used diluents and 
adulterants (Khreit et al., 2012; Brandt et al., 2010; Smith et al., 2014b). The 
qualitative results, obtained from the HPLC-AD (amperometric detector) in the LC-
FC-A system, also confirmed the constitution of the five NRG-2 samples and 
comparison of two detction methods (UV detection  vs. amperometric detection, 
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Table 4.14) indicated that in samples containingcaffeine (NRG-2-C, NRG-2-D and 
NRG-2-E), the two methods were comparable in terms of their ability to quantify the 
components present (Table 4.13).The two samples containing only synthetic 
cathinones (NRG-2-A and NRG-2-B), however, show a significant increase in the 
estimation of the quantities of mephedrone and 4-MEC present (Table 4.13)   
However, a new GSPE was utilised during each sample analysis, the loss in 
analytical performance may be due to adsorption of the analytes onto the surface of 
the GSPE during the time scale of the analysis. Despite the loss in analytical 
performance, it is still adequate for quantifying the synthetic cathinones present 
within the samples. Similar results were observed with the iCell unit (LC-FC-B, Table 
4.14). 
 The amperometric limits of detection (for the electrochemical oxidation of 
mephedrone and 4-MEC reported herein are similar to the values reported in our 
previous work (Smith et al., 2014a) (mephedrone: 39.8 µg mL-1 and 4-MEC: 84.2 µg 
mL-1). This is sufficient for use in the field as opposed to the values reported by 
Krishnaiah et al. (V. Krishnaiah) who utilised a dropping mercury electrode (DME) 
which is not suitable for use in the field and banned in many countries.  This work 
also demonstrates an improvement over our previous work (Smith et al., 2014a), 
which indicated that there was no electrochemical selectivity for the electrochemical 
detection of mephedrone and 4-MEC.  By coupling the amperometric detector to a 
high performance liquid chromatograph, one can now rapidly separate, discriminate 
between and quantify, two structurally related cathinones within a complex street 
sample mixture (NRG-2-E, Table 4.14) indicating that the proposed HPLC-AD 
protocol can be considered suiable for the detection and quantification of the two 
synthetic cathinones either in their pure form, in the presence of common 
adulterants e.g. caffeine or simultaneously within blended street samples of the 
evolved “legal high” product, NRG-2.  
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Table 4.14 Direct comparison between quantitative data obtained by the HPLC-UV and HPLC-AD protocols for the analysis of the synthetic cathinones in a selection of 
purchased NRG-2 samples 
System LC-FC-A LC-FC-B 
Flow rate 0.8 mL min-1 1 mL min-1 
Detection  HPLC-UV (% w/w) (n =3) HPLC-AD (% w/w) (n =3) HPLC-UV (% w/w) (n =3) HPLC-AD (% w/w) (n =3) 
Sample Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC 
tR 5.5 9.4 11.7 5.52 9.42 11.72 4.3 7.5 9.3 4.32 7.52 9.32 
NRG-2-A n.d. n.d. 
24.03 
(±0.03) 
n.d. n.d. 
54.39 
(±1.24) 
n.d. n.d. 
24.01 
(±0.05) 
n.d. n.d. 
65.07 
(±1.21) 
NRG-2-B n.d. 
49.24 
(±0.03) 
n.d. n.d. 
60.8 
(±0.57) 
n.d. n.d. 
48.18 
(±0.02) 
n.d. n.d. 
75.28 
(±1.71) 
n.d. 
NRG-2-C 
76.19 
(±0.22) 
n.d. 
23.58 
(±0.49) 
78.26 
(±0.68) 
n.d. 
20.69 
(±1.72) 
74.83 
(±0.16) 
n.d. 
25.81 
(±0.23) 
80.35 
(±0.99) 
n.d. 
18.77 
(±2.45) 
NRG-2-D 
83.04 
(±0.03) 
15.64 
(±0.45) 
n.d. 
80.54 
(±2.06) 
18.95 
(±2.96) 
n.d. 
82.93 
(±0.35) 
16.58 
(±1.13) 
n.d. 
85.38 
(±0.48) 
8.82 
(±2.21) 
n.d. 
NRG-2-E 
36.55 
(±0.08) 
15.64 
(±0.46) 
24.03 
(±0.03) 
42.22 
(±1.43) 
8.56 
(±3.30) 
54.39 
(±1.24) 
34.09 
(±0.77) 
16.71 
(±0.05) 
25.84 
(±0.01) 
36.42 
(±1.14) 
27.53 
(±0.32) 
44.01 
(±1.59) 
Key: n.d. = not detected. 
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4.7 Conclusions 
The combination of HPLC with electrochemical detection was used for the first 
time for the separation and detection of synthetic cathinones (±)-mephedrone and 
(±)-4-MEC using either an impinging jet (LC-FC-A) or iCell channel (LC-FC-B) flow 
cell incorporating disposable embedded graphite screen-printed macroelectrodes 
(GSPE). The validated HPLC-AD protocol was shown to have similar LODs [HPLC-
AD in the LC-FC-A system: 14.66 μg mL−1 for (±)-mephedrone and 9.35 μg mL−1for 
(±)-4-MEC; HPLC-AD in the LC-FC-B system: 57.92 μg mL−1for (±)-mephedrone 
and 26.91 μg mL−1for (±)-4-MEC] to the previously reported oxidative 
electrochemical protocol [39.8 μg mL−1for (±)-mephedrone and 84.2 μg mL−1for (±)-
4-MEC]. 
 
The impinging jet and iCell channel flow cells show an excellent agreement 
with respect to the quantitative electroanalytical and chromatographic data making 
them suitable for the detection and quantification of (±)-mephedrone and (±)-4-MEC, 
either in their pure form or in combination with adulterant. However, the commercial 
flow cell (LC-FC-A) appeared to be slightly more sensitive than the custom-made 
flow cell (LC-FC-B).  This reduction in sensitivity is due to the larger internal volume 
of the LC-FC-B, which increases sample dispersion, thereby reducing the sensitivity 
of the GSPE sensor platform.  
 
This work demonstrates the effect of the design of the flow-cell on the 
sensitivity of the detection system, with the commercial flow cell (LC-FC-A) giving a 
greater response because it has the smaller method volume. The designs of both 
flow cells are significantly different regarding the flow delivery to the electrode; 
however, the iCell having a volume 15 times that of the commercial cell gives 
detection results of a similar order. This suggests further optimisation of the shape 
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may yield greater sensitivity. The method detailed herein shows a significant 
improvement over previously reported electroanalytical methods (Smith et al., 
2014a), which were either unable to selectively discriminate between structurally 
related synthetic cathinones, or utilised harmful and restrictive materials in their 
design. In addition, this chapter explained the suitability of this protocol for use in 
routine analysis for detection and quantification of (±)-mephedrone and its derivative 
in testing purchased samples. The next chapter presents the analysis of (±)-
mephedrone with (±)-Mexedrone a new (±)-mephedrone derivative. It is envisaged 
that the data presented will be useful to law enforcement officials, for the 
development of robust, electroanalytical detection systems for new psychoactive 
substances and related compounds as they emerge on the recreational drugs 
market. 
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5 Chapter 5: Detection and quantification of (±)-mephedrone and (±)-
mexedrone as new Psychoactive substances using the HPLC-AD protocol 
 
5.1 Introduction 
(±)-mephedrone (Figure 5.1a) is a synthetic cathinone derivative  that entered 
the illicited drugs market about a decade ago and was placed under legislative 
control measures across Europe in 2010. Mephedrone was subjected to 
international control measures by its addition to Schedule 2 of the Convention on 
Psychotropic Substances (1971) in 2015 (McLaughlin et al., 2017; Council Decision, 
2010). NPS manufacturers continue to design new compounds that (potentially) 
circumvent drugs legislation to exploit any gaps created in the market by 
prohibition/control of certain substances.  
 
In August 2015 a “legal” replacement for (±)-mephedrone appeared on the 
NPS market in the UK and Ireland (McLaughlin et al., 2017). The substance was the 
alpha-methoxy-derivative of (±)-mephedrone to be called ‘(±)-mexedrone (Figure 
5.1b) (McLaughlin et al., 2017; Roberts et al., 2017). (±) -Mexedrone was targeted 
at markets in countries where generic cathinone bans had been enforced 
(McLaughlin et al., 2017). Although (±)-Mexedrone has the generic cathinone 
backbone, it was uncontrolled in the UK due to the methoxy moiety at the terminal 
amine of the existing mephedrone molecular (methoxy group on the propane-1-one 
sidechain). The structure of the substance is similar to mephedrone Figure 5.1, 
however, it had been specifically designed to fall outside the generic cathinone ban 
in the UK (UK-Government, 2016). 
Due to the rapid rise in the misuse, (±)-mephedrone and its related synthetic 
cathinone derivatives are controlled under the MDA (1979) as class B substances. 
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According to the Misuse of Drugs Act 1971, any stereoisomeric form and salt of a 
controlled substance, as well as any preparation or other product containing the 
substance is now controlled under Legalisation.gov.uk. 2016 (Morris and Wallach, 
2014; UK-Government, 2016). 
 
 
Figure 5.1Chemical structures of a- (±)-mephedrone.HCl and b- (±)-mexedrone.HCl. 
 
This chapter presents full characterisation data for mexedrone and compares 
the data with (±)-mephedrone using a range of instrumental techniques. The 
development for high performance liquid chromatography in combination with 
amperometric detection HPLC-AD in a LC-FC-A system has been successful in 
chapter 3 and chapter 4 for the analysis of MDMA, PMA, mephedrone and 4-MEC. 
This chapter represents the novel high-performance liquid chromatographic (HPLC-
UV) method combined with amperometric detection (HPLC-AD) for the qualitative 
and quantitative analysis of (±)-Mexedrone and (±)-mephedrone using a 
commercially available impinging jet flow-cell system incorporating embedded 
graphite screen-printed macro-electrodes. In this study,  just a commercially 
impinging jet flow-cell system was used because in chapter 3 it showed a higher 
sensitivity  than the iCell channel flow cell due to the difference in chamber volumes 
of the two flow cells, as explained in chapter 4 (Zuway et al., 2015). Both detectors 
(UV and amperometric) allow discrimination between the two compounds, however, 
HPLC-UV was the more sensitive technique.  
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5.2 Characterisation 
A reference standard of (±)-mephedrone was prepared in-house using the 
method reported by Santali et al.(Santali et al., 2011). The reference standard of 
(±)-Mexedrone was obtained from BRC Fine Chemicals (London, UK), and 
recrystallised from the minimum amount of acetone prior to use. (±)-mephedrone is 
an off-white powder (m.p. 249-251 ⁰C) which is in agreement with the data published 
by Santali et al. (m.p. 251.18 ⁰C) by differential scanning calorimetry( DSC)(Santali 
et al., 2011). In addition, (±)-Mexedrone was obtained as white-coloured crystals 
(m.p. 189-190 ⁰C), in agreement with the melting point reported by McLaughlin et 
al. (m.p.190-192 ⁰C) (McLaughlin et al., 2017). TLC was performed using ethyl 
acetate and methanol as the solvent (1:3). Results showed that the two analytes 
were pure, as only one spot was observed per analyte. In addition, it was possible 
to distinguish between both analytes. The retention factor of each spot was 
measured, that for (±)-Mexedrone was 0.49 cm and for (±)-mephedrone was 0.32 
cm. 
 
The infrared spectra for (±)-mephedrone produced for C=C at 1606 cm-1 is 
indicative of an aromatic nucleus. Also, the absorption of C=O was obtained at 1685 
cm-1, and at 2717.5 cm-1 the absorption of the NH2+ stretch, and that was similar to 
what was reported for (±)-mephedrone by Santali el al. (Santali et al., 2011), the 
infrared spectra for (±)-Mexedrone represent a strong C=O absorption band at 1690 
cm-1. It also displays C=C absorptions at 1605 cm-1indicating the presence of an 
aromatic nucleus. The absorption band observed at 2775 cm-1 is indicative of the 
NH2+. These results confirmed the similarity of (±)-mephedrone and (±)-mexedrone. 
However, there is a strong absorption at 1247 cm-1 corresponding to the C-O in (±)-
Mexedrone spectra and this absorption is not presented in (±)-mephedrone data, 
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therefore, this spectrum distinguishes between (±)-mephedrone and (±)-
mexedrone. 
 
5.3 Nuclear magnetic resonance spectroscopy (NMR) 
NMR results obtained for (±)-mephedrone and (±)-Mexedrone were very 
similar, as expected. 
 
5.3.1 (±)-Mephedrone: 
A 1H NMR spectrum of the (±)-mephedrone salt was obtained at 60 ⁰C in d6-
DMSO. Figure 5.2shows thatat δ = 9.98 ppm represents the ammonium salt protons 
(2H,br s, CH(NH2+CH3)CH3); and the characteristic AA’BB’  aromatic system for 
anasymmetrically para-di-substituted aromaticsystem at 8.41 ppm (2H,d, J = 8.0 Hz, 
AA’BB’, Ar-H), 7.88 ppm (2H, d, J = 8.0 Hz, AA’BB’, Ar-H), a de-shielded one-
hydrogen quartet at 5.62 ppm (1H,q, J = 7.6 Hz CH(NH2+CH3)CH3),), a de-shielded 
three-hydrogen singlet at 3.04 ppm(3H,s,CH(NH2+CH3)CH3), a slightly de-shielded 
methyl singlet corresponding to themethyl attached to the aromatic ring at 2.88 ppm 
(3H,s, ArCH3,) and lastlya methyl doublet at 1.91 ppm (3H,d, J = 7.6 Hz, 
CH(NH2+CH3)CH3,).The results obtained are similar to what was reported by Santali 
et al. (Santali et al., 2011). 
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Figure 5.21H NMR spectrum (d6-DMSO, 60 °C) of (±)-mephedrone. 
 
13C NMR spectra (obtained at 60 ºC in d6-DMSO, Figure 5.3&Figure 5.4) 
support purity with nine distinct carbon signals. The δ = 196.86 (C=O, C1), 146.47 
(ArC, C4*), 131.49 (ArC, C1*), 130.76 (2 x ArCH, C3*/C5*), 129.96 (2 x ArCH, 
C2*/C6*), 59.10 (CHCH3, C2), 31.64 (NCH3), 22.33 (ArCH3, C7*) and 16.56 
(CHCH3, C3). The N-methyl resonance (δ = 3.04 ppm) gave a 3J correlation to C2 
which is in turn coupled to the methyl doublet (C3). In the HMBC spectrum, the 
protons of the methyl resonance (δ = 1.91 ppm) are coupled to a de-shielded carbon 
(δ = 196.86 ppm, C1) completing the assignment of the 2-aminomethyl-propane-1-
one side chain. Further couplings in the HMBC spectrum between H2*/H6* and C1 
(3J) support the assignment of the propane-1-one side chain at C1* on the aromatic 
nucleus (between C6* and C2*) and the correlations between H2*/H6* and 
H3*/H5*confirmed the AA’BB’ aromatic system. The methyl singlet at 2.88 ppm (C7’) 
displays a 3J HMBC correlation to C3*/C5* and a 2J correlation to C4* finalising the 
assignment of all resonances (Table 5.1). The results obtained are similar to the 
current literature reported for (±)-mephedrone. (Santali et al., 2011).  
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Figure 5.3Chemical structure of (±)-mephedrone.HCl 
 
 
Figure 5.413C NMR spectrum (d6-DMSO, 60 °C) of (±)-mephedrone. 
 
Table 5.11H, 13C NMR spectral data and 1H-13C long-range correlations of (±)-mephedrone in d6-
DMSO. Chemical shifts () in ppm; coupling constants (J) in Hz. 
Position (±)-Mephedrone 
 1H 13C 2J 3J 
1 - 196.86 - - 
2 5.62 q, J = 7.6 Hz 59.10 C1, C3 NCH3 
3 1.91 d, J = 7.6 Hz 16.56 C2 C1 
1* - 131.49 - - 
2*/6* 8.41 d, J = 8.0 Hz 130.76 C3*/C5* C2*/C6*, C1 
3*/5* 7.88 d, J = 8.0 Hz 129.96 C2*/C6* C3*/C5* 
4* - 146.47 - - 
7* 2.88 s 22.33 - C3*/C5* 
NCH3 3.04 s 31.64 - C2 
NH2+ 9.98 br s - - - 
 
The DEPT profile (obtained at 60 ºC in d6-DMSO) further supports the structure 
and shows six signals corresponding to the three CH and three CH3 resonances. 
The two signals at δ = 129.96 ppm and 130.76 ppm correspond to the two different 
CH environments in the aromatic ring, and the aromatic methyl signal is observedat 
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δ = 22.33 ppm. The three signals signifying the resonances in the aliphatic 2-
aminomethyl-propane-1-one chain are observed at δ = 59.10, 31.64, 16.56 ppm (the 
aliphatic CH, aminomethyl and methyl respectively). 
 
5.3.2 (±)-Mexedrone 
The 1H NMR spectrum of (±)-Mexedrone salt was obtained at 60 ⁰C in d6-
DMSO. Figure 5.5 at δ = 9.98 ppm represents the ammonium salt protons (2H,br s, 
CH(NH2+CH3)CH3); and the characteristic AA’BB’  aromatic system for 
anasymmetrically para-disubstituted aromatic system at 8.47 ppm (2H, d, J = 8.0 
Hz, AA’BB’),7.95 ppm (2H, d, J = 8.0 Hz, AA’BB’), a de-shielded one hydrogen 
singlet at 5.88 ppm (1H, m, C(O)CHN), a de-shielded two-hydrogen doublet at 4.36 
ppm (2H, dd, J = 7.79 Hz; CH2OCH3), a de-shielded three-hydrogen singlet at 3.73 
ppm (3H, s, J = 7.79, OCH3) a de-shielded three-hydrogen singlet at 3.17 ppm (3H, 
s, NHCH3) and finally a slightly de-shielded methyl singlet corresponding to the 
methyl attached the aromatic ring at 2.96 ppm (3H ,s, ArCH3). The results obtained 
in this study are similar to what was reported by McLaughlin et al.(McLaughlin et al., 
2017). 
 
13C NMR spectra (obtained at 60 ºC in d6-DMSO, Figure5.6 & Figure 5.7) 
support the idea that the substance is primarily pure, with ten distinct carbon signals. 
The δ = 194.06 (C=O, C1), 146.44 (ArC, C4*), 132.16 (ArC, C1*), 130.75 (2 x ArCH, 
C3*/C5*), 129.87 (2 x ArCH, C2*/C6*), 70.29 (CH2, C3), 64.10 (CH, C2), 59.87 
(OCH3), 32.67 (NCH3) and 22.35 (ArCH3, C7*). These results are similar to what was 
reported by McLaughlin et al (McLaughlin et al., 2017). 
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Figure 5.5 Determination of 1H NMR spectrum (d6-DMSO, 60 °C) of (±)-mexedrone. 
 
 
Confident assignments of all carbon and hydrogen resonances were achieved 
using both HMQC and HMBC methods for a full spectral analysis, which signified 
that the sample was (±)-mexedrone. The N-methyl resonance (δ = 3.17 ppm) gave 
a 3J correlation to C2 which is in turn coupled to the methylene doublet (C3). The 
protons of the methylene resonance (δ = 3.73 ppm) are coupled to a de-shielded 
carbon (δ = 194.06 ppm, C1) and a de-shielded methoxy singlet (δ = 5.88 ppm) 
completing the assignment of the 3-methoxy-2-aminomethyl-propane-1-one side 
chain. Further couplings in the HMBC spectrum between H2*/H6* and C1 (3J) 
supports the assignment of the propane-1-one side chain at C1* on the aromatic 
nucleus (between C6* and C2*) and correlations between H2*/H6* and H3*/H5* 
confirmed the AA’BB’ aromatic system. The methyl singlet at 2.96 ppm (C7*) 
exhibits a 3J HMBC correlation to C3*/C5* and a 2J correlation to C4* concluding 
the assignment of all resonances (Table 5.2). 
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Figure5.6 Chemical structure of (±)-mexedrone.HCl 
 
 
Figure 5.7 13C NMR spectrum (d6-DMSO, 60 °C) of (±)-mexedrone. 
 
Table 5.21H, 13C NMR spectral data and 1H-13C long-range correlations of (±)-Mexedrone in d6-
DMSO. Chemical shifts () in ppm; coupling constants (J) in Hz. 
Position (±)-Mexedrone 
 1H 13C 2J 3J 
1 - 194.06 - - 
2 3.73 s 59.87 C1, C2, C3 NCH3 
3 4.36 d, J = 7.79 70.29 C2 C1 
4 5.88 s 64.10 - C2* 
1* - 132.16 - - 
2*/6* 8.47 d, J = 8.0 130.75 C3*/C5* C2*/C6*, C4*, C1 
3*/5* 7.95 d, J = 8.0 129.87 C2*/C6* C3*/C5*, C1* 
4* - 146.44 - - 
7* 2.96 s 22.35 C4* C3*/C5* 
NCH3 3.17 s 32.67 - C2 
NH2+ 9.94 br s - - - 
 
The DEPT profile (obtained at 60 ºC in d6-DMSO) further supports the structure 
and shows seven signals corresponding to the single CH2, 3 CH and 3 CH3 
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resonances. The two signals at δ = 130.75 ppm and 129.87 ppm correspond to the 
two different CH environments in the aromatic ring, and the aromatic methyl signal 
is observed at δ = 22.35 ppm. The four signals signifying the resonances in the 
aliphatic 3-methoxy-2-aminomethyl-propane-1-one chain are observed at δ = 70.29, 
64.10, 59.87, 32.67 ppm (the aliphatic CH2, methoxy group, aliphatic CH, and 
aminomethyl group respectively). 
 
5.4 Gas chromatography-mass spectrometry (GC-MS) analysis 
GC-MS methods have been previously used for the analysis of (±)-mephedrone and 
(±)-Mexedrone in isolation (Santali et al., 2011; McLaughlin et al., 2017). The 
combined method for the analysis of these substances in combination has not 
previously been reported and the method was developed (see Section 2.8.1.1) 
which allowed rapid analysis within 8 minutes and high resolution of two target 
compounds (Figure 5.8). This method was used to quantitatively analyse the target 
substances and determine their electronic impact fragmentation pattern. 
Mephedrone was eluted at 5.4 minutes and (±)-mexedrone was eluted at 6.1 
minutes, so that means this method can be used to separate and differentiate 
between the two compounds (Figure 5.8).  
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Figure 5.8Gas chromatograms of a mixture containing 100 µg mL-1 of (a) (±)-mephedrone (b) (±)-
Mexedrone and (c) eicosane (internal standard). 
 
A comparison of both electron ionisation mass spectra shows that both 
compounds have similar fragmentation patterns. In the EI-MS of both compounds, 
some fragments were observed in their mass spectra (Figure 5.9). However, mass 
spectrometry allows unambiguous identification of the two molecules as no two 
molecules give the same mass spectrum. The peak with the highest abundance for 
(±)-mephedrone is observed at m/z = 58 (Figure 5.10), whereas, for (±)-Mexedrone 
it appears at m/z = 88 (Figure 5.11). The mass spectra also indicate the [M+] at m/z 
= 178 for (±)-mephedrone and [M+] at m/z = 208 for (±)-Mexedrone (Figure 5.9). 
 
(a) 
(b) 
(c) 
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Figure 5.9 The proposed fragmentation of (±)-mephedrone and (±)-mexedrone, under EI-MS 
conditions.  
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Figure 5.10 Mass spectra of 100 µg mL-1 of (±)-mephedrone. 
 
 
Figure 5.11Mass spectra of 100 µg mL-1 of (±)-mexedrone. 
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5.5 Ultraviolet-visible spectroscopy (UV-vis) (determination of λmax) 
The UV spectrum of (±)-mephedrone in mobile phase 3 shows λmax at 263 nm 
(A = 1.195, c = 9.1x10-4 g 100 mL-1). Likewise, in the ultraviolet spectrum of (±)-
mexedrone, λmax at 263 nm (A = 0.382, c = 9.1x10-4 g 100 mL-1). This is similar to 
that reported by Santali et al. for (±)-mephedrone obtained in deionised water (λmax 
= 263.5 nm, A = 0.651, c = 9.1×10−4 g 100 mL-1) or 0.1 M aqueous hydrochloric acid 
(λmax = 263.5 nm, A = 0.662, c = 9.1×10−4 g 100 mL-1) (Santali et al., 2011). 
 
5.6 HPLC method development 
Mephedrone and mexedrone have been previously characterised using 
various chromatographic, spectroscopic, and mass-spectrometric methods and X-
ray crystal structure analysis (McLaughlin et al., 2017). The previously published 
data were used to confirm the purity of the reference materials prior to developing a 
chromatographic method for their separation and detection. As it can be seen from 
Section 5.4, it is easyto separate and discriminate between these compounds using 
GC-MS, the most commonly used method for routine screening of unknown bulk 
forensic samples. However, the interested was in further developing the application 
of electrochemical detection of new psychoactive substances based on the recent 
success with mephedrone and its N-ethyl derivative (4-MEC) (Zuway et al., 2015; 
Khreit et al., 2012). 
 
In this study, for the first time, high performance liquid chromatography 
combined with an amperometric detection protocol was used for the separation and 
quantitation of mephedrone and mexedrone. The HPLC-UV chromatographic 
method was developed by employing change in an isocratic elution to ensure both 
optimal detection of the analytes and a rapid analysis time. The startingpoint was to 
develop an HPLC-UV method that could separate and identify (±)-mephedrone and 
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(±)-Mexedrone in a mixture with good resolution and shorter relative retention time. 
The method development was carried out using an adaptation of the HPLC-UV 
method was reported in chapter 4. The original method in chapter 4 used 30:70 % 
v/v methanol: 10 mM ammonium acetate buffer containing a suitable electrolyte 
(100 mM KCl) to analysise the (±)-mephedrone and (±)-4-MEC, but in this study, the 
organic modifier was increased. To improve the resolution between (±)-mephedrone 
and (±)-mexedrone, the percentage of organic modifierwas changed to 38:62 % v/v 
methanol: 10 mM ammonium acetate buffer containing a suitable electrolyte (100 
mM KCl) and the flow rate decreased to 0.8 mL min-1. The pH of the eluent was 
adjusted to 3.5 by added as dropwise of acetic acid to ensure (±)–mexedrone and 
(±)-mephedrone were fully ionised. By the above modification, (±)-mephedrone and 
(±)-Mexedrone were eluted at 5.75 and 6.55 min respectively using the HPLC-UV 
(UV detection) with the LC-FC-A system. The resolution between the two peaks was 
2.41 which implies “baseline resolution” under the published ICH guidelines (ICH, 
1996). 
 
 
Figure 5.12The chromatogram of a solution containing uracil (a) 200 µg mL, (±)-mephedrone (b), -
and (±)-Mexedrone (c) obtained on a HPLC-UV system (UV detection) using an ACE 3 C18 column 
(150 mm × 4.6 mm i.d., particle size: 3 μm); flow-rate: 0.8 mL min−1; mobile phase 3; detector 
wavelength (UV): 264 nm. 
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5.7 Amperometric detection method development 
The following optimisation  of the anodic potential, linear velocity and pH had 
to  be performed to achieve the optimal detector response and get the optimum 
conditions of electrochemical response before applying this method to the 
purchased street samples. 
 
5.7.1 Optimisation of anodic potential by amperometric detection (AD)  
By using same HPLC-UV optimal conditions that were obtained in the method 
development in Section 5.6 (temperature = 22⁰C, flow rate = 0.8 mL min-1 and pH = 
3.5) some changes were made in the potential of amperometric detection (HPLC-
AD) to find the best potential to produce a high current response and improve the 
sensitivity. The (±)-mephedrone (300 µg mL-1) and (±)-Mexedrone (300 µg mL-1) 
anodic potentials in mobile phase 3 (Table 2.3) were determined by using the peak 
current (µA) in conjunction with the optimised instrumental configuration. The 
potential required to achieve the optimal detector response for the mixture was 
determined, for HPLC-AD in the LC-FC-A system by measuring the amperometric 
response (peak current, μA) as a function of the anodic potential (E V−1), over the 
range +0.0 to +1.5 V−1. The maximum high current responses (0.602 and 0.688, 
n=3) were detected at +1.4 V-1 for (±)-mephedrone and (±)-Mexedrone respectively 
(Table 5.3). 
Table 5.3 The anodic potential of 300 µg mL-1 of (±)-mephedrone and (±)-Mexedrone over the range 
+ 1.1 to + 1.5 v-1 using mobile phase 3, ACE 3 C18 column (150 mm x 4.6 mm i.d., particle size: 3 
μm); temperature = 22 ⁰C, flow rate = 0.8 mL min-1 and pH = 3.5 using HPLC-AD in the LC-FC-A 
system. 
Potential (v) 
Peak high (µA) 
(±)-Mephedrone (±)-Mexedrone 
1.1 0.119 0.172 
1.2 0.301 0.344 
1.3 0.452 0.552 
1.4 0.602 0.688 
1.5 0.231 0.283 
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5.7.2 Optimisation of the linear velocity of amperometric detection  
The same HPLC-UV optimal conditions obtained from optimisation of the 
potential in Section 5.7.1 were used (temperature = 22⁰C, potential 1.4 V and pH = 
3.5). These conditions were used in the experiment to optimise the linear velocity of 
the amperometric detection. The linear velocity required to achieve the optimal 
detector response for the mixture was determined for LC-FC-A by measuring the 
amperometric response (peak current, μA) as a function of linear velocity over the 
range 0.8 to 1.2 mL min−1. The maximum high current responses (0.602 and 0.688, 
n=3) were detected at 0.8 mL min-1 for (±)-mephedrone and (±)-Mexedrone 
respectively (Table 5.4). 
 
Table 5.4 The linear velocity of 300 µg mL-1 (±)-mephedrone and (±)-Mexedrone over the range  0.8 
to + 1.2 mL min-1 using mobile phase 3, ACE 3 C18 column (150 mm x 4.6 mm i.d., particle size: 3 
μm); at temperature = 22 ⁰C and pH = 3.5 using HPLC-AD in the LC-FC-A system. 
Flow rate 
mL min-1 
Peak high (µA) 
(±)-Mephedrone (±)-Mexedrone 
0.8 0.602 0.688 
1 0.456 0.477 
1.2 0.328 0.383 
 
5.7.3 Optimisation of pH of HPLC-UV and amperometric detection 
One of the important parameters affecting the current response is the pH of 
the mobile phase. The previously used optimised conditions were used to optimise 
the response of the detector for 300 µg mL-1 of (±)-mephedrone and 300 µg mL-1 of 
(±)-Mexedrone with a various pH values for mobile phase 3 (Table 2.3). The pH of 
mobile phase 3 required to achieve the optimal detector response for the mixture 
was determined by measuring the amperometric response (peak current, μA) as a 
function of pH over the range 3.5 to 7.5 mL min−1. The maximum detector response 
was found at pH = 3.5 as 0.602 and 0.688, n=3 for (±)-mephedrone and (±)-
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Mexedrone respectively (Table 5.5). At pH less than 3.5, an overlap of the 
mephedrone and mexedrone peaks was observed in the chromatogram of HPLC-
UV and a loss of the analytes’ activity. At pH values more than 7.5, turbidity was 
observed in the solution, because the ionisation of these drugs was changed and in 
basic solution the drugs will be in their free base form and will be precipitating from 
the solution. By the optimisation of the amperometric detection of HPLC-AD in the 
LC-FC-A system (Sections 5.7.1, 5.7.2, and 5.7.3), the analytes were eluted at 5.77 
and 6.57 minutes for (±)-mephedrone and (±)-Mexedrone respectively (Figure 5.13). 
 
Table 5.5 The effect of pH of the mobile phase on the analysis of (±)-mephedrone and (±)-Mexedrone 
over the range 3.5 to 7 using mobile phase 3, ACE 3 C18 column (150 mm x 4.6 mm i.d., particle 
size: 3 μm); at temperature = 22 ⁰C and flow rate = 0.8 mL min-1using HPLC-AD in the LC-FC-A 
system. 
pH 
Peak high (µA) 
(±)-Mephedrone (±)-Mexedrone 
3.5 0.602 0.688 
5.5 0.435 0.457 
7.5 0.378 0.383 
 
 
Figure 5.13 Amperogram of a solution containing 200 µg mL (±)-mephedrone (a), and (±)-
Mexedrone (b) obtained on the LC-FC-A system (amperometric detection) using an ACE 3 C18 
column (150 mm × 4.6 mm i.d., particle size: 3 μm); flow-rate: 0.8 mL min−1;  mobile phase 3. 
 
5.8 HPLC-AD method validation  
Method validation was used to confirm that the HPLC-AD protocol could 
rapidly separate and detect (±)-mephedrone and (±)-mexedrone. By the results of 
(a) (b) 
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validation it is possible to judge the quality, reliability, and consistency of the HPLC-
AD system to use for analysis of MEX-1, MEX-2, MEX-3 (street samples that were 
obtained from Research Chemicals), and MEX-4 (street sample obtained from 
Bulkled.eu) Table 2.1. The methods were validated for selectivity, linearity, 
resolution, detection and quantification limits, robustness, precision, reproducibility, 
and accuracy in accordance with ICH guidelines (ICH, 1996). Table 5.6 shows the 
optimal conditions used for method validation. 
 
Table 5.6 Summary of the optimal conditions used for method validation of (±)-mephedrone and (±)-
mexedrone using the LC-FC-A system. 
Optimised chromatographic conditions 
Column 
Column A (Section 2.2.1; ACE 3 C18 column 
(150 mm × 4.6 mm i.d., particle size: 3 μm)) 
Flow rate 0.8 mL min-1 
Solvent Mobile phase 3 (Table 2.3) 
Column temperature (⁰C) 22 
Wavelength (nm) 263  
Injection volume (µL) 10  
Run-time (mins) 10 
pH 3.5 
Optimised amperometric detection parameters 
Potential (v) +1.4  
Equilibration time (s) 10  
Data interval (s) 0.05  
Current range (mA) 1× 10-6 – 1  
Total run time (s) 5000  
 
5.8.1 System suitability test 
Retention time, capacity factors, theoretical plates, resolution, and asymmetric 
factors are presented in Table 5.7. The system suitability test is very important to 
evaluate the suitability and effectiveness of the entire chromatographic system, not 
only before use but also during the time of analysis. (±)-Mephedrone was eluted at 
5.75 min and (±)-mexedrone eluted at 6.55 min, with high resolution 2.41. Both 
analytes had theoretical plates within the range >2000, where (±)-mephedrone 
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theoretical plates were 14000 and (±)-mexedrone were 15000. The asymmetric 
factor for both analytes was found to be < 2, where (±)-mephedrone was 0.62 and 
(±)-mexedrone was 0.52. 
 
The summary of the method validation results in Table 5.7 and Table 5.8 were 
obtained from the standard calibration analyses with their respective correlation 
coefficients, slopes, and intercepts resulting from the linear regression analysis. 
 
Table 5.7 Summary of HPLC-UV (UV detection) validation data for the quantification of (±)-
mephedrone and (±)-Mexedrone using HPLC-UV in the LC-FC-A system, column A (Table 2.3mobile 
phase3; wavelength = 263 nm. 
System detection HPLC-UV 
Flow Rate 0.8 mlmin-1 
Analytes (±)-Mephedrone (±)-Mexedrone 
tR(min)(t0= 2.03min)a 5.75 6.55 
RRTb 1 0.9 
Capacity factor (k’) 1.5 1.83 
N (plate) 14000 (68691)c 15000 (61904)c 
H (m) 1.46×10 -05 1.62×10 -05 
Resolution (Rs) / 2.41 
Asymmetry factor (As) 0.62 0.52 
LODd (µg ml-1) 6.52 5.15 
LOQe (µg ml-1) 19.75 15.62 
Co-efficient of regression(r2) 0.999f 0.999g 
Precision (%RSD) (n=6) 
100 µg mL-1 0.024 0.019 
200 µg mL-1 0.091 0.004 
300 µg mL-1 0.040 0.013 
400 µg mL-1 0.280 0.012 
500 µg mL-1 0.045 0.009 
aMeasured from the retention time of uracil (10 μg mL−1) eluting from the column. bRelative 
retention time (concerning (±)-mephedrone. cN expressed in plates per m. dLimit of 
detection.eLimit of quantification.f y = 50.834x - 5.4499. g y = 33.976x + 1312. 
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Table 5.8 Summary of HPLC-AD (amperometric detection) validation data for the quantification of 
(±)-mephedrone and (±)-mexedrone using HPLC-AD in the LC-FC-A system, column A, (Table 2.2), 
mobile phase 3; detector wavelength = 263 nm. 
System detection HPLC-AD 
Flow Rate 0.8 ml min-1 
Analytes (±)-mephedrone (±)-mexedrone 
tR(min)(t0= 2.03min)a 5.77 6.57 
RRTb 1 0.9 
LODc (µg ml-1) 13.21 9.95 
LOQd (µg ml-1) 40.03 30.16 
Co-efficient of regression(r2) 0.996e 0.998f 
Precision (%RSD) (n=6) 
100 µg mL-1 0.65 0.81 
200 µg mL-1 0.14 2.56 
300 µg mL-1 1.41 0.31 
400 µg mL-1 0.68 0.61 
500 µg mL-1 0.27 0.63 
aMeasured from the retention time of uracil (10 μg mL−1) eluting from the column. bRelative 
retention time (concerning (±)-mephedrone. cLimit of detection. dLimit of quantification. ey = 
0.0012x - 0.0068. fy = 0.0013x + 0.0311.  
 
5.8.2 Resolution (Rs)  
Resolution in this study explains the separation between (±)-mephedrone and 
(±)-mexedrone as shown in Table 5.7. (±)-mephedrone was eluted at 5.77 and (±)-
mexedrone was eluted at 6.57 with an excellent resolution of 2.41 that explains this 
method has a good separation between (±)-mephedrone and (±)-mexedrone 
because of their resolution was more than two which implies “baseline resolution” 
under the published ICH guidelines (ICH, 1996). 
 
5.8.3 Linearity  
The linearity was evaluated by using a calibration curve to calculate the 
coefficient of correlation, slope, and intercept values. The linearity was obtained for 
the HPLC-UV system by a plot constructed from the concentration and peak area 
(Figure 5.14 a). In this study, the high concentration standards’ range used in this 
study was (100-500 µg mL-1); the 50 µg mL-1 as was that run in the previous chapter 
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4 could not be used because the amperometric detection in this study needed a high 
concentration to have a good detection for both the (±)-mephedrone and (±)-
mexedrone. , Six replicates were injected under the optimal conditions used in the 
method development.  
 
The calibration standards all showed excellent linearity responses. That for (±)-
mephedrone was R2 = 0.999 with good repeatability and RSD values in the range 
0.02-0.28%; n = 6 (Appendix: Table 9.22), and for (±)-mexedrone, R2 = 0.999 with 
RSD values in the range of 0.003–0.02%; n = 6 (Appendix: Table 9.23). 
 
The corresponding liquid chromatography-amperometric detection system, the 
impinging jet, flow cell LC-FC-A was used. The calibration standard (100-500 µg 
mL-1, with six replicated injections) showed good linearity by a plot constructed from 
the concentration and peak high (Figure 5.14b). The (±)-mephedrone linearity of 
was R2 = 0.996 with good repeatability with RSD values in the range 0.14-0.722%; 
n = 6 (Appendix: Table 9.24) and for (±)-mexedrone, R2 = 0.997 with RSD values in 
the range 0.31–0.81%; n = 6 (Appendix: Table 9.25). However, both HPLC-UV and 
HPLC-AD in the LC-FC-A system have a good linearity but the linearity of HPLC-
UV was better than the linearity of HPLC-AD in LC-FC-A system due to the HPLC-
UV detectionhaving a higher sensitivity to the analytes than HPLC-AD in the LC-FC-
A system. 
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Figure 5.14 The linearity of (±)-mephedrone (squares) and (±)-mexedrone (triangles) by using a) 
HPLC-UV in the LC-FC-A system b) HPLC-AD in the LC-FC-A system. 
 
 
5.8.4 Limit of detection (LOD)  
LOD was estimated from the calibration standard curve. The standards were 
used over a concentration range of 100-500 µg mL-1 and injected as six replicates. 
The LOD of analysis (±)-mephedrone was determined using HPLC-UV in the LC-
FC-A system (UV detector) and found to be 6.52 µg mL-1 which was slightly similar 
to the previous study in chapter 4 where it was 2.5 µg mL-1,  and that was due to the 
change in concentration range of the calibration standard in both studies. The LOD 
of (±)-mexedrone was 5.15 µg mL-1. Even although the McLaughlin et al. 
0
5000
10000
15000
20000
25000
30000
0 100 200 300 400 500 600
p
e
a
k
 a
re
a
 (
m
A
U
) 
concentration (µg mL-1)
Mephedrone
Mexedrone
a
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 100 200 300 400 500 600
p
e
a
k
 h
ig
h
  
(µ
A
)
concentration (µg mL-1)
b 
157 
(McLaughlin et al., 2017) published a liquid chromatographic method for the 
characterisation of (±)-mexedrone, no LOD and LOQ were  reported, therefore, this 
study is the first to report the LOD for (±)-mexedrone within bulk forensic samples.  
 
The LOD of analysis of (±)-mephedrone was determined using HPLC-AD in 
the LC-FC-A system (amperometric detector) and was found to be 13.21 µg mL-1, 
similar to the previously reported levels of 14.66 μg mL−1in chapter 4. The LOD of 
(±)-mexedrone was 9.95 µg mL-1. In both detection systems, the LOD of the LC-FC-
A system was two times higher than the LOD of HPLC-UV. Which previously 
observed, HPLC-UV has higher sensitivity than HPLC-AD in this study (Table 5.7 
and Table 5.8). 
 
5.8.5 Limit of quantification (LOQ) 
LOQ was calculated using a calibration standard curve (standard range 100-
500 µg mL-1 and injected six replicates). The LOQ for (±)-mephedrone was 
determined to be 19.75 µg mL-1 by using HPLC-UV and 40.03 µg mL-1 by using 
HPLC-AD in the LC-FC-A system. Compared to a previous study (chapter 4), the 
LOQ was 7.58 µg mL-1 using HPLC-UV and 44.42 µg mL-1 using HPLC-AD in the 
LC-FC-A system. In comparing between the previous and this study, there was a 
clear difference in the LOQ due to a change in the concentrations of the calibration 
range utilised in this study. In addition, the LOQ for (±)-mexedrone was 15.62 µg 
mL-1 using the HPLC-UV system and 30.16 µg mL-1 by using HPLC-AD in the LC-
FC-A system (Table 5.7 andTable 5.8). 
 
5.8.6 Robustness 
A robustness test was performed in this study to confirm this method can be 
used for analysis of mixture solutions of 300 µg mL-1 of (±)-mephedrone and 300 µg 
mL-1 of(±)-mexedrone which were prepared in Section 2.8.7, although with a minor 
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change in some parameters such as temperature and organic composition ratio. 
Table 5.9 shows the effect of a minor change in temperature on the analysis of (±)-
mephedrone and (±)-mexedrone using HPLC-UV in the LC-FC-A system. 
Temperature plays a very important role in confirming the robustness of the 
analytical method. The temperatures used were  20⁰C, 22⁰C and 24⁰C and the 
relative standard deviation (RSD %) of relative retention time (RRT) was found to 
be less than 1% for (±)-mephedrone and (±)-mexedrone using HPLC-UV in the LC-
FC-A system, therefore this method is robust. 
  
Table 5.10 shows the effect of a minor change in mobile phase: Mobile phase 
3 (Table 2.3), the ratios between methanol: buffer solution A (Section 2.3.1) used 
were 40:60, 38:62, and 36:64. The relative standard deviation (RSD %) of relative 
retention time was found to be less than 1% for (±)-mephedrone and (±)-mexedrone 
respectively, using HPLC-UV in the LC-FC-A system. Due to no significant change 
in RSD%, this confirmed this method is robust. 
 
Table 5.9 The effect of minor changes of temperature on relative retention time (RRT) of analysis of 
300 µg mL-1 of (±)-mephedrone and (±)-mexedrone using HPLC-UV in the LC-FC-A system. (The 
highlighted area is a standardised condition for this study). 
Concentration 
RRT 
(20 °C) (22 °C) (24 °C) 
Mephedrone Mexedrone Mephedrone Mexedrone Mephedrone Mexedrone 
400 0.876 1.000 0.878 1.000 0.878 1.000 
400 0.876 1.000 0.878 1.000 0.878 1.000 
400 0.876 1.000 0.878 1.000 0.879 1.000 
400 0.874 1.000 0.876 1.000 0.876 1.000 
400 0.876 1.000 0.878 1.000 0.878 1.000 
400 0.876 1.000 0.879 1.000 0.879 1.000 
Average 0.875 1.000 0.878 1.000 0.878 1.000 
RSD% 0.110 0.000 0.108 0.000 0.108 0.000 
 
 
Table 5.10 The effect of a minor change in organic composition of mobile phase 3 on the relative 
retention time (RRT) of 300 µg mL-1 of (±)-mephedrone and (±)-mexedrone using HPLC-UV in the LC-
FC-A system. (The highlighted area is a standardised condition for this study). 
Concentration RRT 
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 (40:60% v/v  
methanol: buffer solution 
pH = 3.5,  
Section 2.4 
 (38:62% v/v  
methanol: buffer solution 
pH = 3.5,  
Section 2.4 
 (36:64% v/v  
methanol: buffer solution 
pH = 3.5,  
Section 2.4 
Mephedrone Mexedrone Mephedrone Mexedrone Mephedrone Mexedrone 
400 0.876 1.000 0.878 1.000 0.878 1.000 
400 0.876 1.000 0.878 1.000 0.878 1.000 
400 0.876 1.000 0.878 1.000 0.879 1.000 
400 0.874 1.000 0.876 1.000 0.876 1.000 
400 0.876 1.000 0.878 1.000 0.878 1.000 
400 0.876 1.000 0.879 1.000 0.879 1.000 
Average 0.875 1.000 0.878 1.000 0.878 1.000 
RSD% 0.110 0.000 0.108 0.000 0.108 0.000 
 
5.8.7 Inter- and intra-day precision  
12 replicate injections of a mixture solution of 300 µg mL-1 of (±)-mephedrone 
and 300 µg mL-1 of (±)-mexedrone were prepared as in Section 2.8.7. The intra-day 
test was performed on the same day (6 in the morning and 6 in the afternoon), and 
inter-day test was performed by the same procedure with six injections on the 
following day. However, the results’ precision showed little change between HPLC-
UV and HPLC-AD in the LC-FC-A system, but HPLC-UV had excellent precision for 
(±)-mephedrone and (±)-mexedrone, as shown by the RSD % of the peak area being 
less than 1% (Table 5.11). HPLC-AD achieved good precision for both compounds 
(±)-mephedrone and (±)-mexedrone as shown by the RSD% values (Table 5.11) of 
the peak current being less than 1% (Appendix: Table 9.26). The value of RSD% is 
suggested to be ≤ 1% as an appropriate precision criterion for repetitive injections 
to assess the precision of an instrument in analytical method validation (Green, 
1996). Little drifting of either compoundwas found, and these results illustrate the 
ability of this method and the efficiency of these systems to be applied to routine 
analysis.  
 
Table 5.11 The relative standard deviation (RSD %) of inter- and intra-day precision for (±)-
mephedrone and (±)-mexedrone by using HPLC-UV and HPLC-AD in the LC-FC-A system. 
System RSD% of LC-FC-A (n = 12) 
Detection HPLC-UV  HPLC-AD 
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Peak area (mAU)  Peak current (µA) 
Inter-day precision 
(±)-mephedrone 0.040 0.657 
(±)-mexedrone 0.019 0.584 
intra-day precision 
(±)-mephedrone 0.218 0.703 
(±)-mexedrone 0.174 0.631 
 
5.8.8 Accuracy 
To test the accuracy of the method, two standards, of (±)-mephedrone and (±)-
mexedrone, were prepared as 240, 300 and 360 μg mL-1. All prepared solutions 
were injected three times and showed excellent recovery in the range of 99.9-100.9 
%, and repeatability with RSD % values 0.01-0.8 % using the HPLC-UV system. 
The recovery range was 99.9-101.6 % and repeatability RSD % values were in the 
range 0.3-0.8 % by using HPLC-AD in the LC-FC-A system for (±)-mephedrone and 
(±)-mexedrone   In both systems, the recovery range was within the acceptable limits 
according to ICH (ICH, 1996), therefore this method has a good accuracy. 
Table 5.12 Accuracy data expressed as the percentage recovery of a mixture of (±)-mephedrone 
and (±)-Mexedrone by using both HPLC-UV and HPLC-AD in the LC-FC-A system. 
System LC-FC-A 
Detection HPLC-UV HPLC-AD 
Analyte 
Concentration 
(µg mL-1) 
Theoretical 
recovery 
(µg mL-1) 
Actual recovery 
(µg mL-1) 
%recovery (n=3) 
Actual 
recovery 
(µg mL-1) 
%recovery (n=3) 
Mephedrone 
240 (80%) 
242.5 243.09 100.3 (±0.09) 241.35 99.6 (±0.34) 
Mexedrone 242.5 242.47 100.1 (±0.04) 242.79 100.1 (±0.6) 
Mephedrone 
300 (100%) 
303.0 303.87 100.3 (±0.04) 303.13 100.4 (±1.0) 
Mexedrone 303.0 302.21 99.7 (±0.01) 304.44 100.5 (±0.3) 
Mephedrone 
360 (120%) 
363.6 360.60 99.2 (±0.23) 365.09 100.4 (±0.57) 
Mexedrone 363.6 360.62 99.1 (±0.01) 360.09 99. 3 (±0.65) 
 
5.9 Application of the methodology to forensic analysis  
Street samples containing mexedrone and mephedrone were purchased 
(Table 2.1) and the purity of the analytes were analysed using HPLC-UV and HPLC-
AD in the LC-FC-A system. A new electrode was used for each sample. MEX-1 and 
MEX-3 contained 95% of mexedrone and no mephedrone was observed. The MEX-
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2 contained approximately 80% mexedrone and only 20% mephedrone, in contrast, 
MEX-4 was shown to contain 99.84±0.84% mephedrone but mexedrone was not 
observed in MEX-4 sample. The results of the HPLC-UV analysis are summarised 
in Table 5.13. In terms of using HPLC-AD in the LC-FC-A system, the results have 
supported those obtained from the HPLC-UV analysis. Table 5.13 also shows the 
results of the analysis of street samples using HPLC-AD in the LC-FC-A 
system.MEX-1 and MEX-3 contained only mexedrone were more than 95% pure in 
both street samples and were similar to the results obtained by using HPLC-UV in 
the LC-FC-A system. In addition, MEX-2 contained 80.71±0.32 % of mexedrone and 
only 18.48±1.25% of mephedrone. In addition, MEX-4 was shown to contain 
99.9±1.07 % of mephedrone. 
 
Table 5.13 Summary of the quantification analysis of street samples by using HPLC-UV and LC-FC-
A systems. 
System LC-FC-A 
Detection HPLC-UV (%w/w) (n =6) HPLC-AD  (%w/w) ( n= 6) 
Analyte mephedrone mexedrone mephedrone mexedrone 
tR (min) 5.75 6.55 5.79 6.57 
MEX-1 n.d. 99.27±0.39 n.d. 98.35±0.35 
MEX-2 18.16±1.09 82.27±0.35 18.48±1.25 80.71±0.32 
MEX-3 n.d. 99.26±0.04 n.d. 96.02±1.38 
MEX-4 99.84±0.84 n.d. 99.9±1.07 n.d. 
n.d. not detected 
 
5.10 Conclusion 
The combination of high performance liquid chromatography with 
amperometric detection (HPLC-AD) for qualitative and quantitative analysis of (±)-
mephedrone and the new derivative (±)-mephedrone called (±)-mexedrone have 
been reported using an imagining jet flow cell for electrochemical detection (LC-FC-
A) incorporating  disposable embedded graphite screen-printed electrodes (GSPE). 
In addition, the validation of the HPLC-AD protocol has been shown by using HPLC-
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UV to have a higher limit of detection for (±)-mephedrone (6.52 µg mL-1) than that 
obtained for (±)-mephedrone. In chapter 4 it was 2.5 µg mL-1 and these differences 
are due to the change in concentration range utilised in the calibration run. However, 
in terms of using amperometric detection (HPLC-AD), the limit of detection for (±)-
mephedrone was 13.21 µg mL-1 and similar to the LOD in chapter 4 where it was 
14.66 µg mL-1. Finally, the study in this chapter confirmed the last study in chapter 
4 and this new protocol distinguished between mephedrone and its derivatives. 
 
Since this work carried out, the New Psychoactive Substances Act came into force 
(UK-Government, 2016), and subsequently all psychoactive compounds including 
(±)-mexedrone have become banned under the new legalisation. Since the ban, it 
is highly possible that compounds which were previously available in a highly pure 
form may now have become more adulterated with potential cutting agents such as 
caffeine and paracetamol.Therefore, this work will in future be extended taking into 
account possible adulterants.  
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6 Chapter 6: Detection and quantification of regioisomers of new 
psychoactive substances (NPS) using high performance liquid 
chromatography-amperometric detection (HPLC-AD) 
 
 
6.1 Introduction 
Dissociative anaesthetics such as dextromorphan, ketamine and 
phencyclidine (PCP) affect the central nervous system to produce feelings of 
detachment and induce a state of anaesthesia due to antagonising ionotropic N-
methyl-D-aspartate receptors (NMDAR) (Morris and Wallach, 2014). The spread of 
PCP and ketamine derivatives, a new dissociative anaesthetic known as 
diarylethylamine based on leftamine (Table 6. 1a). Diarylethylamine is not a new 
compound, and was actually  reported in 1924. one of diarylethylamine can be found 
in the NPS market, as crystals or a powder, is ephenidine and this  has mild 
psychedelic effects (Beharry and Gibbons, 2016). Recently, ephenidine became 
available and anecdotally appears popular with dissociative users (e.g as an 
alternative to ketamine). The previous study reported the comparison between 
ephenidine and ketamine and showed that ephenidine is a relatively selective, 
voltage-dependent NMDA antagonist, which explains the psychotomimetic effects 
of ephenidine and predicts the side-effects including memory impairments (Kang et 
al., 2017). Ephenididne, also known as NEDPA (N-ethyl-1,2-diphenyl ethylamine) 
and EPE, is a dissociative anaesthetic that exerts its pharmacological action as an 
N-methyl-D-aspartate receptor antagonist (NMDAR) and has been used as a 
potential general anaesthetic for animals and humans (Kang et al., 2017). 
Therefore, ephenidine is referred to as a "dissociative anaesthetic" and is used as 
a recreational drug (Morris and Wallach, 2014). In many countries, ephenidine is 
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illegal as the structural isomer of the banned opioid drug lefetamine (Wink et al., 
2014; Wink et al., 2015).  
 
The variety and evolution of drug types have resulted in a continual analytical 
challenge for detection, identification, and measurement. This challenge has seen 
the use of techniques such as HPLC–DAD and LC or GC coupled with accurate 
mass spectrometry (Favretto et al., 2013). Electrochemistry, as an analytical tool, 
has the advantages of sensitivity and selectivity toward many target analytes (Smith 
et al., 2014a; Smith et al., 2015; Metters et al., 2011). An electrochemistry protocol 
was used in the previous study by Smith et al. for the analysis of the synthetic 
cathinones, (±)-mephedrone and (±)-4-MEC, either in their pure form by using 
electroanalytical oxidation (Smith et al., 2014a), or in an impure form (with 
adulterants) by using direct electrochemical reduction (Smith et al., 2014b). 
Electrochemical analysis using graphite screen-printed macro electrodes (GSPEs) 
has the ability to be a rapid, simple and cost-effective analytical screening tool. 
Moreover, in chapter 4, the HPLC-AD system (high performance liqiud 
chromatography combined with amperometric detection) was used in the 
separation, detection and quantification of the NPSs (±)-mephedrone and (±)-4-
MEC in presence of caffeine as adulterant) (Zuway et al., 2015). 
 
In this chapter, the developed HPLC-AD protocol was applied to the qualitative 
and quantitative analysis of NPSs’ regioisomers (regioisomers of 
methoxyephenidine and fluoroephenidine). Three regioisomer methoxy derivatives 
of ephenidine, namely (±)-2-methoxyephenidine [(±)-2-MEP; Table 6. 1c], (±)-3-
methoxyephenidine [(±)-3-MEP; Table 6. 1d] and (±)-4-methoxyephenidine [(±)-4-
MEP; Table 6. 1e] were analysed for the first time in this study. The second study 
explained the analysis of three regioisomers of fluoroephenidine, namely (±)-2-
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fluoroephenidine [(±)-2-FEP; Table 6. 1f], 3-fluoroephenidine [(±)-3-FEP; Table 6. 
1g] and (±)-4- fluoroephenidine [(±)-4-FEP; Table 6. 1h]. Methoxyephenidine and 
fluoroephenidine are derivatives of ephenidine. 
 
Table 6. 1 Chemical structure of ephenidine, lefetamine, and regioisomers of methoxyephenidine, 
and of fluoroephenidine. 
 
Compound R1 R2 R3 R4 R5 
a Lefetamine CH3 CH3 H H H 
b Ephenidine H CH2CH3 H H H 
c 2-Methoxyephenidine H CH2CH3 OCH3 H H 
d 3-Methoxyephenidine H CH2CH3 H OCH3 H 
e 4-Methoxyephenidine H CH2CH3 H H OCH3 
f 2-Fluoroephenidine H CH2CH4 F H H 
g 3-Fluoroephenidine H CH2CH5 H F H 
h 4-Fluoroephenidine H CH2CH6 H H F 
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6.2 Detection and quantification of regioisomers of methoxyephenidine 
using HPLC-AD  
This study presents the development and full validation data of the analysis of 
2-MEP, 3-MEP, and 4- MEP using high performance liquid chromatography 
combined with amperometric detection. In terms of the use of amperometric 
detection, the impinging jet flow cell (LC-FC-A) was used to obtain the peak current 
(µA) of all the analytes. In addition, it presents the limit of detection and limit of 
quantification data for all the analytes using UV with amperometric detection for all 
the analytes. 
 
6.2.1 Ultraviolet-visible spectroscopy (UV) determination of λmax 
In this study, the wavelength 279 nm was used to detect and quantifythe 
regioisomers of methoxyephenidine, through their absorbance.  The UV maximum 
(λmax) for (±)-2-MEP at 279 nm (A = 0.793, 1.0×10-2 g 100mL-1), for (±)-3-MEP at 
279 nm (A = 0.662, 1.0×10-2 g 100 mL-1 and (±)-4-MEP (0.761, 1.0×10-2 g 100 mL-
1) at 279 nm in mobile phase 4 (Table 2.3). 
 
6.2.2 HPLC method development 
Due to the new regioisomers of ephenidine having no fully validated methods 
(or limits of detection and quantification) reported, different parameters were used 
to develop the HPLC chromatographic method to ensure both optimal detection of 
the analytes and a rapid analysis time. The starting point was to develope a HPLC-
UV method that could separate and identify (±)-2-MEP, (±) 3-MEP and (±)-4-MEP 
with good resolution and shorter retention time. 
 
By this modification, (±)-4-MEP, (±)-2-MEP and (±)-3-MEP were eluted at 21.61, 
23.84 and 25.83 mins respectively using HPLC-UV detection in the LC-FC-A 
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system. The resolution for all analytes in both systems was in the range > 2 (Figure 
6.1). 
 
 
Figure 6.1The chromatogram of a solution containing 300 µg mL-1 of (±)-4-MEP (a), (±)-2-MEP (b) 
and (±)-3-MEP (c) obtained using HPLC-UV in the LC-FC-A system using an ACE 5 C18AR column 
(150 mm × 4.6 mm i.d., particle size: 5 μm); mobile phase 4 detector wavelength (UV): 279 nm. 
 
6.2.3 Amperometric detection method development 
6.2.3.1 Optimisation of potential of amperometric detection 
The anodic potentials for (±)-2-MEP (100.0 μg mL−1), (±)-3-MEP (100.0 μg 
mL−1) and (±)-4-MEP (100.0 μg mL−1) mixture in mobile phase 4 (Table 2.3) were 
determined using the peak current, in conjunction with the optimised instrumental 
configuration. The HPLC optimal conditions were used for optimisation of the 
potential according to the method development in Section 6.4 (temperature = 50 ⁰C, 
flow rate = 2 mL min-1 and pH = 7). The potentials required to achieve the optimal 
detector response for the mixture were determined for LC-FC-A by measuring the 
amperometric response (peak current, μA) as a function of anodic potential, over 
the range +0.0 to +1.5 E V−1. The maximum high current responses (0.51, 0.25 and 
0.29, n=3) were detected at +1.2 EV-1 for (±)-2-MEP, (±)-3-MEP and (±)-4-MEP 
respectively (Table 6. 1). 
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 VWD1 A, Wavelength=279 nm (COLUMN TEST\KZUWAY 2016-03-21 17-12-50\COLUMNTEST00001.D)
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(Uracil) 
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Table 6.1 The anodic potentials for100 µg mL-1 of (±)-2-MEP, (±)-3-MEP and (±)-4-MEP over the 
range 1.0 to + 1.5 V-1 using mobile phase 4, column: ACE 5 C18AR column (150 mm × 4.6 mm i.d., 
particle size: 5 μm). Temperature = 50 ⁰C, flow rate = 2 mL min-1 and pH = 7 using HPLC-AD 
detection in the LC-FC-A system. 
Potential(v) 
Peak height µA 
(±)-4-MEP (±)-2-MEP (±)-3-MEP 
1.0 0.27 0.15 0.16 
1.2 0.53 0.28 0.32 
1.3 0.44 0.26 0.25 
1.4 0.34 0.17 0.19 
1.5 0.30 0.15 0.18 
 
6.2.3.2 Optimisation of linear velocity of amperometric detection 
The flow rate used in Section 6.1.3.1 was 2 mL min-1 because this produced 
the optimal response. However, in this section, due to the effect of the internal 
chamber volumes of the flow cells (LC-FC-A = 8 μL) a solution of the mixture (100 
µg mL-1) was injected (n = 10) at range of flow rates 1-2 mL min-1. The amperometric 
response was measured to determine the optimal linear velocity required for the 
maximum amperometric response of the LC-FC-A system. Table 6.2 shows the 
peak current of (±)-4-MEP, (±)-2-MEP and (±)-3-MEP with a good amperometric 
response [(±)-4-MEP = 0.58 µA, (±)-2-MEP = 0.28 µA and (±)-3-MEP = 0.33] at 1.2 
E V−1 and (pH = 7) using HPLC-AD in LC-FC-A system. In addition, there was no 
response observed at flow rates less than 1 mL min-1, and at flow rates more than 
2 mL min-1, the peaks on the HPLC-UV (UV detection) system overlapped. 
 
Table 6.2 The linear velocity for 100 µg mL-1 of (±)-2-MEP, (±)-3-MEP and (±)-4-MEP over the range 
0.9 to 1.2 ml min-1 using mobile phase 4, column: ACE 5 C18AR column (150 mm × 4.6 mm i.d. 
particle size: 5 μm); at temperature = 50 ⁰C, and pH = 7 using HPLC-AD detection in the LC-FC-A 
system. 
Flow rate 
mL min-1 
Peak current  
(±)-4-MEP (±)-2-MEP (±)-3-MEP 
1 0.46 0.25 0.29 
1.5 0.53 0.28 0.32 
2 0.58 0.28 0.33 
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6.2.3.3 Optimisation of pH of HPLC-UV and amperometric detection 
Table 6.3 shows the different pH (3-7) used to find the best pH to obtain the 
highest response for the analytes. But the best amperometric response for the 
HPLC-UV and HPLC-AD systems was with a mobile phase of  pH = 7, because the 
pH of the mobile phase cannot  be more than 9 or less than 2 to protect the silica 
from degrading and that  affects in the column’s performance as explained in 
Section 3.6. As well as no amperometric response being observed at a mobile 
phase with pH = 3, the maximum responses using HPLC-AD in the LC-FC-A system 
were 0.58 μA for (±)-4-MEP, 0.28 μA for (±)-2-MEP and 0.32 μA for (±)-3-MEP, 
which were observed at a potential = +1.2 E V−1 and flow rate 2 mL min-1 using a 
mobile phase with pH = 7. Moreover, the mobile phase pH effect on the response 
of the HPLC-UV system when using a mobile phase with a pH=5, the peaks in 
HPLC-UV in the LC-FC-A system overlapped and the resolution of the peaks 
decreased.  
 
Table 6.3 The effect of the pH of mobile phase on the analysis of 100 µg mL-1 of (±)-2-MEP, (±)-3-
MEP and (±)-4-MEP over the range 3 to 7 ml min-1 using mobile phase 4, column: ACE 5 C18AR 
column (150 mm × 4.6 mm i.d. particle size: 5 μm); temperature = 50 ⁰C, potential = 1.2 EV-1  and 
flow rate 2 mL min-1 using HPLC-AD detection in the LC-FC-A system. 
pH 
Peak current 
(±)-4-MEP (±)-2-MEP (±)-3-MEP 
3  n.d. n.d. n.d. 
5  0.34 0.16 0.197 
7  0.58 0.28 0.32 
n.d.=not detected 
 
By the optimisation of amperometric detection (Section 6.3.1, 6.3.2, and 6.3.3) in 
the LC-FC-A systems, the analytes were eluted at 21.63, 23.86 and 25.85 minutes 
for (±)-4-MEP, (±)-2-MEP and (±)-3-MEP respectively in the LC-FC-A 
(amperometric detection) system (Figure 6.2). 
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Figure 6.2 Amperogram of a solution containing 300 µg mL-1 of (±)-4-MEP (a), (±)-2-MEP (b) and 
(±)-3-MEP (c) obtained on the LC-FC-A system (amperometric detection) using an ACE 5 C18AR 
column (150 mm × 4.6 mm i.d., particle size: 5 μm); flow-rate: 2 mL min−1; mobile phase 4. 
 
6.2.4 HPLC-AD method validation 
The validation of the LC-FC-A system technique was a procedure aimed at 
obtaining experimentally justified evidence of the ability of this technique to give 
results characterised by the required accuracy and precision (ICH, 1996). The LC-
FC-A analytical techniques used for analysis the methoxyephenidine hydrochloride 
regioisomers required validation prior to deploying them in the analysis of the 
purchased street samples. The LC-FC-A system employing the commercial 
impinging jet flow cell and was validated (in terms of UV- detection) using a standard 
mixture of regioisomers of methoxyephenidine hydrochloride with strong UV 
absorption: (±)-4-MEP, (±)-2-MEP and (±)-3-MEP over the 100-500 μg mL−1 range. 
The optimal conditions used in this study are shown in Table 6.4. 
(a) 
(b) (c) 
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Table 6.4 Summary of the optimal conditions utilised in the analysis of (±)-4-FEP, (±)-2-FEP and (±)-
3-FEP. 
Optimised chromatography conditions 
Column 
Column B (Section 2.2.1) 
ACE 5 C18AR column (150 mm × 4.6 mm i.d., particle size: 5 μm); 
Flow rate (mL min-1) 2 
Solvent Mobile phase 4 (Table 2.3) 
Column temperature 
(⁰C) 
50 
Wavelength (nm) 279 
Injection volume (µL) 10 
Run time (mins) 30 
pH 7.0 
Optimised amperometric detection parameters 
Potential (V) +1.2 
Equilibrium time (s) 10 
Data interval (s) 0.05 
Current range (mA) 1×10-6-1 
Total run time (s) 5000 
 
 
Table 6.5 shows the summary of the validation parameters used for analysis 
the methoxyephenidine hydrochloride regioisomers [(±)-4-MEP, (±)-2-MEP and 
3-MEP] using HPLC-UV in the LC-FC-A  system, and  
Table 6.6 shows the summary of validation parameters of the analysis 
methoxyephenidine hydrochloride regioisomers using HPLC-AD in the LC-FC-A 
(amperometric detection) system. 
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Table 6.5 Summary of HPLC-UV (UV detection) validation data for the quantification of (±)-4-MEP, 
(±)-2-MEP and (±)-3-MEP obtained in the LC-FC-A systemsusing column B,(Table 2.2); mobile 
phase: 4C (Section2.4); UV wavelength: 279 nm. 
System detection LC-FC-A (HPLC-UV detection) 
Flow Rate 2 mlmin-1 
Analytes 4-MEP 2-MEP 3-MEP 
tR(min)(t0= 0.854min)a 21.61 23.84 25.83 
RRTb 0.91 1 1.08 
Capacity factor (k’) 20.61 22.84 24.83 
N (plates) 10304 (68691)c 9286 (61904)c 10395 (69300)c 
H (m) 1.46×10 -05 1.62×10 -05 1.44×10-05 
Resolution (Rs) / 2.41 2.05 
Asymmetry factor (As) 0.62 0.52 0.71 
LODd (µg ml-1) 3.26 6.25 6.78 
LOQd (µg ml-1) 9.89 18.95 20.54 
Co-efficient of regression(r2) 1f 0.999g 0.999h 
Precision (%RSD) (n=6) 
100 µg mL-1 0.17 0.09 0.10 
200 µg mL-1 0.25 0.07 0.08 
300 µg mL-1 0.16 0.03 0.08 
400 µg mL-1 0.16 0.02 0.07 
500 µg mL-1 0.08 0.01 0.01 
aMeasured from the retention time of uracil (10 μg mL−1) eluting from the column. b Relative retention 
time (with respect to 2-MEP). c N expressed in plates per m. dLimit of detection. eLimit of quantification. 
f y = 0.8194x - 0.168. g y = 1.873x + 10.301. hy = 1.587x + 6.9073. 
 
Table 6.6 Summary of HPLC-AD (amperometric detection) validation data for the quantification of 
(±)-4-MEP, (±)-2-MEP and (±)-3-MEP obtained inthe LC-FC-A (impinging jet flow cell) system using 
column B, (Table 2.2. Mobile phase: 4C (Section2.4); UV wavelength: 279 nm. 
System detection LC-FC-A (AD) 
Flow Rate 2 ml min-1 
Analytes 4-MEP 2-MEP 3-MEP 
tR(min)(t0= 0.854min)a 21.63 23.86 25.85 
RRTb 0.91 1 1.08 
LODc (µg ml-1) 15.93 24.54 23.62 
LOQd (µg ml-1) 48.28 74.37 71.57 
Co-efficient of regression(r2) 0.994e 0.986f 0.987g 
Precision (%RSD) (n=6) 
100 µg mL-1 0.52 2.97 3.03 
200 µg mL-1 2.8 3.43 4.17 
300 µg mL-1 3.35 3.38 3.10 
400 µg mL-1 1.49 1.95 1.31 
500 µg mL-1 1.37 1.33 1.27 
aMeasured from the retention time of uracil (10 μg mL−1) eluting from the column. b Relative retention 
time (with respect to 2-MEP). cLimit of detection. dLimit of quantification. ey = 0.0013x + 0.0145. f y = 
0.0008x + 0.0424. gy = 0.0008x + 0.0488. 
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6.2.4.1 System suitability test  
The system suitability principle was explained in Section 3.5.1. In the LC-FC-
A system, the resolution, effectiveness and reproducibility of the chromatograph 
system were confirmed by the system suitability test. This was established using 
HPLC-UV detection data (resolution, number of plates, capacity factors and 
asymmetric in Table 6.5). Figure 6.2 shows the elution time of (±)-4-MEP at 21.61, 
(±)-2-MEP at 23.84 with a good resolution of 2.41and (±)-3-MEP at 25.83 mins 
respectively, with a resolution of 2.05. The theoretical plates numbers (N) were 
10604 for (±)-4-MEP, 9286 for (±)-2-MEP and 10395 for (±)-3-MEP, that explained 
the excellent effectiveness of the sharpness of the peak and good efficiency of the 
column. In addition, the capacity factors that showed the effect of the stationary 
phase on compound retention were calculated from HPLC-UV data and found to be 
20.61, 22.84 and 24.83 for (±)-4-MEP, (±)-2-MEP and (±)-3-MEP respectively. 
Moreover, the asymmetric factor was calculated from the HPLC-UV data to be found 
more than 1 meaning there was no peak tailing. 
 
6.2.4.2 Resolution (Rs) 
The resolution of separation of the three compounds is shown in Table 5.6 
where (±)-4-MEP was eluted at 21.61 mins, (±)-2-MEP was eluted at 23.84 mins, 
with an excellent resolution of2.41, and (±)-3-MEP was eluted at 25.83 mins with a 
good resolution of 2.05. Therefore, from the resolutions mentioned above, this 
method has a good separation for the three compounds because their resolution 
was more than 1.5 which is accepted according ICH validation (ICH, 1996). 
 
6.2.4.3 Selectivity factor (α) 
The selectivity principle was explained in Section 3.5.3. In this study, the 
results of the HPLC-UV system were that (±)-2-MEP was eluted at 21.61 mins and 
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(±)-3-MEP was eluted at 23.84 mins, with a high resolution of 2.41, and (±)-4-MEP 
was eluted at 25.83 mins with a resolution of 2.05. That means this method has a 
good selectivity to separate the regioisomers of methoxyephenidine from each other 
in the mixture (Figure 6.2). In addition, the specificity of this method was expressed 
using the solutions of the UV-inactive analytes sucrose, mannitol, and lactose 
(which are commonly used as diluents, prepared in Section 2.9.7). These were not 
observed to interfere with the analytes, thereby confirming the specificity of the 
proposed method. 
 
6.2.4.4 Linearity 
The linearity principle was explained in Section 3.5.4. In this study the linearity 
of (±)-2-MEP, (±)-3-MEP and (±)-4-MEP using the LC-FC-A (HPLC-UV) system was 
obtained from the calibration standards. The standards were used between 100-500 
µg mL-1 and injected as six replicates using the optimised chromatographic condition 
at 279 nm, temperature 50°C and flow rate 2 mL min-1 using an ACE 5 C18AR 
column (150 mm × 4.6 mm i.d., particle size: 5 μm).The linearity plot was 
constructed from the concentration and peak area obtained (Figure 6.3a). The good 
linear response of the HPLC-UV system for (±)-4-MEP was R2 = 1 with %RSD = 
0.08-0.25%; n = 6, Appendix: Table 9.27, for (±)-2-MEP was R2 = 0.999, with %RSD 
= 0.01–0.9%; n = 6, Appendix: Table 9.28) and for (±)-3-MEP was R2 = 0.999 with 
%RSD = 0.01–0.10%; n = 6, Appendix: Table 9.29). That explains the excellent 
linearity for the HPLC-UV system. 
 
The corresponding liquid chromatography-amperometric detection system, 
(LC-FC-A), employing the commercially available, impinging jet, flow cell, was 
validated using the same standard mixtures as were used in HPLC-UV detection 
containing 100-500 μg mL−1 of (±)-2-MEP, (±)-3-MEP and (±)-4-MEP. The good 
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linear response of the HPLC-AD system (Figure 6.3b) for (±)-4-MEP was R2 = 0.994 
with %RSD = 0.52–1.89%; n = 6, Appendix: Table 9.30, for (±)-2-MEP was R2 = 
0.9863 with %RSD = 0.67–1.05%; n = 6, Appendix: Table 9.31 and for (±)-3-MEP 
was R2 = 0.9874 with %RSD = 0.64–1.76%; n = 6, Appendix: Table 9.32.That 
explained the linearity for the LC-FC-A system. In comparing the linearity of HPLC-
UV and HPLC-AD systems, the linearity of HPLC-AD was less than the linearity of 
HPLC-UV because HPLC-UV has a higher sensitivity to the analytes than HPLC-
AD. 
 
 
Figure 6.3The linearity of (±)-4-MEP (triangles), (±)-2-MEP (squares) and (±)-3-MEP (circles) using 
the LC-FC-A system a) HPLC-UV (UV detection), b) HPLC-AD (amperometric detection. 
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6.2.4.5 Limit of detection (LOD) 
The LOD principle was explained in Section 3.5.5. In this study, the LOD was 
estimated from calibration standard curves by six injections performed over a 
concentration range 100-500 µg mL-1. The LODs for analysis of the 
methoxyephenidine hydrochloride regioisomers were determined using the LC-FC-
A (HPLC-UV detection) system and were found to be 3.26 µg mL-1 for (±)-4-MEP, 
6.25 µg mL-1 for (±)-2-MEP and 6.78 µg mL-1 (±)-3-MEP. The LODs of analysis of 
methoxyephenidine hydrochloride regioisomers were determined by using the LC-
FC-A (amperometric detection) system and found to be 15.93 µg mL-1 for (±)-4-
MEP, 24.54 µg mL-1 for (±)-2-MEP and 23.62 µg mL-1 for (±)-3-MEP.  
 
To compare the reliability of the presented results of LODs for the two 
approaches, these values are undoubtedly different because the LODs of HPLC-
UV are less than the LODs of HPLC-AD due to HPLC-UV having a higher sensitivity 
than HPLC-AD. In addition, in amperometric detection, a high concentrations of the 
analytes need to be used. However, in the literature there is no fully validated 
method for detecting regioisomers of methoxyephenidine to compare the LODs, but 
for the first time this method explains a fully validated method using the HPLC-AD 
protocol for analysis of these regioisomers.  
 
6.2.4.6 Limit of quantification  
The LOQ principle was explained in Section 3.5.6. In this study, the LOQ was 
estimated from calibration standard curves by six injections performed over a 
concentration range 100-500 µg mL-1. The LOQs of analysing the 
methoxyephenidine hydrochloride regioisomers were determined using the LC-FC-
A system (HPLC-UV detection) and found to be 9.89 µg mL-1 for (±)-4-MEP, 18.95 
µg mL-1 for (±)-2-MEP and 20.54 µg mL-1 (±)-3-MEP. The LOQs of analysis for 
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methoxyephenidine hydrochloride regioisomers were determined by using the LC-
FC-A (amperometric detection) system and found to be 48.28 µg mL-1 for (±)-4-
MEP, 74.37 µg mL-1 for (±)-2-MEP and 71.57 µg mL-1 for (±)-2-MEP. On comparing 
the reliability of the results of LOQs for the two approaches, these values are 
different for the same reason that LODs differ (Section 6.1.7). In addition, as 
explained in Section 6.2.4.4, due to no fully validated method being in the literature, 
comparison of the LOQs in this method cannot be compared with the literature. 
 
6.2.4.7 Robustness  
The robustness test principle was explained in chapter 3 section 3.7.7. In this 
study, the effect of temperature variation and change of composition ratio of the 
mobile phase were analysed to ensure if this method was unaffected by these 
changes.  
 
The first parameter of the robustness test was the minor change in temperature 
using different temperatures of 48⁰C, 50⁰C and 52⁰C, as shown in Table 6.7. The 
method was carried out using column ACE 5 C18-AR (150 x 4.6 mm, 5 µm particle 
size) and a solution containing the three components at a concentration of 300 µg 
mL-1. The relative retention times of the three analytes were measured and the 
%RSD calculated to determine the precision. Table 6.7 shows the analysis of (±)-4-
MEP, (±)-2-MEP and (±)-3-MEP using the optimum conditions obtained from the 
method development with minor changes in temperature. In comparing the relative 
retention time (RRt), all the results were similar and gave %RSDs which were <1% 
and within the guidelines stipulated by the ICH. These data indicate that this method 
is robust and should be suitable for use in the routine analysis of seized samples. 
Highlighted data in Table 6.7 represent the optimal conditions used in this validation 
study.
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Table 6.7 The effect of minor changes of temperature on relative retention time (RRT) of the analysis 
of 300 µg mL-1 of (±)-4-MEP, (±)-2-MEP and (±)-3-MEP using HPLC-UV in the LC-FC-A system, (the 
highlighted area is a standardised condition for this study). 
Concentration 
µg mL-1 
RRT 
(48⁰C) (50⁰C) (52⁰C) 
4-MEP 2-MEP 3-MEP 4-MEP 2-MEP 3-MEP 4-MEP 2-MEP 3-MEP 
300 0.903 1.000 1.074 0.905 1.000 1.081 0.906 1.000 1.083 
300 0.902 1.000 1.074 0.905 1.000 1.081 0.906 1.000 1.084 
300 0.902 1.000 1.073 0.905 1.000 1.081 0.906 1.000 1.083 
300 0.903 1.000 1.074 0.905 1.000 1.081 0.906 1.000 1.083 
300 0.902 1.000 1.074 0.905 1.000 1.080 0.907 1.000 1.086 
300 0.902 1.000 1.073 0.906 1.000 1.083 0.907 1.000 1.086 
Average 0.902 1.000 1.074 0.905 1.000 1.081 0.906 1.000 1.084 
RSD% 0.024 0.000 0.019 0.047 0.000 0.105 0.047 0.000 0.139 
 
The second parameter of the robustness test was minor changes in the ratio of the 
mobile phase to determine whether this method is robust or not. In addition, the 
method was performed by injecting 300µg mL-1of(±)-4-MEP, (±)-2-MEP and (±)-3-
MEP and Table 6.8 shows the similarity in results of relative retention time by using 
minor changes of mobile phase 4 ratios, section 2.4, to analysis methoxyephenidine 
hydrochloride regioisomers and from the results, this method is robust. Highlighted 
data in Table 6.8 presents the optimal conditions used in validation of this study. 
 
Table 6.8 The effect of a minor change inorganic composition of the mobile phase 4 on the relative 
retention rime (RRT) of 300 µg mL-1 of (±)-4-MEP, (±)-2-MEP and (±)-3-MEP using HPLC-UV in the 
LC-FC-A system. The highlighted area is a standardised condition for this study. 
Concentration 
µg mL-1 
RRT 
 (20:80 v/v)  (18:82 v/v)  (16:84 v/v) 
4-MEP 2-MEP 3-MEP 4-MEP 2-MEP 3-MEP 4-MEP 2-MEP 3-MEP 
300 0.907 1.000 1.086 0.907 1.000 1.088 0.903 1.000 1.074 
300 0.907 1.000 1.086 0.907 1.000 1.088 0.902 1.000 1.074 
300 0.907 1.000 1.086 0.907 1.000 1.088 0.905 1.000 1.081 
300 0.907 1.000 1.087 0.907 1.000 1.089 0.905 1.000 1.081 
300 0.915 1.000 1.096 0.907 1.000 1.088 0.907 1.000 1.086 
300 0.907 1.000 1.086 0.917 1.000 1.097 0.907 1.000 1.086 
Average 0.908 1.000 1.088 0.909 1.000 1.090 0.905 1.000 1.080 
RSD% 0.364 0.000 0.381 0.420 0.000 0.342 0.213 0.000 0.517 
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6.2.4.8 Inter-and intra-day precision 
One of the most important tests has been expressed as the precision of the 
analytical procedure used in this study to analyse the methoxyephenidine 
hydrochloride regioisomers and this was the inter- and intra-day test. This test has 
been done under the same conditions over a short interval of time (repeatability). 12 
replicate injections of a mixture solution of 300 µg mL-1 of (±)-4-MEP, 300 µg mL-1 
of (±)-2-MEP and 300 µg mL-1 of (±)-3-MEP were prepared as in Section 2.9.6. This 
test was performed on the same day (6 in the morning and 6 in the afternoon), and  
the same procedure with six injections repeated  the following day to obtained the 
relative standard deviation for all analytes in both detection systems (HPLC-UV and 
HPLC-AD). However, the precision results showed little change in both systems 
(HPLC-UV, HPLC-AD), but both systems have good precision for the three 
compounds ((±)-4-MEP, (±)-2-MEP and (±)-3-MEP) as shown by RSD% of less than 
1% (Table 6.9). The value of RSD% was calculated from the supplementary data in 
Appendix: Table 9.39  found to be < 1% for all analytes. This is an appropriate 
precision criterion for repetitive injections to assess the precision of the instrument 
in analytical method validation (Green, 1996). In addition, these results illustrate the 
ability of this method and the efficiency of these systems to be applied to routine 
analysis.  
 
Table 6.9 The relative standard deviation (RSD %) of inter- and intra-day measurements for (300 µg 
mL-1) (±)-4-MEP, (±)-2-MEP and (±)-3-MEP using HPLC-UV detection and amperometric detection 
in the LC-FC-A system. 
n=12 analytes 
RSD % of LC-FC-A 
HPLC-UV (peak area) Amperometric detection (peak current) 
Inter-day 
precision 
4-MEP 0.15 0.98 
2-MEP 0.03 0.81 
3-MEP 0.08 0.72 
intra-day 
precision 
4-MEP 0.83 0.7 
2-MEP 0.16 0.76 
3-MEP 0.17 0.83 
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6.2.4.9 Accuracy test 
Accuracy test principle was explained in Section 3.5.8. The test performed at 
the 80, 100 and 120% level of target concentration. Recovery data were in triplicate 
at each level of label claim. Percentage recovery for (±)-4-MEP, (±)-2-MEP and (±)-
3-MEP were calculated for each sample and demonstrated excellent accuracy 
range 98±0.09% to 102±0.53% for HPLC-UV in LC-FC-A system (Table 6.10). In 
addition, the recovery percentages for amperometric detection of LC-FC-A system 
were   99.7±0.51 % to 101.8±0.94 % by using HPLC-AD in LC-FC-A system (Table 
6.10). 
 
Table 6.10 Percentage recovery of (±)-4-MEP, (±)-2-MEP and (±)-3-MEP using both system HPLC-
UV and LC-FC-A 
System LC-FC-A 
Detection HPLC-UV HPLC-AD 
Compound 
Concentration 
µg mL-1 
Theoretical 
recovery µg 
mL-1 
Actual 
recovery 
µg mL-1 
%recovery 
(n=3) 
Actual 
recovery 
µg mL-1 
%recovery 
(n=3) 
 
4-MEP 
240 (80%) 
241 241 100±0.05 237 101.8±0.94 
2-MEP 240 236 102±0.53 241 99.7±0.51 
3-MEP 242 242 100±0.22 239 101.4±0.56 
4-MEP 
300 (100%) 
304 305 99±0.05 302 100.7±0.44 
2-MEP 303 297 102±0.12 300 100.7±0.77 
3-MEP 303 302 100±0.42 303 99.9±0.54 
4-MEP 
360 (120%) 
363 366 99±0.18 360 100.9±0.32 
2-MEP 362 365 98±0.09 362 99.9±0.55 
3-MEP 362 364 99±0.21 360 100.5±0.35 
 
6.2.5 Forensic Application 
The two street samples were obtained from Great Manchester Police (GMP). 
These samples were homogenised and labelled as MEP-1 and MEP-2. Both street 
samples were analysed with duplicated weight (in triplicate) by using the validated 
LC-FC-A system,  and using the commercial impinging flow cell for amperometric 
detection, at concentration 300 µg ml-1. The HPLC-UV results (Table 6.11) 
confirmed that the first street sample (MEP-1) contained 101±0.6 %w/w of pure 3-
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MEP but another sample contained 11.8±0.86 %w/w of 2-MEP and  90.3±0.2 of 3-
MEP. In term of amperometric detection by using HPLC-AD in LC-FC-A system 
were 101.6±1.4 of 3-MEP (pure form) in the first street sample (MEP-1) and 
10.1±1.7 and 91.9±1.8 of 2-MEP and 3-MEP in second street sample (MEP-2) with 
the ratio (10:90) respectively. 
 
Table 6.11 Direct comparison between quantitative data obtained by HPLC-UV and HPLC-AD 
(impinging jet flow cell) system, for the analysis 300 µg mL-1of the regioisomer of methoxyephenidine 
in a selection of purchased street samples 
System LC-FC-A 
Detection HPLC-UV (%w/w) (n= 6) HPLC-AD (%w/w) (n =6) 
Analyte 4-MEP 2-MEP 3-MEP 4-MEP 2-MEP 3-MEP 
MEP-1 n.d. n.d. 101±0.6 n.d. n.d. 101.6±1.4 
MEP-2 n.d. 11.8±0.86 90.3±0.2 n.d. 10.1±1.7 91.9±1.8 
n.d. = not detected. 
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6.3 Detection and quantification of regioisomer of fluoroephenidine by using 
HPLC-AD protocol: 
 
The previous Section represents the analysis of regioisomers of 
methoxyephenidine as new psychoactive substances by using high performance 
liquid chromatography in combined with amperometric detection protocol. This 
protocol was succeeded for detection, separation, and quantification the 
regioisomers of methoxyephenidine. Therefore, the HPLC-AD protocol will used in 
this Section to detect, separate and quantify the regioisomers of fluoroephenidine 
as new psychoactive substances with the same analogue manner of regioisomers 
of methoxyephenidine.   
 
6.3.1 Ultraviolet-Visible Spectroscopy (UV) (Determination of λmax) 
The fluoroephenidine regioisomers can be detected at 270 nm and the UV max 
(nm) measurement of regioisomers of fluoroephenidine were (±)-2-FEP at 270 nm 
(A = 0.89, 4.0×10-2g 100mL-1), (±)-3-FEP at 270 nm (A = 1.3, 4.0×10-2g 100mL-1), 
and (±)-4-FEP at 270 nm (A = 0.98, 4.0×10-2 g 100mL-1) in mobile phase 5 (Table 
2.3). 
 
6.3.2 HPLC Method Development: 
The started point was to developed HPLC-UV method that could separate and 
identify (±)-2-FEP, (±)-3-FEP and (±)-4-FEP with good resolution and shorter 
retention time Figure 6.4. The method development was carried out by using an 
adaptation of HPLC-UV method was used for analysis regioisomers of 
methoxyephenidine in the first Section of this chapter with the following modification: 
change the ration of mobile phase by using (25: 75) Acetonitrile: 20mM ammonium 
acetate and 100mM KCl at pH=7. 
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Figure 6.4The chromatogram for 200 µg mL-1 of (±)-4-FEP (a), (±)-2-FEP (b) and (±)-3-FEP (c) 
obtained by using HPLC-UV detection in LC-FC-A system using an ACE 5 C18AR column (150 mm 
× 4.6 mm i.d., particle size: 5 μm); Mobile phase: mobile phase 4; UV wavelengths 279 nm, the peak 
( S) is a system peaks associated with the sample. 
 
6.3.3 Amperometric detection method development: 
6.3.3.1 Optimization of potential of Amperometric detection: 
The anodic potential for (±)-2-FEP (300.0 μg mL−1), (±)-3-FEP (300.0 μg mL−1) 
and (±)-4-FEP (300.0 μg mL−1) mixture in the Mobile Phase 5 (Table 2.3) were 
determined by using the peak current, in conjunction with the optimised instrumental 
configuration. The optimal conditions were used for optimization of potential 
according to the best condition were obtained in method development in Section 
6.3.2 (temperature = 50 ⁰C, flow rate = 1.5 mL min-1 at pH = 7). The potential 
required to achieve the optimal detector response for the mixture were determined, 
for LC-FC-A system by measuring the amperometric response (peak current, μA) 
as a function of anodic potential (E V−1), over the range +0.0 to +1.5 E V−1. The 
maximum high current responses (1.26, 0.93 and 1.06, n=3) were detected at +1.2 
EV-1 for (±)-4-FEP, (±)-2-FEP and (±)-3-FEP respectively (Table 6.12). 
(a) 
(b) (c) 
(S) 
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Table 6.12The anodic potential of 300 µg mL-1 (±)-4-FEP, (±)-2-FEP and (±)-3-FEP over the range 
+ 0.0 to + 1.5 v-1 at temperature = 50 ⁰C, flow rate = 1.5 mL min-1 and pH = 7 by using LC-FC-A 
 Peak current(µA) 
potential (v) (±)-4-MEP (±)-2-MEP (±)-3-MEP 
0 n.d. n.d. n.d. 
0.8 0.15 0.09 0.12 
1 0.79 0.54 0.65 
1.2 1.26 0.93 1.06 
1.5 0.32 0.29 0.30 
Key: n.d. not detected 
 
6.3.3.2 Optimization of linear velocity of Amperometric Detection: 
The linear velocity of fluoroephenidine regioisomers was measured as 
methoxyephenidine regioisomers. The mixture of (±)-4-FEP, (±)-2-FEP and (±)-3-
FEP (300 µg mL-1) was injected (n = 10) at range of flow rates 0.5-1.5 mL min-1. 
Table 6.12 shown the peak current of (±)-4-FEP, (±)-2-FEP and (±)-3-FEP with a 
good amperometric response [(±)-4-FEP = 1.26 µA, (±)-2-FEP = 0.93 µA and (±)-3-
FEP = 1.06 µA] at 1.2 E V−1 and (pH = 7) by using LC-FC-A system. In addition, 
there is not any response observed at flow rate less than 0.5 mL min-1 and if the 
flow rate more than 1.5 mL min-1 the peaks on the HPLC-UV system will overlap. 
 
Table 6.13 the linear velocity of 300 µg mL-1 of (±)-4-FEP, (±)-2-FEP and (±)-3-FEP over the range 
0.5 to 1.5 ml min-1 at temperature = 50 ⁰C, potential = 1.2 EV-1 and pH = 7) by using LC-FC-A system. 
Flow rate 
mL min-1 
Peak current(µA) 
(±)-4-FEP (±)-2-FEP (±)-3-FEP 
1 0.77 0.52 0.62 
1.5 1.26 0.93 1.06 
2 1.06 0.74 0.82 
 
6.3.3.3 Optimization of pH of HPLC-UV and Amperometric detection: 
Table 6.14 shown the different pH (3-7) of mobile phase 5 was used to find the 
best pH could use to obtain the highest response for the analytes. This method 
carried out by injected 100 µg mL-1 of regioisomer of fluoroephenidine in LC-FC-AD 
system. The best response for HPLC-UV and HPLC-AD in LC-FC-A system was pH 
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= 7, because cannot increase the pH of the mobile phase more than 9 or less than 
2 to protect the column from degradation as explained in chapter 3 Section 3.6. As 
well as low amperometric response was observed at mobile phase 5C with pH = 3 
which is 0.043 µA for (±)-4-FEP, 0.045 µA for (±)-2-FEP and 0.415 µA for (±)-3-FEP. 
The maximum responses by using LC-FC-A system were 1.24 μA for (±)-4-FEP, 
0.919 μA for (±)-2-FEP and 1.055 μA for (±)-3-FEP which observed at potential = 
+1.2 E V−1 and flow rate 1.5 mL min-1 mobile phase with pH = 7.  
Table 6.14The effect of pH of mobile phase on analysis 100 µg mL-1 of (±)-4-FEP, (±)-2-FEP and 
(±)-3-FEP over the range 3 to 7 at temperature = 50 ⁰C, potential = 1.2 EV-1 by using LC-FC-A 
system. 
pH 
Peak current (µA) 
(±)-4-FEP (±)-2-FEP (±)-3-FEP 
3  0.043 0.045 0.0415 
5  0.039 0.046 0.0336 
7  1.24 0.919 1.055 
 
By optimization of amperometric detection (Section 6.3.3) in LC-FC-A system, 
the fluoroephenidine regioisomer were eluted at 14.37 of (±)-4-MEP, 17.78 of (±)-2-
FEP and 19.15 of (±)-3-FEP in HPLC-AD of LC-FC-A system (Figure 6.5). 
 
Figure 6.5 Amperogram of 200µg mL-1 (±)-4-FEP (a), (±)-2-FEP (b) and (±)-3-FEP (c) obtained on 
the HPLC-AD system using an ACE 5 C18AR column (150 mm × 4.6 mm i.d., particle size: 5 μm); 
mobile phase 5; detector wavelengths (UV): 279 nm. 
(a) 
(b) 
 
(c) 
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6.3.4 Method Validation 
HPLC-AD analytical techniques used for analysis the regioisomers of 
fluoroephenidine hydrochloride required validation prior to deploying them in the 
analysis of the purchased street samples. The LC-FC-A system was validated (in 
term of UV- detection) using a standard mixture of regioisomer of fluoroephenidine 
hydrochloride with strongly UV- absorbing: (±)-4-FEP, (±)-2-FEP and (±)-3-FEP over 
50-300 μg mL−1 range. Table 6.15 shows the optimal condition was used for 
validation the standard mixture of fluoroephenidine regioisomer in both HPLC-UV 
and HPLC-AD.  
 
Table 6.16 shows the summary of the validation parameters that were used 
for analysis the fluoroephenidine hydrochloride regioisomers [(±)-4-FEP, (±)-2-FEP 
and (±)-3-FEP] using the HPLC-UV system, and Table 6.17 shows the summary of 
validation parameters of the analysis of fluoroephenidine hydrochloride 
regioisomers using HPLC-AD in the LC-FC-A system. 
 
Table 6.15 Summary of the optimal conditions utilised in the analysis (±)-4-FEP, (±)-2-FEP and (±)-
3-FEP 
Optimised chromatographic conditions 
Column ACE 5 C18AR (150 mm × 4.6 mm i.d., particle size: 5 μm 
Flow rate 2 mL min-1 
Solvent Mobile phase 5 (Table 2.3) 
Column temperature (⁰C) 50 
Wavelength (nm) 270 
Injection volume (µL) 10 
Run time (mins) 30 
Optimised amperometric detection parameters 
Potential (V) +1.2 
Equilibration time (s) 10 
Data interval (s) 0.05 
Current range (mA) 1×10-6 
Total run time (s) 5000 
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Table 6.16 Summary of HPLC-UV validation data for the quantification of regioisomers of 
fluoroephenidine obtained on the LC-FC-A (impinging jet flow cell) system, using column B, (Table 
2.2)  mobile phase 5; detector wavelength (UV): 270 nm. 
System detection LC-FC-A (HPLC-UV) 
Flow Rate 1.5ml/min 
Analytes 4-FEP 2-FEP 3-FEP 
tR(min) (t0= 1.078 min)a 14.35 17.76 19.13 
RRTb 0.81 1.00 1.08 
Capacity factor (k’) 13.35 16.76 18.13 
N (plate)c 12267(80032) 11327(73660) 12077(79318) 
H (m) 1.25×10-05 1.36×10-05 1.26×10-05 
Resolution (Rs) / 5.68 2.03 
Asymmetry factor (As) 1.14 1.54 1.46 
LODd (µg ml-1) 3.58 3.74 3.52 
LOQe (µg ml-1) 10.86 11.34 10.70 
Coefficient of regression (R2) 0.999f 0.999g 0.999h 
Precision (%RSD) (n=6) 
50 µg ml-1 0.62 0.29 0.23 
100 µg ml-1 0.32 0.28 0.33 
150 µg ml-1 0.22 0.15 0.18 
200 µg ml-1 0.31 0.04 0.17 
250 µg ml-1 0.22 0.11 0.16 
300 µg ml-1 0.20 0.12 0.09 
aMeasured from the retention time of uracil (10 μg mL−1) eluting from the column. bRelative 
retention time (with respect to 2-MEP). cN expressed in plates per m. dLimit of detection. eLimit of 
quantification. f y = 0.3912x + 0.7088. gy = 0.957x + 1.3817. hy = 0.9731x + 0.4059. 
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Table 6.17 Summary of validation data for regioisomers of fluoroephenidine obtained on the LC-FC-
A (impinging jet flow cell) system using column B, (Table 2.2 mobile phase 5, detector wavelength 
(UV): 270 nm. 
System detection LC-FC-A (HPLC-AD) 
Flow Rate 1.5ml/min 
Analytes 4-FEP 2-FEP 3-FEP 
tR(min) (t0= 1.078min)a 14.37 17.78 19.15 
RRTb 0.81 1.00 1.08 
Capacity factor (k’) 13.37 16.78 18.15 
LODc (µg ml-1) 4.69 6.38 4.62 
LOQd (µg ml-1) 15.11 19.34 13.99 
Co-efficient of 
regression(R2) 
0.999e 0.997f 0.998g 
Precision (%RSD) (n=6)  
50 µg ml-1 0.24 1.88 1.1384 
100 µg ml-1 0.25 1.70 1.26 
150 µg ml-1 0.64 1.19 1.44 
200 µg ml-1 0.36 0.27 0.23 
250 µg ml-1 0.16 0.21 0.44 
300 µg ml-1 0.56 0.88 0.62 
aMeasured from the retention time of uracil (10 μg mL−1) eluting from the column. bRelative 
retention time (with respect to 2-FEP).climit of detection. dLimit of quantification. ey = 0.0028x + 
0.0002. fy = 0.0024x + 0.0066. gy = 0.0024x - 0.0016. 
 
6.3.4.1 System suitability test  
This test was performed to confirm this method is stable and the effectiveness 
of the chromatographic system before use for analysis of street samples. Figure 6.4 
shows excellent separation between the analytes and the resolution was more than 
2. The numbers of theoretical plates in this study for all analytes were > 2000, 
confirming that the column has great efficiency in separating the analytes in a 
mixture. In addition, the capacity factors were calculated and found to be 13.35, 
16.76 and 18.13 minutes for (±)-4-FEP, (±)-2-FEP and (±)-3-FEP respectively and 
that represents the retention of the analyte in the stationary phase. The asymmetric 
factor in this study was less than 1 that confirms no peak tailing in this system (Table 
6.16). 
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6.3.4.2 Resolution (Rs) 
In this study the resolution of separation of the three regioisomers of 
fluoroephenidine hydrochloride shown in Table 6.16 were that  (±)-4-FEP was eluted 
at 14.35 min, (±)-2-FEP was eluted at 17.76 min with excellent resolution 5.68 and 
(±)-3-FEP was eluted at 19.13 min with good resolution 2.03. Therefore, from the 
resolution mentioned above, this method has a good separation for regioisomers of 
fluoroephenidine hydrochloride because their resolution was more than 2 which is 
acceptable according to ICH validation (ICH, 1996; ICH, 2017). 
 
6.3.4.3 Selectivity factor (α) 
The selectivity principle was explained in Section 3.5.3. In this study the results 
of the HPLC-UV system were that (±)-4-FEP was eluted at 14.35 mins and (±)-2-
FEP was eluted at 17.76 mins with high resolution 5.68 and (±)-3-FEP  was eluted 
at 19.13 mins with resolution 2.03. These results of this method have a good 
separation for the regioisomers of fluoroephenidine from each other in a mixture 
(Figure 6.4 and Figure 6.5). In addition, the specificity of this method was expressed 
using solutions of the UV-inactive analytes sucrose, mannitol, and lactose (which 
are commonly used as diluents, prepared in Section 2.10.7). These were not 
observed to interfere with the analytes, thereby confirming the specificity of the 
proposed method. 
 
6.3.4.4 Linearity 
In this study the linearity of (±)-4-FEP, (±)-2-FEP and (±)-3-FEP using the 
HPLC-UV system was obtained from the calibration standards. The calibration 
standards were used (50-300 µg mL-1) and injected (six replicates) using the 
optimised chromatographic conditions at 270 nm, temperature 50°C and flow rate 
1.5 mL min-1 using ACE 5 C18AR column (150 mm × 4.6 mm i.d., particle size: 5 
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μm). The linearity plot was constructed from the concentration and peak area 
obtained (Figure 6.6a). The good linear response of the HPLC-UV system for (±)-4-
FEP R2 = 0.999 with precision %RSD = 0.19-0.62 %; n = 6 (Appendix: Table 9.33), 
for (±)-2-FEP R2 = 0.999 with precision (%RSD = 0.04–0.29%; n = 6) (Appendix: 
Table 9.34) and for (±)-3-FEP R2 = 0.999 with precision (%RSD = 0.09–0.33 %; n = 
6) (Appendix: Table 9.35). That explained the excellent linearity for HPLC-UV in LC-
FC-A system. 
 
The corresponding liquid chromatography-amperometric detection system, 
[LC-FC-A], employing the commercially available, impinging jet, flow cell (LC-FC-
A), was validated using the same standard mixtures as were used for HPLC-UV 
containing 50-300 μg mL−1 of (±)-4-FEP, (±)-2-FEP and (±)-3-FEP. The good linear 
response of LC-FC-A system (Figure 6.6b) for (±)-4-FEP R2 = 0.999 with precision 
(%RSD = 0.15–0.64%; n = 6) (Appendix: Table 9.36), (±)-2-FEP R2 = 0.997 with 
precision (%RSD = 0.20–1.23%; n = 6) (Appendix: Table 9.37) and for (±)-3-FEP R2 
= 0.999 with precision (%RSD = 0.23–1.43%; n = 6) (Appendix: Table 9.38). That 
explained the linearity for HPLC-AD in LC-FC-A system. In comparing the linearity 
of HPLC-UV and HPLC-AD in LC-FC-A systems, the linearity of HPLC-AD 
(amperometric detection) was less than the linearity of HPLC-UV, the same as the 
linearity results obtained in analysis of regioisomers of methoxyephenidine, 
because the HPLC-UV is more highly sensitive to the analytes more HPLC-AD in 
the LC-FC-A system. 
 
 
191 
 
Figure 6.6 The linearity of (±)-4-FEP (circles), (±)-2-FEP (squares) and (±)-3-FEP (triangles) by using 
a) HPLC-UV and b) HPLC-AD in LC-FC-A system. 
 
6.3.4.5 Limit of detection (LOD): 
The LOD was estimated from calibration standard curve by six injections 
performed over concentration range 50-300 µg mL-1. The LOD of analysis the 
fluoroephenidine hydrochloride regioisomers were determined using HPLC-UV (UV 
detector) in the LC-FC-A system and found to be 3.58 µg mL-1 for (±)-4-FEP, 3.74 
µg mL-1 for (±)-2-FEP and 3.52 µg mL-1 (±)-3-FEP (Table 6.16). The LOD of 
analysis of fluoroephenidine hydrochloride regioisomers were determined by using 
the HPLC-AD (amperometric detector) in the LC-FC-A system and found to be 4.69 
µg mL-1 for (±)-4-FEP, 6.38 µg mL-1 for (±)-2-FEP and 4.62 µg mL-1 for (±)-2-FEP 
(Table 6.17).  
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As in previous chapters, the LOD of HPLC-UV (UV detection) always lower 
than the LOD of HPLC-AD because the LOD for HPLC-UV is less than LOD of 
HPLC-AD in this study.  
 
6.3.4.6 Limit of quantification  
The LOQ of regioisomers of fluoroephenidine were estimated from the 
calibration standard curve by six injections performed over the concentration range 
50-300 µg mL-1. The LOQ of the analysis of the fluoroephenidine hydrochloride 
regioisomers were determined by using HPLC-UV system (UV detector) and found 
to be 10.86 µg mL-1 for (±)-4-FEP, 11.34 µg mL-1 for (±)-2-FEP and 10.70 µg mL-1 
(±)-3-FEP (Table 6.16). The LOQ of analysis of fluoroephenidine hydrochloride 
regioisomers were determined by using the HPLC-AD in the LC-FC-A system 
(amperometric detector) and found to be 15.11 µg mL-1 for (±)-4-FEP, 19.34 µg mL-
1 for (±)-2-FEP and 13.99 µg mL-1 for (±)-3-FEP (Table 6.17). To compare results of 
LOQ for the two approaches (HPLC-UV and HPLC-AD), LOQ were different due to 
the high concentration range of calibration standard concentrations that were used 
in this study, which is for the same reason as for the LOD. 
 
6.3.4.7 Robustness 
In this study the effect of temperature variation and change of composition ratio 
of the mobile phase were analysed to ensure that the LC-FC-A method was 
unaffected by these changes.  
The first parameter of the robustness test was a minor change in temperature 
(by using 48⁰C, 50⁰C and 52⁰C, as show in Table 6.18) to ensure whether this 
method is robust or not. Table 6.18 shows the analysis of (±)-4-FEP, (±)-2-FEP and 
(±)-3-FEP using the optimum conditions (highlighted) that were obtained from 
method development with minor changes in temperature to ensure this method is 
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robust. In comparing the relative retention time (RRT) in Table 6.18, all results had 
similar relative retention times, therefore the minor change in temperature did not 
affect the analysis and this method is robust. 
 
Table 6.18 The effect of minor changes of temperature on relative retention time (RRT) of analysis 
of 300 µg mL-1 of (±)-4-FEP, (±)-2-FEP and (±)-3-FEP using HPLC-UV in the LC-FC-A system, (the 
highlighted area is a standardised condition for this study). 
Concentration 
(µg mL-1) 
RRT 
(48⁰C) (50⁰C) (52⁰C) 
4-FEP 2-FEP 3-FEP 4-FEP 2-FEP 3-FEP 4-FEP 2-FEP 3-FEP 
300 0.807 1.000 1.077 0.809 1.000 1.077 0.807 1.000 1.077 
300 0.806 1.000 1.077 0.808 1.000 1.077 0.807 1.000 1.078 
300 0.807 1.000 1.076 0.808 1.000 1.077 0.807 1.000 1.078 
300 0.807 1.000 1.076 0.808 1.000 1.077 0.807 1.000 1.077 
300 0.807 1.000 1.076 0.808 1.000 1.077 0.808 1.000 1.077 
300 0.807 1.000 1.076 0.807 1.000 1.077 0.808 1.000 1.077 
Average 0.807 1.000 1.076 0.808 1.000 1.077 0.808 1.000 1.077 
RSD% 0.037 0.000 0.006 0.054 0.000 0.012 0.033 0.000 0.006 
 
The second parameter of the robustness test used in this study was a minor 
change in ratio of mobile phase 5 (section 2.4) to ensure this method is robust. Table 
6.19 shows the similarity of results of relative retention time using minor changes of 
mobile phase ratio to analyse fluoroephenidine regioisomers. These results explain 
this method is robust. The highlighted data in Table 6.19 represents the optimal 
conditions used in this study for analysis of the regioisomers of fluoroephenidine.
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Table 6.19 The effect of a minor changes in organic composition of mobile phase 4 on the relative 
retention time (RRT) of 300 µg mL-1 of  (±)-4-FEP, (±)-2-FEP and (±)-3-FEP using HPLC-UV in the 
LC-FC-A system, (the highlighted area is a standardised condition for this study). 
Concentration 
(µg mL-1) 
RRT 
 (23:77 v/v)  (25:75 v/v)  (27:73 v/v) 
4-FEP 2-FEP 3-FEP 4-FEP 2-FEP 3-FEP 4-FEP 2-FEP 3-FEP 
300 0.810 1.000 1.077 0.808 1.000 1.076 0.808 1.000 1.076 
300 0.810 1.000 1.076 0.808 1.000 1.076 0.807 1.000 1.076 
300 0.810 1.000 1.077 0.809 1.000 1.077 0.808 1.000 1.077 
300 0.810 1.000 1.077 0.808 1.000 1.076 0.808 1.000 1.077 
300 0.810 1.000 1.077 0.808 1.000 1.076 0.807 1.000 1.076 
300 0.809 1.000 1.077 0.808 1.000 1.076 0.808 1.000 1.077 
Average 0.810 1.000 1.077 0.808 1.000 1.076 0.808 1.000 1.076 
RSD% 0.0003 0.000 0.0002 0.0002 0.000 0.0001 0.0002 0.000 0.0001 
 
6.3.4.8 Inter-and intra-day precision 
This test has been done under the optimum conditions obtained in 
development method Section 6.3.2 over a short interval of time (repeatability). The 
12 replicate injections of mixture solution of 300 µg mL-1 of (±)-4-FEP, 300 µg mL-1 
of (±)-2-FEP and 300 µg mL-1 of (±)-3-FEP were prepared as in Section 2.10.6. The 
intra- and inter-day test was performed on the same day (6 in the morning and 6 in 
the afternoon),  and the same procedure repeated with six injections on the following 
day to obtained the relative standard deviation for all analytes in both detection 
systems (HPLC-UV and HPLC-AD). However, the results’ precision showed little 
change in the two detection systems (HPLC-UV, HPLC-AD), but HPLC-UV has 
excellent precision for the three compounds ((±)-4-FEP, (±)-2-FEP and (±)-3-FEP) 
as shown in Table 6.20 with the RSD% of the peak area being less than 1%.  
 
The HPLC-AD system achieved good precision for all compounds ((±)-4-FEP, 
(±)-2-FEP and (±)-3-FEP) as shown in Table 6.20. The RSD% values of the peak 
current were less than 1%. The value of RSD% is suggested to be <1% as an 
appropriate precision criterion for repetitive injections to assess the precision of the 
instrument in analytical method validation (Green, 1996). In addition, these results 
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illustrate the ability of this method and the efficiency of these systems to be applied 
to the routine analysis. The value of RSD% was calculated by the supplementary 
data in Appendix: Table 9.39 and found to be < 1% for all analytes. This is an 
appropriate precision criterion for repetitive injections to assess the precision of the 
instrument in analytical method validation (Green, 1996). 
 
Table 6.20 Relative standard deviation (RSD %) of inter- and intra-day peak values for (±)-4-FEP, 
(±)-2-FEP and (±)-3-FEP. 
System  LC-FC-A 
Detection 
HPLC-UV 
(Peak area) 
Amperometric detection 
(Peak current) 
Inter-day precision (n=12) 
4-FEP 0.18 0.66 
2-FEP 0.10 0.68 
3-FEP 0.09 0.56 
Intra-day precision (n=12) 
4-FEP 0.23 0.23 
2-FEP 0.07 0.99 
3-FEP 0.09 0.69 
 
6.3.4.9 Accuracy test 
The principle of accuracy test was explained in Section 3.7.9. The test performed at 
the 80, 100 and 120% level of target concentration. Recovery data were in triplicate 
at each level of label claim. Percentage recovery for (±)-4-FEP , (±)-2-FEP and (±)-
3-FEP were calculated for each sample and demonstrated excellent accuracy range 
100±0.11% to 102±0.14% for the HPLC-UV system (Table 6.21), and  100±0.19% 
to 102±0.56% using the HPLC-AD system (Table 6.21). 
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Table 6.21 Percentage recovery of (±)-4-FEP, (±)-2-FEP and (±)-3-FEP using both HPLC-UV and 
HPLC-AD in the LC-FC-A system. 
System LC-FC-A 
Detection HPLC-UV HPLC-AD 
Compound 
Concentration 
(µg mL-1) 
Theoretical 
recovery (µg mL-1) 
Actual 
recovery 
(µg mL-1) 
% 
Recovery 
(n=3) 
Actual 
recovery 
(µg mL-1) 
% 
Recovery 
(n=3) 
4-FEP 
240 (80%) 
243 240 101±0.4 242 100±0.19 
2-FEP 242 240 101±0.11 241 100±0.61 
3-FEP 244 243 100±0.23 242 100±0.77 
4-FEP 
300 (100%) 
305 304 100±0.47 299 102±0.56 
2-FEP 301 297 101±0.12 300 100±0.89 
3-FEP 303 302 100±0.18 301 100±0.62 
4-FEP 
360 (120%) 
364 363 100±0.37 361 100±0.77 
2-FEP 371 369 101±0.15 368 100±0.93 
3-FEP 370 364 102±0.14 369 100±0.98 
 
6.3.5 Forensic Application 
The three street samples were obtained from Great Manchester Police (GMP). 
These samples were homogenised and labelled as FEP-1, FEP-2, and FEP-3. All 
samples were analysed with duplicated weight (in triplicate) with the validated LC-
FC-A system, using UV detection and the commercial impinging flow cell for 
amperometric detection, at concentration 300 µg ml-1. The HPLC-UV results in LC-
FC-A system (Table 6.22) confirmed that the first sample (FEP-1) contained about 
48.2±0.5 % of 2-FEP and 51.8±0.5 % of 3-FEP but the second sample (FEP-2) 
contained 100.2±0.3 % of 2-FEP. Last sample (FEP-3) contained about 80:20 % of 
2-FEP and 3-FEP respectively. By using amperometric detection (HPLC-AD) for 
analysis of the three street samples (Table 6.22) that confirmed the results were 
obtained by using UV detection (HPLC-UV) in LC-FC-A system. The FEP-1, contain 
2-FEP and 3-FEP nearly about 50:50 and FEP-2 contain pure 2-FEP with 
100.3±0.4%. The third street sample FEP-3 contain 79.6±0.6% of 2-FEP and 
20.4±2.1% 3-FEP. 
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Table 6.22Direct comparison between quantitative data obtained by HPLC-UV and HPLC-AD 
(impinging jet flow cell) in LC-FC-A system, for the analysis of the regioisomers of fluoroephenidine 
in a selection of purchased street samples 
System LC-FC-A 
Detection HPLC-UV (%w/w) (n= 6) HPLC-AD (%w/w) (n =6) 
Analytes 4-FEP 2-FEP 3-FEP 4-FEP 2-FEP 3-FEP 
FEP-1 n.d. 48.2±0.5 51.8±0.5 n.d. 48.5±0.4 51.5±0.4 
FEP-2 n.d. 100.2±0.3 n.d. n.d. 100.3±0.4 n.d. 
FEP-3 n.d. 78.5±0.7 21.5±2.7 n.d. 79.6±0.6 20.4±2.1 
n.d. = not detected. 
 
6.4 Conclusions 
Overall, this chapter has been shown for the first time that high performance 
liquid chromatography in combination with amperometric detection can be used for 
analysis of the regioisomers of new psychoactive substances (ephenidine 
derivatives). This chapter presented two studies for the detection and quantification 
of the regioisomers of methoxyephenidine and of fluoroephenidine. This work 
improves previous work in chapters 3, 4 and 5. However, the HPLC-UV system has 
a higher sensitivity than HPLC-AD in the LC-FC-A system, but this study obtained 
new separation and electrochemical detection method. The limits of detection of  
regioisomers of methoxyephenidine (±)-4-MEP, (±)-2-MEP and (±)-3-MEP were 
3.26, 6.25 and 6.78 µg mL-1 respectively using UV detection (HPLC-UV), and by 
using amperometric detection (HPLC-AD) the LODs were 15.93 µg mL-1 for (±)-4-
MEP, 24.54 µg mL-1 and 23.62 for (±)-2-MEP and (±)-3-MEP respectively. in the 
same way the limit of detection for regioisomer of fluoroephenidine using HPLC-UV 
were 3.58, 3.74 and 3.52 µg mL-1 for (±)-4-FEP, (±)-2-FEP and (±)-3-FEP 
respectively.In terms ofthe amperometric detection (HPLC-AD), the limits of 
detection were 4.69, 6.38 and 4.62 for (±)-4-FEP, (±)-2-FEP and (±)-3-FEP 
respectively.  
Separation of the analytes by chromatography demonstrated a rapid 
separation and discrimination between the regioisomers of methoxyephenidine and 
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between the regioisomers of fluoroephenidine within the purchased street samples. 
This indicates this protocol for HPLC-AD can be considered suitable for the routine 
quantification and detection of regioisomers of new psychoactive substances. In 
addition, in these studies, the same limitations were reported in the conclusion of 
chapter 3 Section 3.7. Additionally, in this study there were two λmax (220 nm and 
279 nm) that can be used for detecting the regioisomers of methoxyephenidine. 
However, the peak absorbance was obtained when λmax = 220 nm was used, but at 
the same time, there were some small peaks observed in the chromatogram 
because an ingredient in the mobile phase or analytical sample could be detected 
at this wavelength and produced noise. In addition, further work to this study will use 
λmax 220 nm, to detect and quantifying the regioisomers of methoxyephenidine and 
to improve the absorbance of UV detection. 
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7 Chapter 7: Conclusions & Future Perspectives 
 
This thesis demonstrates the application of fully validated methods combining 
high performance liquid chromatography with amperometric detection (HPLC-AD) 
for the analysis of three different classes of the new psychoactive substances (NPS) 
(namely: amphetamines [Chapter 3], cathinones [Chapters 4 and 5] and dissociative 
anaesthetics [Chapter 6]), within purchased or seized samples. Method 
development and optimisation of the key experimental parameters has facilitated a 
rapid and sensitive method of separation and detection of the illicit drugs in both 
their pure form and in the presence of common adulterants – these methods are 
comparable to standard detection by HPLC-UV.   
 
The methods have demonstrated an ability to separate chemical entities which 
are different in structure (e.g. PMA vs. MDMA), derivatives of each other (e.g. 
methcathinone vs. N-ethylcathinones) and/or regioisomers of the same NPS (e.g. 
methoxy-ephenidine derivatives). The last example is of significance as 
regioisomeric discrimination is normally difficult to achieve in some classes of NPS 
and requires complex and expensive approaches (e.g. high-field NMR).  
 
Amperometric detection incorporating disposable embedded graphite screen-
printed macroelectrodes (GSPE) has been developed/optimised in each study using 
both a commercially available impinging jet flow cell (LC-FC-A system), or a custom-
made iCell channel flow cell (LC-FC-B system).  
 
This work also demonstrates that the design of the flow-cell affects the overall 
sensitivity of the measurement system, with the flow-cell (having the smaller fluid 
volume), giving a greater response. However, the two designs are significantly 
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different in terms of the flow delivery to the electrode, yet the iCell (having a volume 
15 times that of the impinging jet flow cell) gives detection results of a similar 
order.This suggests that further optimisation of the shape may yield greater 
sensitivity; such work is underway with NPSs and the HPLC-AD protocol.   
 
The simultaneous HPLC-UV and amperometric detection protocol detailed 
herein shows a marked improvement and advantage over previously reported 
electroanalytical methods, which were either unable to selectively discriminate 
between structurally related synthetic cathinones or utilised harmful and restrictive 
materials in their design. In addition, the cost effectiveness of the approach of using 
amperometric detection, rather than a more expensive secondary technique (for 
example: mass spectrometry), is clearly apparent as the cost of a disposable GSPE 
is approximately a few pence compared to a mass spectrometer (circa. £50K) and 
is significantly less complicated/expensive in terms of technological complexity, 
running/repair costs and specialised technical training. It is envisaged that the proof-
of-concept study will be invaluable to analytical scientists and law enforcement 
officials, for the development of miniaturised and robust, electroanalytical detection 
systems for new psychoactive substances and related compounds as they emerge 
on the recreational drugs market.  
 
Clearly, the global battle against drug (mis)use is showing no signs of relenting 
and the potential application of HPLC-AD to the general/wider detection and 
quantification of controlled/NPSs is clearly apparent.  Nevertheless, our application 
of this technique has been applied only to bulk forensic samples, the wide range of 
potential stationary and mobile phase combinations (for example hydrophilic 
interaction liquid chromatography, HILIC) opens up the possibility of expanding this 
method to metabolites and/or biomarkers associated with clinical detection and/or 
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post-mortem toxicology in drug users.  At present, the technology is limited to a 
laboratory environment, however, with the advent of customised microfluidic cells 
(for example: labs-on-a-chip incorporating a stationary phase material), the potential 
for reducing the system is possible and therefore opens up the potential for field-
deployable separation/detection for use by law enforcement, first-responders and 
other relevant agencies. 
202 
8 References 
 
Aboul-Enein, H. Y. (2000) 'Selectivity versus specificity in chromatographic 
analytical methods.' Accreditation and Quality Assurance, 5(5) pp. 180-181. 
 
ACMD, A. C. o. t. M. o. D. (2011) Consideration of the Novel Psychoactive 
Substances (‘Legal Highs’). London: Home office.  
 
Adamowicz, P., Tokarczyk, B., Stanaszek, R. and Slopianka, M. (2013) 'Fatal 
mephedrone intoxication--a case report.' J Anal Toxicol, 37(1), Jan-Feb, pp. 37-42. 
 
Addiction, E. E. M. C. f. D. a. D. (2012) Annual report on the state of the drugs 
problem in Europe.  
 
Adenier, A., Chehimi, M. M., Gallardo, I., Pinson, J. and Vila, N. (2004) 
'Electrochemical oxidation of aliphatic amines and their attachment to carbon and 
metal surfaces.' Langmuir, 20(19), Sep 14, pp. 8243-8253. 
 
Al-Motarreb, A., Baker, K. and Broadley, K. J. (2002) 'Khat: pharmacological and 
medical aspects and its social use in Yemen.' Phytother Res, 16(5), Aug, pp. 403-
413. 
 
Alvarez, J. C., Etting, I., Abe, E., Villa, A. and Fabresse, N. (2017) 'Identification 
and quantification of 4-methylethcathinone (4-MEC) and 3,4-
methylenedioxypyrovalerone (MDPV) in hair by LC-MS/MS after chronic 
administration.' Forensic Sci Int, 270, Jan, pp. 39-45. 
 
Arora, B., Velpandian, T., Saxena, R., Lalwani, S., Dogra, T. D. and Ghose, S. 
(2016) 'Development and validation of an ESI-LC-MS/MS method for simultaneous 
identification and quantification of 24 analytes of forensic relevance in vitreous 
humour, whole blood and plasma.' Drug Test Anal, 8(1), Jan, pp. 86-97. 
 
Arunotayanun, W. and Gibbons, S. (2012) 'Natural product 'legal highs'.' Natural 
Product Reports, 29(11), Nov, pp. 1304-1316. 
 
Ayres, T. C. and Bond, J. W. (2012) 'A chemical analysis examining the 
pharmacology of novel psychoactive substances freely available over the internet 
and their impact on public (ill)health. Legal highs or illegal highs?' BMJ Open, 2(4) 
 
Balbino, M. A., Eleoterio, I. C., de Oliveira, M. F. and McCord, B. R. (2016) 
'Electrochemical Study of Delta-9-Tetrahydrocannabinol by Cyclic Voltammetry 
Using Screen Printed Electrode, Improvements in Forensic Analysis.' Sensors & 
Transducers, 207(12) p. 73. 
203 
 
Baldania, S. L., Bhatt, K. K., Mehta, R. S., Shah, D. A. and Gandhi, T. R. (2008) 
'RP-HPLC Estimation of Venlafaxine Hydrochloride in Tablet Dosage Forms.' 
Indian J Pharm Sci, 70(1), Jan, pp. 124-128. 
 
Beharry, S. and Gibbons, S. (2016) 'An overview of emerging and new 
psychoactive substances in the United Kingdom.' Forensic Science International, 
267, 10//, pp. 25-34. 
 
Bhoomaiah, B. (2012) 'RP-HPLC Method for the Quantification of Cladribine in 
Pharmaceutical formulation.' International Journal of Science and Technology, 2(2) 
pp. 93-101. 
 
Blanco, E., Banks, C. E., Foster, C. W., Cumba, L. R. and do Carmo, D. R. (2016) 
'Can solvent induced surface modifications applied to screen- printed platforms 
enhance their electroanalytical performance?' Analyst, 141(9) pp. 2783-2790. 
 
Bogusz, M. J. (2000) 'Liquid chromatography–mass spectrometry as a routine 
method in forensic sciences: a proof of maturity.' Journal of Chromatography B: 
Biomedical Sciences and Applications, 748(1) pp. 3-19. 
 
Borges, K. B., Freire, E. F., Martins, I. and de Siqueira, M. E. P. B. (2009) 
'Simultaneous determination of multibenzodiazepines by HPLC/UV: Investigation 
of liquid–liquid and solid-phase extractions in human plasma.' Talanta, 78(1) pp. 
233-241. 
 
Bourquin, D. and Brenneisen, R. (1987) 'Confirmation of cannabis abuse by the 
determination of 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid in urine with 
high-performance liquid chromatography and electrochemical detection.' Journal of 
Chromatography B: Biomedical Sciences and Applications, 414 pp. 187-191. 
 
Brandt, S. D., Sumnall, H. R., Measham, F. and Cole, J. (2010) 'Analyses of 
second-generation ‘legal highs’ in the UK: Initial findings.' Drug Testing and 
Analysis, 2(8) pp. 377-382. 
 
Brunt, T. M., Poortman, A., Niesink, R. J. M. and van den Brink, W. (2011) 
'Instability of the ecstasy market and a new kid on the block: mephedrone.' Journal 
of Psychopharmacology, 25(11), Nov, pp. 1543-1547. 
 
Butler, D. and Guilbault, G. G. (2004) 'Analytical Techniques for Ecstasy.' 
Analytical Letters, 37(10), 2004/12/27, pp. 2003-2030. 
 
Caldicott, D. G., Edwards, N. A., Kruys, A., Kirkbride, K. P., Sims, D. N., Byard, R. 
W., Prior, M. and Irvine, R. J. (2003) 'Dancing with "death": p-
methoxyamphetamine overdose and its acute management.' J Toxicol Clin 
Toxicol, 41(2) pp. 143-154. 
204 
 
Carhart-Harris, R. L., King, L. A. and Nutt, D. J. (2011) 'A web-based survey on 
mephedrone.' Drug Alcohol Depend, 118(1), Oct 1, pp. 19-22. 
 
Carmo, H., Remião, F., Carvalho, F., Fernandes, E., de Boer, D., dos Reys, L. A. 
and de Lourdes Bastos, M. (2003) '4-Methylthioamphetamine-induced 
hyperthermia in mice: influence of serotonergic and catecholaminergic pathways.' 
Toxicology and applied pharmacology, 190(3) pp. 262-271. 
 
Carvalho, M., Carmo, H., Costa, V. M., Capela, J. P., Pontes, H., Remiao, F., 
Carvalho, F. and Bastos, M. D. (2012) 'Toxicity of amphetamines: an update.' 
Archives of Toxicology, 86(8), Aug, pp. 1167-1231. 
 
Castaneto, M. S., Barnes, A. J., Concheiro, M., Klette, K. L., Martin, T. A. and 
Huestis, M. A. (2015) 'Biochip array technology immunoassay performance and 
quantitative confirmation of designer piperazines for urine workplace drug testing.' 
Analytical and Bioanalytical Chemistry, 407(16) pp. 4639-4648. 
 
Chèze, M., Deveaux, M., Martin, C., Lhermitte, M. and Pépin, G. 'Simultaneous 
analysis of six amphetamines and analogues in hair, blood and urine by LC-ESI-
MS/MS.' Forensic Science International, 170(2) pp. 100-104. 
 
Clemens, K. J., McGregor, I. S., Hunt, G. E. and Cornish, J. L. (2007) 'MDMA, 
methamphetamine and their combination: possible lessons for party drug users 
from recent preclinical research.' Drug Alcohol Rev, 26(1), Jan, pp. 9-15. 
 
Cole, J. C., Bailey, M., Sumnall, H. R., Wagstaff, G. F. and King, L. A. (2002) 'The 
content of ecstasy tablets: implications for the study of their long-term effects.' 
Addiction, 97(12), Dec, pp. 1531-1536. 
 
Cosbey, S. H., Peters, K. L., Quinn, A. and Bentley, A. (2013) 'Mephedrone 
(methylmethcathinone) in toxicology casework: a Northern Ireland perspective.' J 
Anal Toxicol, 37(2), Mar, pp. 74-82. 
 
Council Decision, E. (2010) Submitting 4-methylmethcathinone (mephedrone) to 
control measures.  
 
Council Decision, J. (2005) The information exchange, risk-assessment and 
control of new psychoactive substances.  
 
Cumba, L. R., Smith, J. P., Zuway, K. Y., Sutcliffe, O. B., do Carmo, D. R. and 
Banks, C. E. (2016) 'Forensic electrochemistry: simultaneous voltammetric 
detection of MDMA and its fatal counterpart "Dr Death" (PMA).' Analytical 
Methods, 8(1) pp. 142-152. 
 
205 
Cumba, L. R., Smith, J. P., Brownson, D. A. C., Iniesta, J., Metters, J. P., do 
Carmo, D. R. and Banks, C. E. (2015) 'Electroanalytical detection of pindolol: 
comparison of unmodified and reduced graphene oxide modified screen-printed 
graphite electrodes.' Analyst, 140(5) pp. 1543-1550. 
 
D. J. Pike, N. K., P. A. Milner and D. I. Stewart, Sensors, 2013, 13, 58–70.  
 
da Costa, J. L. and Chasin, A. A. d. M. (2004) 'Determination of MDMA, MDEA 
and MDA in urine by high performance liquid chromatography with fluorescence 
detection.' Journal of Chromatography B, 811(1), 2004/11/05/, pp. 41-45. 
 
Dams, R., De Letter, E. A., Mortier, K. A., Cordonnier, J. A., Lambert, W. E., 
Piette, M. H. A., Van Calenbergh, S. and De Leenheer, A. P. (2003) 'Fatality Due 
To Combined Use of the Designer Drugs MDMA and PMA: A Distribution Study.' 
Journal of Analytical Toxicology, 27(5) pp. 318-323. 
 
Dargan, P. I. and Wood, D. M. (2013) Novel Psychoactive Substances: 
Classification, Pharmacology and Toxicology. (9780124159112) 
 
Dargan, P. I., Albert, S. and Wood, D. M. (2010) 'Mephedrone use and associated 
adverse effects in school and college/university students before the UK legislation 
change.' QJM, 103(11), Nov, pp. 875-879. 
 
Daws, L. C., Irvine, R. J., Callaghan, P. D., Toop, N. P., White, J. M. and Bochner, 
F. (2000) 'Differential behavioural and neurochemical effects of para-
methoxyamphetamine and 3, 4-methylenedioxymethamphetamine in the rat.' 
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 24(6) pp. 955-
977. 
 
de Figueiredo, N., Oiye, E., de Menezes, M., de Andrade, J., Silva, M. and de 
Oliveira, M. (2010) 'Determination of 3, 4-methylenedioxymethamphetamine 
(MDMA) in confiscated tablets by High-Performance Liquid Chromatography 
(HPLC) with Diode Array Detector.' J Forensic Res, 1(2) pp. 1-4. 
 
de MenezesA, M. M. T., de AndradeA, J. F., de Oliveira, M. F., TristãoB, H. M., 
Aparecida, A. and SaczkC, L. L. O. (2012) 'Analysis of Δ9-THC in cosmetics by 
high performance liquid chromatography with UV-Vis detection.' Br J Anal Chem, 8 
pp. 341-344. 
 
de Oliveira, L. S., Balbino, M. A., de Menezes, M. M. T., Dockal, E. R. and de 
Oliveira, M. F. (2013) 'Voltammetric analysis of cocaine using platinum and glassy 
carbon electrodes chemically modified with Uranyl Schiff base films.' 
Microchemical Journal, 110 pp. 374-378. 
 
Dhakane, V. D. and Ubale, M. B. (2012) 'A Validated Stability-Indicating HPLC 
Related substances method for Carmustine in bulk drug.' Elixir Int. J, 50 pp. 
10383-10386. 
206 
 
Dragan, R. (2003) 'Definition and classification of drug addiction and drug misuse 
issues.' Sociologija, 45(1) pp. 1-14. 
 
Dunne, F. J., Jaffar, K. and Hashmi, S. (2015) 'Legal Highs-Not so new and still 
growing in popularity.' British Journal of Medical Practitioners, 8(1) 
 
ElSohly, M. A., ElSohly, H. N., Jones, A. B., Dimson, P. A. and Wells, K. E. (1983) 
'Analysis of the major metabolite of delta 9-tetrahydrocannabinol in urine II. A 
HPLC procedure.' J Anal Toxicol, 7(6), Nov-Dec, pp. 262-264. 
 
EMCDDA, E. M. C. f. D. a. D. A. (2007) Early-warning system on new 
psychoactive substances — operating guidelines.  
 
EMCDDA, E. M. C. f. D. a. D. A. (2010) Europol–EMCDDA Joint Report on a new 
psychoactive substance: 4-methylmethcathinone (mephedrone).  
 
EMCDDA, E. M. C. f. D. a. D. A. (2011) New drugs and emerging trends.  
 
EMCDDA, E. M. C. f. D. a. D. A. (2013) EU drug markets report: a strategic 
analysis.  
 
EMCDDA, E. M. C. f. D. a. D. A. (2015) New psychoactive substances in Europe. 
An update from the EU Early Warning System (March 2015).  
 
EMCDDA, E. M. C. f. D. a. D. A. (2016) EMCDDA–Europol 2016 Annual Report on 
the implementation of Council Decision 2005/387/JHA.  
 
Farghaly, O., Hameed, R. A. and Abu-Nawwas, A.-A. H. (2014) 'Analytical 
application using modern electrochemical techniques.' Int. J. Electrochem. Sci, 
9(1) 
 
Fass, J. A., Fass, A. D. and Garcia, A. S. (2012) 'Synthetic cathinones (bath salts): 
legal status and patterns of abuse.' Annals of Pharmacotherapy, 46(3) pp. 436-
441. 
 
Favretto, D., Pascali, J. P. and Tagliaro, F. (2013) 'New challenges and innovation 
in forensic toxicology: focus on the "New Psychoactive Substances".' J 
Chromatogr A, 1287, Apr 26, pp. 84-95. 
 
Freeman, S. and Alder, J. F. (2002) 'Arylethylamine psychotropic recreational 
drugs: a chemical perspective.' European Journal of Medicinal Chemistry, 37(7), 
2002/07/01/, pp. 527-539. 
 
207 
Garrido, E. M., Garrido, J. M., Milhazes, N., Borges, F. and Oliveira-Brett, A. M. 
(2010) 'Electrochemical oxidation of amphetamine-like drugs and application to 
electroanalysis of ecstasy in human serum.' Bioelectrochemistry, 79(1), Aug, pp. 
77-83. 
 
Gibbons, S. and Zloh, M. (2010) 'An analysis of the 'legal high' mephedrone.' 
Bioorg Med Chem Lett, 20(14), Jul 15, pp. 4135-4139. 
 
Gil, D., Adamowicz, P., Skulska, A., Tokarczyk, B. and Stanaszek, R. (2013) 
'Analysis of 4-MEC in biological and non-biological material—Three case reports.' 
Forensic Science International, 228(1), 2013/05/10/, pp. 11-15. 
 
Gillman, P. K. (2005) 'Monoamine oxidase inhibitors, opioid analgesics and 
serotonin toxicity.' BJA: British Journal of Anaesthesia, 95(4) pp. 434-441. 
 
Glover, S. J. and Allen, K. R. (2010) 'Measurement of benzodiazepines in urine by 
liquid chromatography-tandem mass spectrometry: confirmation of samples 
screened by immunoassay.' Ann Clin Biochem, 47(Pt 2), Mar, pp. 111-117. 
 
Green, J. M. (1996) 'Peer Reviewed: A Practical Guide to Analytical Method 
Validation.' Analytical Chemistry, 68(9), 1996/05/01, pp. 305A-309A. 
 
Greifenstein, F. E., Devault, M., Yoshitake, J. and Gajewski, J. E. (1958) 'A study 
of a 1-aryl cyclo hexyl amine for anesthesia.' Anesth Analg, 37(5), Sep-Oct, pp. 
283-294. 
 
Guidelli, R. (1971a) 'Diffusion toward planar, spherical, and dropping electrodes at 
constant potential: II. Examples.' Journal of Electroanalytical Chemistry and 
Interfacial Electrochemistry, 33(2), 1971/12/01/, pp. 303-317. 
 
Guidelli, R. (1971b) 'Diffusion toward planar, spherical, and dropping electrodes at 
constant potential: I. Theory.' Journal of Electroanalytical Chemistry and Interfacial 
Electrochemistry, 33(2), 1971/12/01/, pp. 291-302. 
 
Gulaboski, R., Cordeiro, M. N., Milhazes, N., Garrido, J., Borges, F., Jorge, M., 
Pereira, C. M., Bogeski, I., Morales, A. H., Naumoski, B. and Silva, A. F. (2007) 
'Evaluation of the lipophilic properties of opioids, amphetamine-like drugs, and 
metabolites through electrochemical studies at the interface between two 
immiscible solutions.' Anal Biochem, 361(2), Feb 15, pp. 236-243. 
 
Gunasingham, H. (1984) 'Large-volume wall-jet cells as electrochemical detectors 
for high-performance liquid chromatography.' Analytica Chimica Acta, 159, 
1984/01/01, pp. 139-147. 
 
Gunasingham, H., Tay, B. T., Ang, K. P. and Koh, L. L. (1984) 'Electrochemical 
detection of polynuclear aromatic hydrocarbons following reversed-phase gradient 
208 
high-performance liquid chromatography using a large-volume wall-jet detector.' 
Journal of Chromatography A, 285, 1984/01/01/, pp. 103-114. 
 
Gura, S., Guerra-Diaz, P., Lai, H. and Almirall, J. R. (2009) 'Enhancement in 
sample collection for the detection of MDMA using a novel planar SPME (PSPME) 
device coupled to ion mobility spectrometry (IMS).' Drug Test Anal, 1(7), Jul, pp. 
355-362. 
 
Hadlock, G. C., Webb, K. M., McFadden, L. M., Chu, P. W., Ellis, J. D., Allen, S. 
C., Andrenyak, D. M., Vieira-Brock, P. L., German, C. L., Conrad, K. M., 
Hoonakker, A. J., Gibb, J. W., Wilkins, D. G., Hanson, G. R. and Fleckenstein, A. 
E. (2011) '4-Methylmethcathinone (mephedrone): neuropharmacological effects of 
a designer stimulant of abuse.' J Pharmacol Exp Ther, 339(2), Nov, pp. 530-536. 
 
Hanson, G., Venturelli, P. J. and Fleckenstein, A. E. (2015) Drugs and society. 
Vol. Twelfth. Burlington, MA: Jones & Bartlett Learning. 
 
He, H., Shay, S. D., Caraco, Y., Wood, M. and Wood, A. J. (1998) 'Simultaneous 
determination of codeine and it seven metabolites in plasma and urine by high-
performance liquid chromatography with ultraviolet and electrochemical detection.' 
Journal of Chromatography B: Biomedical Sciences and Applications, 708(1) pp. 
185-193. 
 
Helmlin, H.-J., Bracher, K., Bourquin, D., Vonlanthen, D., Brenneisen, R. and Styk, 
J. (1996) 'Analysis of 3,4-Methylenedioxymethamphetamine (MDMA) and its 
Metabolites in Plasma and Urine by HPLC-DAD and GC-MS.' Journal of Analytical 
Toxicology, 20(6) pp. 432-440. 
 
Hill, S. L. and Thomas, S. H. L. (2011) 'Clinical toxicology of newer recreational 
drugs.' Clinical Toxicology, 49(8), 2011/10/01, pp. 705-719. 
 
HomeOffice. (2009) Drug Misuse Declared: Findings from the 2008/09 British 
Crime Survey  
 
Honeychurch, K. (2016) 'Review: The Application of Liquid Chromatography 
Electrochemical Detection for the Determination of Drugs of Abuse.' Separations, 
3(4) p. 28. 
 
Honeychurch, K. C. and Hart, J. P. (2008) 'Determination of flunitrazepam and 
nitrazepam in beverage samples by liquid chromatography with dual electrode 
detection using a carbon fibre veil electrode.' Journal of Solid State 
Electrochemistry, 12(10) pp. 1317-1324. 
 
Honeychurch, K. C., Smith, G. C. and Hart, J. P. (2006) 'Voltammetric behavior of 
nitrazepam and its determination in serum using liquid chromatography with redox 
mode dual-electrode detection.' Analytical chemistry, 78(2) pp. 416-423. 
209 
 
Hudson, J. H., J.; Wagner, R., Harper, C. and Friel, P. (2013) Validation of a 
Cannabiniod Quantitation Method Using an Agilent 6430 LC/MS/MS.  
 
Huettl, P., Koester, S., Hoffer, L. and Gerhardt, G. A. (1999) 'Separation and 
identification of drugs of abuse in drug cottons by high performance liquid 
chromatography coupled with electrochemical array detectors.' Electroanalysis, 
11(5) pp. 313-319. 
 
Hysek, C. M., Domes, G. and Liechti, M. E. (2012) 'MDMA enhances "mind 
reading" of positive emotions and impairs "mind reading" of negative emotions.' 
Psychopharmacology (Berl), 222(2), Jul, pp. 293-302. 
 
Hysek, C. M., Schmid, Y., Simmler, L. D., Domes, G., Heinrichs, M., Eisenegger, 
C., Preller, K. H., Quednow, B. B. and Liechti, M. E. (2014) 'MDMA enhances 
emotional empathy and prosocial behavior.' Soc Cogn Affect Neurosci, 9(11), Nov, 
pp. 1645-1652. 
 
ICH, I. C. f. H. (1996) Validation ofanalytical procedure: Text and Methododlogy.  
 
ICH, I. C. f. H. (2017) The International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use.  
 
Isabel Colado, M., O'Shea, E. and Richard Green, A. (2007) 'MDMA and Other 
“Club Drugs”.' In Handbook of Contemporary Neuropharmacology. John Wiley & 
Sons, Inc.,  
 
Iversen, L. (2008) Speed, ecstasy, ritalin: the science of amphetamines. Oxford 
University Press. 
 
Iversen, L., White, M. and Treble, R. (2014) 'Designer psychostimulants: 
pharmacology and differences.' Neuropharmacology, 87 pp. 59-65. 
 
Jankovics, P., Varadi, A., Tolgyesi, L., Lohner, S., Nemeth-Palotas, J. and 
Koszegi-Szalai, H. (2011) 'Identification and characterization of the new designer 
drug 4'-methylethcathinone (4-MEC) and elaboration of a novel liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) screening method for 
seven different methcathinone analogs.' Forensic Sci Int, 210(1-3), Jul 15, pp. 213-
220. 
 
Johnson, L. A., Johnson, R. L. and Portier, R. B. (2013) 'Current "legal highs".' J 
Emerg Med, 44(6), Jun, pp. 1108-1115. 
 
Jordan, P. H. and Hart, J. P. (1991) 'Voltammetric behaviour of morphine at a 
glassy carbon electrode and its determination in human serum by liquid 
210 
chromatography with electrochemical detection under basic conditions.' Analyst, 
116(10), Oct, pp. 991-996. 
 
Kalix, P. (1981) 'Cathinone, an alkaloid from khat leaves with an amphetamine-like 
releasing effect.' Psychopharmacology (Berl), 74(3) pp. 269-270. 
 
Kalix, P. (1983) 'A Comparison of the Catecholamine Releasing Effect of the Khat 
Alkaloids (-)-Cathinone and (+)-Norpseudoephedrine.' Drug and Alcohol 
Dependence, 11(3-4) pp. 395-401. 
 
Kalix, P. (1991) 'The Pharmacology of Psychoactive Alkaloids from Ephedra and 
Catha.' Journal of Ethnopharmacology, 32(1-3), Apr, pp. 201-208. 
 
Kalix, P. (1992) 'Cathinone, a Natural Amphetamine.' Pharmacology & Toxicology, 
70(2), Feb, pp. 77-86. 
 
Kalix, P. (1996) 'Catha edulis, a plant that has amphetamine effects.' Pharmacy 
World & Science: PWS, 18(2) pp. 69-73. 
 
Kalix, P. and Braenden, O. (1985) 'Pharmacological aspects of the chewing of khat 
leaves.' Pharmacological Reviews, 37(2), Jun, pp. 149-164. 
 
Kang, H., Park, P., Bortolotto, Z. A., Brandt, S. D., Colestock, T., Wallach, J., 
Collingridge, G. L. and Lodge, D. (2017) 'Ephenidine: A new psychoactive agent 
with ketamine-like NMDA receptor antagonist properties.' Neuropharmacology, 
112(Part A), 2017/01/01/, pp. 144-149. 
 
Kato, N., Fujita, S., Ohta, H., Fukuba, M., Toriba, A. and Hayakawa, K. (2008) 
'Thin layer chromatography/fluorescence detection of 3,4-methylenedioxy-
methamphetamine and related compounds.' J Forensic Sci, 53(6), Nov, pp. 1367-
1371. 
 
Kaur, J., Srinivasan, K. K., Joseph, A., Gupta, A., Singh, Y., Srinivas, K. S. and 
Jain, G. (2010) 'Development and validation of stability indicating method for the 
quantitative determination of venlafaxine hydrochloride in extended release 
formulation using high performance liquid chromatography.' J Pharm Bioallied Sci, 
2(1), Jan, pp. 22-26. 
 
Kazakevich, Y. and Lobrutto, R. (2007) HPLC for pharmaceutical scientists. John 
Wiley & Sons. 
 
Kelly, J. P. (2011) 'Cathinone derivatives: a review of their chemistry, 
pharmacology and toxicology.' Drug Test Anal, 3(7-8), Jul-Aug, pp. 439-453. 
 
211 
Khreit, O. I. G., Irving, C., Schmidt, E., Parkinson, J. A., Nic Daeid, N. and 
Sutcliffe, O. B. (2012) 'Synthesis, full chemical characterisation and development 
of validated methods for the quantification of the components found in the evolved 
“legal high” NRG-2.' Journal of Pharmaceutical and Biomedical Analysis, 
61(Supplement C), 2012/03/05/, pp. 122-135. 
 
King, L. and Kicman, A. (2011) 'A brief history of ‘new psychoactive substances’.' 
Drug testing and analysis, 3(7‐8) pp. 401-403. 
 
Kokubun, H., Uezono, Y. and Matoba, M. (2014) 'Novel method of determination of 
D9-tetrahydrocannabinol (THC) in human serum by high-performance liquid 
chromatography with electrochemical detection.' Gan to kagaku ryoho. Cancer & 
chemotherapy, 41(4) pp. 471-473. 
 
Kumar, K. K., Nagoji, K. E. and Nadh, R. V. (2012) 'A Validated RP-HPLC Method 
for the Estimation of Lapatinib in Tablet Dosage form using Gemcitabine 
Hydrochloride as an Internal Standard.' Indian J Pharm Sci, 74(6), Nov, pp. 580-
583. 
 
Kumar, K. R., Rao, C. M. P., Rao, C. B. and Chandra, K. (2010) 'RP-HPLC 
method development and validation for estimation of capecitabine in capsules.' 
International Journal of ChemTech Research, 2(1) pp. 307-311. 
 
Kumihashi, M., Ameno, K., Shibayama, T., Suga, K., Miyauchi, H., Jamal, M., 
Wang, W., Uekita, I. and Ijiri, I. (2007) 'Simultaneous determination of 
methamphetamine and its metabolite, amphetamine, in urine using a high 
performance liquid chromatography column-switching method.' Journal of 
chromatography. B, Analytical technologies in the biomedical and life sciences, 
845(1), 2007/01//, pp. 180-183. 
 
Kusu, F. (2015) 'Development and Application of Electroanalytical Methods in 
Biomedical Fields.' Yakugaku Zasshi-Journal of the Pharmaceutical Society of 
Japan, 135(3), Mar, pp. 415-430. 
 
Le Gall, E., Haurena, C., Sengmany, S., Martens, T. and Troupel, M. (2009) 
'Three-component synthesis of alpha-branched amines under Barbier-like 
conditions.' J Org Chem, 74(20), Oct 16, pp. 7970-7973. 
 
Lee, Y. W. (2013) 'Simultaneous Screening of 177 Drugs of Abuse in Urine Using 
Ultra-performance Liquid Chromatography with Tandem Mass Spectrometry in 
Drug-intoxicated Patients.' Clin Psychopharmacol Neurosci, 11(3), Dec, pp. 158-
164. 
 
Liechti, M. (2015) 'Novel psychoactive substances (designer drugs): overview and 
pharmacology of modulators of monoamine signaling.' Swiss Med Wkly, 145 p. 
w14043. 
 
212 
Liechti, M. E. and Vollenweider, F. X. (2001) 'Which neuroreceptors mediate the 
subjective effects of MDMA in humans? A summary of mechanistic studies.' Hum 
Psychopharmacol, 16(8), Dec, pp. 589-598. 
 
Liechti, M. E., Kunz, I. and Kupferschmidt, H. (2005) 'Acute medical problems due 
to Ecstasy use. Case-series of emergency department visits.' Swiss Med Wkly, 
135(43-44), Oct 29, pp. 652-657. 
 
Litman, A., Levav, I., Saltz-Rennert, H. and Maoz, B. (1986) 'The use of khat. An 
epidemiological study in two Yemenite villages in Israel.' Cult Med Psychiatry, 
10(4), Dec, pp. 389-396. 
 
Liu, H. C., Lee, H. T., Hsu, Y. C., Huang, M. H., Liu, R. H., Chen, T. J. and Lin, D. 
L. (2015) 'Direct Injection LC-MS-MS Analysis of Opiates, Methamphetamine, 
Buprenorphine, Methadone and Their Metabolites in Oral Fluid from Substitution 
Therapy Patients.' J Anal Toxicol, 39(6), Jul-Aug, pp. 472-480. 
 
Logan, B. K. (2002) 'Methamphetamine - Effects on Human Performance and 
Behavior.' Forensic Sci Rev, 14(1-2), Feb, pp. 133-151. 
 
Lurie, Y., Gopher, A., Lavon, O., Almog, S., Sulimani, L. and Bentur, Y. (2012) 
'Severe paramethoxymethamphetamine (PMMA) and paramethoxyamphetamine 
(PMA) outbreak in Israel.' Clin Toxicol (Phila), 50(1), Jan, pp. 39-43. 
 
Maldener, G. (1989) 'Requirements and tests for HPLC apparatus and methods in 
pharmaceutical quality control.' Chromatographia, 28(1) pp. 85-88. 
 
Marchand, D. H., Croes, K., Dolan, J. W. and Snyder, L. R. (2005) 'Column 
selectivity in reversed-phase liquid chromatography. VII. Cyanopropyl columns.' J 
Chromatogr A, 1062(1), Jan 7, pp. 57-64. 
 
Martin, T. L. (2001) 'Three cases of fatal paramethoxyamphetamine overdose.' J 
Anal Toxicol, 25(7), Oct, pp. 649-651. 
 
Maskell, P. D., De Paoli, G., Seneviratne, C. and Pounder, D. J. (2011) 
'Mephedrone (4-methylmethcathinone)-related deaths.' J Anal Toxicol, 35(3), Apr, 
pp. 188-191. 
 
Masui, M., Sayo, H. and Tsuda, Y. (1968) 'Anodic oxidation of amines. Part I. 
Cyclic voltammetry of aliphatic amines at a stationary glassy-carbon electrode.' 
Journal of the Chemical Society B: Physical Organic,  pp. 973-976. 
 
McElrath, K. and O'Neill, C. (2011) 'Experiences with mephedrone pre- and post-
legislative controls: Perceptions of safety and sources of supply.' International 
Journal of Drug Policy, 22(2), Mar, pp. 120-127. 
213 
 
McLaughlin, G., Morris, N., Kavanagh, P. V., Power, J. D., O'Brien, J., Talbot, B., 
Elliott, S. P., Wallach, J., Hoang, K., Morris, H. and Brandt, S. D. (2016) 'Test 
purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and 
differentiation from its meta- and para-substituted isomers.' Drug Test Anal, 8(1), 
Jan, pp. 98-109. 
 
McLaughlin, G., Morris, N., Kavanagh, P. V., Power, J. D., Dowling, G., Twamley, 
B., O'Brien, J., Talbot, B., Walther, D., Partilla, J. S., Baumann, M. H. and Brandt, 
S. D. (2017) 'Synthesis, characterization and monoamine transporter activity of the 
new psychoactive substance mexedrone and its N-methoxy positional isomer, N-
methoxymephedrone.' Drug testing and analysis, 9(3), 09/21, pp. 358-368. 
 
Metters, J. P., Kadara, R. O. and Banks, C. E. (2011) 'New directions in screen 
printed electroanalytical sensors: an overview of recent developments.' Analyst, 
136(6), Mar 21, pp. 1067-1076. 
 
Michel, R. E., Rege, A. B. and George, W. J. (1993) 'High-pressure liquid 
chromatography/electrochemical detection method for monitoring MDA and MDMA 
in whole blood and other biological tissues.' Journal of Neuroscience Methods, 
50(1), 1993/10/01/, pp. 61-66. 
 
Milhazes, N., Martins, P., Uriarte, E., Garrido, J., Calheiros, R., Marques, M. P. M. 
and Borges, F. (2007) 'Electrochemical and spectroscopic characterisation of 
amphetamine-like drugs: Application to the screening of 3,4-
methylenedioxymethamphetamine (MDMA) and its synthetic precursors.' Analytica 
Chimica Acta, 596(2), 2007/07/23/, pp. 231-241. 
 
Min, J. Z., Yamashita, K., Toyo'oka, T., Inagaki, S., Higashi, T., Kikura-Hanajiri, R. 
and Goda, Y. (2010) 'Simultaneous and group determination methods for 
designated substances by HPLC with multi-channel electrochemical detection and 
their application to real samples.' Biomedical Chromatography, 24(12) pp. 1287-
1299. 
 
Moeller, K. E., Lee, K. C. and Kissack, J. C. (2008) 'Urine drug screening: practical 
guide for clinicians.' Mayo Clin Proc, 83(1), Jan, pp. 66-76. 
 
Moeller, M. R., Steinmeyer, S. and Kraemer, T. (1998) 'Determination of drugs of 
abuse in blood.' Journal of Chromatography B: Biomedical Sciences and 
Applications, 713(1) pp. 91-109. 
 
Moreno, D., Diaz de Grenu, B., Garcia, B., Ibeas, S. and Torroba, T. (2012) 'A 
turn-on fluorogenic probe for detection of MDMA from ecstasy tablets.' Chem 
Commun (Camb), 48(24), Mar 21, pp. 2994-2996. 
 
Morgan, C. J., Noronha, L. A., Muetzelfeldt, M., Feilding, A. and Curran, H. V. 
(2013) 'Harms and benefits associated with psychoactive drugs: findings of an 
214 
international survey of active drug users.' Journal of Psychopharmacology, 27(6) 
pp. 497-506. 
 
Morris, H. and Wallach, J. (2014) 'From PCP to MXE: a comprehensive review of 
the non-medical use of dissociative drugs.' Drug Test Anal, 6(7-8), Jul-Aug, pp. 
614-632. 
 
Morris, K. (2010) UK places generic ban on mephedrone drug family. Elsevier. 
 
Muller, I. B. and Windberg, C. N. (2005) 'Validation of an HPLC method for 
quantitation of MDMA in tablets.' J Chromatogr Sci, 43(8), Sep, pp. 434-437. 
 
Nakahara, Y. and Sekine, H. (1985) 'Studies on confirmation of cannabis use. I. 
Determination of the cannabinoid contents in marijuana cigarette, tar, and ash 
using high performance liquid chromatography with electrochemical detection.' J 
Anal Toxicol, 9(3), May-Jun, pp. 121-124. 
 
Nakahara, Y., Sekine, H. and Cook, C. E. (1989) 'Confirmation of cannabis use. II. 
Determination of tetrahydrocannabinol metabolites in urine and plasma by HPLC 
with ECD.' J Anal Toxicol, 13(1), Jan-Feb, pp. 22-24. 
 
Nakashima, K., Kaddoumi, A., Ishida, Y., Itoh, T. and Taki, K. (2003) 
'Determination of methamphetamine and amphetamine in abusers' plasma and 
hair samples with HPLC‐FL.' Biomedical Chromatography, 17(7) pp. 471-476. 
 
Natalia Biziak de Figueiredo1, É. N. O., Matheus Manoel Teles de Menezes1, 
José Fernando de Andrade1, Maria Cristina Brunini and Oliveira1*, S. a. M. F. d. 
(2010) 'Determination of 3,4-methylenedioxymethamphetamine (MDMA) in 
Confiscated Tablets by High-Performance Liquid Chromatography (HPLC) with 
Diode Array Detector.' Journal of Forensic Research, 1(2) 
 
Nencini, P., Amiconi, G., Befani, O., Abdullahi, M. A. and Anania, M. C. (1984) 
'Possible Involvement of Amine Oxidase Inhibition in the Sympathetic Activation 
Induced by Khat (Catha-Edulis) Chewing in Humans.' Journal of 
Ethnopharmacology, 11(1) pp. 79-86. 
 
Neue, U. D. (1997) 'HPLC troubleshooting: Complex sample matrices.' American 
Laboratory, 29(14), Jul, pp. 48-49. 
 
Neue, U. D. (2010) 'Geometrically deformed tubes as efficient vessels for post-
column derivatization in high-performance liquid chromatography.' Chemical 
Engineering and Processing, 49(7), Jul, pp. 662-671. 
 
Neville, T. (1995) 'The Case of the Frozen Addicts - Langston,Jw, Palfreman,J.' 
Library Journal, 120(7), Apr 15, pp. 105-105. 
215 
 
Nieddu, M., Boatto, G., Sini, L. and Dessì, G. (2007) 'Determination of p‐
Methoxyamphetamine by Capillary Electrophoresis with Diode Array Detection 
from Urine and Plasma Samples.' Journal of Liquid Chromatography & Related 
Technologies, 30(3), 2007/02/01, pp. 431-438. 
 
Nyoni, E. C., Sitaram, B. R. and Taylor, D. A. (1996) 'Determination of Δ9-
tetrahydrocannabinol levels in brain tissue using high-performance liquid 
chromatography with electrochemical detection.' Journal of Chromatography B: 
Biomedical Sciences and Applications, 679(1), 1996/04/26/, pp. 79-84. 
 
Ochiai, L. M., Agustini, D., Figueiredo-Filho, L. C. S., Banks, C. E., Marcolino-
Junior, L. H. and Bergamini, M. F. (2017) 'Electroanalytical thread-device for estriol 
determination using screen-printed carbon electrodes modified with carbon 
nanotubes.' Sensors and Actuators B: Chemical, 241(Supplement C), 2017/03/31/, 
pp. 978-984. 
 
Oldham, K. B. (1973) 'Diffusive transport to planar, cylindrical and spherical 
electrodes.' Journal of Electroanalytical Chemistry and Interfacial Electrochemistry, 
41(3), 1973/02/09/, pp. 351-358. 
 
Osorio-Olivares, M., Rezende, M. C., Sepulveda-Boza, S., Cassels, B. K. and 
Fierro, A. (2004) 'MAO inhibition by arylisopropylamines: the effect of oxygen 
substituents at the beta-position.' Bioorganic & Medicinal Chemistry, 12(15), Aug 
1, pp. 4055-4066. 
 
Pápai, Z. and Pap, T. L. (2002) 'Analysis of peak asymmetry in chromatography.' 
Journal of Chromatography A, 953(1), 2002/04/12/, pp. 31-38. 
 
Paton, D. M., Bell, J. I., Yee, R. and Cook, D. A. (1975) 'Pharmacology and toxicity 
of 3,4-methylenedioxyamphetamine, para-methoxyamphetamine and related 
dimethoxyamphetamines.' Proc West Pharmacol Soc, 18 pp. 229-231. 
 
Pecková, K. (2011) 'Utilization of Unmodified Screen-Printed Carbon Electrodes in 
Electroanalysis of Organic Compounds (An Overview).'  
 
Phillips, D. J., Capparella, M., Neue, U. D. and ElFallah, Z. (1997) 'A new small 
particle packing for faster analysis with high resolution.' Journal of Pharmaceutical 
and Biomedical Analysis, 15(9-10), Jun, pp. 1389-1395. 
 
Pichini, S., Navarro, M., Pacifici, R., Zuccaro, P., Ortuno, J., Farre, M., Roset, P. 
N., Segura, J. and de la Torre, R. (2003) 'Usefulness of sweat testing for the 
detection of MDMA after a single-dose administration.' J Anal Toxicol, 27(5), Jul-
Aug, pp. 294-303. 
 
Pike, D. J., Kapur, N., Millner, P. A. and Stewart, D. I. (2012) 'Flow cell design for 
effective biosensing.' Sensors (Basel), 13(1), Dec 20, pp. 58-70. 
216 
 
Prosser, J. M. and Nelson, L. S. (2012) 'The toxicology of bath salts: a review of 
synthetic cathinones.' J Med Toxicol, 8(1), Mar, pp. 33-42. 
 
PYLA, S., SRINIVAS, K., YVV, J. and PANDA, J. 'DEVELOPMENT AND 
VALIDATION OF NEW ANALYTICAL METHOD FOR PACLITAXEL IN BULK AND 
PHARMACEUTICAL DOSAGE FORM BY REVERSE PHASE HPLC (RP-HPLC).'  
 
R. J. Flanagan, D. P. a. R. W., Electrochemical Detection in HPLC: Analysis of 
Drugs and Poisons, RSC Chromatography Monographs, 2005, vol. 10, pp. 1–244.  
 
Ren, D.-B., Yang, Z.-H., Liang, Y.-Z., Fan, W. and Ding, Q. (2013) 'Effects of 
injection volume on chromatographic features and resolution in the process of 
counter-current chromatography.' Journal of Chromatography A, 1277, 
2013/02/15/, pp. 7-14. 
 
Reuter, P. and Pardo, B. (2017) 'Can new psychoactive substances be regulated 
effectively? An assessment of the British Psychoactive Substances Bill.' Addiction, 
112(1), Jan, pp. 25-31. 
 
Ribeiro, M., Fernanda, M., da Cruz Júnior, J. W., Dockal, E. R., McCord, B. R. and 
de Oliveira, M. F. (2016) 'Voltammetric Determination of Cocaine Using Carbon 
Screen Printed Electrodes Chemically Modified with Uranyl Schiff Base Films.' 
Electroanalysis, 28(2) pp. 320-326. 
 
Riezzo, I., Cerretani, D., Fiore, C., Bello, S., Centini, F., D'Errico, S., Fiaschi, A. I., 
Giorgi, G., Neri, M., Pomara, C., Turillazzi, E. and Fineschi, V. (2010) 'Enzymatic-
nonenzymatic cellular antioxidant defense systems response and 
immunohistochemical detection of MDMA, VMAT2, HSP70, and apoptosis as 
biomarkers for MDMA (Ecstasy) neurotoxicity.' J Neurosci Res, 88(4), Mar, pp. 
905-916. 
 
Roberts, L., Ford, L., Patel, N., Vale, J. A. and Bradberry, S. M. (2017) '11 
analytically confirmed cases of mexedrone use among polydrug users.' Clinical 
Toxicology, 55(3), 2017/03/16, pp. 181-186. 
 
Saito, K., Saito, R., Kikuchi, Y., Iwasaki, Y., Ito, R. and Nakazawa, H. (2011) 
'Analysis of Drugs of Abuse in Biological Specimens.' Journal of Health Science, 
57(6) pp. 472-487. 
 
Sandhya, P., Vishnu, P. and Anjali, N. (2013) 'Method development and validation 
of Imatinib Mesylate in Pharmaceutical dosage form by RP-HPLC.' World Journal 
of Pharmacy and Pharmaceutical Sciences, 3(1) pp. 682-688. 
 
Santagati, N. A., Ferrara, G., Marrazzo, A. and Ronsisvalle, G. (2002) 
'Simultaneous determination of amphetamine and one of its metabolites by HPLC 
217 
with electrochemical detection.' Journal of pharmaceutical and biomedical 
analysis, 30(2) pp. 247-255. 
 
Santali, E. Y., Cadogan, A.-K., Daeid, N. N., Savage, K. A. and Sutcliffe, O. B. 
(2011) 'Synthesis, full chemical characterisation and development of validated 
methods for the quantification of (±)-4′-methylmethcathinone (mephedrone): A new 
“legal high”.' Journal of Pharmaceutical and Biomedical Analysis, 56(2), 
2011/09/10/, pp. 246-255. 
 
Sawyer, W. R., Waterhouse, G. A., Doedens, D. J. and Forney, R. B. (1988) 
'Heroin, morphine, and hydromorphone determination in postmortem material by 
high performance liquid chromatography.' J Forensic Sci, 33(5), Sep, pp. 1146-
1155. 
 
Schifano, F., Albanese, A., Fergus, S., Stair, J. L., Deluca, P., Corazza, O., Davey, 
Z., Corkery, J., Siemann, H., Scherbaum, N., Farre, M., Torrens, M., Demetrovics, 
Z., Ghodse, A. H., Psychonaut Web, M. and Re, D. R. G. (2011) 'Mephedrone (4-
methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical 
issues.' Psychopharmacology (Berl), 214(3), Apr, pp. 593-602. 
 
Seger, C. (2012) 'Usage and limitations of liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) in clinical routine laboratories.' Wien Med Wochenschr, 
162(21-22), Nov, pp. 499-504. 
 
Shabir, G. A. (2003) 'Validation of high-performance liquid chromatography 
methods for pharmaceutical analysis.' Journal of Chromatography A, 987(1), 
2003/02/14/, pp. 57-66. 
 
Shevyrin, V., Melkozerov, V., Eltsov, O., Shafran, Y. and Morzherin, Y. (2016) 
'Synthetic cannabinoid 3-benzyl-5-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1,2,4-
oxadiazole. The first detection in illicit market of new psychoactive substances.' 
Forensic Science International, 259, 2//, pp. 95-100. 
 
Shulgin, A. T. (1978) 'Psychotomimetic drugs: Structure-activity relationships.' In 
Stimulants. Springer, pp. 243-333. 
 
Siegel, G. J. and Agranoff, B. W. (1999) Basic neurochemistry : molecular, 
cellular, and medical aspects. 6th ed. / editors Bernard W. Agranoff ... [et al.], 
illustrations by Lorie M. Gavulic. ed., Philadelphia: Lippincott-Raven Publishers. 
 
Simmler, L. D. (2018) 'Monoamine Transporter and Receptor Interaction Profiles of 
Synthetic Cathinones.' In Zawilska, J. B. (ed.) Synthetic Cathinones: Novel 
Addictive and Stimulatory Psychoactive Substances. Cham: Springer International 
Publishing, pp. 97-115. 
 
218 
Simmler, L. D., Hysek, C. M. and Liechti, M. E. (2011) 'Sex differences in the 
effects of MDMA (ecstasy) on plasma copeptin in healthy subjects.' J Clin 
Endocrinol Metab, 96(9), Sep, pp. 2844-2850. 
 
Simmler, L. D., Wandeler, R. and Liechti, M. E. (2013b) 'Bupropion, 
methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize 
methamphetamine-induced efflux of dopamine according to their potencies as 
dopamine uptake inhibitors: implications for the treatment of methamphetamine 
dependence.' BMC Res Notes, 6, Jun 05, p. 220. 
 
Simmler, L. D., Rickli, A., Hoener, M. C. and Liechti, M. E. (2014) 'Monoamine 
transporter and receptor interaction profiles of a new series of designer 
cathinones.' Neuropharmacology, 79(Supplement C), 2014/04/01/, pp. 152-160. 
 
Simmler, L. D., Buser, T. A., Donzelli, M., Schramm, Y., Dieu, L. H., Huwyler, J., 
Chaboz, S., Hoener, M. C. and Liechti, M. E. (2013a) 'Pharmacological 
characterization of designer cathinones in vitro.' Br J Pharmacol, 168(2), Jan, pp. 
458-470. 
 
Smith, J. P., Sutcliffe, O. B. and Banks, C. E. (2015) 'An overview of recent 
developments in the analytical detection of new psychoactive substances (NPSs).' 
Analyst, Jun 2, 
 
Smith, J. P., Metters, J. P., Irving, C., Sutcliffe, O. B. and Banks, C. E. (2014a) 
'Forensic electrochemistry: the electroanalytical sensing of synthetic cathinone-
derivatives and their accompanying adulterants in "legal high" products.' Analyst, 
139(2) pp. 389-400. 
 
Smith, J. P., Metters, J. P., Khreit, O. I. G., Sutcliffe, O. B. and Banks, C. E. 
(2014b) 'Forensic Electrochemistry Applied to the Sensing of New Psychoactive 
Substances: Electroanalytical Sensing of Synthetic Cathinones and Analytical 
Validation in the Quantification of Seized Street Samples.' Analytical Chemistry, 
86(19), 2014/10/07, pp. 9985-9992. 
 
Smith, J. P., Metters, J. P., Kampouris, D. K., Lledo-Fernandez, C., Sutcliffe, O. B. 
and Banks, C. E. (2013) 'Forensic electrochemistry: the electroanalytical sensing 
of Rohypnol (R) (flunitrazepam) using screen-printed graphite electrodes without 
recourse for electrode or sample pre-treatment.' Analyst, 138(20) pp. 6185-6191. 
 
Soar, K., Turner, J. J. and Parrott, A. C. (2001) 'Psychiatric disorders in Ecstasy 
(MDMA) users: a literature review focusing on personal predisposition and drug 
history.' Hum Psychopharmacol, 16(8), Dec, pp. 641-645. 
 
Soares, M., Carvalho, M., Carmo, H., Remiao, F., Carvalho, F. and Bastos, M. 
(2004) 'Simultaneous determination of amphetamine derivatives in human urine 
after SPE extraction and HPLC‐UV analysis.' Biomedical Chromatography, 18(2) 
pp. 125-131. 
219 
 
Somaini, L., Saracino, M. A., Marcheselli, C., Zanchini, S., Gerra, G. and Raggi, 
M. A. (2011) 'Combined liquid chromatography-coulometric detection and 
microextraction by packed sorbent for the plasma analysis of long acting opioids in 
heroin addicted patients.' Anal Chim Acta, 702(2), Sep 30, pp. 280-287. 
 
Sreedevi, A., Rao, L. and Kalyani, L. (2013) 'Stability-indicating HPLC Method for 
analysis of Epirubicin in Pharmaceutical dosage form.' Indo American Journal of 
Pharmaceutical Research, 3(10) pp. 8249-8259. 
 
Stoll, D. R., Paek, C. and Carr, P. W. (2006) 'Fast gradient elution reversed-phase 
high-performance liquid chromatography with diode-array detection as a high-
throughput screening method for drugs of abuse. I. Chromatographic conditions.' J 
Chromatogr A, 1137(2), Dec 29, pp. 153-162. 
 
Stradiotto, N. R., Yamanaka, H. and Zanoni, M. V. B. (2003) 'Electrochemical 
sensors: a powerful tool in analytical chemistry.' Journal of the Brazilian Chemical 
Society, 14(2) pp. 159-173. 
 
Švorc, Ľ., Vojs, M., Michniak, P., Marton, M., Rievaj, M. and Bustin, D. (2014) 
'Electrochemical behavior of methamphetamine and its voltammetric determination 
in biological samples using self-assembled boron-doped diamond electrode.' 
Journal of Electroanalytical Chemistry, 717, 2014/03/15/, pp. 34-40. 
 
Tadini, M. C., Balbino, M. A., Eleoterio, I. C., de Oliveira, L. S., Dias, L. G., Jean-
François Demets, G. and de Oliveira, M. F. (2014) 'Developing electrodes 
chemically modified with cucurbit[6]uril to detect 3,4-
methylenedioxymethamphetamine (MDMA) by voltammetry.' Electrochimica Acta, 
121, 2014/03/01/, pp. 188-193. 
 
Tagliaro, F., Franchi, D., Dorizzi, R. and Marigo, M. (1989) 'High-performance 
liquid chromatographic determination of morphine in biological samples: An 
overview of separation methods and detection techniques.' Journal of 
Chromatography B: Biomedical Sciences and Applications, 488(1), 1989/03/17/, 
pp. 215-228. 
 
UK-Governement. (1971) Misuse of Drugs Act 1971(c.38). London.  
 
UK-Governement (1973) 'The Misuse of Drugs (Safe Custody) Regulations 1973.'  
 
UK-Governement. (2001) The Misuse of Drugs Regulations 2001.  
 
UK-Governement (2012) 'The Human Medicines Regulations.'  
 
UK-Government. (2016) Psychoactive Substances Act 2016.  
220 
 
UNODC (1961) 'United Nations Single Convention on Narcotic Drugs.'  
 
UNODC, U. N. O. o. D. a. C. (2013) The International Drug Control Conventions.  
 
USE, I. C. O. H. O. T. R. F. R. O. P. F. H. (2005) 'VALIDATION OF ANALYTICAL 
PROCEDURES: TEXT AND METHODOLOGY Q2(R1) '  
 
Uslu, B. and Ozkan, S. A. (2011) 'Electroanalytical Methods for the Determination 
of Pharmaceuticals: A Review of Recent Trends and Developments.' Analytical 
Letters, 44(16), 2011/11/01, pp. 2644-2702. 
 
V. Krishnaiah, Y. V. R. R., V. Hanuman Reddy, M. Thirupalu Reddy, G. M. Rao, 
Int. J. Sci Res., 2012, 1, 14 – 17.  
 
Valente, M. J., Guedes de Pinho, P., de Lourdes Bastos, M., Carvalho, F. and 
Carvalho, M. (2014) 'Khat and synthetic cathinones: a review.' Arch Toxicol, 88(1), 
Jan, pp. 15-45. 
 
Verschraagen, M., Maes, A., Ruiter, B., Bosman, I. J., Smink, B. E. and Lusthof, K. 
J. (2007) 'Post-mortem cases involving amphetamine-based drugs in The 
Netherlands. Comparison with driving under the influence cases.' Forensic Sci Int, 
170(2-3), Aug 06, pp. 163-170. 
 
Vessman, J. (1996) 'Selectivity or specificity? Validation of analytical methods from 
the perspective of an analytical chemist in the pharmaceutical industry.' J Pharm 
Biomed Anal, 14(8-10), Jun, pp. 867-869. 
 
Wada, M., Ochi, Y., Nogami, K., Ikeda, R., Kuroda, N. and Nakashima, K. (2012) 
'Evaluation of hair roots for detection of methamphetamine and 3,4-
methylenedioxymethamphetamine abuse by use of an HPLC-chemiluminescence 
method.' Anal Bioanal Chem, 403(9), Jul, pp. 2569-2576. 
 
Waddell, S. A., Fernandez, C., Inverarity, C. C. and Prabhu, R. (2017) 'Extending 
the capability of forensic electrochemistry to the novel psychoactive substance 
benzylpiperazine.' Sensing and Bio-Sensing Research, 13, 2017/04/01/, pp. 28-39. 
 
Wallach, J., Kavanagh, P. V., McLaughlin, G., Morris, N., Power, J. D., Elliott, S. 
P., Mercier, M. S., Lodge, D., Morris, H., Dempster, N. M. and Brandt, S. D. (2015) 
'Preparation and characterization of the 'research chemical' diphenidine, its 
pyrrolidine analogue, and their 2,2-diphenylethyl isomers.' Drug Test Anal, 7(5), 
May, pp. 358-367. 
 
Whelpton, R. (2007) 'Speed, Ecstasy, Ritalin: The Science of Amphetamines.' 
British Journal of Clinical Pharmacology, 63(6) pp. 763-763. 
221 
 
White, C., Edwards, M., Brown, J. and Bell, J. (2014) 'The impact of recreational 
MDMA 'ecstasy' use on global form processing.' J Psychopharmacol, 28(11), Nov, 
pp. 1018-1029. 
 
Wilkins, C. (2014) 'A critical first assessment of the new pre-market approval 
regime for new psychoactive substances (NPS) in New Zealand.' Addiction, 
109(10) pp. 1580-1586. 
 
Wink, C. S., Meyer, G. M., Wissenbach, D. K., Jacobsen-Bauer, A., Meyer, M. R. 
and Maurer, H. H. (2014) 'Lefetamine-derived designer drugs N-ethyl-1,2-
diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): 
metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-
MS/MS.' Drug Test Anal, 6(10), Oct, pp. 1038-1048. 
 
Wink, C. S. D., Meyer, G. M. J., Meyer, M. R. and Maurer, H. H. (2015) 
'Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-
Contribution of human cytochrome P450 isozymes to their main phase I metabolic 
steps.' Toxicology Letters, 238(3), Nov 4, pp. 39-44. 
 
Winstock, A. R., Marsden, J. and Mitcheson, L. (2010) 'What should be done 
about mephedrone?' BMJ, 340 p. c1605. 
 
Winstock, A. R., Mitcheson, L. R., Deluca, P., Davey, Z., Corazza, O. and 
Schifano, F. (2011) 'Mephedrone, new kid for the chop?' Addiction, 106(1), Jan, 
pp. 154-161. 
 
Wolff, K. and Winstock, A. R. (2006) 'Ketamine: from medicine to misuse.' CNS 
Drugs, 20, 2006/03// 
//, p. 199+. 
 
Xiang, P., Shen, M. and Drummer, O. H. (2015) 'Review: Drug concentrations in 
hair and their relevance in drug facilitated crimes.' J Forensic Leg Med, 36, Nov, 
pp. 126-135. 
 
Xu, F., Gao, M., Wang, L., Zhou, T., Jin, L. and Jin, J. (2002) 'Amperometric 
determination of morphine on cobalt hexacyanoferrate modified electrode in rat 
brain microdialysates.' Talanta, 58(3), 2002/09/12/, pp. 427-432. 
 
Zanda, M. T. and Fattore, L. (2017) 'Chapter 29 - Novel Psychoactive Substances: 
A New Behavioral and Mental Health Threat A2 - Watson, Ronald Ross.' In Zibadi, 
S. (ed.) Addictive Substances and Neurological Disease. Academic Press, pp. 
341-353. 
 
Zhao, H., Brenneisen, R., Scholer, A., McNally, A. J., ElSohly, M. A., Murphy, T. P. 
and Salamone, S. J. (2001) 'Profiles of urine samples taken from Ecstasy users at 
222 
Rave parties: analysis by immunoassays, HPLC, and GC-MS.' J Anal Toxicol, 
25(4), May-Jun, pp. 258-269. 
 
Zuba, D. (2012) 'Identification of cathinones and other active components of 'legal 
highs' by mass spectrometric methods.' Trac-Trends in Analytical Chemistry, 32, 
Feb, pp. 15-30. 
 
Zuway, K. Y., Smith, J. P., Foster, C. W., Kapur, N., Banks, C. E. and Sutcliffe, O. 
B. (2015) 'Detection and quantification of new psychoactive substances (NPSs) 
within the evolved "legal high" product, NRG-2, using high performance liquid 
chromatography-amperometric detection (HPLC-AD).' Analyst, 140(18), Sep 21, 
pp. 6283-6294. 
 
223 
9 Appendix 
Table 9.1 Rsults of linearity measurements for (±)-MA using HPLC-UV detection in the LC-FC-A 
system, column A (Table 2.2), Mobile phase 1, detector wavelength (UV): 210 nm. 
(±)-MA 
Concentration (µg mL-1) 10 20 40 60 80 100 
Peak area 1 180.46 371.38 736.63 1123.78 1493.72 1852.48 
Peak area 2 182.01 371.66 735.68 1124.83 1494.54 1852.47 
Peak area 3 183.24 370.15 740.69 1124.99 1493.97 1853.36 
Peak area 4 182.92 371.31 738.51 1125.37 1492.49 1856.64 
Peak area 5 180.04 372.04 739.72 1124.00 1494.07 1851.54 
Peak area 6 181.33 371.49 739.43 1122.15 1492.50 1847.63 
Average  181.67 371.34 738.44 1124.19 1493.55 1852.35 
RSD% 0.71 0.17 0.26 0.10 0.06 0.16 
 
Table 9.2 Results of linearity measurements for (±)-PMA using HPLC-UV detection in theLC-FC-A 
system, column A (Table 2.2), Mobile phase 1, detector wavelength (UV): 210 nm. 
(±)-PMA 
Concentration (µg mL-1) 10 20 40 60 80 100 
Peak area 1 140.83 283.62 562.49 859.49 1146.62 1421.60 
Peak area 2 140.81 284.72 560.55 859.57 1144.25 1425.26 
Peak area 3 143.00 283.84 565.50 861.99 1143.09 1424.07 
Peak area 4 140.81 283.05 563.86 860.75 1142.99 1424.11 
Peak area 5 143.74 283.67 560.07 860.25 1143.91 1420.69 
Peak area 6 142.97 286.05 565.36 855.30 1142.58 1417.41 
Average 142.03 284.16 562.97 859.56 1143.91 1422.19 
RSD% 0.95 0.38 0.42 0.27 0.13 0.20 
 
Table 9.3 Results of linearity measurements for (±)-MDMA using HPLC-UV detection in theLC-FC-
A system, column A (Table 2.2), mobile phase 1, detector wavelength (UV): 210 nm. 
(±)-MDMA 
Concentration (µg mL-1) 10 20 40 60 80 100 
Peak area 1 134.54 289.03 571.74 870.28 1157.05 1425.17 
Peak area 2 135.35 290.59 570.04 868.03 1156.29 1427.81 
Peak area 3 134.58 290.54 570.67 868.87 1156.28 1424.35 
Peak area 4 135.97 288.47 572.12 869.47 1155.60 1426.27 
Peak area 5 135.21 289.04 570.14 868.48 1155.37 1425.50 
Peak area 6 134.51 290.10 571.66 867.96 1156.49 1425.29 
Average 135.03 289.63 571.06 868.85 1156.18 1425.73 
RSD% 0.44 0.31 0.16 0.10 0.05 0.08 
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Table 9.4 Results of linearity measurements for (±)-PMA by using HPLC-AD detection in the LC-FC-
A system, column A (Table 2.2), mobile phase 1. 
(±)-PMA 
Concentration (µg mL-1) 10 20 40 60 80 100 
Peak current 1 0.079 0.154 0.246 0.565 0.840 0.962 
Peak current 2 0.079 0.152 0.241 0.561 0.826 0.958 
Peak current 3 0.078 0.154 0.241 0.560 0.833 0.965 
Peak current 4 0.077 0.154 0.243 0.557 0.828 0.965 
Peak current 5 0.079 0.154 0.244 0.556 0.828 0.958 
Peak current 6 0.077 0.155 0.244 0.558 0.830 0.956 
Average 0.07 0.154 0.243 0.559 0.831 0.961 
RSD% 0.99 0.62 0.71 0.58 0.60 0.39 
 
Table 9.5 Results of linearity measurements for (±)-MDMA using HPLC-AD detection in the LC-FC-
A system, column A (Table 2.2), mobile phase 1. 
(±)-MDMA 
Concentration (µg mL-1) 10 20 40 60 80 100 
Peak current 1 0.123 0.206 0.393 0.884 1.163 1.457 
Peak current 2 0.122 0.206 0.392 0.883 1.160 1.460 
Peak current 3 0.122 0.206 0.392 0.882 1.160 1.457 
Peak current 4 0.124 0.206 0.392 0.883 1.162 1.458 
Peak current 5 0.123 0.205 0.392 0.884 1.163 1.458 
Peak current 6 0.122 0.207 0.392 0.881 1.162 1.457 
Average 0.120 0.210 0.390 0.880 1.160 1.460 
RSD% 0.52 0.25 0.11 0.13 0.12 0.08 
 
Table 9.6 Results of linearity measurements for (±)-PMA using HPLC-AD detection in the LC-FC-B 
system, column (A) Table 2.2, mobile phase 1. 
(±)-PMA 
Concentration (µg mL-1) 10 20 40 60 80 100 
Peak current 1 0.0871 0.144 0.164 0.223 0.274 0.297 
Peak current 2 0.089 0.142 0.162 0.227 0.269 0.298 
Peak current 3 0.088 0.143 0.164 0.223 0.269 0.295 
Peak current 4 0.087 0.143 0.162 0.224 0.273 0.297 
Peak current 5 0.088 0.143 0.163 0.224 0.274 0.295 
Peak current 6 0.087 0.143 0.164 0.223 0.274 0.295 
Average 0.087 0.140 0.160 0.224 0.272 0.296 
RSD% 0.88 0.50 0.65 0.74 0.94 0.45 
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Table 9.7 Raw data of the inter- and intra-day peak values and relative standard deviations (RSD %) for (±)-MA, (±)-PMA and (±)-MDMA using HPLC-UV detection and 
amperometric detection in the LC-FC-A and LC-FC-B systems. 
LC-FC-A 
Concentration  
(µg mL-1) 
Intra-day values of HPLC-UV 
peak area (mA) 
Intra-day values of HPLC-AD 
peak current (µA) 
Inter-day values of HPLC-UV 
peak area (mA) 
Inter-day values of HPLC-AD 
peak current (µA) 
MA PMA MDMA MA PMA MDMA MA PMA MDMA MA PMA MDMA 
60 1123.78 859.48 870.27 n.d. 0.550 0.830 1123.78 859.48 868.27 n.d. 0.550 0.830 
60 1124.83 859.57 868.03 n.d. 0.560 0.826 1124.83 859.574 866.03 n.d. 0.560 0.820 
60 1124.98 861.99 868.86 n.d. 0.580 0.820 1124.98 861.99 868.86 n.d. 0.580 0.820 
60 1125.36 860.74 869.47 n.d. 0.560 0.830 1125.36 860.74 869.47 n.d. 0.560 0.830 
60 1125.99 860.25 868.48 n.d. 0.540 0.840 1125.99 860.25 868.48 n.d. 0.540 0.840 
60 1124.15 855.30 867.95 n.d. 0.560 0.810 1124.15 855.30 867.95 n.d. 0.560 0.820 
60 1123.78 860.48 870.27 n.d. 0.560 0.884 1123.78 860.48 870.27 n.d. 0.550 0.830 
60 1123.83 859.57 870.03 n.d. 0.560 0.883 1125.83 859.57 870.03 n.d. 0.550 0.820 
60 1123.98 861.99 870.86 n.d. 0.550 0.882 1124.98 861.99 870.86 n.d. 0.560 0.820 
60 1122.36 860.74 869.47 n.d. 0.550 0.883 1125.36 862.74 870.47 n.d. 0.550 0.830 
60 1123.99 860.25 869.48 n.d. 0.550 0.884 1125.99 861.25 870.48 n.d. 0.550 0.820 
60 1122.15 860.30 867.95 n.d. 0.550 0.881 1125.15 859.30 869.95 n.d. 0.550 0.830 
Average 1124.10 860.05 869.26 n.d. 0.553 0.883 1125.02 860.22 869.26 n.d. 0.552 0.825 
RSD% 0.09 0.19 0.11 n.d. 0.933 0.128 0.06 0.22 0.16 n.d. 0.740 0.664 
n.d. = not detected 
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Table 9.8 Results of linearity measurements for (±)-caffeine using HPLC-UV in the LC-FC-A system, 
column A (Table 2.2), mobile phase 2, detector wavelength (UV): 264 nm. 
Concentration  
(µg mL-1) 
50 100 200 300 400 500 
Peak area(µA) 1 1454.60 2824.40 5635.50 8224.10 11214.80 13923.30 
Peak area(µA) 2 1454.90 2824.20 5635.80 8223.30 11213.00 13923.40 
Peak area(µA) 3 1454.60 2823.80 5635.70 8223.10 11213.80 13925.50 
Peak area(µA) 4 1453.50 2823.90 5636.80 8224.90 11212.30 13925.40 
Peak area(µA) 5 1453.40 2824.20 5636.60 8223.90 11213.00 13923.30 
Peak area(µA) 6 1453.50 2823.80 5635.90 8224.40 11212.00 13924.30 
Average 1454.08 2824.05 5636.05 8223.95 11213.15 13924.20 
RSD% 0.05 0.01 0.01 0.01 0.01 0.01 
 
 
Table 9.9 Results of linearity measurements for (±)-mephedrone using HPLC-UV in the LC-FC-A 
system, column A (Table 2.2), mobile phase 2, detector wavelength (UV): 264 nm. 
Concentration (µg 
mL-1) 
50 100 200 300 400 500 
Peak area(µA) 1 2166.70 4211.40 8464.80 12386.30 16984.30 21224.20 
Peak area(µA) 2 2166.30 4211.30 8467.40 12383.00 16983.10 21224.00 
Peak area(µA) 3 2166.50 4211.80 8463.80 12385.80 16983.80 21223.50 
Peak area(µA) 4 2165.80 4212.10 8465.00 12386.50 16982.50 21224.10 
Peak area(µA) 5 2166.10 4211.70 8460.60 12386.60 16983.00 21223.60 
Peak area(µA) 6 2166.90 4211.90 8462.30 12385.10 16982.50 21222.80 
Average 2166.383 4211.700 8463.983 12385.550 16983.200 21223.700 
RSD% 0.40 0.30 2.35 1.37 0.72 0.52 
 
 
Table 9.10 Results of linearity measurements for (±)-4-MEC using HPLC-UV in the LC-FC-A system, 
column A (Table 2.2), mobile phase 2 C, detector wavelengths (UV): 264 nm. 
Concentration  
(µg mL-1) 
50 100 200 300 400 500 
Peak area(µA) 1 2051.90 3991.20 8022.80 11763.00 16133.10 20177.00 
Peak area(µA) 2 2050.90 3991.10 8025.70 11763.00 16135.20 20172.00 
Peak area(µA) 3 2051. 4 3990.10 8025.00 11767.60 16133.33 20170.00 
Peak area(µA) 4 2051.60 3990.80 8025.90 11766.80 16133.90 20177.40 
Peak area(µA) 5 2050.70 3991.60 8024.10 11764.10 16134.70 20174.70 
Peak area(µA) 6 2051.90 3991.40 8024.40 11766.40 16135.50 20273.20 
Average 2051.400 3991.033 8024.65 11765.15 16134.28 20190.71 
RSD% 0.028 0.013 0.014 0.017 0.006 0.20 
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Table 9.11 Results of linearity measurements for (±)-caffeine using HPLC-AD in the LC-FC-A 
system, column A (Table 2.2), mobile phase 2, detector wavelength (UV): 264 nm. 
Linearity of caffeine 
Concentration  
(µg mL-1) 
50 100 200 300 400 500 
Peak current(µA) 1 0.650 1.228 2.514 3.219 4.427 5.370 
Peak current(µA) 2 0.641 1.232 2.522 3.245 4.467 5.375 
Peak current(µA) 3 0.647 1.234 2.528 3.231 4.432 5.431 
Peak current(µA) 4 0.641 1.236 2.542 3.203 4.411 5.437 
Peak current(µA) 5 0.649 1.231 2.548 3.247 4.431 5.437 
Peak current(µA) 6 0.643 1.225 2.543 3.217 4.496 5.397 
Average 0.645 1.231 2.533 3.227 4.444 5.408 
RSD% 0.004 0.004 0.014 0.017 0.031 0.031 
 
Table 9.12 Results of linearity measurements for (±)-mephedrone using HPLC-AD in the LC-FC-A 
system, column A (Table 2.2), mobile phase 2, detector wavelength (UV): 264 nm. 
Linearity of (±)-4-MMC 
Concentration  
(µg mL-1) 
50 100 200 300 400 500 
Peak current(µA) 1 0.129 0.214 0.498 0.670 0.926 1.252 
Peak current(µA) 2 0.127 0.217 0.487 0.677 0.930 1.265 
Peak current(µA) 3 0.128 0.212 0.497 0.680 0.930 1.262 
Peak current(µA) 4 0.129 0.213 0.488 0.687 0.942 1.254 
Peak current(µA) 5 0.128 0.213 0.496 0.678 0.928 1.263 
Peak current(µA) 6 0.129 0.216 0.49 0.679 0.946 1.283 
Average 0.128 0.214 0.493 0.678 0.934 1.263 
RSD% 0.550 0.870 0.005 0.808 0.913 0.872 
 
Table 9.13 Results of linearity measurements for (±)-4-MEC using HPLC-AD in the LC-FC-A system, 
column A (Table 2.2), mobile phase 2, detector wavelength (UV): 264 nm. 
Linearity of (±)-4-MEC 
Concentration (µg mL-1) 50 100 200 300 400 500 
Peak current(µA) 1 4393.81 6458.28 8642.43 10909.90 4393.81 6458.28 
Peak current(µA) 2 4392.52 6453.37 8655.18 10934.80 4392.52 6453.37 
Peak current(µA) 3 4393.04 6457.33 8556.70 10944.00 4393.04 6457.33 
Peak current(µA) 4 4393.91 6454.09 8555.94 10948.00 4393.91 6454.09 
Peak current(µA) 5 4394.15 6457.41 8554.57 10912.90 4394.15 6457.41 
Peak current(µA) 6 4392.98 6452.50 8551.02 10911.10 4392.98 6452.50 
Average 4393.40 6455.50 8585.97 10926.78 4393.40 6455.50 
RSD% 0.02 0.04 0.57 0.16 0.02 0.04 
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Table 9.14 Results of linearity measurements for (±)-caffeine using HPLC-UV in the LC-FC-B 
system, column A (Table 2.2), mobile phase 2, detector wavelength (UV): 264 nm. 
Concentration (µg mL-1) 200 300 400 500 
Peak current(µA) 1 4393.81 6458.28 8642.43 10909.90 
Peak current(µA) 2 4392.52 6453.37 8655.18 10934.80 
Peak current(µA) 3 4393.04 6457.33 8556.70 10944.00 
Peak current(µA) 4 4393.91 6454.09 8555.94 10948.00 
Peak current(µA) 5 4394.15 6457.41 8554.57 10912.90 
Peak current(µA) 6 4392.98 6452.50 8551.02 10911.10 
Average 4393.40 6455.50 8585.97 10926.78 
RSD% 0.02 0.04 0.57 0.16 
 
 
Table 9.15 Results of linearity measurements for (±)-mephedrone using HPLC-UV in the LC-FC-B 
system, column A (Table 2.2), mobile phase 2, detector wavelength (UV): 264 nm. 
Concentration (µg mL-1) 200 300 400 500 
Peak current(µA) 1 6682.87 9866.16 13216.60 17087.90 
Peak current(µA) 2 6688.88 9869.84 13203.30 17017.90 
Peak current(µA) 3 6685.21 9867.37 13164.00 16953.30 
Peak current(µA) 4 6689.61 9864.71 13123.40 16899.00 
Peak current(µA) 5 6684.94 9865.10 13131.50 16858.40 
Peak current(µA) 6 6688.56 9865.36 13102.10 16861.00 
Average 6686.68 9866.42 13156.82 16946.25 
RSD% 0.04 0.02 0.35 0.54 
 
Table 9.16 Results of linearity measurements for (±)-4-MEC by using HPLC-UV in the LC-FC-B 
system, column A (Table 2.2), mobile phase 2, detector wavelength (UV): 264 nm. 
Concentration (µg mL-1) 200 300 400 500 
Peak current(µA) 1 6583.34 9761.26 13031.30 16867.00 
Peak current(µA) 2 6585.96 9724.31 13035.10 16809.10 
Peak current(µA) 3 6587.77 9723.58 12985.80 16746.00 
Peak current(µA) 4 6587.31 9720.96 12947.60 16687.70 
Peak current(µA) 5 6586.41 9720.03 12952.80 16749.00 
Peak current(µA) 6 6585.35 9723.60 12924.40 16746.20 
Average 6586.02 9728.96 12979.50 16767.50 
RSD% 0.02 0.16 0.35 0.37 
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Table 9.17Results of linearity measurements for (±)-mephedrone using HPLC-AD in the LC-FC-B 
system, column A (Table 2.2), mobile phase 2, detector wavelength (UV): 264 nm. 
Concentration (µg mL-1) 200 300 400 500 
Peak current(µA) 1 0.307 0.468 0.597 0.704 
Peak current(µA) 2 0.307 0.469 0.596 0.703 
Peak current(µA) 3 0.307 0.467 0.594 0.704 
Peak current(µA) 4 0.306 0.465 0.596 0.703 
Peak current(µA) 5 0.306 0.468 0.595 0.704 
Peak current(µA) 6 0.306 0.468 0.596 0.705 
Average 0.307 0.468 0.596 0.704 
RSD% 0.179 0.295 0.173 0.107 
 
Table 9.18 Results of linearity measurements for caffeine using HPLC-AD in the LC-FC-B system, 
column A (Table 2.2), mobile phase 2, detector wavelength (UV): 264 nm. 
Linearity of (±)-mephedrone 
Concentration (µg mL-1) 200 300 400 500 
Peak current(µA) 1 0.055 0.103 0.123 0.147 
Peak current(µA) 2 0.056 0.103 0.124 0.144 
Peak current(µA) 3 0.055 0.104 0.124 0.147 
Peak current(µA) 4 0.055 0.102 0.125 0.145 
Peak current(µA) 5 0.055 0.103 0.124 0.144 
Peak current(µA) 6 0.055 0.102 0.124 0.145 
Average 0.055 0.103 0.124 0.145 
RSD% 0.740 0.732 0.510 0.940 
 
Table 9.19 Results of linearity measurements for (±)-4-MEC using HPLC-AD in the LC-FC-B system, 
column A (Table 2.2), mobile phase 2, detector wavelength (UV): 264 nm. 
Concentration (µg mL-1) 200 300 400 500 
Peak current(µA) 1 0.045 0.053 0.066 0.073 
Peak current(µA) 2 0.045 0.054 0.065 0.073 
Peak current(µA) 3 0.044 0.054 0.066 0.072 
Peak current(µA) 4 0.045 0.053 0.066 0.073 
Peak current(µA) 5 0.044 0.054 0.066 0.073 
Peak current(µA) 6 0.045 0.054 0.065 0.072 
Average 0.045 0.054 0.066 0.073 
RSD% 0.74 0.68 0.44 0.37 
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Table 9.20 Raw data of inter- and intra-day peak area values and relative standard deviations (RSD %) for (±)-caffeine, (±)-mephedrone and (±)-4-MEC using HPLC-UV 
detection and amperometric detection in the LC-FC-A system. 
Concentration  
(µg mL-1) 
Intra-day values of HPLC-UV  
peak area (mA) 
Intra-day values of HPLC-AD  
peak current (µA) 
Intra-day values of HPLC-UV  
peak area (mA) 
Intra-day values of HPLC-AD  
peak current (µA) 
Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC 
400 11214.8 16984.3 16133.1 4.427 0.926 0.458 11214.8 16984.3 16133.1 4.427 0.926 0.458 
400 11213.0 16983.1 16135.2 4.467 0.930 0.452 11213.0 16983.1 16135.2 4.467 0.930 0.452 
400 11213.8 16983.8 16133.3 4.432 0.930 0.460 11213.8 16983.8 16133.3 4.432 0.930 0.460 
400 11212.3 16982.5 16133.9 4.411 0.942 0.455 11212.3 16982.5 16133.9 4.411 0.942 0.455 
400 11213.0 16983.0 16134.7 4.431 0.928 0.460 11213.0 16983.0 16134.7 4.431 0.928 0.460 
400 11212.0 16982.5 16135.5 4.496 0.946 0.460 11212.0 16982.5 16135.5 4.496 0.946 0.460 
400 11267.0 16969.2 16115.3 4.410 0.917 0.463 11212.8 16719.2 15845.0 4.421 0.922 0.455 
400 11265.9 16964.7 16115.3 4.446 0.927 0.463 11212.1 16718.8 15844.8 4.435 0.924 0.456 
400 11265.6 16968.5 16121.6 4.426 0.931 0.464 11210.3 16720.8 15840.8 4.442 0.920 0.450 
400 11268.0 16969.5 16120.5 4.388 0.941 0.463 11210.9 16721.9 15843.4 4.450 0.927 0.456 
400 11266.7 16969.6 16116.8 4.448 0.929 0.458 11211.8 16720.6 15846.7 4.432 0.927 0.449 
400 11267.3 16967.5 16119.9 4.407 0.930 0.464 11210.4 16721.3 15845.7 4.410 0.927 0.447 
Average 11239.9 16975.7 16126.2 4.43 0.93 0.46 11212.3 16851.8 15989.3 4.44 0.93 0.45 
RSD% 0.249 0.047 0.053 0.656 0.860 0.829 0.012 0.814 0.947 0.544 0.830 0.967 
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Table 9.21 Raw data of the inter- and intra-day peak area values and relative standard deviations (RSD %) of for (±)-caffeine, (±)-mephedrone and (±)-4-MEC using HPLC-
UV detection and amperometric detection in the LC-FC-B system. 
Concentration  
(µg mL-1) 
Intra-day values of HPLC-UV  
peak area (mA) 
Intra-day values of HPLC-AD  
peak current (µA) 
Intra-day values of HPLC-UV  
peak area (mA) 
Intra-day values of HPLC-AD  
peak current (µA) 
Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC Caffeine 4-MMC 4-MEC 
400 11214.8 16984.3 16133.1 4.427 0.926 0.458 11214.8 16984.3 16133.1 4.427 0.926 0.458 
400 11213.0 16983.1 16135.2 4.467 0.930 0.452 11213.0 16983.1 16135.2 4.467 0.930 0.452 
400 11213.8 16983.8 16133.3 4.432 0.930 0.460 11213.8 16983.2 16133.3 4.432 0.930 0.460 
400 11212.3 16982.5 16133.9 4.411 0.942 0.455 11212.3 16982.5 16133.9 4.411 0.942 0.455 
400 11213.0 16983.0 16134.7 4.431 0.928 0.460 11213.0 16983. 16134.7 4.431 0.928 0.460 
400 11212.0 16982.5 16135.5 4.496 0.946 0.460 11212.0 16982.5 16135.5 4.496 0.946 0.460 
400 11267.0 16969.2 16115.3 4.410 0.917 0.463 11212.8 16719.2 15845.0 4.421 0.922 0.455 
400 11265.9 16964.7 16115.3 4.446 0.927 0.463 11212.1 16718.8 15844.8 4.435 0.924 0.456 
400 11265.6 16968.5 16121.6 4.426 0.931 0.464 11210.3 16720.8 15840.8 4.442 0.920 0.450 
400 11268.0 16969.5 16120.5 4.388 0.941 0.463 11210.9 16721.9 15843.4 4.450 0.927 0.456 
400 11266.7 16969.6 16116.8 4.448 0.929 0.458 11211.8 16720.6 15846.7 4.432 0.927 0.449 
400 11267.3 16967.5 16119.9 4.407 0.930 0.464 11210.4 16721.3 15845.7 4.410 0.927 0.447 
Average 11239.9 16975.7 16126.2 4.43 0.93 0.46 11212.3 16851.8 15989.3 4.44 0.93 0.45 
RSD% 0.249 0.047 0.053 0.656 0.860 0.829 0.012 0.814 0.947 0.544 0.830 0.967 
232 
 
Table 9.22 Results of linearity measurements for (±)-mephedrone using HPLC-UV in the LC-FC-A 
system, column A (Table 2.2), mobile phase 3, detector wavelength (UV): 263 nm. 
Concentration (µg mL-1) 100 200 300 400 500 
Peak high (µA)-1 5101.70 10414.80 15431.60 20107.70 25880.30 
Peak high (µA)-2 5101.00 10389.90 15444.80 20087.90 25902.40 
Peak high (µA)-3 5102.30 10395.70 15445.30 20141.20 25912.00 
Peak high (µA)-4 5100.70 10392.30 15437.01 20139.80 25904.30 
Peak high (µA)-5 5103.30 10396.20 15443.60 20249.30 25887.10 
Peak high (µA)-6 5103.80 10389.70 15447.80 20166.30 25896.60 
Average 5102.10 10396.40 15441.70 20148.70 25897.10 
RSD% 0.02 0.09 0.03 0.28 0.04 
 
Table 9.23 Results of linearity measurements for (±)-mexedrone using HPLC-UV in the LC-FC-A 
system, column A (Table 2.2), mobile phase 3, detector wavelength (UV): 263 nm. 
Concentration (µg mL-1) 100 200 300 400 500 
Peak high (µA)-1 4888.2 8037.7 11578.4 14923.3 18604.2 
Peak high (µA)-2 4888.41 8038.45 11579.3 14920.5 18606.7 
Peak high (µA)-3 4889.82 8038.12 11582 14922.6 18602.6 
Peak high (µA)-4 4886.96 8038.57 11579.1 14923.6 18603.0 
Peak high (µA)-5 4887.69 8038.3 11581.7 14920.5 18603.6 
Peak high (µA)-6 4888.2 8038.3 11581.3 14924.8 18602.2 
Average 4888.21 8038.2 11580.30 14922.5 18603.7 
RSD% 0.02 0.003 0.01 0.01 0.01 
 
Table 9.24 Results of linearity measurements for (±)-mephedrone using HPLC-AD in the LC-FC-A 
system, column A (Table 2.2),mobile phase 3, detector wavelength (UV): 263 nm. 
Concentration (µg mL-1) 100 200 300 400 500 
Peak high (µA)-1 0.1200 0.2309 0.3436 0.4509 0.6047 
Peak high (µA)-2 0.1194 0.2303 0.3430 0.4523 0.6030 
Peak high (µA)-3 0.1206 0.2300 0.3380 0.4515 0.6021 
Peak high (µA)-4 0.1185 0.2305 0.3412 0.4525 0.6020 
Peak high (µA)-5 0.1200 0.2307 0.3428 0.4577 0.6000 
Peak high (µA)-6 0.1190 0.2305 0.3452 0.4576 0.6010 
Average 0.1196 0.2305 0.3425 0.4538 0.6021 
RSD% 0.65 0.14 0.722 0.67 0.27 
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Table 9.25 Results of linearity measurements for (±)-mexedrone using HPLC-AD in the LC-FC-A 
system, column A (Table 2.2),mobile phase 3, detector wavelength (UV): 263 nm. 
Concentration (µg mL-1) 100 200 300 400 500 
Peak high (µA)-1 0.1741 0.2826 0.4166 0.5567 0.6922 
Peak high (µA)-2 0.1730 0.2834 0.4160 0.5584 0.6865 
Peak high (µA)-3 0.1730 0.2830 0.4174 0.5524 0.6864 
Peak high (µA)-4 0.1720 0.2820 0.4193 0.5554 0.6884 
Peak high (µA)-5 0.1700 0.2810 0.4160 0.5598 0.6844 
Peak high (µA)-6 0.1730 0.2790 0.4160 0.5510 0.6791 
Average 0.1725 0.2818 0.4169 0.5556 0.6862 
RSD% 0.81 0.58 0.31 0.61 0.63 
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Table 9.26 Raw data of the inter- and intra-day peak values and relative standard deviations (RSD %) of for (±)-mephedrone, and (±)-mexedrone using HPLC-UV detection 
and amperometric detection in the LC-FC-A system. 
Concentration 
 (µg mL-1) 
Intra-day HPLC-UV peak 
area (mAU) 
Intra-day HPLC-AD peak current 
(µA) 
Inter-day HPLC-UV peak area 
(mAU) 
Inter-day HPLC-AD peak area 
(µA) 
4-MMC Mexedrone 4-MMC Mexedrone 4-MMC Mexedrone 4-MMC Mexedrone 
300 15431.6 11578.4 0.344 0.417 15431.6 11578.4 0.344 0.417 
300 15444.8 11579.3 0.343 0.416 15444.8 11579.3 0.343 0.416 
300 15445.3 11582.0 0.344 0.417 15445.3 11582.0 0.344 0.417 
300 15437.1 11579.1 0.341 0.419 15437.1 11579.1 0.341 0.419 
300 15443.6 11581.7 0.348 0.416 15443.6 11581.7 0.348 0.416 
300 15447.8 11581.3 0.345 0.416 15447.8 11581.3 0.345 0.416 
300 15392.9 11557.5 0.343 0.420 15432.9 11577.5 0.348 0.414 
300 15382.9 11535.2 0.344 0.424 15432.9 11585.2 0.345 0.417 
300 15391.8 11552.1 0.344 0.421 15431.8 11582.1 0.348 0.410 
300 15490.0 11548.3 0.345 0.421 15440.0 11578.3 0.345 0.412 
300 15394.8 11539.3 0.342 0.422 15444.8 11579.3 0.345 0.416 
300 15385.3 11532.0 0.338 0.420 15445.3 11582.0 0.348 0.414 
Average 15424.0 11562.2 0.343 0.419 15439.8 11580.5 0.345 0.415 
STD 33.661 20.137 0.002 0.003 6.211 2.222 0.002 0.002 
RSD% 0.218 0.174 0.703 0.631 0.040 0.019 0.657 0.584 
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Table 9.27 Results of linearity measurements for (±)-4-MEP using HPLC-UV in the LC-FC-A system, 
column B (Table 2.2), mobile phase 4, detector wavelength (UV): 279 nm. 
Concentration (µg mL-1) 100 200 300 400 500 
Peak area 1 81.47 166.01 248.23 334.67 411.02 
Peak area 2 81.21 166.79 247.57 333.52 411.74 
Peak area 3 81.15 166.56 248.15 333.63 411.48 
Peak area 4 81.28 165.91 247.22 333.99 411.36 
Peak area 5 81.29 165.97 247.57 333.69 411.02 
Peak area 6 81.48 166.79 247.65 333.08 411.75 
Average 81.31 166.34 247.73 333.76 411.40 
RSD% 0.17 0.25 0.16 0.16 0.08 
 
Table 9.28 Results of linearity measurements for (±)-2-MEP using HPLC-UV in the LC-FC-A system, 
column B (Table 2.2), mobile phase 4, detector wavelength (UV): 279 nm. 
Concentration (µg mL-1) 100 200 300 400 500 
Peak area 1 191.22 391.28 582.20 775.08 943.50 
Peak area 2 191.48 391.24 582.38 775.49 943.36 
Peak area 3 191.04 391.15 582.29 775.02 943.20 
Peak area 4 191.25 391.60 581.92 775.09 943.36 
Peak area 5 191.19 391.76 582.38 775.37 943.13 
Peak area 6 191.05 391.82 582.29 775.17 943.35 
Average 191.20 391.47 582.24 775.20 943.32 
RSD% 0.09 0.07 0.03 0.02 0.01 
 
Table 9.29 Results of linearity measurements for (±)-3-MEP using HPLC-UV in the LC-FC-A system, 
column B (Table 2.2), mobile phase 4, detector wavelength (UV): 279 nm. 
Concentration (µg mL-1) 100 200 300 400 500 
Peak area 1 162.07 329.85 491.08 661.18 799.86 
Peak area 2 162.17 329.23 491.32 660.31 799.64 
Peak area 3 162.43 329.48 491.74 661.28 799.72 
Peak area 4 162.49 329.40 491.68 660.37 799.68 
Peak area 5 162.20 329.68 491.32 660.44 799.67 
Peak area 6 162.14 329.23 492.23 660.22 799.65 
Average 162.25 329.48 491.56 660.63 799.71 
RSD% 0.10 0.08 0.08 0.07 0.01 
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Table 9.30 Results of linearity measurements for (±)-4-MEP using HPLC-UV in the LC-FC-A system, 
column B (Table 2.2), mobile phase 4, detector wavelength (UV): 279 nm. 
Concentration (µg mL-1) 100 200 300 400 500 
Peak current(µA)-1 0.15 0.29 0.41 0.58 0.69 
Peak current(µA)-2 0.15 0.29 0.41 0.57 0.68 
Peak current(µA)-3 0.14 0.29 0.41 0.57 0.68 
Peak current(µA)-4 0.15 0.29 0.42 0.57 0.68 
Peak current(µA)-5 0.15 0.28 0.42 0.58 0.67 
Peak current(µA)-6 0.15 0.29 0.41 0.59 0.66 
Average 0.15 0.29 0.41 0.58 0.68 
RSD% 0.52 1.89 1.25 1.40 1.35 
 
Table 9.31 Results of linearity measurements for (±)-2-MEP using HPLC-AD in the LC-FC-A system, 
column B (Table 2.2), mobile phase 4, amperometric detector 
Concentration (µg mL-1) 100 200 300 400 500 
Peak current(µA)-1 0.13 0.20 0.26 0.38 0.44 
Peak current(µA)-2 0.13 0.20 0.26 0.38 0.45 
Peak current(µA)-3 0.13 0.21 0.26 0.38 0.46 
Peak current(µA)-4 0.13 0.20 0.26 0.38 0.45 
Peak current(µA)-5 0.13 0.20 0.26 0.38 0.45 
Peak current(µA)-6 0.13 0.2 0.26 0.37 0.4 
Average 0.130 0.20 0.26 0.38 0.45 
RSD% 1.05 0.67 0.95 0.71 1.02 
 
Table 9.32 Results of linearity measurements for (±)-3-MEP using HPLC-AD in the LC-FC-A system, 
column B (Table 2.2), mobile phase 4, amperometric detector 
Concentration (µg mL-1) 100 200 300 400 500 
Peak current(µA)-1 0.13 0.22 0.27 0.39 0.43 
Peak current(µA)-2 0.13 0.22 0.27 0.38 0.43 
Peak current(µA)-3 0.12 0.22 0.27 0.38 0.44 
Peak current(µA)-4 0.13 0.22 0.27 0.37 0.44 
Peak current(µA)-5 0.13 0.22 0.27 0.38 0.44 
Peak current(µA)-6 0.13 0.22 0.28 0.38 0.43 
Average 0.13 0.22 0.27 0.38 0.43 
RSD% 1.57 0.64 1.17 1.30 1.24 
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Table 9.33 Results of linearity measurements for (±)-4-FEP using HPLC-UV in the LC-FC-A system, 
column B (Table 2.2), mobile phase 5;  detector wavelength (UV): 270 nm. 
Concentration  
(µg mL-1) 
50 100 150 200 250 300 
Peak area 1 20.41 40.27 59.83 80.76 96.90 119.92 
Peak area 2 20.37 40.14 59.93 80.32 96.77 119.73 
Peak area 3 20.44 40.00 60.14 80.33 96.77 119.91 
Peak area 4 20.46 40.26 60.18 80.90 96.71 120.32 
Peak area 5 20.44 40.00 60.03 80.46 96.41 119.86 
Peak area 6 20.13 40.01 60.06 80.34 97.06 120.28 
Average 20.37 40.12 60.03 80.52 96.78 120.00 
RSD% 0.62 0.32 0.218 0.31 0.22 0.19 
 
Table 9.34 Results of linearity measurements for (±)-2-FEP using HPLC-UV in the LC-FC-A system, 
column B (Table 2.2), mobile phase 5, detector wavelength (UV): 270 nm. 
Concentration (µg mL-1) 50 100 150 200 250 300 
Peak area 1 49.19 97.67 146.82 196.86 235.84 292.74 
Peak area 2 48.93 98.01 146.63 196.82 236.21 293.05 
Peak area 3 49.25 98.29 147.19 196.77 235.74 292.84 
Peak area 4 49.16 97.91 146.96 196.81 236.12 293.38 
Peak area 5 48.94 98.27 146.82 196.71 236.39 293.40 
Peak area 6 48.95 98.39 146.60 196.63 236.37 293.65 
Average 49.07 98.09 146.83 196.77 236.11 293.18 
RSD% 0.29 0.28 0.15 0.04 0.11 0.12 
 
Table 9.35 Results of linearity measurements for (±)-3-FEP using HPLC-UV in the LC-FC-A system, 
column B, (Table 2.2), mobile phase 5, detector wavelength (UV): 270 nm. 
Concentration (µg mL-1) 50 100 150 200 250 300 
Peak area 1 49.22 97.81 149.69 197.41 239.05 297.32 
Peak area 2 49.01 98.27 149.29 197.65 239.85 297.29 
Peak area 3 48.99 98.56 149.70 197.23 239.21 297.76 
Peak area 4 49.04 98.37 149.77 197.95 239.69 297.47 
Peak area 5 49.25 98.36 149.41 197.16 239.07 297.66 
Peak area 6 49.06 98.76 149.08 197.08 239.87 297.04 
Average 49.09 98.36 149.49 197.41 239.46 297.42 
RSD% 0.23 0.33 0.18 0.17 0.16 0.09 
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Table 9.36 Results of linearity measurements for (±)-4-FEP using HPLC-AD in LC-FC-A system, 
column B (Table 2.2), mobile phase 5, amperometric detector 
Concentration (µg mL-1) 50 100 150 200 250 300 
Peak current(µA) 1 0.140 0.281 0.421 0.563 0.704 0.830 
Peak current(µA) 2 0.141 0.282 0.419 0.561 0.703 0.842 
Peak current(µA) 3 0.141 0.281 0.418 0.560 0.703 0.841 
Peak current(µA) 4 0.140 0.280 0.417 0.565 0.702 0.842 
Peak current(µA) 5 0.140 0.282 0.418 0.561 0.702 0.840 
Peak current(µA) 6 0.141 0.281 0.413 0.560 0.704 0.843 
Average 0.141 0.281 0.418 0.562 0.71 0.839 
RSD% 0.24 0.25 0.64 0.36 0.15 0.56 
 
Table 9.37 Results of linearity measurements for (±)-2-FEP using HPLC-AD in the LC-FC-A system, 
column B (Table 2.2), mobile phase 5, amperometric detector 
Concentration (µg mL-1) 50 100 150 200 250 300 
Peak current(µA) 1 0.125 0.248 0.248 0.379 0.583 0.739 
Peak current(µA) 2 0.127 0.249 0.249 0.375 0.586 0.737 
Peak current(µA) 3 0.126 0.247 0.247 0.369 0.585 0.728 
Peak current(µA) 4 0.128 0.249 0.249 0.369 0.584 0.739 
Peak current(µA) 5 0.127 0.249 0.249 0.369 0.583 0.734 
Peak current(µA) 6 0.127 0.248 0.241 0.378 0.583 0.748 
Average 0.127 0.248 0.247 0.373 0.584 0.738 
RSD% 0.76 0.39 1.23 1.19 0.20 0.87 
 
Table 9.38 Results of linearity measurements for (±)-3-FEP using HPLC-AD in the LC-FC-A system, 
column B (Table 2.2), mobile phase 5, amperometric detector 
Concentration (µg mL-1) 50 100 150 200 250 300 
Peak current(µA)-1 0.124 0.246 0.365 0.471 0.612 0.731 
Peak current(µA)-2 0.125 0.245 0.366 0.473 0.618 0.738 
Peak current(µA)-3 0.124 0.245 0.364 0.470 0.617 0.735 
Peak current(µA)-4 0.123 0.246 0.361 0.471 0.617 0.725 
Peak current(µA)-5 0.123 0.247 0.365 0.469 0.613 0.732 
Peak current(µA)-6 0.124 0.248 0.361 0.471 0.613 0.729 
Average 0.124 0.246 0.364 0.471 0.615 0.732 
RSD% 0.608 0.475 0.594 0.230 0.440 0.610 
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Table 9.39 Raw data of inter- and intra-day peak area values and relative standard deviations (RSD %) for (±)-4-MEP, (±)-2-MEP and (±)-3-MEP by using HPLC-UV detection 
and amperometric detection in the LC-FC-A system. 
Concentration 
(µg mL-1) 
Intra-day of HPLC-UV 
peak area (mA) 
Intra-day of HPLC-AD 
peak current (µA) 
Inter-day of HPLC-AD 
peak area (mA) 
Inter-day of HPLC-AD 
peak current (µA) 
 4-MEP 2-MEP 3-MEP 4-MEP 2-MEP 3-MEP 4-MEP 2-MEP 3-MEP 4-MEP 2-MEP 3-MEP 
300 248.23 582.2 491.08 0.417 0.262 0.268 244.23 580.2 493.08 0.417 0.262 0.268 
300 247.57 582.38 491.32 0.419 0.259 0.273 243.57 580.38 493.32 0.419 0.259 0.273 
300 248.15 582.29 491.74 0.424 0.262 0.269 243.15 580.29 492.74 0.424 0.262 0.269 
300 247.22 581.92 491.68 0.417 0.261 0.270 244.22 581.92 492.68 0.41 0.261 0.270 
300 247.57 582.38 491.32 0.426 0.262 0.270 244.57 580.38 493.32 0.426 0.262 0.270 
300 247.65 582.29 492.23 0.419 0.262 0.273 243.65 581.29 493.23 0.419 0.262 0.273 
300 248.23 582.2 491.08 0.417 0.261 0.268 248.23 582.2 491.08 0.418 0.257 0.273 
300 247.57 582.38 491.32 0.418 0.257 0.273 247.57 582.38 491.32 0.419 0.262 0.273 
300 248.15 582.29 491.74 0.424 0.263 0.268 248.15 582.29 491.74 0.417 0.261 0.268 
300 247.22 581.92 491.68 0.417 0.261 0.271 247.22 581.92 491.68 0.418 0.257 0.273 
300 247.57 582.38 491.32 0.426 0.259 0.270 247.57 582.38 491.32 0.417 0.262 0.268 
300 247.65 582.29 492.23 0.417 0.261 0.270 247.65 582.29 492.23 0.419 0.259 0.273 
Average 247.73 582.24 491.56 0.42 0.26 0.27 245.82 581.49 492.31 0.42 0.26 0.27 
RSD% 0.15 0.03 0.08 0.90 0.66 0.71 0.83 0.16 0.17 0.70 0.76 0.83 
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Table 9.40 Raw data of the inter and intra-day peak values and relative standard deviations (RSD %) for (±)-4-FEP, (±)-2-FEP and (±)-3-FEP using HPLC-UV detection and 
amperometric detection in the LC-FC-A system. 
Concentration  
(µg mL-1) 
Intra-day of HPLC-UV 
peak area (mA) 
Intra-day of HPLC-AD 
peak current (µA) 
Inter-day of HPLC-AD 
peak area (mA) 
Inter-day of HPLC-AD 
peak current (µA) 
4-FEP 2-FEP 3-FEP 4-FEP 2-FEP 3-FEP 4-FEP 2-FEP 3-FEP 4-FEP 2-FEP 3-FEP 
300 119.92 292.74 297.32 0.838 0.740 0.731 119.92 292.74 297.32 0.838 0.740 0.731 
300 119.73 293.05 297.30 0.842 0.738 0.738 119.73 293.05 297.30 0.842 0.738 0.738 
300 119.91 292.84 297.76 0.841 0.729 0.736 119.91 292.84 297.76 0.841 0.729 0.736 
300 120.32 293.38 297.47 0.842 0.740 0.725 120.32 293.38 297.47 0.842 0.740 0.725 
300 119.86 293.40 297.66 0.840 0.735 0.732 119.86 293.40 297.66 0.840 0.735 0.732 
300 120.28 293.20 297.04 0.843 0.749 0.730 120.28 293.20 297.04 0.843 0.749 0.730 
300 119.78 293.04 297.29 0.829 0.730 0.724 120.14 293.39 297.77 0.841 0.729 0.738 
300 119.93 292.87 297.72 0.849 0.734 0.734 119.25 293.28 297.09 0.838 0.729 0.736 
300 120.31 293.38 297.43 0.829 0.740 0.726 120.01 293.20 297.03 0.840 0.726 0.725 
300 119.87 293.40 297.09 0.844 0.736 0.728 119.88 293.21 297.32 0.840 0.734 0.730 
300 119.72 293.07 297.74 0.839 0.736 0.731 119.73 292.98 297.23 0.836 0.721 0.723 
300 119.82 292.49 297.08 0.842 0.741 0.728 120.21 293.34 297.54 0.840 0.740 0.726 
Average 119.95 293.07 297.41 0.840 0.737 0.730 119.94 293.17 297.38 0.840 0.734 0.731 
RSD% 0.18 0.10 0.09 0.659 0.678 0.558 0.23 0.07 0.09 0.227 0.991 0.688 
 
 
 
 
